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Abstract 
Introduction: Knowledge on RSV infection and disease is sparse in much of sub-Saharan 
Africa. Disease incidence is highest in infants, but there is little understanding on how and 
where they become infected. Characteristics of RSV transmission are poorly defined. 
Understanding transmission of RSV within the community is important in understanding 
infection and disease in infants and in defining potential effects of vaccination 
Methods: A prospective longitudinal surveillance of ARI in a random selection of households 
in Kilifi District, coastal Kenya, was established in early 2003, and continued until 2005. 
Participants were under active and passive surveillance and were reviewed using a standard 
proforma. Nasal washings from symptomatic household members were screened for RSV 
antigen using IFAT. Oral-fluid for serological determination of infection was collected at 
enrolment and every 3 months. 
Results: 81 households were recruited, 25 were lost to followup. 121 infections were 
identified approximately half of which were re-infections. The virus infected 54% of the 
households. Incidence of RSV infection was 218 cases/1000 cyo (95% CI, 182- 264). The 
incidence of primary infection was 476 cases/1000 cyo (95% CI, 361-630) and re-infection 
was 147/1000 cyo (95% CI, 115-189). Risk of disease was higher during primary infection 
than re-infection with the highest risk of disease in children 12-17months old. Estimated 
duration of viral shedding was short, <1 week. Age, sex, infection history and severity of 
infection were not found to significantly affect duration of shedding. Pre-school children with 
siblings in school had higher rates of infection. Index to secondary case interval was shorter 
for younger children and SARs were higher in smaller households. Crowding and stunting 
were associated with increased risk of both LRTI and RSV specific LRTI. Sanitation, type of 
house, and having siblings under the age of 6 years of age were associated with increased risk 
of RSV-disease. 
Conclusion: We have defined several aspects of RSV transmission and demonstrated an 
important burden of RSV infection and disease in a rural Kenyan community addressing a 
need for more information from developing countries. 
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Chapter One 
General Introduction 
1.1 Defining the question 
Respiratory syncytial virus (RSV) is the major viral cause of severe childhood acute 
respiratory infections (ARI) worldwide. Most disease occurs in infants and young children 
making them an important group that would be a target population for vaccines. The last few 
years have seen significant progress in the development of a vaccine against RSV [1-3]. A 
recent success is that of a recombinant live attenuated vaccine which has been shown to be 
sufficiently attenuated and apparently still immunogenic in the target age group, infants 1-2 
months old [2]. This vaccine will potentially play a major role in the control of disease rather 
than providing sterilizing immunity to infection (it is unlikely to elicit herd immunity in a 
locality. ) 
To correctly evaluate the potential effect of a vaccine in a population, it is necessary to 
understand the infection dynamics prior to vaccination. However the characteristics of RSV 
transmission are poorly understood - its persistence and recurrence, re-infection, potentially 
predisposing risk factors, age-related risks, role of household contacts, and the effect of prior 
exposure and past strain infection are not well defined. Much of this information is lacking in 
developed countries and is in particular shortage - practically absent - from developing 
countries. 
Previous studies from developing countries [4-10] report widely varying incidence of RSV- 
associated lower respiratory infection (RSV-LRI) between 8/1000 cyo to 220/1000 cyo. 
While population or biological factors might account for some of this variation, 
methodological issues provide a more likely explanation. More recently, 4 studies arising 
from the same generic protocol (although not strictly adhered to) were undertaken [11]. From 
these studies the incidence of RSV-LRI in children <5 years was 34/1000 and 94/1000 in 
Indonesia and Nigeria, respectively. The incidence of severe RSV-LRI per 1000 child years 
was 5 in Mozambique, 10 in Indonesia and 9 in South Africa with the majority of RSV cases 
occurring in infants. Though generally lower, two studies in the developed world (one in low 
income families in the US [12]) have reported similar rates [13]. Although variable, these 
results make a substantial case for the burden of RSV-LRI as well as creating a need for the 
investigation of putative individual and household risk factors which may alter a child's risk 
of infection and disease. This is of general interest as children bear the greatest burden of 
disease and should be the main beneficiaries of a vaccine. 
It appears unlikely that primary infections, while resulting in most disease [ 12], drive 
transmission; infants mostly stay in the home, and it's more likely that they are in fact the 
recipients and not the suppliers of infection. Transmission of RSV is known to be via droplet 
transmission and fomites [14] implying that close contact is necessary and that family 
transmission may play an important role in community transmission. Longitudinal studies of 
households can thus serve to describe aspects of the spread and transmission of infection. Our 
interest in older siblings and other household members (householders) is because they are 
probably the source of infection generally, and specifically the source for infants. 
Household studies [12,15-17] and community studies [18-20] from developed countries show 
RSV to re-infect repeatedly throughout life which points to a potentially significant role for 
re-infections within the population that may be fundamental to RSV persistence within the 
community. Finally, RSV is typical of many viral infections with respect to inducing less than 
solid immunity, and being antigenically and genotypically diverse. Hence the general 
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questions of persistence and the importance of re-infection in the transmission process are 
important to ask. 
The research presented in this thesis was part of and nested within the main RSV birth cohort 
project. The aim of the overall project was to undertake longitudinal epidemiological studies 
within a well defined rural Kenyan population to further the understanding of RSV 
transmission dynamics and immunity. In particular the objectives were to: 
1. Quantify through active and passive surveillance of an infant cohort the protective 
efficacy to re-infection of past history of infection, in particular homologous or 
heterologous strain infection and also a) single or multiple infections b) time since 
and, c) age at, infection. 
2. Describe differences between RSV infections identified through hospital surveillance 
and those through community surveillance, with respect to spatial, temporal and 
genotypic characteristics. 
3. Estimate rates of RSV infection and re-infection in the community in all ages, and 
elucidate the seasonal incidence characteristics of the virus (i. e. where is the virus 
circulating between major seasonal epidemics). 
4. Advance understanding of the antibody responses to the immunologically important 
attachment (G) protein in RSV variants, in relation to infection and re-infection. 
5. Elucidate, using results from the above combined with mathematical modeling, the 
mechanisms underlying the observation on spatio-temporal dynamics in RSV 
genotypes. 
The research reported in this thesis was designed to contribute to the overall project by 
generating key information on the community dynamics of RSV infection by the 
identification and quantification of who is being infected, how much infection (and re- 
infection) is occurring in the different age groups, how they contract infection, who acquires 
infection from whom (WAIFW), and how severe is the resultant disease. These data will be 
established in a context of the relationship to past exposure, infecting group (antigenic 
`strain') and genotype and level of shedding from the infected individual. 
1.2 Thesis research objectives 
The general objective was to develop understanding of the mechanism of RSV transmission 
and related influencing factors, within a Kenyan population, in a spatial-temporal setting and 
with emphasis on events within the household. 
Specific objectives (a) Within households 
1. Describe RSV re-infection patterns in relation to age, family structure, RSV group 
and genotype, season, and environmental risk factors. 
2. Monitor the time course of sequential infections to shed light on the source of primary 
RSV infections in infancy. 
3. Estimate the duration of shedding of RSV following infection as an important 
transmission factor, in relation to influences such as age and previous infection. 
4. Quantify incidence rates of RSV infection with respect to age. 
5. Identify the occurrence of transmission outside of the main epidemic season to 
elucidate the mechanism of RSV persistence. 
6. Investigate severity of RSV infection within the household in relation to age, virus 
genotype and household structure. 
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(b) Within a birth cohort 
7. Identify and compare household and individual risk-factors for all cause LRTI and 
RSV infection and disease. 
1.3 Approach 
In the present research there was a detailed surveillance of infection in a birth cohort which 
was used to identify risk factors for clinical RSV infection and RSV-LRTI as well as those for 
all-cause lower respiratory tract infection. This cohort study provided an ideal opportunity to 
explore transmission at the household level by recruiting households of a sub-sample of the 
main cohort study. 
1.4 Declaration of author's role 
The study was designed by the principal investigators; Dr James D. Nokes, Prof. Graham 
Medley and Dr Patricia Cane. The author of this thesis was the field coordinator responsible 
for the overall management of the projects field activities, including; overseeing recruitment 
of study participants, follow-up, data and specimen collection. The author was also 
responsible for creating the risk factor database within the main study database. The 
household study was proposed in the original project but without great detail and the author 
was co-responsible for the design, and took lead in the study implementation. The author 
managed a team of 9 field workers and was responsible for managing the day-to-day activities 
and for task allocation. Unless otherwise stated the author took lead in the analyses presented 
in this thesis. Publications that have so far arisen from the project are listed below: 
1. Nokes, D. J., Okiro, E. A., Ngama, M., White, L. J., Ochola, R., Scott, P. D., Cane, P. 
A. and Medley, G. F. Respiratory syncytial virus epidemiology in a birth cohort from 
Kilifi district, Kenya: infection during the first year of life. Jlnfect Dis, 2004; 190: 
1828-32. 
2. Scott, P. D., Ochola, R., Ngama, M., Okiro, E. A., Nokes, D. J., Medley, G. F. and 
Cane, P. A. Molecular epidemiology of respiratory syncytial virus in Kilifi district, 
Kenya. JMed Virol, 2004; 74: 344-354. 
3. Scott, P. D., Ochola, R., Ngama, M., Okiro, E. A., Nokes, D. J., Medley, G. F. and 
Cane, P. A. Molecular analysis of respiratory syncytial virus reinfections in infants 
from coastal Kenya Jlnfect Dis, 2006; 193: 59-67. 
4. Okiro, E. A., Ngama, M., White, L. J., Cane, P. A., Medley, G. F. and Nokes, D. J 
Estimation of the duration of shedding of Respiratory syncytial virus (In Preparation) 
1.5 Overview of thesis 
A review chapter follows directly after the Introduction. The aim of the review is to provide 
an introduction to RSV, its epidemiology and transmission by which to establish the 
background from which the questions in this thesis are raised. An overview of putative risk 
factors for RSV and those for all-cause lower respiratory infcetion (LRTI) is also presented. 
Chapter 3 describes the overall study design giving specific details on methods of 
surveillance and all study processes both field and laboratory. Some general results on the 
description of households and study population, the completeness of follow-up (dropout rate), 
surveillance intensity and occurrence of epidemics are also presented. The fourth chapter 
presents an evaluation of a non-invasive method for examining rates of infection, through the 
detection of changes in levels of RSV-specific IgG in oral-fluid samples. The fifth chapter 
provides general results from the household surveillance study on patterns of infection and 
correlates of transmission within the household. Secondary attack rates and the relative risk of 
introduction of infection into the home by different age categories of individuals are derived 
and discussed. In Chapter 6 the estimation of the duration of shedding using a survival 
analysis approach is described. Chapter 7 details the age-stratified incidence estimates for this 
study population, based upon clinically apparent cases confirmed by antigen assay of nasal 
washings. This analysis does not include evidence from non-invasive methods, because the 
identification of infection through oral-fluid samples proved unsuccessful. In Chapter 8, 
details of the risk factor survey and a background of the statistical methods used to analyse 
this data are presented. In the ninth chapter results of the analysis of the risk factor data are 
presented. This data is used to determine the risk factors for RSV infection (RSVI) and for 
RSV specific lower respiratory tract infection (RSV-LRTI) which is then compared with 
those risk factors for all cause LRTI. The final chapter provides a summary and discussion of 
the main finding of this thesis, considers possible improvements on the study and discusses 
the direction of future research. 
Chapter Two 
Literature Review 
2.1 Summary 
Acute respiratory disease (ARD) in infants is a worldwide public health problem [21,22]. 
The World Health Organization (WHO) estimates the annual deaths in children under 5 
years to be 12.2. million, one third of which are attributed to acute infections of the lower 
respiratory tract (ALRIs - pneumonia, bronchiolitis and bronchitis) [23]. Other studies have 
since confirmed that ARIs cause a considerable percentage of childhood mortality [24] with 
the highest percentage occurring in Africa. More recently, Bryce et al [25] reported that 
19% of childhood deaths worldwide are caused by pneumonia. In Kenya, ARIs are the 
second leading cause of morbidity (after malaria) accounting for up to one quarter of 
outpatient attendance in health facilities, thereby being a key health concern [26]. Causative 
organisms for LRTI may be bacterial 4.5%- 40% (most commonly Streptococcus 
pneumoniae and Haemophilus influenzae) or viral 14% -64% [27]. 
RSV has been described as the single most important viral cause of ALRI in children 
particularly in those younger than six months [27-29]. In addition, RSV infections are 
responsible for most cases of severe symptoms such as bronchiolitis and pneumonia and for 
high numbers of hospitalisations, as for example shown in classic studies in the US (Table 
2.1. ) 
Table 2.1. Proportion of respiratory disease of infancy and childhood associated with RSV 
infection in various studies 
Diagnosis Study, Location Virus recovery Serological Evidence 
of Infection 
No. % No. % positive 
tested positive tested 
Brochiolitis NIH study 154 25 230 18 
[30] Washington D. C 
[31] Chicago 34 50 - - 
[32] Philadelphia - - 26 38 
[33] Columbia 48 42 39 67 
[34] Rhone Alpes - 45 - 
[35] Washington D. C - 43 - 30 
[36] India - 58 - - 
[37] Tuscon - 65 - - 
Pneumonia NIH study 278 10 522 14 
[30] Washington D. C 
[31] Chicago 22 36 - - 
[32]Philadelphia 24 39 
[33] Columbia 58 - 45 44 
[35] Washington D. C - 25 - 22 
[36] India - 19 - - 
[37] Tuscon - 33 - - Other acute NIH study 1999 4.4 678 10 
respiratory [30]Washington D. C 
diseases 
[31] Chicago - 15 - 
[32] Philadelphia -- 481 16 
[35] Washington D. C -9- 18 
Most of the information that is available on RSV is from studies of paediatric patients 
admitted to hospital with serious respiratory disease and these have formed the basis for 
understanding the behaviour of RSV in young children. These data are useful but have 
limitations which include: i) the assumption that all serious cases get to hospital; an issue 
that is of particular concern in developing countries where a minority of cases actually 
make it to hospital [5,91 and ii) ignores the individually less serious, but still important, 
disease burden in the community in general. Relatively few community based studies of 
RSV have been carried out [12,15,16,19,37], and even fewer still have been set in the 
developing world (Figure 2.1). 
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Figure 2.1. Aetiology of ALRTI in developing countries in community based studies 
(adapted from review by Weber et al [28]). Note: 5 studies on right hand side did not use 
immunofluorescent antigen test (IFAT); use of IFAT increased proportion of RSV by 
twofold in the other studies. PIV- Parainfluenza virus, Adeno- Adenovirus 
Morbidity attributable to RSV in the community is not negligible as evidenced by 
denominator based disease burden estimates from community studies in developing 
countries summarized in Figure 2.2 and discussed further in section 2.5. 
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Figure 2.2. Incidence of RSV-LRTI stratified by age for disease burden community studies 
(adapted from review by Nokes [38]) 
Case fatality due to RSV is deemed generally to be low but has been shown to be higher in 
developing countries [28,39]. Two reviews of studies in tropical and developing countries 
[28,39] reported mortality rates of between 0-12% with a mode of 0%. However, estimated 
magnitude may be in question; in one Indonesian study [8] the majority of deaths of 
children admitted with pneumonia did so before a viral diagnosis could be undertaken; this 
potential bias may not be uncommon in resource poor settings. Furthermore, RSV causes 
considerable burden on health resources accounting for up to 40% of ARI admissions 
during RSV epidemics (unpublished data from Kilifi, DJ Nokes). This has significant 
implications to availability of beds and use of resources (such as oxygen for supportive 
therapy) that are scarce in developing countries. 
Currently there is no vaccine in use although a recent recombinant live attenuated vaccine 
has demonstrated sufficient attenuation while retaining immunogenicity in the key target 
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age group (1-2 months) for the first time [2]. It is possible that in the not too distant future, 
later phase clinical trials will be undertaken and these will invariably benefit from 
improved data on disease burden estimates, re-infection patterns and community 
transmission all of which are at present scarce in the developing countries. Data from this 
study will go towards improving the knowledge on RSV epidemiology in developing 
countries. 
2.2 Epidemiology of RSV 
2.2.1 Seasonality 
The epidemiology of RSV infection and disease is characterised by marked seasonal 
patterns. It is not entirely clear what triggers these epidemics or what happens to the virus 
in the inter-epidemic period but it is apparent that the timing of epidemics varies 
considerably. Patterns of transmission and persistence differ strikingly; ranging from 
typically long (-. 6 months) annual epidemics followed by periods of fade out to shorter 
discrete epidemics of one month [40], to reported cases of year round occurrence [41]. 
Repeat infection with RSV is common throughout life despite previous exposure which 
suggests that transmission should not have this strong seasonal pattern. This contribution of 
re-infection to the circulation of the virus, both during and between seasonal epidemics (of 
infection and disease), within the community has not been well defined. 
Two reviews have documented the seasonal patterns of RSV [28,39]. In general, epidemics 
occur annually during winter in temperate countries with the exception of some countries 
e. g. Finland where every two years there is a minor peak in April followed by a major peak 
in December [28,42-44]. In areas with tropical or subtropical climate and seasonal rainfall, 
RSV outbreaks were more frequently associated with the rainy rather than the colder season 
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[28]. Countries closer to the equator with high rainfall through out the year were found to 
have a different seasonal pattern with most cases appearing in one half of the year but not 
in the other. In the review by Stensballe [39], seasonality in the Northern tropical areas was 
associated with a decrease in temperature and an increase in rainfall [45,46] while 
epidemics south of the equator were associated with both decreased temperature and 
rainfall [47,48]. Epidemics can occur completely out of phase in areas not far apart and 
with similar weather patterns [11,28]. In Kilifi, unpublished surveillance data collected 
over the last five years indicates that RSV seasonality does not appear to be defined by the 
rainfall patterns (Chapter 3) but seems to exhibit a pattern similar to that seen in Finland. 
From these findings it appears that neither temperature nor rainfall are main determinants 
of the timing of these outbreaks. What seems clear is that the seasonal pattern of RSV is 
multifaceted without a clearly defined mechanism. Climatic and geographic factors appear 
to play a part although not exclusively, pointing to the possible role of other social- 
behavioral or viral characteristics as factors that may contribute to this epidemic pattern. 
Socio-behavioral factors, for instance less indoor crowding or vacationing of school 
children, may play a part [49]. Several studies done in the developed countries provide 
evidence that younger children acquire infection from school-aged children within the 
household [15,16,50], indicating a significant contribution of within-school transmission 
to the dynamics of the epidemics. Waris and White [49] indeed make such a case pushing 
forward the idea of the school year as a possible explanation for the seasonal signal of RSV 
infection in many countries. This idea has at present not been explored in a developing 
country study and forms an aspect of one of the objectives of the planned study. 
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This seasonal pattern of RSV is also likely to be affected and /or determined by its natural 
dynamics. This includes the combination of the short-lived immunity to RSV infection 
resulting in a build up of susceptibility to re-infection (explored further in section 2.3) and 
new births creating cohorts also losing maternal antibody protection. These concepts and 
other possible seasonal triggers lead into the molecular epidemiology and antigenic 
variation exhibited by RSV, and how these may influence its epidemiological features (this 
aspect will be covered in further detail in section 2.2.4). Its mode of transmission 
(discussed below) doesn't seem to correlate with its rapid spread within communities 
during epidemic. RSV requires closes contact for spread to occur and is also shed for 
relatively short durations which would imply restricted spread of infection. 
2.2.2 Characteristics of transmission 
The major mode of spread is by large droplets or through fomite contamination [51]. 
Aerosol particles are not considered to be a major mode of spread, since the virus is not 
stable when aerosolized [52,53]. Spread thus requires close contact with infected people or 
contamination of the hands with fomites from surfaces to which infected respiratory 
secretions have spread [51,54]. Past studies clearly demonstrate that RSV is efficiently 
transmitted within hospitals apparently due to this propensity for transmission on fomites 
[14,55,56]. This then implies that social contacts are also important for spread. RSV is 
unstable in the environment surviving only a few hours on environmental surfaces, and is 
readily inactivated with soap, water and disinfectants [54]. 
Experimental challenge studies and duration of shedding studies report that most people 
shed virus for between 1-3 days before clinical symptoms with a great majority of illness 
onsets following initial viral recovery [57-59]. Individuals developing symptoms were 
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observed to start shedding virus earlier than those asymptomatic; 3-4 days vs. 5+ days post 
inoculation. Most children recover from illness in 7 to 15 days [51,54]. This duration of 
infection and its variability is an important element in the dynamics of infection 
transmission. Hence, it is important to quantify the infection / recovery process, and in 
particular to know how past infection modifies the infectiousness of individuals [60]. 
Published estimates of the duration of shedding of RSV are few. A number of studies done 
were from children hospitalized with acute respiratory infection (ARI) [61-64]. Such 
estimates tend to be biased towards infections causing severe disease (arising from -1% of 
primary cases) and from a narrow (young) age group. It has been shown that greater 
severity of infection within in-patients results in increased duration of shedding [62]. A 
generalization of these hospital-based estimates to all infections occurring within a 
community is unlikely to be accurate. One study estimated the duration of RSV shedding 
through home based monitoring, a study of individuals of all ages in 36 families in the 
United States during a single epidemic [15]. A mean duration of 3.5-7.4 days in otherwise 
healthy children was recorded (range 1-36 days), with higher duration for children under 2 
years than for children under 16 years (9 vs. 3.9 days). Estimates, however, were not 
defined in relation to past infection status which is an aspect we intend to explore in the 
present study. A second family study following children under 4 years of age reported over 
70% of cultures positive up to 7 days post illness onset, falling to less than 10% in week 2 
and 3 [59]. No evidence for a difference in shedding duration between primary and re- 
infections was observed in this study (although with only 12 re-infections the power to 
detect even quite a large difference would be small). Studies of adults [65] in the 
community show shedding to be of similar or slightly shorter duration than shedding for 
children 1.6-3.9 days (range 1-27). 
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Despite the fact that the median duration of RSV shedding tends to be of the order of days, 
considerable variation exists: in the family studies referred to earlier, 5-10% of individuals 
shed for more than 14 days, and periods of shedding of 30-40 days have been recorded [15, 
59,62,63]. Similarly, immunocompromised individuals have been known to shed RSV for 
longer possibly keeping RSV ticking over in low season [41]. Given the prevalence of HIV 
infection in much of sub-Saharan Africa, this issue of long term shedding needs to be 
investigated and quantified as it has implications epidemiologically for persistence [39]. 
This led us to investigate the duration of shedding in individuals within household in 
relation to past exposure - number of previous infections, severity, age and infecting group 
(Chapter 6). 
2.2.3 Molecular structure 
RSV is antigenically diverse with group and genotype structure an aspect that potentially 
affects its epidemiolgy and is explored further in the next section. There are two major 
antigenic categories of RSV, known as group A and B. Group B viruses are less variable 
than the group A viruses [66,67]. The RSV genome contains 15200 nucleotides that are 
transcribed into 11 major subgenomic mRNAs each coding for a protein (Table 2.2). 
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Table 2.2. RSV Proteins and their functions (modified from Hacking et al [68]) 
Protein Function 
Non-structural proteins 
NS1/2 anti-interferon a and ß activity 
Nucleocapside proteins 
N Nucleoprotein essential for transcriptional activity 
P Phosphoprotein essential for transcriptional activity 
L RNA polymerase 
Transmembrane glycoproteins (surface proteins and important in immune stimulation) 
SH Small Hydrophobic protein: function unknown 
G Glycoprotein: viral attachment to cell 
F Fusion protein: viral entry and syncytia formation 
Matrixproteins 
M Matrix protein: viral assembly 
M2 M2-1: transcription elongation factor 
M2-2: regulation of viral transcription 
The G and F proteins are the major antigenic determinants of the virus because they 
stimulate the production of protective immune response. Both these proteins can induce the 
production of potent RSV-neutralizing antibodies by host cells [69] but only the F 
stimulates signifcant cytotoxic T-lymphocyte responses [55,70]. It is less clear what the 
relative roles of F and G are to the strain structure observed as the virus has been shown to 
replicate and reinfect (in animal studies) in the absence of the G protein [71]. Still, it is the 
G protein that seems to be variable under immune pressure due to the high proportion of 
nucleotide changes that result in amino acid coding changes [72,73]. The major antigenic 
and nucleotide sequence differences between the two groups are thus found on the G 
attachment glycoprotein [55,74]. There is further genotypic structure, with numerous 
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genotypes within each group [75] but the functional importance of this structure is not 
known. It is thought that this antigenic variation both within and between groups may 
enable re-infections to occur [76] (explored further in section 2.3.1). However, it is unclear 
what cross-immunity exists between the two Groups - it is known that the subtypes have 
antigenic cross reactivity for the F protein [77]. This is an aspect that is explored within the 
main project (Paper by P. Scott listed above). Molecular epidemiological studies 
(discusssed below) show evidence for interaction between Groups and genotypes i. e. clear 
patterns of A and B prevalence and sequential replacement of genotype variants in some 
longitudinal studies. 
2.2.4 RSV molecular epidemiology: Circulation of Groups A and B 
The epidemiological picture is complicated by the antigenic group variation [78-81]. RSV 
groups A and B co-circulate; however, there is usually a distinct temporal pattern of 
frequency. For example, long term surveillance of hospital admissions in Birmingham UK 
show two years of higher prevalence of RSV A followed by one year of RSV B [42,75]. In 
Finland another example, the pattern is of two epidemics of one type followed by two of 
the alternative group [44]. In general, years in which Group A dominates (i. e. is of higher 
frequency) exceed those for Group B [66,67,81-83]. The pattern observed in Finland is 
more complex insofar as 2 epidemics (one small and one large) of the same Group occur in 
close succession (average interval of one month or less) followed by a longer inter- 
epidemic period (-7 months). The same pattern has been seen elsewhere in Scandinavia 
and North European countries [84], and a similar pattern appears to be observed in Kilifi 
(Figure 2.3 & 2.4). 
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Figure 2.3. RSV IP cases by month in Kilifi, January 2002- December 2005 
This sequential dominance suggests that there is an underlying non-random structure at 
play; possibly some level of immunity forcing these shifts. Cane et al [42] hypothesize that 
strain differences affect protective immunity. In this case a novel virus may be transmitted 
more efficiently thus resulting in a situation where the epidemic strain would be determined 
by the levels of strain specific immunity in the community, with different social structures 
explaining the different patterns observed between communities. 
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Figure 2.4. Analysis of genotypes from IP samples KDH 2002-2006. >85% of the samples 
were successfully typed. Group A viruses are dominant in alternating years. 
The consistency of the patterns is indeed suggestive of an underlying mechanism. 
Modelling approaches have been used in an attempt to better understand the processes at 
work. Mathematical models capturing the host-pathogen interaction and the population 
dynamics (immunity) were explored by White et al and Weber et al [60,85]. The work of 
White et al [60], suggests the structure to be the result of (i) A being more transmissible 
than B and (ii) differential within to between group specific immunity. Immunity was 
estimated to be greater for homologous challenge (60%) than heterologous (16%). 
Seasonality in transmission is known to relate to contact rate for measles [86,87] and was 
in this case dependent on waning immunity. From mathematical models, it appears that 
several different assumptions can explain the observed patterns thus providing no definitive 
clarification on this seasonal phenomenon. These observations together would suggest a 
potentially complex relationship between the viral genetic variation, strain specific 
immunity and how these relate to the process of infection / disease as well as to 
transmission dynamics. In order to further understanding on RSV transmission dynamics 
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and to try and explain these patterns, there is need to assess aspects of infection and 
transmission as well as community factors i. e. infection in the off season, role of family 
structure, infants versus siblings transmission, and factors potentially contributing to and/or 
affecting the observed patterns all of which are issues explored in this thesis. 
2.3 Immunity to infection and disease and to subsequent re-infection 
Maternally derived protection and immunity to primary infection is an area that remains 
controversial as there are contradictory results about the role of maternal antibody in 
protection. Antibody found in serum of newborn infants represents passively acquired 
antibody, and commonly last less than six months [88,89]. The high incidence of infection 
and disease in infants appear to support the hypothesis that maternal antibodies do not offer 
complete protection. In fact it was previously suggested that maternal antibodies interfered 
with the immune response of the infants resulting in more severe disease [90] similar to 
what was seen with the formalin vaccine where vaccinated infants had more severe natural 
infection [91]. Subsequent studies since have given differing results. In some cases, the 
severity of illness resulting from RSV infection in the first months of life has been shown 
to be modified by high levels of maternal antibody [92-94], while in other studies primary 
infection in infants involving the lower respiratory tract has been shown to occur despite 
the existence of passively acquired maternal IgG antibodies in the circulation [95]. More 
recently, prophylactic administration of RSV-specific immunoglobulin (pooled 
immunoglobulin with high titers of anti-RSV antibody) given to high-risk infants and 
young children has been shown to be effective in reducing severe disease (by reducing the 
number and duration of hospitalizations) due to RSV [96,97] arguing strongly in favour of 
the protective effect of RSV antibody. Rather counter intuitively, this RSV-specific 
immunoglobulin provides no protection when administered during acute infection [52]. 
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RSV is primarily a mucosal virus thus immunoglobulin A (IgA) is also likely to be 
important for protection. A study of RSV-specific IgA in community dwelling elderly 
persons, those with congestive heart failure and chronic pulmonary disease, and healthy 
young adults (19-40 years) with respiratory illness found that low RSV specific nasal IgA 
was an independent significant risk factor for RSV infection [98]. Similar findings were 
reported from the studies by Mills et al [99] and Watt et al [100] which involved the 
experimental challenge of healthy adults. Mills et al found that high titers of nasal antibody 
were correlated with lower titres of virus shed and with resistance to illness. Nasal 
neutralizing antibody was also found to be a better correlate for protection than serum 
neutralizing antibody. In yet another study [101], the presence of IgA was to some extent 
correlated with resistance to re-infection though this finding was not consistent in all 
instances. Seemingly from these findings IgA levels are an important protective factor. 
As is the case with maternal acquired antibody, the presence of antibodies in individuals 
who have had a previous infection in general does not seem to be protective against 
infection, although the risk of re-infection has been associated with the number of previous 
infections and level of pre-existing antibody [12,20,101]. Systemic neutralizing antibodies 
(to F and G) are produced in increasing concentrations in response to annual infections of 
the same or different strains in young children [102] with serologic surveys showing that 
levels of neutralizing antibodies increase with age [89,103]. Several studies show an 
association between increasing levels of humoral antibody and increasing protection from 
re-infection [12,20,101] and/or disease following re-infection [12,44]. Two of these 
studies used microneutralization assays on serum samples while the other used an RSV 
specific IgG ELISA on saliva samples [20]. The study by Hall et al was an adult challenge 
study with 15 subjects repeatedly challenged. The other studies were of children followed 
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up from birth [12] and school children [20] both with larger sample sizes; 123 and 121 
children respectively. These data in addition to the observation that infection rates decrease 
with age [44] provide evidence that serum antibody appears to offer some protection 
against disease and or infection albeit never completely. One study [104] was able to define 
a minimum protective threshold against RSV-associated-hospitalization. Evidence from 
this study suggests that neutralizing antibodies of >_ 6.0 log 2 (arithmetic titer of 64) and > 
8.0 109 2 (arithmetic titer of 256) to RSV A and B respectively are protective against RSV- 
associated-hospitalization; levels that were achieved by majority of older children and 
adults by natural RSV infection. 
Another finding of interest is the observation that the serum antibody responses are closely 
linked to the genotype causing the infection [105,106]. Due to the antigenic diversity it 
may be that if the immune response is group specific, infection by one group could occur 
despite the presence of neutralizing antibodies specific to another group [107,108]. This 
then may explain general re-infection, re-infections in infants with maternal antibody and 
the yearly variation seen in the dominant genotypes isolated. The issue of cross immunity 
has not been comprehensively explored and forms the basis of the current RSV birth 
cohort. 
2.3.1 Viral characteristics that permit re-infection 
The seasonal shift in the dominant subgroup (or group) suggests that antigenic variation 
may play a role in the ability of RSV to escape the immune response and establish re- 
infections. Mufson et al [81,109] assessed the group characteristics of the viruses which 
caused re-infections in 13 children. Of the 10 children with initial group A virus infections, 
6 had group B viruses and 4 had group A viruses upon re-infection representing more group 
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B virus infections than would otherwise have been expected by chance, given the ratio of 
circulating groups during the study. The conclusion proposed is that an initial infection 
with a group A virus provided some degree of protection against re-infection by group A 
viruses. This conclusion is undermined by the fact that Group B was the dominant variant 
during the period of reinfections. Waris et al [44] observed that children older than 6 
months during their first RSV infection were more resistant to homologous than 
heterologous group re-infections. A recent study by Scott et al [110], using samples 
collected within the main birth cohort project, identified 12 cases of re-infections. Out of 
the 12,6 infants were infected in two consecutive epidemics. 4 were infected with RSV-A 
in the first epidemic followed by RSV-B in the second epidemic while the 2 others were 
infected with RSV-A during both epidemics. The RSV-A for these 2 infections had no 
significant G gene sequence variability between samples. A similar result was documented 
by Hall et al who showed that re-infections (that are very close in time) could occur by 
repeated exposure to the same viral isolate, so that antigenic variation was not strictly 
required to allow re-infections [101]. Two other infants in the Kilifi study were infected 
and subsequently re-infected with different RSV-A strains during the same epidemic. In the 
remaining 4 cases viral persistence was suspected, although re-infection with the same 
variant could not be ruled out. Data from this study suggests that after primary infection, 
some infants lose strain-specific immunity within a period of 7-9 months (i. e. between 
epidemics), while others lose group specific immunity and become infected with the same 
group (different variant) within 2-4 months (i. e. within an epidemic). 
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2.4 Infection and re-infection 
To date, numerous studies have been carried out [4-9,11,27] and the literature is replete 
with evidence to indicate that RSV is a major cause of serious life threatening disease of the 
lower respiratory tract during early life. 
i) Infection in children 
In general approximately 50% of children contract their first RSV infection during their 
first year of life and by the time they are three years old the majority of children have 
experienced at least one RSV infection [12,90,111]. A summary of some reported 
infection rates in children is given in Table 2.3. Though relatively uncommon in the first 
month of life, a study carried out in Chile [112] reported that 28% percent of the cases 
observed were in children who were less than 1 month old and infection is frequently very 
severe if it occurs at this age [94,113]. 
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Table 2.3. RSV infection by age in young children from studies in developed and 
developing countries 
Location (Reference) Age of children Risk of infection (proportion with 
evidence of infection) 
Virus isolation Serology 
Kilifi [5] 0-11 months 39%# 
US [191 2 month- 3 years 98%* 
75%$ 
65%& 
Houston, Texas 0-11 months 68% 
[12] 13-24 months 82.6 °` 
Sweden 0-18 months 87% 
[114] 0-3 years 100% 
Tecumseh, Michigan <1 years 14% 17% 
[115] 1-2 years 17% 
1-1 3-4 years 2b"/0 
1-4 years 17% 
Chile [112] 0-5 months 46% 
6-11 months 35% 
12-33 months 25% 
* first 'second and 'third infections 
# 9% re-infections 
a rate /100 cy 
ii) Symptomatic versus asymptomatic infection 
RSV infection is apparently rarely asymptomatic in primary infection or infection in the 
first year of life and results in disease in young children with a wide spectrum of symptoms 
[18,55,101,116,117]. Evidence from several studies show that RSV infection in older 
children and adults is associated with mostly mild illness [15,16,57,58,101,118,119]} 
though may sometimes be asymptomatic [101,120]. In some cases it has been shown to be 
associated with a moderately severe or severe illness [101,121,122]. Several adult 
challenge studies have been carried out (Table 2.4). The adult multiple challenge study by 
Hall et al [101] reported a decline in symptomatic infections with each subsequent 
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challenge; 85% of the infected subjects developed symptomatic infection on first challenge 
compared to >_50% of infections in the subsequent challenges being asymptomatic. 
Contradicting this are the results from the family study by Hall et al [15] in which they 
reported little difference in the type of illness or frequency of symptoms according to age. 
This may be related to the infecting dose known to be higher within the household setting 
[123] possibly resulting in more cases of symptomatic infection although it may also 
probably be a factor of the sample size. In this study there were no cases warranting 
hospitalization. Cases warranting hospitalization would be more likely to be in the 
primary/youngest individuals. However, studies of nosocomial infection (also presumably 
constituting higher infecting dose) have shown that 86% of infected adults will have a 
symptomatic infection and in some cases may be protracted [122,124]. 
Findings from another adult challenge study corroborate this hypothesis of dose-dependent 
severity. Even though extensive infection occurred at both low and high dose levels (500 
and 100,000 pfu), it was observed that illness only occurred following administration of the 
high dose of virus [99]. Illness was observed at levels of viral excretion less than or equal to 
those observed in the low dose study suggesting that the temporal pattern of viral 
replication is an important determinant of illness. It was suggested that illness seemed to be 
associated with a particular pattern of virus multiplication (rapid production of moderate 
amount of virus at high dose versus delayed replication observed at the low dose but 
ultimately resulting in greater total amount of virus). This rapid production therefore seems 
more effective at inducing illness. 
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Table 2.4. Adult challenge studies showing infection and illness rates after RSV infection 
Study Population Presence of antibody 
before Infection 
Infections Illness 
[58] 41 adult males Neutralizing antibody 33 20 
volunteers pre-challenge 
[99] 16 adult males low Neutralizing and 16 0 
dose 500pfu secretory antibody pre- 
challenge 
17 adult males Neutralizing and 9 5 
high dose secretory antibody pre- 
100000pfu challenge 
[101] 15 adults 1)Natural infection 15 15 
repeatedly 
challenged after 2)Challenged at most 6 15 51% of total 
natural infection times challenge 
infections 
This issue of symptomatic versus asymptomatic infections is important insofar as it 
suggests that surveillance based on clinical signs only may not be effective at identifying 
most and/or all cases of infection; an issue that is potentially critical in this study. Viral- 
specific antibodies in blood or saliva can thus provide information on the infection status of 
the host in the absence of clinical illness, and are particularly of use in support of clinical 
surveillance information and will be used to compliment clinical surveillance. 
2.5. Severity of RSV infection in children 
The risk of developing lower respiratory tract disease (LRTD) following primary infection 
is between 25- 40% [12,18,19,55,96]. This risk has been shown to be age related in most 
hospitalization studies [37]. Evidence for declining risk of disease has also been shown in 
community studies. Data from the community study in US by Glezen et al [ 12] showed a 
decline in risk from infants upwards; 22.4/100 child-years to 7.7/100 child-years in children 
37-48 months. The published data from Kilifi [5] showed no significant age-related 
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variation in risk in the first year of life, but more recent data (unpublished, DJ Nokes) 
suggests highest risk in infants (particularly children aged 3-5m) declining into the second 
and third year of life. This decline in disease rates in primary infection with increasing age 
is most probably a reflection of increased airway size of the infant but may also reflect 
increased immunocompetence. Disease burden estimates from different studies are covered 
in detail below. 
Community versus Hospital infections: Incidence data from Developing Countries 
Data from community studies are relatively scarce. The majority of the information is from 
hospitalised children. There is little that can be inferred about what is actually happening in 
the community as studies performed on admitted children, whose selection is based on 
severity, only represent a partial view of the impact of RSV in the community. 
The BOSTID studies reviewed the role of viruses in causing ALRI in developing countries 
[27]; 70% of the ALRI were attributable to viruses and RSV was found to be the major 
cause in children less than 5 years of age. Few studies since then have attempted to 
quantify the incidence of RSV-LRTI in developing countries. These studies are not exactly 
comparable because of several reasons; different populations studied (hospital (Table 2.5) 
vs. community (Table 2.6)), differing study designs and surveillance methods used (column 
3 and 4) as well as the definition of LRTI employed by each study (not included in table). 
From these studies the incidence of RSV-associated LRI is quite variable and ranges 
between 8/1000 cyo - 220/1000 cyo. Other factors that might contribute in part to this 
variation include the frequency of sampling, reason for sampling (i. e. whether or not 
clinical symptoms had to be present), the type of samples collected (Nasopharyngeal 
aspirate vs. nasal wash or swab) and the method of determining that an infection had 
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occurred. Laboratory diagnosis on the basis of immunofluorescent antibody test alone, the 
favoured method of RSV diagnosis in children [125], is still not as sensitive as that by 
assay combinations (serology and immunoflourescence) or molecular methods (PCR) [5], 
although is more sensitive than older methods such as the complement fixation text and 
some enzyme imunoassays [28]. Some of these influencing factors have been included in 
the Tables and are also important practical considerations in the intended study (Chapter 3). 
Studies adopting similar designs report relatively similar rates [5,6,11]. The reported rates 
from the studies in Kilifi and Columbia were arguably on the higher side possibly due to 
the short duration of studies in addition to the method of surveillance employed 
(combination of active and passive). 
More recently as a result of a WHO initiative to generate more evidence on the role of RSV 
in causing LRTI, 4 studies arising out of (but not adhering to) the same generic protocol 
were undertaken [11,117]. From these studies the incidence of RSV-LRI in children <5 
years was 34/1000 in Indonesia and 94/1000 in Nigeria while the incidence of severe RSV- 
LRI per 1000 child years was 5 in Mozambique, 10 in Indonesia and 9 in South Africa with 
majority of RSV cases occurring in infants. It seems decidedly necessary to generate such 
epidemiological data prior to starting any immunization programmes. Moreover, it would 
be important to compare incidence data from Kenya to that generated from other countries, 
both developed and developing, to identify similarities and any potential differences that 
may require further investigation. 
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It seems probable that socio-economic or cultural risk factors for infection/disease differing 
between communities may contribute in part to some of the differences observed, a subject 
that is explored in the current study. Although the findings from these studies are variable 
and to the greater extent underestimates (i. e. do not capture all cases of disease), these 
results make a substantial case for a significant burden of RSV-LRI. Some studies in the 
developed world [12,13] have reported rates similar to those discussed above. 
Incidence rates of RSV-LRI in the Developed World 
The rates of severe illness among children <1 year in developing countries [11] are 
comparable to the reported hospitalisation rates in developed countries (Table 2.7). The 
incidence of RSV-associated lower respiratory tract infection in developed countries varies 
from 3 tol2 per 100 children in the first year of life [113]. Two community studies have 
reported incidence rates similar to those detailed in Table 2.6. A birth cohort study of low 
income families in the US reported an incidence rate of 224/1000 child years in infants [12] 
similar to reports from Kenya and Columbia. The second study of out patient presentations 
of LRTI in infants reported an incidence of 44/1000 cy [13] similar to reported rates from 
OP surveillance in Mozambique [11] and Columbia [7]. The majority of these RSV 
associated lower respiratory tract diseases occur in infants younger than 12 months of age 
with the most severe cases occurring in infants younger than 6 months of age with a peak 
incidence between the age of 2 and 6 months [90,94,113,128]. 
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Table 2.7. Incidence rates of hospitalization for RSV among children < lyear in studies 
from industrialized countries 
Location, Reference Surveillance Specimen details, RSV incidence/ 
diagnostic tests 1000 cy 
United States [12] Longitudinal follow up NW at ARI culture 16 
of birth cohort Serum 
Microneutralization 
assay 
Austria [129] Population-based 
retrospective review of 
admission over 1 year 
NPA IFAT 6 
England [130] IP admissions-primary 
and nosocomial 
infection of city 
children 
Germany [131] Hospitalized children 
with ARTI 
United States [13] OP clinic 
Norway [132] Hospital admissions 
with ARI 
NPA, cough and nasal 20 
swabs IFAT and 
culture 
NPA Multiplex RT- 12 
PCR 
NW Culture 8 
NP sample Rapid IF 10 
and culture 
Switzerland Hospital admissions NW DIA, indirect 5 
[133] ELISA confirmed by 
culture 
NPA-Nasopharyngeal aspirate 
RT-PCR Reverse Transcriptase Polymerase Chain Reaction 
*Children <2 years 
2.6 Re-infection 
These data presented above highlight the substantial burden caused by RSV disease in 
young children resulting mainly from primary infection. RSV is also known to re-infect 
repeatedly throughout life. Appreciable attack rates in older age groups was suggested by 
Berglund [50] and later documented in the Seattle and Tecumseh studies [16,134]. In the 
family study conducted after these by Hall et al [15], substantial attack rates were seen in 
all age groups; 16.8% in adults compared to 29.4% in infants. Results from this study 
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showed that age was not a primary factor in determining the attack rate (infection rates 
were substantial in all ages groups). Following these studies, two other studies involving 
young children also documented significant re-infection rates in children [12,19]. 
Subsequently, Hall et al in repeat challenge studies in adults documented the frequent and 
potential ease of repetitive infection even with the same viral strain [101]; 73% of adults in 
this study were re-infected two times or more after a natural infection. More recently, 
several studies (reviewed below) have shown RSV to be an important cause of respiratory 
tract infection in adults and especially in the elderly [135,136]. A summary of reported re- 
infection rates is given in Table 2.8. 
The majority of these studies used serological testing to define infection rates and was 
carried out in developed countries. Mild illness in adults and older children indeed point to 
the potential benefit of a combination of methods; antigen positive and serology for the 
identification of infection in this population. Diagnosis of RSV during acute infection in 
adults is difficult because of the poor sensitivity of viral culture and antigen detection. 
Thus, a combination of diagnostic methods including molecular based techniques would 
enhance the diagnostic yield and provide a more accurate picture of the epidemiology of 
RSV in the present study. 
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These findings suggest that re-infection is common although disease is reduced (discussed 
below) indicating that natural immunity is incomplete. Factors that may contribute to the 
occurrence of re-infections include the time interval between infections or viral challenge 
[101], antigenic variation of the virus (covered in detail in section 2.3.1), age and serum 
neutralizing antibody response of the host (section 2.3) as well as the duration of acquired 
immunity. The frequency of RSV re-infection throughout life seems to indicate that a large 
susceptible proportion is consistently available. It seems probable, given the epidemic 
pattern observed, that once infected individuals have some immunity resulting in the 
depletion of these susceptible individuals. This acquired immunity is then lost relatively 
quickly allowing the virus to invade the population resulting in another epidemic. These re- 
infections in older individuals may be the primary source of serious infections in infants 
and young children. Indeed some studies have shown a link between school children and 
introduction of infection into the home [15,55,117,128,139]. This contribution of re- 
infections in older children and adults in the developing world and to the observed pattern 
has not been evaluated. The household study presented here was therefore carried out with 
the aim of describing community re-infection patterns and illuminating the possibility of 
viral persistence in the off-season using regular oral-fluid sampling (see chapter 4). 
Infection in Adults 
In contrast to studies in children, few studies have looked at RSV infections in adults. RSV 
infection in adults, though previously recognized, has largely been overlooked because of 
the significance of RSV in children. In adults the rate of infections (re-infection) is about 
5% per epidemic [16,134]. Studies carried out in the United Kingdom and in the United 
States, have reported incidences of increased antibody titre to RSV of between 17 and 19 % 
in older individuals during an epidemic [16,20]. In other studies involving surveys of 
40 
serum from adults, it has been shown that 33-99% of individuals possessed compliment- 
fixing antibody (marker of present or recent past infection) for RSV [140,141]. Recent 
findings from a study by Hall et al [65] in the adult population suggests that RSV re- 
infection in healthy working adults is an under-recognized cause of morbidity. Healthy 
subjects 18 to 60 years of age were evaluated for respiratory virus infection over a 20 year 
period through a surveillance program. 7% of total number of subjects studied experienced 
an acute RSV infection. The infections were symptomatic in 84% of subjects, involved 
only the upper respiratory tract in 74%, and included lower respiratory tract symptoms in 
26%. A similar community-based observational study from the UK whose focus was also 
on the burden of RSV disease in healthy, working adults [142] also found a significant 
burden of RSV infection in adults. Individuals presenting with an influenza-like illness 
between 1995 -1998 were evaluated. RSV was isolated from 20% of patients 
between 15 to 
44 years of age. These findings show that the health care burden imposed by RSV on 
healthy working adults is not negligible and that quite substantial proportions are 
symptomatic. As noted, all these studies have been in the developed countries and as yet 
there is no data from developing countries on the role of RSV in older members of 
populations. This study will aim to quantify the community rates of re-infection in older 
children and adults. It would be expected that nearly similar rates of infection as discussed 
above would be observed in the Kilifi population; also classified as generally healthy. 
2.7 Household Studies 
Family studies also provide an ideal opportunity to study RSV re-infections in older age 
groups. Family studies conducted by Fox et al [143] showed that illnesses with a 
respiratory component comprised 78% of the total sickness observed. RSV infection has 
since been shown to spread within families with a substantial proportion of children as well 
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as adult family members contracting infection [15]. In this prospective study, siblings were 
found to be the most common primary case in the family setting [15]. Approximately 40% 
of all family members over one year of age were infected. This family occurrence seems to 
be one of the epidemiological characteristics of RSV infection [15,50] since it requires 
close contact for spread implying that social situations existing in home and school settings 
are important for transmission. Indeed respiratory infections are often carried home by a 
school-age child and passed onto a younger child, especially an infant [15,16,128,144]. 
Despite the potential importance for transmission and disease, little is known about the 
occurrence of RSV infections in families and about intra-familial spread of those infections 
(Table 2.9). No such studies have been carried out in the recent past. 
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In the Tecumseh sero-epidemiological study, a serological response to RSV was seen most 
often in school children aged 5-9 years old [16]. 20% of them were infected during each 
yearly epidemic. The rate of re-infection was observed to fall rapidly with increasing age 
during childhood and then more slowly among adults (Table 2.9). Contrary to the 
observation by Hall et al [15], in this study differences in the spread of RSV within 
different families were noticed. As the number of members in the family increased from 
three to six people, there was an increase in the proportion of families in which RSV 
infected one or more individuals; 5.5% in families with 3 members vs. 16.3% in families 
with six members. This is most likely due to the additional opportunity for introduction of 
the virus with increasing family size. Larger families also experienced more multiple 
infections once the virus was introduced. As was the case in the Rochester study [15], data 
from this study supported the idea that it is the school-aged child who more often than not 
introduces the infection into the family unit. Infection and illness rates were also found to 
be higher in mothers than fathers as presumably the mothers had more intimate contact with 
the children than did the fathers [50]. A similar observation (increased number of ARI 
episodes in mothers) was seen in the Cleveland family studies [145]. This observation 
seems to suggest that virus dosage and exposure time may play a part in the development of 
RSV infection in adults. All these studies have been carried out in developed countries, 
countries whose social structures are different to those in developing countries. Thus the 
current study provides an ideal opportunity to examine infection within families and 
generate information on infection in the community in rural Africa. 
2.8 Risk factors for ARI and ALRI 
Comparative studies have shown that while the incidence of ARI in developed and 
developing countries does not differ markedly [16,115,146-152], the case fatality rates in 
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children <5 years is 5-10 times higher in developing as compared to industrialized 
countries [153]. The excess mortality rates from ARI in the developing world suggest that 
several risk factors may be responsible. If these risk factors in developing countries 
predisposing children to severe disease after initial infection can be identified and 
prevented, much of this mortality burden due to AR! can be prevented in developing 
countries as well. 
Factors that increase the risk of acquiring disease 
It is known that certain risk factors increase the likelihood of a young child or infant 
acquiring a respiratory infection consequently increasing the risk of severe respiratory 
disease. These risk factors for ALRI can be categorized into (i) those which act at the 
individual level which are child specific and include birth factors (birth weight, gestational 
age), breastfeeding status, nutritional status and some immune factors (antibody levels, 
infection history) and (ii) those at the household level which include parental characteristics 
(education, age), household size and income, crowding and indoor air pollution [154]. A 
summary of risk factors for ARI and ALRI as described in the literature is presented (Table 
2.10). 
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Table 2.10. Factors associated with ARI and ALRTI: summary of findings form various 
studies 
Factor Findings and comments Reference 
Household 
characteristics 
Household 
income level 
Parental 
characteristics 
a) Maternal 
Education 
Association between a low level family income [115,146-1481 
and ARI in developed countries. 
Similar relationship from studies in developing [155,156] 
countries 
Higher income level is usually associated with 
better general health, less crowding index 
Conflicting results - no clear established 
relationship. 
Low parental literacy was a significant risk [157] 
factor for ALRI 
Mother's education was also inversely and [155,1581 
linearly associated with ALRI mortality 
Maternal education was not associated with [27,156,159] 
ALRI mortality or with the incidence of ARI or 
ALRI 
b) Maternal age Differing results on maternal age as a RF 
Association between maternal age and ALRI [155,156] 
mortality 
No consistent association observed between [271 
maternal age and incidence of ARI or ALRI 
Crowding and Crowding generally enhances the spread of 
Family Size respiratory agents 
Increased incidence of ARI with crowding in [156,157,160-162] 
studies done in both developed and developing 
countries 
The presence of acute respiratory tract disease [163] 
in other household members was a significant 
risk factor for acute lower respiratory tract 
infection in children OR 5.6 (IP) and 5.2 (OP). 
Smoking Various studies have consistently shown an [155,156,164,165] 
increase in the risk of ARI with smoking 
Indoor Air In developing countries, pollution of the indoor 
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pollution air from biomass fuel is quite high 
Conflicting results [166] 
Several studies from developing countries have [163,166-169] 
shown associations of ALRI with indoor air 
pollution in the crude analysis other studies 
have found no association 
Few studies have adjusted for confounders- [170-172] 
Increased risk in children in developing [164,173]. 
countries who were carried on their mother's 
back during cooking 
Child Level 
factors 
Malnutrition PEM has consistently been reported as a 
determinant of ALRI and ALRI mortality from 
studies conducted in several countries 
Strong association between moderate/severe 
protein energy malnutrition (PEM) and 
incidence of Pneumonia 
Linear association between weight-for-age z- 
scores and/ or weight-for-height and height-for- 
age and ALRI and/or ALRI mortality 
Breastfeeding Studies have generally shown a protective role 
of breast feeding against infection 
Significant association, increased rates of 
pneumonia/ALRI and lack of breastfeeding 
Breast feeding was shown to provide some 
protection for pneumonia and/or ALRI 
mortality 
[7,174,1751 
[27,155-157,159, 
168,176,1771 
[1781 
[175,179] 
[180,181] 
No protective effect of breast feeding against [156] 
ALRI mortality 
Breastfeeding has for many years been 
recommended as being good for child health. 
Established Increasing age, female sex, birth weight over [160,161,175,179] 
determinants 2,500 grams, and immunization against 
childhood disease (like measles, Hib) are 
factors that are known to be protective against 
ARI and ALRI 
PEM -Protein energy malnutrition; RF- Risk factor 
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The observed difference in the effect of various risk factors may be a reflection of the 
differing study designs (case-control or cohort) and populations studied (hospitalized cases 
vs. milder community infection) and differences in the methods of analysis used- some 
studies adjusting for potential confounding [163,164,166,172,173] whilst others 
reporting crude estimates. Moreover, some of the studies reported had a retrospective data 
collection design and were thus susceptible to the usual methodological limitations of such 
studies (for example recall bias). Recall accuracy declines as the level of detail requested 
increases. Nonetheless, there is evidence from various studies supporting the effect of 
different factors; socio-economic classification, crowding, malnutrition and exposure to 
smoke. PEM has consistently been reported as a determinant of ALRI and ALRI mortality 
from studies conducted in several countries over the past two decades. This underlines the 
importance of considering this variable as a potential confounder in any evaluation of ALRI 
and potential risk factors. There are several interventions some as simple as breastfeeding 
that potentially alleviate malnutrition as a risk factor. Data on established determinants such 
as increasing age, female sex, birth weight over 2,500 grams, and immunization are 
individual factors that are known to be protective of ARI and ALRI [160,161,175,179] 
and need to be included in ALRI risk factor studies to adjust for them in the analysis. 
There is limited data on the prevalence of concurrent infections in cases of LRTI and their 
potential effects on the disease manifestation. A study of co-morbidity in childhood in 
Africa [182], found significant co-occurrence of infection in the community and evidence 
of co-occurrence of diarrhoeal diseases and pneumonia, with greater co-morbidity with 
increasing severity of disease. However, there was no evidence of a synergistic effect on 
mortality risk. There is potential in such cases for overlap between risk factors for the 
different infections or it may be that one infection predisposes or results in increased risk of 
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the other infection e. g. with Malaria which is thought to suppress host resistance to viral// 
bacterial pathogens [182]. Still it is possible that this observed co-morbidity may be 
artefactual; in malaria endemic areas, the potential for an over-estimation of LRTI cases 
exists since the symptoms of LRTI can be consistent with malaria diagnosis [11,183]. In 
the Kilifi study [5], 5% of children with LRTI also had malaria parasitaemia. No difference 
was observed in the occurrence of sLRTI or ARI mortality in an intervention trial in 
Gambia in two groups of young children one of which received malaria treatment [184]. In 
addition, viral pneumonia aetiology studies report the presence of more than one virus in a 
fraction of the cases with one study showing increased disease severity in cases of dual 
viral infection. Studies are indicated in developing countries to further investigate the 
prevalence of dual infections. 
Risk factor for RSV Infection and Disease 
Although risk factors for RSV infection and disease in developing countries are not well 
defined, differences in disease estimates (section 2.5) compiled from various localities [5, 
6,11,176] point to the possibility of some underlying differences in risk factors. This 
creates a need to understand the underlying risk factor dynamics in these regions and 
thereby possibly explain the differences in observed estimates. Table 2.12 provides data 
from a number of studies mostly from developed countries. 
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Table 2.11. Factors associated with RSV infection and disease: summary of findings form 
various studies 
Factor Findings and comments Reference 
Gender Boys suffer more severe disease than girls - [94,116,131,133, 
Boys have shorter and narrower airways and 185-188] 
therefore are more likely to have development 
of bronchial obstruction upon RSV infection 
An analysis of representative studies by Simoes [189] 
found that the risk ratio of boys to girls was 
1.425: 1 (95% Cl: 1.40,1.45; range, 1.2 to 
1.7: 1). 
Gestation/ Birth Independent association of gestational age and [186] 
weight birth weight and risk of RSV hospitalisation - 
more disease occurring in premature (i. e. low 
birth weight) babies. 
Birth month and Several studies show association between birth [94,113,186,190] 
Age month and risk of RSV-LRTI and RSV 
hospitalisation 
Probably to do with presence of Maternal Ab 
i. e. births occurring 2-4 months before an 
epidemic are likely to be infected when MatAb 
are decayed but they are still very young. 
Several studies have reported a relationship [94,132,133,185, 
between age and infection with most disease 186,191-1931 
occurring in infancy 
i) Most disease occurs in the first few [94,189] 
months of life so birth during the first 
half of the RSV season would be an 
obvious risk factor 
ii) Also a reflection of the maternal 
antibody levels i. e. children born in the 
first half are born to mothers without 
recent infection history thus have lower 
antibody levels 
Breastfeeding Contradictory results reported as far as breast [188,191,194,195] 
feeding is concerned with some studies [189,191] 
showing protection and some not 
The biological processes proposed for [189] 
protection included: 
i) Colostrum, which contains both anti- 
RSV IgA87 and lactoferrin, may have 
an important antiviral property. 
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ii) ii) Breast milk promotes lung 
maturation, perhaps through prolactin 
Crowding and Most of the evidence seems to show that 
siblings crowding is a risk factor. 
RF for hospital admission - cases came from [194] 
larger more crowded compounds and the risk 
was greater depending on the number of kids 
between 3-5 years in the homestead 
Significant effect of the number of persons [113] 
sharing a bedroom 
Living with siblings in school was a significant [190,196] 
risk for RSV hospitalization in infants. 
Having 4 or more children under the age of 12 [191] 
in the household was a significant risk factor 
for RSV hospitalization. 
Older siblings identified to be the most likely to [15] 
introduce the virus into the family. 
Significant association between respiratory [144] 
infections in infants and having at least one 
sibling especially if they were school age 
siblings. 
Presence of siblings in the family was found to [197) 
double the risk of hospitalization 
Presence of siblings up to 5yrs older than the [186]. 
case was a significant independent risk factor. 
No effect with the presence of more than one 
older sibling or of siblings more than 5 years 
older than the case and also with crowding 
(m2/resident) 
Lower rates of infection in infants without [144] 
siblings and significantly fewer kids in [198] 
households of controls. 
Crowding is probably related to higher viral 
innoculum through interpersonal contact as well 
as to the increased probability of contact with 
an infectious person in a crowded environment 
Maternal Observed a positive correlation between [94] 
_Antibody protection against 
infection and level of 
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antibody 
Mean titer of IgG higher in mothers whose [93] 
children were uninfected 
Increased risk RSV-LRI in first year of life [113] 
associated with low cord serum antibody. 
No association between the level of maternal [1911 
neutralizing antibody and the risk of 
hospitalization 
Study of patients <1 yr (i. e. first infection) [198] 
found no protective effect of either detectable 
IgG or neutralizing antibody to two major 
groups of RSV 
Case control study showed relationship between [199] 
high Mat Ab and reduced risk of RSV disease 
Results from these studies are inconclusive. 
Malnutrition Interestingly, several studies have found no [45,116,188,200- 
association or negative association between 202] 
malnutrition and RSV LRTI. 
It has been suggested that malnourished [189] 
children do not mount an exuberant immune 
response to RSV thus inadvertently protecting 
them from severe disease. 
Smoking and Conflicting reports on the effect of smoke 
Environmental exposure 
Smoke 
Smoking during pregnancy was found to be an [186] 
independent risk factor for hospitalization 
Significant relationship between RSV and [144] 
smoking mothers at home 
No appreciable differences observed in [15] 
smoking patterns in households in which cases 
of RSV occurred compared to those without 
cases of RSV infection. 
Controls were more likely to have been exposed [194] 
to cooking smoke. 
Mode of action of smoke exposure unclear; is it 
increased risk of infection or is it an increase in 
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severity once infected. 
Co-infection Evidence in the RSV literature for effect of co- 
infections is scarce. 
Malaria 
Mechanisms for positive and negative 
associations between malaria and RSV exist. 
Malaria infection was supressed in children [203] 
infected with other viruses 
2.3% of RSV cases in Kilifi (malaria endemic [5] 
area) had concurrent malaria 
Placental malaria was associated with reduced [2041 
transplacental transfer of RSV specific 
antibodies, potentially predisposing infants to 
earlier and more severe RSV. 
In Mozambique, a study of paediatric IP found [205] 
a significant negative association between RSV 
associated LRTI and falciparum malaria- 
possible false association as the prevalence of 
parasitaemia in RSV cases was similar to that 
observed in community 
HIV 
There is little data available on the association 
between HIV status and RSV infection/disease. 
In paediatric admission with RSV positive [2061 
sLRTI, mortality was higher (7.6 vs. 1.7%) and 
the prevalence of bacteraemia increased (15% 
vs. 3%), in HIV infected (HIV+) relative to 
HIV uninfected (HIV-) individuals 
The burden of RSV in the HIV+ population was [41] 
observed to be significantly greater than in the 
HIV- population (14 vs. 3 cases sLRTU1000) 
although the prevalence of RSV was lower in 
HIV+ compared to HIV- cases (in contrast to 
the relationship with bacterial pathogens. 
No association between HIV and RSV disease [201] 
severity was identified in admissions <2 years 
old with LRTI. The population prevalence of 
HIV was low and majority (87%) of cases were 
non-severe LRTI which may explain the 
observed difference with previous study above. 
Other viruses 
It appears that the epidemic behaviour of RSV [9] 
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can also be modified by interaction with other 
viruses 
Dual infection with hMPV and hRSV confers a [207] 
10-fold increase in relative risk (RR) of 
admission to a pediatric intensive-care unit for 
mechanical ventilation 
High risk groups Studies in developed countries have identified 
several high risk groups in relation to RSV 
infection and hospitalization. 
Increased risk of severe RSV infection and [185,191,192,197] 
increased hospitalization in premature children, 
in children with CLD and CHD and history of 
BPD 
Mothers of cases were more likely to be [194] 
asthmatic. 
CLD - Congenital Lung Disease, CHD- Congenital Heart Disease, BPD- Brocho- 
pulmonary disorder 
Generally from these studies the main factors associated with increased risk of RSV disease 
or RSV hospitalization seem to be: primary infection at a young age, infection in children 
with underlying predisposing risk factors such as prematurity (presumably because of 
absence of maternal antibody), and cardio-pulmonary disease, male gender. Some 
environmental and social factors such as crowding, exposure to smoke or socio-economic 
classification have also been reported to increase the risk of acquiring disease. 
Interestingly, unlike what is reported for ARI/ ALRTI several studies have reported no 
association or negative association between malnutrition and incidence of RSV disease 
[200,208]. A negative association between RSV infection and malnutrition in children 
admitted with LRTI was observed in Mozambique [205], Indonesia [8], Nigeria [202], and 
Mexico [209]. A comprehensive review of the strength of evidence (mainly from developed 
countries) on risk factors for RSV-LRTI was done by Simoes [189]. The risk factors 
identified include: the male sex, age <6 months, birth during the first half of the RSV 
season, crowding/siblings and daycare exposure. The evidence for tobacco exposure was 
mixed while low maternal education (proxy for SES), lack of breast-feeding, and 
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malnutrition did not appear to increase the risk of severe RSV LRI. Few risk factor studies 
for RSV have been carried out in developing countries [126,194,200,202] providing an 
ideal opportunity with this study to add to the body of knowledge. Furthermore, from the 
literature, risk factors for infection and disease are not differentiated thus there exists some 
confusion between the two. However, it is possible that the risk factors for infection and 
disease may well be quite distinct and this has not been assessed. The birth cohort provides 
a unique frame work for the comparison of risk factors for mild infection and disease as 
well as comparing risk factors for non-specific LRTI with those of RSV-LRTI. It has been 
shown that differences may exist (e. g. malnutrition) in the risk factors associated with the 
two outcomes. An attempt was therefore made in the present study to determine risk factors 
for clinical infection, RSV disease and compare these with those identified for non-specific 
LRTI (Chapter 8 and 9). 
2.9 Potential use of Oral Fluid to determine infection rates 
Antibodies in blood are useful as specific markers of immunity and past infection for 
various infections. Serological studies therefore have the potential to identify infections 
whether asymptomatic or symptomatic. However, it is not always feasible or desirable to 
collect blood samples by which to determine specific antibody status or titre. Less invasive 
biological samples for the detection of antibodies would and indeed have proved invaluable 
[210-218) in exploration of current infection (IgM, rising titre of IgG or seroconversion) or 
past infection and immunity (IgG). Anti-viral immunoglobulin M (IgM) is usually used as 
an indicator of recent infection [219,220]. The presence of virus-specific immunoglobulin 
G (IgG) antibodies provides evidence of passive maternally-transferred antibodies or a past 
or present acquired infection in some infections is indicative of immunity (e. g. measles, 
rubella, but not in RSV). 
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Over the last few years various techniques have been developed to identify anti-viral 
antibodies in other body fluids [215-217]. Oral fluid samples offer a minimally invasive 
alternative to serum collection for the detection of virus specific antibody to common 
infections. It can thus be used as a means of determining incidence estimates. However, in 
infant (especially in first 6 months) serological response following infection is not always 
detectable [88,90,221-223] hence it not advisable for use as the only method of incidence 
estimation and thus would be supplementary or in addition to clinical surveillance. The 
collection of an oral fluid sample is easy, safe and is acceptable to the general public [213, 
214]. 
Oral fluid is a mixture of several components. Most of antibody of diagnostic importance is 
present as a transudate from the capillary bed beneath the margin that separates the teeth 
and the gum known as the gingival crevice [224]. The antibody content of this crevicular 
fluid closely reflects the immunoglobulin class and specificities of the antibody found in 
plasma although saliva contains much lower concentrations of antibody than is found in 
blood [225] (Table 2.12). The concentration varies with the antibody component of the oral 
fluid sample tested which is determined by the way the sample is collected. The antibodies 
found in the crevicular fluid represent the composition of antibody in plasma including 
IgM, IgG and IgA class antibodies. Although the antibody concentrations fluctuate with the 
changing proportion of saliva and crevicular fluid [224], oral fluid is a good substitute for 
serum and can be used to determine recent, past or current infection. 
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Table 2.12. Mean immunoglobulin concentrations (mg/L) in different salivary components 
(adapted from Mortimer et al [225]) 
Antibody Component IgG IgM 
Plasma 14,730 1,280 
Parotid Saliva 0.36 0.43 
Crevicular Fluid 3,500 250 
Whole Saliva 14.4 2.1 
Because of the low and fluctuating levels of immunoglobulins in oral fluid, there is need for 
tests of high sensitivity, and which are standardized in some way against total specific- 
isotype level e. g. total IgG. Oral fluid assays are thus still less sensitive than serum assays. 
In spite of this, the advantages for the use of oral fluid clearly outweigh the disadvantages 
in circumstances where blood collection is undesirable e. g. outside the clinic setting. The 
process is minimally invasive, does not necessarily require professionally trained personnel, 
easy to use in children, and avoids needle stick injury and the inadvertent transmission of 
blood borne pathogens [212,213]. 
2.10 RSV infection in Kenya 
In Kenya, little information is available regarding the burden of RSV infection and disease. 
One study in Kenya in the 1980s, in the National Referral Hospital, revealed RSV to be the 
major viral pathogen accounting for approximately 20% of the hospitalised ARI cases 
[226]. To the researcher's knowledge no detailed surveillance of aetiology of ARI has been 
undertaken elsewhere in Kenya and no data is available on community level of 
transmission. In Kilifi district, prior to 2002, almost nothing was known about the 
importance of the RSV on population health, and at Kilifi District Hospital (KDH) little 
was known of the frequency of admissions of ARI due to RSV. From 2002 continuous 
surveillance was undertaken of RSV disease in child in-patients admitted with ARI to 
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KDH. The aim was to determine the burden of RSV disease in this patient population, the 
relationship of this disease to specific genotypes (variants of the virus), and the seasonal 
and spatial distribution of the cases in the community. 
Children admitted to KDH with a diagnosis of ARI can be grouped according to severity 
(based on WHO guidelines [227]), into non-pneumonia, and mild, severe and very severe 
pneumonia. As the vast majority of RSV disease occurs in children under the age of 5 years 
[12,19,186,228], sampling was restricted to children under 5 years, who were either 
admitted with severe or very severe pneumonia, or who on admission required treatment for 
LRTI. An additional inclusion criterion was children with a requirement for oxygen due to 
oximetry saturation reading <90% (hypoxia) as adopted in similar studies in The Gambia 
[116]. The graph below (Fig. 2.5) shows the outcome of surveillance at the KDH paediatric 
ward over four years between 2002 and 2005. 
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Figure 2.5. Kilifi District Hospital inpatient surveillance of RSV. 
On average, approximately 400 children <5 years old are admitted each month (Fig. 2.5 
black line), with about one third of these having an admission ARI diagnosis (square 
markers). Of these, approximately 80% were sampled (nasal washing or nasal pharyngeal 
aspiration) and tested for RSV using an immunofluorescent test (IFAT) (dotted line). Of 
samples tested, between 10-40 samples were RSV antigen positive during the epidemics. 
While RSV accounts for only 3% of all admissions, annually, RSV accounts for some 10% 
of all ARI. Furthermore this burden is highly seasonal, and the proportion of ARI due to 
RSV can be as high as 40% during epidemics. 
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Chapter Three 
Study Description 
3.1 Overview 
This chapter describes in detail the methodological approach adopted to collect field data in 
this study. The household study (results are presented in Chapters 5-7) was based on a 
cohort design and was nested within the RSV birth cohort. This entailed the intensive 
surveillance of a birth cohort of which there were two phases of recruitment staggered by 
one year (see Fig. 3.5 later). Household members of selected birth cohort children (those 
recruited in the second phase) were recruited into the household study and followed up over 
a period of two and a half years. The risk factor survey for LRTI and RSV-LRTI described 
in Chapter 8 was carried out within the main RSV birth cohort. These methods are 
described in the paper by Nokes et al [5]. 
3.1.1 Chapter Aims 
The main objective of the study was to describe RSV transmission dynamics within the 
household and in the community. Specifically, this chapter seeks to give a general 
description of the study area and of the population studied. Details of the study design 
specifically describing the relationship of the household study to the birth cohort are given. 
The mechanics of field work, the enrolment, ethical issues, sampling, implementation, 
surveillance procedures, quality control (reliability) and data handling are detailed. 
Laboratory methods employed in the study are summarized and discussed and comparisons 
made between the methods used in this study and other options. Finally, some general 
results (i. e. % response, dropouts, surveillance intensity) are given as well as a description 
of epidemics in the main cohort and in the household cohort. 
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3.2 Study area 
3.2.1 Geography 
The study area falls within Kilifi district, a rural location in Coast province of Kenya. 
Kenya spans the equator on the east coast of Africa between latitudes 5° north and 5° south. 
Kilifi district borders the Indian Ocean to the east, Mombasa to the south, Taita Taveta to 
the west and Malindi to the north (Figure 3.1. ). Kilifi district covers an area of 4,779 km2 
with a density of 114 persons/ km2. Kilifi town is home to some 36,000 residents out of a 
total district population of 544,303 people (1999 census) [229]. According to the Central 
Bureau of Statistics population projections, Kilifi district has a population of 679,499 in 
2007. The equivalent for Kilifi Township is about 45,000 people. The district population 
consists predominantly of farmers, 80% of whom depend primarily on agriculture [230]. 
According to the Central Bureau of Statistics report (2003), Kilifi District is one of the least 
developed districts in the country with 72% of its people living in absolute poverty as 
measured by the head count index (i. e. the proportion of the population whose economic 
welfare is less than the poverty line, Ksh 1239 and 2648 for rural and urban households 
respectively, this is the expenditure required to buy a food basket that allows minimum 
nutritional requirements set at 2250 calories per adult person). The head count index for 
Coast province within which Kilifi district falls is 61% [231]. The literacy level in this 
district is 63% (males 76.9% and females 35%), is lower than the national average of 78% 
[232]. 
The population growth rate of Kilifi Town is put at 3.05% with a birth rate of 49.2 per 
1000. The infant mortality rate for Kilifi District as reported by the Government is 85/1000 
with an <5 mortality rate of 141/1000 [230]. The immunization coverage in the 
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demographic surveillance system (DSS-discussed below) stands at between 85% and 96% 
by both child health card records and history [233]. 
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Figure 3.1. Map of Kenya showing the location of the study area (black) within Kilifi 
district (blue) set in Coast province (one of eight provinces in Kenya delimited by black 
lines). 
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3.2.2 Epidemiological-Demographic surveillance system (Epi-DSS) 
The study was carried out in an area that was under continuous demographic surveillance. 
In 2000 a demographic surveillance system was set up to monitor a population of about 
200,000 people living within an area of 900 km2 around the hospital. The establishment of 
this Epi-DSS in Kilif was based on the rationale that there was potential for synergistic 
gains from the combination of resources for the several overlapping extensive field studies 
that were coming up (e. g. the creation of a common sampling frame for all epidemiological 
studies and co-ordination of fieldwork). At inception, the size of the DSS was linked to 
hospital utilization rates and included a population that was estimated to give rise to 80% of 
all paediatric admissions. Part of the system is now directly linked to all paediatric 
admissions and maternity ward deliveries. It comprises periodic population census 
(enumeration rounds every 4 months), geographical positioning system (GPS)/ 
geographical information system (GIS) mapping of homesteads/roads/paths as well as 
serving to create community awareness regarding the work done by KEMRI. At present the 
resident population of the Epi-DSS is 227,000 (Mid 2005 - Fig. 3.2) people 47% of whom 
are less than 15 yrs old with a birth cohort of about 7,000/yr. 
Kilifi has one major well-utilized government health care facility; the Kilifi District 
Hospital (KDH), situated in Kilifi town. More than 80% of paediatric admissions to the 
KDH were found to originate from this DSS indicating good access to and utilization of the 
hospital. Approximately 15% of births in the DSS area occurred in KDH. KEMRI CGMR- 
C runs the KDH paediatric wards comprising at the time of this study a general ward of 40 
beds with an occupancy usually > 100%, sometimes up to 200% during the malaria season 
and a 6-bed high dependency ward (occupancy between 50 -150%) where severely ill 
children are managed. It also manages an Out patient (OP) clinic within the hospital 
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grounds. The paediatric OP and IP services are supported by well equipped laboratories to 
undertake haematological, microbiological, biochemical and blood gas analyses. Malaria is 
endemic in the area, with peaks during the long (April-July) and short (November- 
December) rainy seasons [234]. A break down of hospital presentations from the resident 
population of the DSS is detailed in Figure 3.2. Overall, Malaria is the main diagnosis 
followed by LRTI. In the <1 population LRTI is the main presentation. 
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Figure 3.2. Comparative annual incidences of various diseases within the DSS over a five 
year period, 2002-05 by age group. s/vs- severe/ very severe pneumonia, GARY- Group A 
rotavirus. 
3.2.3 The Population 
The local people (within the DSS) are predominantly Giriama, one of the nine Mijikenda 
tribes of the East African coastal region. Whereas traditional cultural and religious practices 
like polygamy are still adhered to, other religions particularly Islam and Christianity have 
infiltrated the community. A substantial number of men from this region aged 20-50 are 
not resident within the DSS having migrated to urban areas such as Mombasa and Malindi 
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under 5 under 1 
in search of employment mainly in the tourism and hotel industry as illustrated by the 
population pyramid (Figure 3.3). 
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Figure 3.3. Population pyramid of the Demographic Surveillance System in Kilifi 
3.2.4 Climate 
Data used in this study was collected at the Kilifi Agricultural Institute located less than 2 
kilometers away from Kilifi Hospital. Though not part of the national network of 
meteorological stations (the nearest one is 30 km away), data from the institute is routinely 
used by the research unit. 
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Kilifi DSS Age-Sex Population as at 11th April, 2005 
N= 227,180 
Daily data on rainfall, relative humidity and maximum and minimum temperatures was 
available for the whole follow up period (Figure 3.4). The climate of Kenya is tropical with 
the rainfall pattern in Kilifi district and Kenya as a whole divided into two seasons; short 
and long rainy season. The long rains fell between April-July while the short rains occurred 
between October - December. Temperatures during the study period ranged from 21 °C to 
34 °C, with max daily temperature ranging from 28-34°C. The hottest months were between 
October and April. The District is generally hot and humid all the year round with monthly 
average relative humidity ranging between 70-78 %. The weather pattern was relatively 
consistent during the whole study period, although the short rains varied quite considerably 
In the amount of rainfall. 
100 
90 
80 aýý K 
70 
60 
50 
40 
cu 30 
0 
as 
ead 
e-e' 
20 
10 
12345678 9101112 1 234567891011121 234567891011121 23456 
Nbr#h 2002/5 
Rain -f- RH -a- Maos temp --- o- -- Mn temp 
40 
35 
30 
25 
._ T L 
20 £ 
d 
15 
10 d 
5 
0 
Figure 3.4. Climatic conditions in Kilifi district between the years 2002-2005. Shows for 
each month the average daily precipitation (mm), relative humidity (RH), and maximum 
and minimum temperatures. 
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3.3 Methodology 
Household - Study design 
Season 1 Season 2 Season 3 Season 4 
end 
Yr 1 Yr 2 Yr 3 Yr 4 
Recruit HH 81 
At birth Households Cohort 2 recruited 
3 monthly saliva 
recruit 
11' 1' 111 ýl 1 Active and Passive Visits 
RSV events ARI episodes 
Figure 3.5. Schematic of the household study design. Two birth cohorts (orange blocks) 
recruited in two consecutive years and followed up intensively for 3 years. Households 
(HH) were selected from Cohort 2. For a typical recruit, surveillance by active and passive 
means (see text section 3.3.5) for ARI episodes was carried out (blue lines), identifying 
cases of RSV infection (red lines) in nasal washings. Oral-fluid samples were collected 
every three months (black arrows). 
The household (HH) study was nested within an intensive birth cohort study set up to 
explore the natural history of RSV infection [5]. All occupants from a sub-sample of the 
families of these children formed the HH study population. Roughly, 600 infants were 
recruited at birth in the maternity ward at KDH or from the maternal child health (MCH) 
clinic if less than 2 weeks old. Recruitment was in two phases as shown on the study 
schematic: about 300 infants in the first year of the study and another 300 in the second 
year each followed for two to three calendar years. The first phase of recruitment was 
between January and May 2002 while the second phase was between December 2002 and 
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May 2003. The birth cohort provided data for chapter 7 and 8 on risk factors for LRTI and 
RSV infection (RSVI) and disease. 
3.3.1 Sample size calculation 
The sample size required for the household cohort was estimated by the principal 
investigator and was calculated to achieve precision in the estimates of incidence rates in 
the different age groups and between seasons: one of the principle objectives of the 
household study. Using a sample size of 70 households each assumed to have 10 
individuals, the age distribution of individuals within each age class was estimated to be: 0- 
4 years 13% (n=91); 5-14 years 27% (n=189); 15+ 60% (n=420). A single years follow up 
of these sample sizes would generate 95% confidence intervals on assumed incidence rates 
[235-237] of 50%+/-15%; 15%+/-6% and 5%+/-2% /annum for each age group 
respectively. Considerably greater precision would be achieved over the whole study 
period. 
3.3.2 Sampling design 
Recruitment into the birth cohort was not intended to provide a representative sample of the 
community. The key aims of the birth cohort were related to immunity to infection rather 
than incidence estimation. Hence, for convenience recruitment was undertaken from 
deliveries at KDH, and (see next section) maternal child health clinic (MCHC). This 
sampling method afforded a relatively easy method of recruitment as opposed to random 
selection of births from within the community. Sampling was purposive insofar as to select 
within a defined region that would afford relatively easy access by field teams to the 
households (for active surveillance - see later section) and also by mothers/babies to the 
research OP clinic at the hospital (passive surveillance - see later section). The sampling 
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method also recognized the potential hazard of choosing all recruits from one small area, 
which might have resulted in (a) a complete absence of infection during an epidemic by 
chance, and (b) reduced variability of strains to which the study group was exposed. The 
method by which we established a sampling area was to conduct an exit poll from the 
MCHC clinic at KDH as described in the next section. 
3.3.3 Selection of study area 
Eight study locations from the DSS were selected as the study area. A location is an 
administrative demarcated area of the district (i. e. province-district-location-sub-location)- 
Selection of these locations was done after an exit poll carried out at the KDH MCH clinic 
as mothers were leaving the clinic. The survey was undertaken primarily with the objective 
of (i) establishing if we could supplement recruitment from maternity with recruitment 
from MCHC, at an early age. (ii) Given that we were recruiting from the hospital we 
wanted to recruit those mothers/babies who lived within reasonable access of the hospital 
both to enable us to get to them, but also so that they were within reasonable access to the 
hospital (i. e. to facilitate OP clinic passive surveillance). An indication of this accessibility 
was to determine the locations from which mothers came to visit MCHC (rather than 
locations from which they came to give birth as this would be biased as some mums for 
example would travel very far if they had a problem birth). 
150 mothers were randomly selected and a questionnaire administered enquiring on aspects 
of residence location, length of time to get to hospital and the travel costs incurred 
(Appendix A, p 287). The age of the child at first clinic visit was also determined as we 
wanted to assess the possibility of recruiting children from the MCH clinic. Results from 
this exit poll showed that majority of those presenting at the clinic came from 8 locations 
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namely: Ngerenya, Roka, Tezo, Kilifi Township, Chonyi, Matsangoni, Sokoke and 
Takaungu-Mavueni. These were selected as the study area. 
3.3.4 Surveillance of infection 
Surveillance of infections was by two methods, clinical and serological (Fig. 3.5). Clinical 
surveillance comprised of two methods, that is, active and passive surveillance 
(section. 3.3.6. ), of respiratory infection. Active represents visits to households on a regular 
basis by field teams either weekly or monthly and passive represents visits to the OP clinic 
by study participants with respiratory symptoms. In each instance the identification of 
symptoms consistent with an-acute respiratory infection (upper or lower) occasioned the 
collection of a nasal specimen by nasal wash method (section. 3.3.7) and subsequent 
laboratory detection of RSV by antigen assay (section 3.3.9). Serological identification of 
infection was through repeated sampling of oral fluid every 3 months, by which to 
determine antibody boosting or seroconversion which would indicate infection 
(section. 3.3.6 and Chapter 4). The reasons for the two methods of surveillance were: (i) 
clinical to identify actual time of RSV infection, determine genotype and severity, and 
hence things like WAIFW. (ii) serological to support estimation of age-specific incidence 
in the knowledge that clinical surveillance would under-estimate total infections (due to any 
or all of the following mild undetected or sub-clinical infection, cessation of shedding 
before sample collected, or sensitivity of antigen assay). A problem with serological 
identification of infection is that it would not identify with precision the time of infection 
and thus is not useful in determining sequences of infections. 
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3.3.5 Implementation 
Field worker Training 
The field workers (FW) involved in the project underwent extensive and intermittent 
training in various techniques. At the outset, they were trained on how to carry out the 
consenting process as well as the translation of the consent form into the local language in 
which they were all fluent. Training on obtaining consent was accomplished by means of 
role plays simulating the actual consent process. Role plays were also used to enact 
different case scenarios that could be encountered in the field. A second element of training 
was in the identification of clinical symptoms that were consistent with an RSV infection. 
This was achieved by showing the FW training videos as well as by the actual observation 
of sick children presenting to the ward with ARI under the supervision of a clinician. 
Thirdly, they received training on sample collection; collection of nasal wash samples and 
saliva samples and performance of venepuncture for blood collection. A field worker 
manual was developed with guidelines for both fieldwork and outpatient cover. It contained 
detailed accounts of procedures to be followed for different situations within the study. 
Training was ongoing throughout the study period with repeated training sessions every so 
often in order to maintain quality of performance. 
Consent Form Development 
Consent forms to be used in both studies were developed and submitted to the consent 
review committees (initial review locally by the Scientific Coordinating Committee of 
KEMRI-CGMR(C), and nationally at the Scientific Steering Committee of KEMRI and the 
National Ethical Review Board, Nairobi) for approval (Appendix B- E, p 289-301). This 
was followed by a translation of the forms from English into Kiswahili and Kigiriama, both 
of which are languages used by the local community. The process of translation and back 
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translation into English was done as a joint task between the project field workers who hail 
from the local community and spoke the language and the researcher in order to ensure that 
fieldworkers clearly understood the study and thus were able to translate accurately. The 
back translated version and the original version of the consent form were then cross- 
checked to ensure that no aspect of the original consent form had been omitted or its 
meaning altered during the translation process. 
Recruitment of cohort children 
A child was eligible for recruitment if (i) residing in one of the eight locations selected as 
the study area, (ii) one-way travel cost to their home was <50 Kenyan shillings, (iii) the 
journey time was <1 h. Some children were later excluded due to poor road access to their 
homes. Informed consent for participation in the study was obtained from each infant's 
mother or from both parents whenever possible before delivery or soon after birth. Children 
in this birth cohort were subject to two methods of surveillance, namely, active and passive. 
Active surveillance involved visits made to individual households by the study field 
workers and passive surveillance was by presentation to the KEMRI outpatient (OP) clinic 
encouraged for every episode of respiratory infection (including mild URTI e. g. including a 
runny nose). It is within this framework that we extended the second birth cohort study to 
include families of a selection of infants to be observed for the spread of RSV within the 
household. 
Recruitment of Households 
Recruitment of households was staggered over five months between February and May 
2003. Household members of selected cohort infants (i. e. those with siblings) were asked to 
enroll into the study. After identification of eligible (Table 3.1) children from the larger 
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birth cohort, families of these children were visited soon after the delivery and discharge 
from the hospital to obtain consent to taking part in the household study. A family unit was 
defined as the individuals that normally eat and live together. This definition was used 
mainly because of the polygamous nature of members of this community and also because 
of the fact that extended family members tend to live together. The definition therefore 
covered the stepmother and stepsiblings of the birth cohort infant and in some cases aunts 
and cousins and meant that study families did not necessarily live in the same house but 
always within the same homestead. Figure 3.6 shows the spatial distribution of households 
in the study. 
Table 3.1. The inclusion and any exclusion criteria for the households 
Inclusion criteria Exclusion criteria 
(i) Born at the Maternity, or (i) consent with held 
presents to the KDH CHC <_14 (ii) excludes family to children who 
days. Recruited form ward on died very young i. e. only those 
primary infection who survived for one visit 
(ii) Resident within one of the 8 contact (passive or active) 
study locations 
(iii) one-way travel cost to their home 
was <_50 Kenyan shillings 
(iv) journey time to the hospital <1h 
(v) infants must have at least one 
other sibling 
Consenting Process 
The consenting process for the main project took place at the hospital while that for the HH 
study took place at the family home. A deliberate attempt was made to have both parents 
present whenever possible. A trained fieldworker explained the details of the study in the 
local language and gave a translated copy of the consent form to the parents to read if they 
could. Information covered during the consenting process included details of the family's 
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involvement in the study including what would be required of them in terms of allowing 
visits to their homes by the field workers or visits by them to the research clinic; details on 
what, and how samples would be collected; anticipated risks and benefits of the study and 
issues of confidentially (Appendix C, p 293). Parents were informed that participation was 
entirely voluntary. If, on understanding their involvement the parents decided to take part in 
the study, they were asked to sign two copies of the consent form, one of which was given 
to them for reference purposes. Active and passive surveillance was initially limited to 
children i. e. any member of the family who was less than 15 years of age at the time of 
recruitment. At a later stage the protocol was revised to include adult family members (>_15 
years old; see section below). 
Inclusion ofAdults 
At HH enrollment all members were requested to participate in providing oral-fluid 
samples at 3 monthly intervals to identify infections by serological methods (see later 
section). These samples were to be screened for antibody changes to identify infection in 
adults and to calculate rates of infection. Initially, clinical surveillance was limited to 
children under 15 years of age. However, upon realization that the original study design 
(excluding adults from clinical surveillance) would not provide a clear picture of infections 
in the household, an amendment to the original proposal was submitted for review and 
approval received. Subsequently, at the beginning of 2004 all adults in the household study 
were asked to take part in routine clinical (active and passive) surveillance. This was done 
through a repeat consent process of individuals >_15 years in study households (Appendix 
D, p 298). 
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Extension of Study 
The initial study design planned to follow up children in the second cohort for two RSV 
epidemics only. However, in the epidemic of 2003 far fewer of the 300 infants in cohort 2 
were identified as having been infected than was expected (see Fig 3.9b). As a consequence 
permission was sought and obtained from the review committees to extend follow up to 3 
epidemics and therefore to monitor children (and families) for another RSV season that 
would extend the study into 2005. Thus in the last quarter of 2004 participants were asked to 
continue taking part in the study through to the end of the expected epidemic of 2005 
(Appendix E, p 301). 
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3.3.6 Surveillance methods 
To monitor study participants for any signs of acute respiratory infection two methods of 
surveillance were in operation throughout the study period: active and passive surveillance. 
The main aim was to identify every case of RSV infection experienced by participants 
during the study period. Each particapnat was provided with a study book for keeping visit 
records. 
1. Active household surveillance. 
These entailed visits made to the homes of those in the study to track ARIs. Active visits 
were carried out weekly during RSV epidemics. The start of the RSV season was identified 
by an increase in RSV cases at the hospital or within the birth cohorts. During non-RSV 
seasons, visits to households were made once a month, primarily to remind mothers of the 
study and about passive referral to the clinic (see next section), but also to identify 
respiratory symptoms as for the weekly visits. Study participants were reviewed using a 
standard form during each visit (Appendix F, p 304). A nasal washing was collected if a 
study participant had either an acute cough, difficulty in breathing, or nasal 
congestion/discharge at the time of the visit or if elicited by the history during the past 
week. If a child had tested positive for RSV within the last 2 weeks (14 days), no action 
was taken and a review was scheduled for the next visit (Appendix G, pp 307,314). An 
assessment of the severity of the ARI was made based on WHO guidelines [227] described 
in Nokes et al [5] and where necessary referred to the research clinic for review by a 
clinician (Appendix G, pp 307,315). A blood slide (thick and thin film) to diagnose a 
possible malaria infection was collected if the individual had a history of fever (within prior 
7 days) or an auxiliary temperature ? 37.5 °C (as measured by digital Thermometer, Becton- 
Dickinson, USA) on the day of the visit. Participants with temperature ? 37.5 °C on the day 
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of the visit were referred to the KEMRI research clinic (Appendix G, pp 307,313). A 
record of the number of complete weeks in between active hospital visits was kept to 
facilitate an accurate record of the days of observation. 
2. Passive surveillance 
Passive surveillance was through self-referral to the KEMRI outpatient (OP) research clinic 
located in KDH. All year round mothers were encouraged to present to KDH (i. e. 
self/parental referral) with an infant or child who had signs of respiratory disease that was 
possibly caused by RSV i. e. ranging from mild URTI including a runny nose or difficulty 
in breathing to LRTI. Parents of infants and children in the study were primed on how to 
recognize symptoms consistent with a possible RSV infection. The clinic operated on 
weekdays between 8 a. m. -5p. m. Study participants presenting at the OP research clinic 
were interviewed by a FW to assess need for a nasal washing, and to take measurements 
(oxygen saturation, axillary temperature, weight and heart rate) and subsequently reviewed 
by a clinical officer using a proforma method to ascertain the severity of ARI (Appendix H, 
p 323). The criteria for collecting a nasal washing were the same as for active visits. 
Transport costs were reimbursed and treatment provided without charge. Limitations of 
support for other members of the family attending the OP clinic operated as defined in the 
form appended (Appendix I, p 328). Children referred to the clinic by a FW undertaking an 
active visit to the house, would be reviewed by a CO as described above using the proforma 
detailed in Appendix H. 
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3.3.7 Study processes 
1. Follow-up visits 
Follow up visits for a positive slide or nasal washing are as detailed in Appendix G (pp 
316-317). In the case of absent participants, an inquiry was made with the next door 
neighbours on the whereabouts of the study participants. If they were said to be close by 
then the FW either waited at the homestead for the participants or tracked them. Follow up 
of unavailable participants was done either the next day or at the weekend. 
2. Sample collection and processing 
Nasal specimen 
Nasal washings were collected by use of an ear syringe bulb (Abbort, Ashland, Ohio-USA) 
using a method described in the standard operating procedure (SOP) in Appendix G, p 319. 
The method is based on that described by Hall and Douglas [238] with minor modifications 
[5]; essentially normal saline (quantity according to age) is squirted into one nostril and 
collected from the other (Fig. 3.7). Samples collected in the field were stored in cold boxes 
and brought back to the microbiology laboratory at the research centre at the end of each 
field day where they were stored in a -4°C freezer. Those collected 
in the OP clinic were 
delivered within the hour. Nasal washing samples were processed usually within 24 hours 
or invariably within 4 days usually over the weekend. First, any mucus in the sample was 
broken up, and then slides were prepared from 200 ml of specimen by use of a cytology 
centrifuge (Cytospin 3; Thermo Shandon Ltd, Cheshire UK; 67 g for 10 min) (Appendix J, 
p 330) and screened for RSV antigen by use of a direct immunofluorescent antibody test 
(DFA) (Light Diagnostics RSV screen; Chemicon, Temecula, CA USA), according to the 
manufacturer's protocol described later. Samples were assigned as either positive or 
negative for RSV antigen, on the basis of DFA result. 
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Oral-fluid samples 
Oral fluid was collected using a sponge swab (Fig. 3.8) known as Oracol (Malvern Medical 
Developments, Worcester, UK). This sponge swab consists of a cylinder of expanded 
polystyrene foam attached to a plastic stick and is used like a toothbrush [212]. The swab 
was brushed along the gums and mouth for 60 seconds and the device then inserted into a 
plastic tube, stoppered, stored on ice and returned to the laboratory upon return from the 
field (Appendix G, p 320) or within one hour when taken in the OP clinic. In the laboratory 
lml of preservative buffer (20% foetal calf serum and 0.2% sodium azide in PBS) was 
added to the sample. The oral fluid was then squeezed out of the foam and clarified by 
centrifugation and the supernatant stored in a -70 
°C freezer for processing at a later stage 
using both the IgG Capture Assay and the direct ELISA (described in Chapter 4). 
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Figure 3.7. Nasal specimen collection by nasal wash (N W) bulb method in the clinic and in 
the field setting 
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Blood samples 
Acute and convalescent samples were collected by venepunture (Appendix G, p 321) at 
each episode of RSV infection identified by IFAT on NWs. The acute sample was collected 
as soon as possible after a positive IFAT result was received from the laboratory and a 
convalescent sample collected one month later. Once in the laboratory, the clotted blood 
was centrifuged and serum stored for processing by direct ELISA at a later stage (Appendix 
N, p 344). 
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Figure 3.8. Oral-fluid collection in the field using an Oracol device 
3.3.8 Quality control (reliability) 
1. Quality Control for collection of data 
Each FW was provided with a field manual containing all study details. They had the 
manual at hand at all times enabling referral for clarification of any study details. It was 
impressed upon the FW to ensure forms and questionnaires were completed carefully and 
as required. They were instructed not to make assumptions about answers elicited but rather 
to ask the question again if they were unsure. The FWs were trained to be methodical in 
their actions as well as to make sure they were clear on exactly what they intended to do 
before arriving at the household. At the end of each visit, a review of the entry was carried 
out before leaving the home. On their return to the unit the FW had to (i) go through their 
individual field forms to ensure that no blatant mistakes had been made (ii) relate any 
problems encountered in the field to the field co-ordinator (the researcher) and also note 
them down for discussion during fieldworker meetings and, (iii) enter the rsv number of 
individuals from whom nasal washings had been collected on each day into the sample 
book in the OP clinic. This was updated as and when the NW result was received from the 
laboratory and any follow-up appointments were made as necessary. Active visit data 
sheets were checked at the end of each field day either by the field work coordinator or by a 
senior project FW for any inconsistency and were then given to the data entry clerk. 
As an additional monitoring system to ensure quality of data and samples collected, senior 
project members accompanied the feldworkers on the household visits during certain days 
of the week on a rotational basis. The aim was to ensure that study questions were asked 
correctly, that samples were collected in the proper manner and that the information 
provided by the mother was entered into the forms correctly. A similar process was also 
carried out in the outpatient clinic. Any mistakes made were reviewed and the fieldworker 
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advised accordingly. Training of the field workers on study protocol and sample collection 
was done periodically throughout the whole study period. 
2. Quality Control for sample collection 
Strict measures were taken to ensure that i) all bottles and tubes for saliva, nasal specimen 
and blood collection were labelled before any sample was taken ii) all samples had the 
individual's name, serial number, sample designation and the date of collection of the 
sample iii) saliva samples were collected for one minute to ensure uniformity (Appendix G, 
p 320) and iv) that the saline solution used in the nasal wash reached the nasopharynx (i. e. 
observing saline emitted from the alternative nostril to that in which it was instilled). If this 
was not verified the procedure was repeated (Appendix G, p 319). Every effort was then 
made to return collected specimens to the laboratory as quickly as possible, on ice as 
required. For specimens that were spoilt or inadequate (e. g. slides or nasal washings), or 
where specimen tubes could not be read a fresh specimen was requested. 
3.3.9 Laboratory Methods 
1. Direct Immunofluorescent Antibody Test (IFAT). 
An immuno-fluorescent antibody test (Light Diagnostics RSV DFA, Chemicon, Temecula, 
CA USA) was used to detect RSV antigen in the nasal washing collected. The test utilizes a 
direct immunofluorescent antibody technique for identifying RSV in cell preparations made 
from nasopharyngeal aspirates (NPA) or nasal washings. The monoclonal antibodies to the 
viral antigen are labelled with FITC (fluorescein isothiocyanate), which fluoresces apple- 
green when illuminated with ultraviolet light. The labelled antibody binds to the viral 
antigen present in the specimen and any unbound reagent is removed by washing with 
buffer. Cells in positive specimens will fluoresce apple-green, while uninfected cells stain 
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dull red due to the presence of the counter-stain Evans blue (IFAT SOP - Appendix K, p 
331). The IFAT assay was performed by the project technicians (John Abwao and Anne 
Bett). 
2. Molecular methods for genotyping RSV isolates 
RSV positive cases identified by antigen IFAT were subjected to molecular 
characterization. The method involved RNA extraction and subsequent by reverse- 
transcription (RT) to obtain complementary DNA (cDNA), followed by a multiplex PCR to 
identify RSV or influenza target sequences within the sample. Multiplex PCR uses a 
combination of several primer pairs in the same amplification reaction, with the objective 
of producing different specific amplicons depending on the target present in the sample. 
This method is increasingly used for the diagnosis of infectious diseases caused by 
DNA/RNA containing viruses in which the starting nucleic acid template may be low in 
copy number or of poor quality compared to chromosomal DNA [239]. In this case the 
method was set up in the laboratory for general respiratory viral diagnostic reasons and 
adopted in the present study. Further characterization of MPX positive samples involved 
genotyping of the virus based on restriction fragment length polymorphism (RFLP) 
analysis of the N or G genes and selective sample sequencing of the G gene (see reference 
Scott et al. [83]. 
(i) RNA extraction and cDNA synthesis 
RNA was extracted from RSV positive samples using QiAmp Viral RNA kits (Qiagen UK, 
Ltd), according to the manufacturer's instructions (supplied with the kit). The addition of 
the carrier RNA to buffer AVL is not done. cDNA was synthesised using the Omniscript 
RT kit (Qiagen UK Ltd). Briefly, 4 gl l OX RT buffer, 4 µ15 mM dNTPs, 250 ng pdN(6) 
random hexamers (Amersham Pharmacia, UK), 1 µl Omniscript reverse transcriptase, 10 µl 
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nuclease free water and 20 µl RNA were mixed and incubated at 37°C for 1 hour. The 
cDNA was either used directly or stored at -20 °C for later use. 
(ii) PCR and N and G gene RFLP 
All positive samples were subjected to an RSV/influenza multiplex PCR (MPX) based on 
the method developed by Stockton et al [239] as detailed in the SOP (Appendix L, p 336). 
N Gene PCR was carried out on the first round products from the RSV/Flu multiplex assay. 
RSV N gene typing was done according to procedure described by Cane et al [240] and 
RSV G gene typing by RFLP as described in Scott et al [83] and detailed in the SOP in 
Appendix L (p 336). These molecular assays were performed by Anne Bett one of the 
project technicians and Dr. Paul Scott (Post doc on the project). 
3.3.10 Data Handling 
Data collected in the field was entered the next day into a FileMaker Pro 5.5v1 Dev, 
(FileMaker, Inc. Santa Clara, CA USA) RSV study database. The entered data was then 
checked by second data clerk to ensure correct entry of study details. Any inconsistencies 
were corrected. Data collected in the OP clinic was entered directly onto the study database 
on a real time basis (as for all data at admission review). The database had inbuilt 
consistency and range checks to minimise errors of entry (although cant ensure they are 
correct). All the data was analyzed using Excel (Microsoft Office XP), and STATA 
software Version 8.0 (Stata Corp., College Station TX, USA). Details on the analysis 
conducted are described in Chapters 5-9. 
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3.3.11 Ethical considerations 
The study underwent local internal review by the unit Scientific Coordinating Committee 
prior to submission to KEMRI Scientific Steering Committee. Subsequent ethical approval 
for the study was sought and granted by the Kenya Medical Research Institute/National 
Ethical Review Committee and Coventry Research Ethics Committee. Any amendments to 
study procedure went through the same ethical approval process. 
3.4 General Results 
3.4.1 Recruitment 
A total of 81 households were recruited into the HH study, being associated with 84 birth 
cohort children (there were twin birth cohort children in three instances. ) The vast majority 
(79) were selected from birth cohort children recruited at delivery in the Maternity Ward. 
Of the 73 households under surveillance in 2004, the adults members of 41 households 
agreed to participate in clinical surveillance and the remaining 32 refused. The main reason 
given by adults in these household was- they did not want to have a nasal wash. No 
differences were identified between these HHs and those that agreed to participate. 
Households lost to follow up before the second epidemic (8) were replaced with HHs of 
other birth cohort children (Figure 3.10). Replacement was with those households in which 
the birth cohort child had not been identified (by clinical surveillance) as having already 
been infected. The 81 households had a total of 447 individuals, 133 (29.8%) of whom 
were adults (>_15 years) and 314 children; 84 (18.8%) birth cohort children and 230 (51.5%) 
were siblings less than 15 years of age at the time of recruitment. Specific details of 
households recruited and characteristics of study participants have been provided in 
Chapter 5. 
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3.4.2 Loss to follow-up 
In the main cohort 31 % of the children were lost to follow-up. The risk of loss to follow-up 
in the household cohort was the same 31% (25/8 1) households. 16% (13) of the families 
moved out of the study area while 14% (11) withdrew consent before the end of the study. 
One household was removed from the study as a result of the death of the birth cohort child 
as recorded in Table 3.2.36% (4) of the households that withdrew consent did so at the 
time when follow-up was being extended (i. e. late 2004). 
Table 3.2. Reasons for exiting the HH study 
Reason for exiting the study Frequency Percentage 
Died I I 
Moved 13 16 
Refused 11 14 
Study end 56 69 
Total 81 100 
To assess whether the households that were lost to follow up were a biased group several 
characteristic were assessed: household size, number of pre-school and school children, 
travel time and travel costs to hospital, respiratory episodes and social economic status. 
There was no evidence to suggest an association between any of the factors and drop out (x2 
test, P>0.05) except in the case of number of pre-school children. The proportion of pre- 
school children in households that remained in the study was significantly higher than in 
households that were lost to follow up (x2 (1) = 6.151, P=0.013). 
3.4.3 Epidemics in the main birth cohort and in individuals of the household cohort 
The working definition of an epidemic was a period delimited by weeks in which greater 
than or equal to one case was found and within which at least three cases were found in any 
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contiguous 3-week period [5]. The interval between epidemics (inter-epidemic period) was 
defined as the time interval between the end of one epidemic and the start of the next 
epidemic. Between the years of 2002 and 2005 during which this project was carried out 
there were 4 RSV epidemics within the dates 12/3/02 to 1/7/02,3/12/02 to 15/4/03,8/1/04 
to 2/6/04 and 11/11/04 to 18/2/05. The first cohort experienced three epidemics while the 
second cohort recruited towards the end of 2002 extending into 2003 experienced the tail 
end effects of the second epidemic as well as epidemics three and four as shown in Figure 
3.9. 
16 
14 
12 
10 
U) 
Q) 
U) 
co 
U 
Y6 
Q) 
a) 
34 
2 
350 16 
300 14 
250 12 
N üi 10 
200 rn v aý 
V- a) m O .? cý $ 
150 pma 
Eä6 
100 03 
4 
50 
2 
1 15 29 43 5 19 33 47 9 23 37 
Week of ym 
cthcrt-btal -cases 
350 
300 
250 
ýN 
2DO U 
O> 
O ca 150 u 75 
E 
7 
100 
0 
50 
0 
a. b. 
Figure 3.9. Temporal pattern of RSV infection in the birth cohorts: panel (a) cohort 1, 
panel (b) cohort 2. Grey area shows cohort size at each time point, and ascending line from 
left to right in each panel shows the accumulation of the shown weekly cases. 
Households that were lost to follow up before the epidemic of 2004 were replaced with 
other households for which there was no evidence (from clinical surveillance) that the 
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index child had been infected in the 2003 epidemic. After this initial replacement of 
households, no further replacement was undertaken (Figure 3.10). 
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Figure 3.10. The course of the epidemics (weekly cases shown as blue bars) on a backdrop 
of recruitment and exit (grey area) for the HH study. For comparison KDH IP cases are 
shown by the dark blue line. 
3.4.4 Surveillance intensity 
Of the 447 individuals in the HH study, 373 had at least one visit (i. e. either interviewed in 
an active visit by a field team, or passively presented to the OP research clinic at KDH). 
The 74 individuals who had no contact were mostly adults who were not under routine 
surveillance (only part of the serological - oral fluid - surveillance. 
) In total, follow-up 
amounted to 626 person years of observation (pyo), which represents the summation of time 
for each individual from recruitment to study end or drop out, excluding periods spent away 
from the DSS (see Active visit form Appendix F, p 304). A total of 16,115 visits 
(active/passive) were made (Table 3.3). A passive-active visit was an active visit that 
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resulted in a referral to the research clinic by the FW due to the severity of infection as 
discussed previously. Passive visits arising from active of which there were 15 were 
subsumed into active. A visit occurring on the day of recruitment is described as an 
active/passive recruitment visit and is also subsumed into either active or passive 
respectively. The median number of visits was 24 (IQR of 12-38). The contact rate (per 
pyo) for home visits was 22 and for clinic visits 4.3,122 visits resulted in a nasal washing 
(Table 3.4). In 7 instances there were no laboratory result available and these were 
classified as negative. The nasal washing rate in HH children (excluding birth cohort 
children) was 4 /pyo while that in the birth cohort child in the HH study was 10/ pyo. 1,098 
(35.25%) NWs were taken during active visits, 2,006 (64.4%) resulted from a passive visit 
while 11 NWs were taken from what was defined as a passive-active visit (Table 3.4). The 
proportion of active visits that resulted in NW was 8% while the proportion of passive 
visits resulting in a NW was 79%. The proportion of NWs testing positive was the same 
from both active and passive visits. 
Table 3.3. Details on surveillance intensity 
Cohort type 
visit type adult birth cohort child Total 
active 1,694 3,295 8,574 13,563 
passive 151 1,256 1,145 2,552 
Total 1,845 4,551 9,719 16,115 
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Table 3.4. Details on nasal washings taken during the study 
Nasal wash results (%) 
visit type negative positive Total 
active 1,062* 48 (4.3) 1,110 
passive 1,927* 85 (4.2) 2,012 
Total 2,989 133 (4.4) 3,122 
*7 children had no results and are assumed to be negative 
3.4.5 RSV infection 
Virus was introduced into 65% (53) of households during the whole follow-up period. 
There were 121 separate RSV related clinical infections -1 adult was positive, and there 
were 56 infections in the siblings and 64 infections in the birth cohort child (Table 3.5). 79 
infections were identified from a passive visit while 42 infections were from an active visit. 
Table 3.5. RSV infection in the household study 
Cohort type 
Number of RSV infections adult birth sibling Total 
1 1 49 49 99 
2 0 13 6 19 
3 0 2 1 3 
Total 1 64 56 121 
Definitions: adult is >_15 years, sibling is brother or sister to a birth cohort child (=birth) and 
<15 years old 
3.4.6 Seasonality 
The epidemics observed during follow-up did not appear to be associated with the rainy 
season; epidemics occurred in the hottest months with lowest rainfall (Figure 3.11). 
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Figure 3.11. Cases of infection in the Household cohort (black bars) and 
in the IP (red 
bars) correlated to meteorological data during follow-up. 
3.5 Discussion 
The household study was scheduled to run for 2 years or two RSV seasons (that 
is until the 
end of 2004). However, this was extended to a third epidemic (that is until 
2005) because 
the epidemic of 2003 began around 3 months earlier than expected (i. e. around 
9 months 
after the preceding epidemic) and the cohort was scarcely exposed during the 
first year of 
follow up (i. e. there were very few infections identified). This could explain the 
increase in 
rate of drop outs at the end of year 2, due to refusal to continue, as some of these 
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households (36%) were unwilling to remain in the study longer than the period to which 
they had originally committed. Field studies are generally unpredictable and allowances 
therefore need to be made in terms of sample size and the length of study whenever 
possible. More than one epidemic period of observation was desirable mainly because it 
would give longitudinal estimates of re-infection and identify risk of infection in those 
known to be infected in the previous year to compares with those not pre-infected making 
this study quite unusual. in addition Longer follow-up improves the precision of incidence 
estimates. 
The logistical setup for surveillance is critical when planning a field study. In The Gambia, 
Weber et al [9] reported a negative association between the incidence of hospitalisation 
with RSV associated LRTI and increasing travel cost (linked to distance from the study 
hospitals). Cost (or time) thus seems to have important implications for presentation 
efficiency. In this study children were recruited from eight locations. These were widely 
spread out around the referral clinic based at KDH but was based on selection criteria used 
to facilitate relatively easy access for passive referrals. Moreover, selection criteria based 
on accessibility are also of importance for active surveillance by field teams and it may be 
necessary to limit the area from where study participants are recruited to maximize 
successful contacts, or make manageable the number of household visits required. There is 
a need to remember that a scheduled visit is not always successful necessitating repeat 
visits and hence requires an additional allowance of time. Other issues to consider are: i) 
accessibility to homes (i. e. the road conditions or whether one exists) ii) available modes of 
transportation and a contingency vehicle is essential. The use of a motorbike for follow-up 
was found to be a better alternative to a vehicle where road accessibility was particularly 
problematic and in remote parts with few households to visit where a motorcycle was 
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considerably more cost-effective. However, special training is often required and road 
accidents (none more serious than a broken leg in this study) a threat to the smooth 
operating of surveillance. 
Balancing the requirements of ease of access and a manageable study area for field visit is 
the recognition of chance events in infectious disease transmission. The recruitment area 
was the largest manageable within budget constraints in order not to suffer the possibility 
that the study population might miss an epidemic and that it would not experience a limited 
repertoire of viral strains if each variant was spatially restricted. 
Previous studies reviewed by Nokes [38] suggest that a combination of methods of 
surveillance is required to identify all cases of RSV hence in this study we adopted both 
clinical and serological surveillance. Crucial to this study however, was not only to identify 
if someone had been infected but the time of infection by which to infer from whom 
infected and (for the main project) by what strain. Hence in an effort, to improve 
ascertainment by clinical means we adopted both passive and active surveillance. A 
majority (65%) of the ARIs were identified through a passive visit implying that study 
participants were conscientious about presenting to the OP clinic. For the typical passive 
visit there was a high probability that the symptoms would indicate the need to collect a 
nasal washing (79%), compared to that for an active visit (8% - 
ý, P< 0.001). This suggests 
that parents well understood the reasons given for bringing their children to the OP clinic. 
Interestingly, the contribution of RSV to acute ARI in the children was the same whether 
identified by a passive or active visit. Thus both proved very useful. Even so, it is likely 
that many infections were probably missed as there are significant problems in the clinical 
surveillance: mild or sub-clinical cases, end of shedding before sampling, low sensitivity of 
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IFAT if shedding is low [125,241]. And unfortunately the oral fluid method which was 
intended to compliment clinical surveillance failed (reviewed in Chapter 4). 
Our surveillance methods may possibly have been improved upon if the study design had 
been such that: i) households were visited every 2-3 days, ii) nasal washing were taken 
even when individuals did not displaying signs of respiratory infection, and iii) used a more 
sensitive method of virus detection as in PCR for all samples. This would have been 
logistically near to impossible, maybe difficult to justify ethically (i. e. since the nasal wash 
is not without some pain) and also very expensive. There are problems also in terms of 
method of taking nasal sample i. e. washing in adults which proved tricky. 
Studies that include older children and adult participants must give careful consideration to 
sample collection. In this study collecting a sample from adult participants was a challenge 
as most adults were not keen on having a nasal specimen taken, viewing it as a strange and 
uncomfortable procedure. The bulb also had to be modified for use in adults; needing to be 
cut shorter to prevent penetration too deep into the nostril which can cause additional 
discomfort. The original study proposal did not have approval to collect nasal samples from 
adults and therefore this had to be sought at a later stage. The fact that adults were initially 
not under routine surveillance and were only included later in the study, resulted in 
incomplete data. Future studies would need to evaluate the acceptability of sampling 
procedures in each participant group prior to the start of the study. 
The method of collecting nasal specimens adopted in this study was the Nasal Washing. 
Although Nasal Pharyngeal Aspirates (NPAs) are regarded as the most appropriate 
specimen from which to recover pathogens that do not colonize the nasal pathway [242], 
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NW is considered to be the optimal specimen for rapid antigen tests [125] and is also 
feasible for use in larger field studies. A study carried out in Kilifi [243] showed that 
samples collected by NW were of good quality (82% had >20 epithelial cells). Titres of 
RSV virus in NW specimens have been shown to be similar to those in NPA samples, and 
markedly higher than in nasopharyngeal swabs [238,244,245]. The applicability of NPA 
outside the clinic setting is questionable. It requires a mechanical or electric suction device 
and with apparent greater invasiveness is likely to create greater anxiety to children and 
their parents. The nasal washing method has previously been used in community based 
studies [94,246] and the experience in the present study was that it was generally well 
accepted within the family for infants and children - as much or more by the parents as by 
the children themselves. However, as described above use of the NW on adults was not 
well received. 
Diagnosis of RSV infection can be made by several methods; virus isolation, detection of 
viral antigens, detection of viral RNA, demonstration of a rise in serum antibodies, or a 
combination of these approaches. The present study adopted the direct immunofluorescent 
test (IFAT). Early studies have used the more specific culture methods for virus isolation 
although most clinical laboratories now use antigen detection assays to diagnose infection. 
Studies that have compared different virus detection methods have shown 
immunoflourescence techniques to be equally or more sensitive for the detection of RSV 
infection than culture [247-250]. The review by Weber et al [28] clearly showed that 
following the introduction of IFAT in studies, the proportion of ARI patients in which RSV 
was identifiable increased considerably (Fig 2.1). However, the ideal is a combination of 
culture, IFAT and perhaps PCR where possible [248]. 
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Of importance is the quality of the samples collected. For a reliable IFAT, the integrity of 
the specimen must be maintained as it requires an adequate number of epithelial cells for 
acceptable sensitivity [125,251]. Falsey et al [241] found that the direct antigen tests often 
lacked sensitivity for specimens obtained from adults and older children which may explain 
why there was only one positive sample identified from an adult in this study. It is thought 
that the reduced performance of the test may be due to a combination of certain factors in 
adults: lower viral titres, a shorter duration of shedding and dry mucosa [125]. 
One of the advantages of using the antigen detection assay in this study was that the results 
were available within a relatively short time enabling the collection-of an acute sample, an 
important component of the project. Also this study was nested within the main birth 
cohort and immunofluorescence is the recommended RSV diagnostic assay for samples 
from children. To investigate some of the sensitivity problems we may have with the 
diagnostic method in this study, it is possible to screen all the nasal specimens that were 
negative by IFAT test using Polymerase Chain Reaction (PCR) based methods to identify 
any false negatives. PCR offers enhanced sensitivity combined with rapid diagnosis and 
sub-typing ability [239]. Until recently, PCR for pathogens with RNA genomes has been 
limited because of the difficulties involved in the RT (reverse transcription) step of the 
method and in the extraction of the nucleic acid when the starting material is of poor quality 
[239]. It is also relatively expensive compared to IFAT. Rapid ELISA was an option, but 
its sensitivity is lower than for IFAT. 
Training procedures, methods of assuring quality of performance and related materials used 
at the KBMRI-WT operated paediatric wards and out-patient research clinic were 
established as a result of the studies carried out by English et al [252,253]. These 
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procedures were in place prior to the start of the present study, and totally independent. All 
clinical officers (CO- clinical workers with 4 years of medical training) in the present study 
had previously undergone this training process. Respiratory rate was assessed by direct 
observation of the number of breaths taken per 30 seconds and scaled up to one minute. 
Clinical assessment was therefore based on previously established and standardized 
procedures. 
Findings from the studies of English et al (English, 1995 #433; English, 1996 #434) 
showed that health workers could be trained to recognize standard agreed definitions of 
respiratory signs suggestive of severe disease. For the present study a mechanism was 
needed that would reliably identify signs and symptoms reflecting respiratory infection 
(cough, difficulty in breathing, rapid breathing for age) for the collection of nasal 
specimens and importantly to trigger referral of cases to the research clinic from the field 
for definitive evaluation. We therefore trained FWs for this purpose assisted by the same 
video recordings of patients used to train clinical staff. Assessment of the success of 
training in recording respiratory rates was indicated by an improved correlation between 
measurements by FW and by CO taken on the same child at the same time (where the CO 
result was the assumed "gold" standard). No specific inter-rater reliability analysis was 
carried out. Note that study FW were only charged with the responsibility of using the 
respiratory rate to make an assessment for referral to the clinic for a comprehensive review 
by CO of possible severe cases identified in the field (Appendix G3). Field workers 
referred a child seen at home to the clinic if they identified symptoms or signs reflecting a 
lower respiratory tract involvement, i. e. a history of acute cough or difficulty in breathing 
plus fast breathing (>50 per min for ages less than 12 months, and otherwise >40). The 
severity of respiratory disease was ascribed following review by a study CO, which would 
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include (a repeat) measurement of respiratory rate. A comparison of the two respiratory rate 
values showed significant correlation (r=0.7, P<0.0001). Further, an assessment of inter 
observer agreement on fast breathing using the kappa statistic was 0.371 representing fair 
agreement between the CO and FW. Of interest here is the sensitivity of the FW 
measurement of fast breathing assuming the clinician's assessment as the gold standard. 
Instances of misclassification (false negatives) occurred in 55% of the cases (Table 3.6). 
Admittedly this is quite high however this highlights the need for more than one method of 
referral in such studies - an issue that was taken into account in this study. 
At each home 
visit mothers were encouraged to attend the Research OP clinic if they observed any signs 
of respiratory infection at any time between FW visits, and asked to watch out for 
deterioration in the child's condition following a FW visit and requested to seek immediate 
help at the OP clinic in such an event. 
Table 3.6. Correlation between Fieldworker and Clinicians' clinical classification 
Fast breathing FW 
Fast breathing CO 
0 
Total 
01 Total 
7,161 647 7,808 
757 613 1,370 
7,918 1,260 9,178 
A proforma uniform to the research clinic and the paediatric ward was adopted to facilitate 
consistency between admitted cases and cohort cases. LRTI was assigned to children with 
acute cough or difficulty in breathing in association with any one or more of the following 
(i) raised respiratory rate for age, (ii) intercostal indrawing, or (iii) inability to feed, reduced 
conscious level, or hypoxia (02 saturation <90% by Oximetry), the latter group only if 
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confirmed by the clinician's own diagnosis of LRTI or bronchiolitis. Severe LRTI was 
assigned to a child with criteria (ii) or (iii), or both, of the above. 
An analysis of digit preference of the respiratory rate measurement taken by the CO using a 
frequency distribution of the second digit did not indicate a preference for particular values 
(Figure). It should be noted that measurements were taken for half a minute and doubled to 
get the number of breaths per minute thus the second digit was always even. The frequency 
distribution plot shows no digit preference. 
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Figure 3.12 Frequency distribution of the second digits of respiratory rate variable 
Lastly, as has been reported in numerous published studies (discussed in Chapter 2), RSV 
outbreaks are highly seasonal and usually appear in the rainy season in areas with tropical 
or subtropical climate [28,39] such as that seen in Kenya. However, data from the present 
study suggests that epidemics are independent of rainfall, and were observed to occur in the 
hottest months with lowest rainfall. As discussed in Chapter 2, the issues surrounding this 
seasonality (i. e. how it persists and what triggers epidemics) remain unclear. Data collected 
over a longer period would be required to establish a clearer understanding of the 
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mechanisms at work. Surveillance is ongoing in the IP ward in Kilifi and it is hoped that 
such data will greatly enhance present knowledge. 
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Chapter Four 
Evaluation of the dynamics of RSV-specific antibodies in oral-fluid samples 
4.1. Introduction 
Viral-specific antibodies provide information on the infection status of the host, and are 
particularly of use in support of clinical surveillance information (discussed in Chapter 2). 
The presence of anti-viral immunoglobulin M (IgM) is an indicator of recent infection. The 
presence of virus-specific immunoglobulin G (IgG) antibodies provides evidence of passive 
maternally-transferred antibodies or a past or present acquired infection. More specifically, 
paired samples from an individual which show a change from specific-IgG absence to 
presence (known as seroconversion) or a significant rise in viral-specific immunoglobulin 
G (IgG) antibodies (conventionally 4 fold) provides evidence of a current infection which 
could be a primary or a re-infection. Except where maternal antibodies persist to interfere 
with the immune response [88,93], serial sampling for the determination of serum RSV- 
specific antibodies has yielded useful information on occurrence of infections [12,19,101] 
and is seen to be of particular use in age groups where clinical signs of infection may go 
unnoticed by surveillance due to decreasing severity of RSV infection with age or in those 
re-infected [12]. Furthermore, specific-antibody methods are of importance where the 
collection of nasal specimens is not easily undertaken, for example in older children and 
adults. 
As previously described (Chapter 2), it is not always possible or desirable to collect blood 
samples by which to determine serological status, and oral-fluid sampling has shown 
promise as an alternative [20,218]. It has been shown that oral fluid collected from around 
the gums is rich in exudated serum antibodies and thus reflects the antibody profile within 
serum [224,225]. This has been shown for other viruses [212,218) but not specifically for 
103 
RSV. The extent to which these data are analogous to RSV dynamics is unknown as a 
single study only has investigated anti-RSV antibodies in oral-fluid [20]. 
One of the key objectives of the household study was to determine and compare the 
incidence rates of RSV infection in different age groups. Birth cohort children were being 
serially bled to provide serological evidence of infections, but ethical approval for the same 
for older children had not been sought. Instead approval was sought and limited to the 
collection of oral-fluid samples at 3 monthly intervals from all family members, children 
and adults. This was to complement clinical sampling to identify possible missed 
asymptomatic infections in other household members thus overcoming the limitations of 
our clinical surveillance methods i. e. nasal washing collected only when symptoms were 
present, as well as to identify serological infection in adults. The oral-fluid was to be used 
to monitor the changing levels of IgG during the study with the incidence of RSV 
determined by examining seroconversion or boosting of anti-RSV antibodies in oral-fluid 
samples [20] from pairs of samples separated by a3 month interval. 
Existing data on oral-fluid antibody detection in relation to RSV and how this correlates 
with serum antibody ("gold standard") is, to the best of my knowledge, non-existent. The 
single study that has used oral-fluid to determine incidence of RSV infection in a 
population of children [20] did not make any comparison of antibodies in oral-fluid to 
serum. To overcome this problem in this study a comparison between serum and oral-fluid 
was included in the study design. 
Presently, no known data detailing time-related changes or individual level variation in 
anti-RSV IgG antibody in oral-fluid exists. A subsidiary aspect of the three monthly oral 
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fluid collection surveillance design was therefore to characterize the temporal dynamics of 
RSV-specific antibody in oral fluid and its variability. The aim was to aid the interpretation 
of the 3-monthly interval data and subsequently to estimate re-infection rates. Correct 
interpretation of this data requires accurate measurement of each individual's exposure to 
RSV infection within a particular 3 month interval. 
For the accurate interpretation of antibody measurements from sequential three-monthly 
oral-fluid samples, there are three aspects of antibody dynamics where knowledge is 
lacking (Figure 3.1). These are, i) the rate of natural background decay of IgG RSV specific 
antibody (r1), ii) the threshold for variability in antibody measurement beyond which an 
observed antibody level can be assumed to be due to the boosting effect of re-infection 
within the sampling interval and iii) the possibility of an initial decay (r2) immediately 
following antibody boosting (b) after infection at a rate faster than the background decay 
rate, r2>rl ( as has been seen in the case of measles [254]). In the absence of any information 
on the average level of boosting and subsequent initial rate of decay in RSV-specific 
antibody, it is difficult to ascertain what proportion of infections occurring at various time 
points in an observational interval (3 months) are likely to be followed by antibody decay 
to levels below the predefined criteria for assigning an individual as being re-infected. 
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Figure 4.1. Schematic of antibody dynamics (log scale) of RSV infection over a3 month 
interval, with or without re-infection. ri, background rate of antibody decay in absence of 
boosting effect of re-infection. b, boosting effect following re-infection, and r2 rate of decay 
following re-infection or boosting (b). Vertical axis represents average background 
antibody level [Ab] or multiples thereof. Grey zone indicates region of variability beyond 
which a measured antibody level is indicative of boosting (assuming 4 fold rise in antibody 
indicates infection. ) 
4.2 Chapter Aims 
This chapter describes the study design of an oral-fluid surveillance system (introduced in 
Chapter 3) which complements clinical surveillance of RSV infections within the 
household. A supporting study is described which has the objective of improving our 
understanding of oral-fluid antibody kinetics, important to the interpretation of sequential 3 
monthly data. An account is given of the enzyme-immunoassay used to determine RSV- 
specific antibody in oral fluid. The limitations of the ELISA method and results are 
discussed, together with the implications for the interpretation of household infection data. 
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4.3.. Study Design and Sample sizes 
A description is first given of the study design for sampling of household members, which 
is followed by details of the oral-fluid assay optimisation. Details of the method of 
collection of saliva and blood have previously been given in Chapter 3. Processing of the 
saliva sample was as described in Chapter 3. Details of each component of the oral-fluid 
sampling study are given in Table 4.1. 
Table 4.1. Summary of the elements of the sampling involved in each study 
Study Study Participants Sampling Frequency 
Purpose/Objective Involved 
i) Oral-fluid Complementary All household cohort Oral fluid samples taken 
surveillance. surveillance system. participants, i. e. at enrolment and every 
Used to estimate age- birth cohort, siblings three months thereafter. 
related re-infection 
rates and identify 
missed infection. 
ii) Serum oral- Assess performance of 
fluid comparison oral-fluid assay 
study. against assumed gold 
standard (serum). 
iii) Antibody Quantify RSV- 
dynamics study. specific IgG antibody 
dynamics. 
and adults 
Household members Paired blood and saliva 
of the first 40 samples taken twice 
recruited households over a3 month interval. 
(convenience Samples collected from 
sample). subgroups of 10 
households in sequence. 
30 individuals in 45 individuals sampled 
each of three age weekly for 13 weeks 
groups; 0-5,6-14 within epidemic. 
and 15+ randomly Another 45 individuals 
selected from within sampled weekly in the 
the household inter-epidemic period 
cohort. for 13 weeks. 
107 
Three-monthly oral fluid surveillance 
Oral-fluid samples were collected (see Chapter 2) from all members of each household in 
the main study at enrolment and thereafter samples were collected at intervals of three 
months until the end of the study. The objective of this study was to determine age-specific 
incidence of RSV re-infection within household occupants. 
Serum Oral fluid comparison study 
Paired blood and oral fluid samples from all (whenever possible) occupants of 40 
households were collected on two consecutive occasions (at 3 month intervals), providing 
material by which to assess the performance of the oral-fluid assay for the detection of anti- 
RSV antibodies, in comparison with serum (assumed gold standard). 40 families were each 
sampled twice. For convenience, households selected for this study were the first 40 
recruited into the household cohort. Two consecutive blood samples (at 3 month intervals) 
were subsequently collected from each of 4 subgroups of 10 households, sequentially, to 
compare antibody dynamics over the three month period at different time points. Blood 
samples were collected on the same date as the scheduled routine oral-fluid sample to 
facilitate comparison. 
Antibody dynamics study 
Intensive oral fluid sampling at weekly intervals was carried out for a period of 3 months 
(13 weeks) in a sub-sample of individuals within the participating households with the aim 
of quantifying RSV-specific IgG antibody dynamics over this critical time interval. 
Sampling was undertaken in 30 individuals in each of three age groups, 0-5,6-14 and 15 
and over years, stratified equally among epidemic and inter-epidemic periods. 
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Additionally (i. e. in addition to the 30 in each age class), any child from within the enrolled 
households identified as RSV antigen positive was enrolled into the study and sampled 
weekly for 3 months. It should be noted that the study was designed to include individuals 
experiencing primary and re-infections by which to evaluate differences in their antibody 
kinetics. Further details of the sampling procedures for this study follow. 
i) Non-RSV cases 
In September 2003 (inter-epidemic), 15 individuals within each of three age classes, 0-5,6- 
14, and 15+ years were randomly selected from households using a block random design 
[255] to ensure equal numbers in each age class. Only one person per household was 
recruited. These individuals (total 45) were followed for 3 months (end December 2003) 
with samples of oral fluid collected at enrolment and every week thereafter (a maximum of 
13 samples per person). In February 2004 (within epidemic season), a second sample of 15 
individuals in each of three age classes, 0-5,6-14, and 15+ years was selected and followed 
weekly for 3 months in a similar manner to that during the RSV season (i. e. expected 
number of samples 585). Sampling was necessary both within the RSV epidemic where 
serological identification of cases (by which to estimate boosting and early decay) would be 
highest, and between epidemics investigate any difference in the background decay rate (rl 
of Figure 3.1) relative to that within the epidemic. Based on previous family studies of RSV 
infection [16], it was anticipated that approximately 25% of household members would 
show serological evidence of exposure during one season, i. e. I1 cases (not taking account 
of cases identified by antigen positives - see below. ) 
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ii) RSV cases 
During the epidemic spanning 8/1/2004 -2/6/2004 any child identified to 
be shedding RSV 
antigen (and not already in the intensive sampling study) was recruited into the intensive 
sampling study, as soon as possible after the laboratory result became available. An oral- 
fluid sample was collected at recruitment and each week for a further 13 weeks. The source 
of RSV cases can be separated into (a) birth cohort children, and (b) their siblings (aged<15 
years) from enrolled households. Children already enrolled into the intensive shedding 
study and testing Ag positive were followed-up for a complete 13 weeks from this point. 
Assuming an average of 2.3 siblings to each cohort infant (estimated for households of the 
main birth cohort) it was projected that there would be a total of 160 siblings in the HH 
study. Roughly 20% incidence per annum was observed by antigen shedding in the infant 
cohort in 2002 and the assumption of half this rate (10%)[151 during the 2004 epidemic in 
the siblings would result in recruitment of about 16 infected individuals into the intensive 
oral-fluid surveillance. It followed that among the birth cohort infants (projected number 
70) would give rise to 14 primary infections for intensive follow up. In total it was 
therefore expected that 41 infections would be identified from clinical surveillance and Ag 
testing (30) and serological monitoring (11, see previous section). 
Results of sample collection 
The results of samples collected from these three elements of serological surveillance are 
documented in Table 4.2. There were more antigen cases than was predicted 30 vs. 75. with 
relatively few instances of missed samples (< 15% in all stud arms). There were no 
instances of documented refusal to give repeated samples except in some (3) Muslim 
homesteads during the whole month of Ramadan for religious reasons - the belief that 
nothing (in this case Oracol) should be put in mouth. 
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Table 4.2. Total numbers of samples collected for each of the 3 elements of serological 
study. 
Study Number of 
samples 
projected 
Number of 
samples 
collected 
Reasons for 
missed samples 
i) Oral-fluid 4023* 3536 (88%) i) traveling 
surveillance. ii) loss to follow- 
up 
ii) Serum oral- 434 374(86%)$ iii) refusal to give 
fluid oral-fluid sample 
comparison during the Muslim 
study. fasting holiday 
iii) Antibody In-season 585 493(84%)s (Ramadan) 
dynamics study. RSV Ag 390& 975 (75 
positive cases positives) 
Off-season 585 520 (89%)$ 
* from approximately 24 months of follow-up (the median follow-up time). (9*447 & 30 Ag positive cases expected $ Proportion of expected number of samples 
4.4. Oral-fluid Enzyme Linked Immunosorbent Assay (ELISA) and Optimisation 
Oral-fluid specimens were analyzed for anti-RSV antibody using a published method [201 
to quantify RSV specific IgG. The assay comprises two stages. First, the concentration of 
total IgG is determined using an IgG capture assay. For antibody capture assays very low 
concentrations of IgG are required to saturate the solid phase. The process can therefore be 
successfully used with saliva. A set of standards of known concentrations are included 
in 
this step from which the concentration of the sample is calculated. Second, following from 
step one, a quantity of oral-fluid sample calculated to contain a standard concentration of 
IgG (lmg/L) is used in an indirect sandwich anti-RSV ELISA. These two stages are 
described further in the following sections and the detailed laboratory methods are provided 
in Appendix M (p 342). 
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Step 1: Antibody capture assay (Fig. 4.2) 
A solid support (microtitre plate) is coated with anti-IgG antibody. When the test specimen 
is added, IgG class antibody contained within is captured giving (after washing) a sample 
free from other components. The presence of the antibody-antibody complexes is revealed 
by the addition of an enzyme-conjugated antibody specific to the captured immunoglobulin 
class, which catalyses a suitable substrate added to produce a colorimetric product. 
I. Solid phase anti-IgG 3. Antibody complex probed 
with anti-IgG enzyme conjugate 
0--< 
AL 
AL 
2. lgG antibody in sample 4. Add enzyme substrate 
to visualise 
Figure 4.2. Illustration of stages (1-4) of the IgG Capture ELISA assay [256] 
Step 2: Anti-RSV assay (Fig 4 3) 
The oral-fluid specimen was diluted to a standard concentration of total IgG, following Step 
1, to overcome variation in total IgG associated with crevicular fluid sampling. Virus 
specific antigens (whole cell extract) are immobilised on a solid phase to which the oral- 
fluid specimen is added. Any antibody in the sample against the viral antigen is bound. This 
binding is revealed by the addition of an antibody against the IgG class of interest 
conjugated to an enzyme that generates colour upon the addition of a substrate. 
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Figure 4.3. Illustration of stages (1-4) of the direct ELISA assay[256] 
4.4.1 Optimisation 
Since the assay was not in commercial kit form and had not previously been established 
in 
Kilifi, it required optimization. 
Objectives of the ELISA Optimisation 
1. To determine the optimal working dilution of the standard reference IgG antibody. 
2. To determine the optimal working dilution of the test sample. 
3. To determine the optimal coating concentration of RSV antigen. 
4. To investigate the sensitivity of the assay at low and high titres of anti-RSV antibody. 
5. To evaluate the method against assumed gold standard serum since the only previous 
publication did not compare oral fluid with serum. 
a) Determination of the optimal working dilution of the standard reference IgG antibody 
for 
the IgG capture assay 
A series of experiments were performed to determine the linear limits of the standard 
reference curve. Flat-bottomed 96-well plates were coated overnight at 37°C with 100 
ml/well rabbit antihuman IgG diluted 1/3,000 in sodium carbonate coating buffer. The 
plates were washed four times in phosphate-buffered saline (PBS) containing 0.05% Tween 
20 (PBS-T). The plates were then blocked with 5% dried milk powder in PBS-T (200 
ml/well) at 37°C for 60 minutes. IgG calibrant standards (180µg/ml IgG, Binding Site, 
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Edgbaston, England) (2.5-0.039 mg/1) were prepared by doubling dilution in PBS-T. Saliva 
was diluted 1/100 in PBS-T. Saliva samples and IgG standards were assayed in triplicate. 
Incubation times, wash conditions, and detection conditions are as described in the ELISA 
SOP (Appendix M, p 342). To quantify an unknown, we compare the activity obtained with 
the unknown to the standard curve. The IgG standard curve was plotted to check for 
linearity. 
Result 
, 
There was very good reproducibility of the replicates and log-linearity through out the 
standard dilution range used. 
I 
r 
Figure 4.4. IgG standard curve 
The IgG concentration of an unknown, x, was derived from standard curve as follows. We 
assume a linear relationship between the logarithm (base 10) of x and optical density, OD, 
OD _ a+b(logx) (4.1) 
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where a and b are the intercept and slope of the regression line, respectively. Rearranging 
4.1 we obtain the following expression for x, 
x_ 1O(OD-o)Ib. 
b) Determination of the optimal working dilution of the test sample 
We investigated the optimal working dilution of samples. There was no documented reason 
for using the 1/100 dilution adopted in the reference method paper [20]. Twelve 3-monthly 
oral-fluid samples from children in the first, second or third year of life, and some 
convalescent samples were assayed in triplicate, to improve accuracy, using doubling 
dilutions from 1/10 to 1/20480. To confidently choose a working dilution samples were 
taken from individuals of different ages; children of different ages assumed to have 
differing infection history which would be reflected in the levels of total IgG. One sample 
each from 3 children in each of three age class- 0,1,2 years and 3 children from the IP 
study (< 5 years) (Refer to section 2.12) were tested and the saturation zones and linear 
portions of the dose-response curves defined. Ideally the estimated concentrations from 
absorbance values falling within the linear limits of the curve should be consistent after 
taking account of the dilution factor. 
Results 
The linear region of the dose response curves fell within the 1/20 and 1/640 dilution range 
(Figure 4.5) hence; either the 1/100 or 1/200 dilution would be good working dilutions. The 
results show some variability in amount of total immunoglobulin depending on which 
dilution was used and it was not apparent which of the two dilutions would be better. Two 
options are available. i) Use both dilutions to assay samples and take an average of the two. 
However, this would increase the work load. ii) Choose a single dilution but dilute the 
sample further if absorbance readings were outside the linear limits of the standard curve. 
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The second option was adopted i. e. use the 1/100 dilution allowing for further sample 
dilutions if needed. This resulted in minimal increased work load. 
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Figure 4.5. Absorbance readings for total IgG using doubling dilutions from 1/10 to 1/20480 (identified as labels 1-12) for different oral-fluid samples: 2 birth cohort child, 9 
and 12 months (right) and acute and convalescent samples from IP children, 3 and 3.3 years (left). OD is optical density at 492nm. Includes two replicates of each sample (open diamond and filled square markers). 
c) Optimisation of the RSV specific assay for oral fluid 
The following series of experiments were conducted to optimise the assay for detection and 
quantification of RSV-specific IgG. Briefly for each experiment, six columns of a ninety- 
six-well plate were coated with RSV-A2-infected lysate; the other six coated with mock- 116 
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infected cell lysates as describe in the SOP (See Appendix N, p 344). Infected and 
uninfected lysate was grown at Birmingham University Medical School by Dr Paul Scott. 
Plates were coated in Birmingham and shipped on ice to Kilifi. 
1. ) Initially, 6 oral-fluid samples from adults in Kilifi were used because they should have 
high level of specific IgG from previous infection. A pooled serum sample (mixed serum 
sample form several adults in Kilifi) was included as control. Samples were assayed in 
duplicate from 1/10 to 1/20480. 
Results 
Low absorbance readings (OD<0.2) were observed with negligible difference between 
positive signal (response to infected lysate) and noise (response to mock antigen). Further 
experiments were carried out using 5 samples from cohort children with similar results. 
2. ) The logical next step was to change the sample dilution range to 1/2 to 1/64 to increase 
the specific antibody concentrations. Oral-fluid samples from two groups were assayed, i) 
27 samples from individuals with known clinical infections i. e. acute convalescent sample 
pairs from in-patients (IP) expected to show antibody boosting or seroconversion (1-5 
years), and ii) consecutive three month samples from the same child over the first year of 
life (samples from 3 children). 
Results 
Some acute convalescent paired oral-fluid samples (an example is illustrated in Fig. 4.6) 
showed a rise in antibody. However, most samples tested showed no detectable RSV 
specific antibody. 
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Figure 4.6. Absorbance readings from paired acute and convalescent oral fluid samples 
from Patient 56134, diluted from 1/2 to 1164. OD is optical density at 492nm. Includes two 
replicates of the acute sample (open and filled square markers) and two replicates of the 
convalescent (open and filled circles). 
There were two possibilities to explain the apparent variability in results; some samples 
were showing boosting of antibody between the acute and convalescent sample while 
others were giving no signal. The results could indicate that the assay worked and possibly 
that the samples with no signal did not have detectable levels of specific IgG. Alternatively, 
there was a fault with the assay such as insufficient blocking, inadequate sample volume 
used and/or nature of storing samples (issues explored below). To resolve this, paired oral- 
fluid samples of serum samples that had previously shown rising anti-RSV titre (boosting) 
were assayed (Serum sample results courtesy of Rachel Opiyo). These ideally would show 
the same antibody boosting observed in serum. 
3. ) The assay was therefore repeated using paired serum and oral-fluid samples from 
children into the second year of life. Full range of samples from nine children were assayed 
some results of which are shown in Figure 4.7 
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Figure 4.7. Age plots for serum (left) at 1/100 to 1/400 dilution and oral-fluid (right) at 1/2 
to 1/16 dilution. Note the difference in scales used. OD is optical density at 492nm. The filled black boxes are 1/100 and 1/2 dilutions for serum and oral-fluid respectively, orange is 1/200 and 1/4, the blue 1/400 and 1/8 while the open boxes are 1/16 dilution of oral-fluid. Last two samples in each panel are acute and convalescent samples. Oral-fluid sample was 
not routinely taken at birth and the 6m sample was not collected. 
A roughly similar antibody pattern as that seen in serum was observed in oral-fluid (Figure 
4.7), but still at very low levels (negligible) especially after correcting for background 
(results not shown). The serum plot at 1/100 or 1/200 gives a good profile of decay 
(presumed maternal antibody) and subsequent rise in antibody concentration (following 
infection). The pattern of decay in maternal antibody is not observed in oral fluid. 
However, a rise in the acute/convalescent sera does appear. The assay was repeated using 
adult samples (presumed to have higher antibody levels in general) taken from the 
household study also giving very low absorbance readings (results not shown). Subsequent 
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repeat experiments were carried out using standardized saliva samples corresponding to 
lmg/L IgG for the specific assay to correct for the inherent variability in oral fluid samples. 
4. ) To further investigate the observed results, various other troubleshooting options were 
explored in an attempt to improve the strength of the signal observed and reduce the 
background. For each experiment in this section samples from 8 adults were assayed. 
1) Substrate processing time 
In varying the substrate processing time from 10 minutes to 30 minutes it was found that 
the longer the substrate was left to process the higher the absorbance readings for both the 
signal and mock (noise) (Figure 4.8). 
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Figure 4.8. Comparison of substrate processing times 10 vs. 30 minutes using samples from two adults (Mwa (a) and Mau (b)). OD is optical density at 490nm 
ii) Comparing fresh and frozen samples 
Fresh saliva samples from various adults in Kilifi were used on the working assumption 
that the method of sample storage may affect the outcome observed. Sodium azide used in 
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the preparation of the freezing mixture has been known to inhibit peroxidase reactions. No 
appreciable differences in absorbance readings were observed (results not shown). 
iii) Blocking Optimization 
In an attempt to reduce the signal to noise ratio the use of a higher concentration of 
blocking solution was explored. Working on the assumption that increasing the block 
would reduce the background problem, plates were blocked using 5% (as per SOP) and 
10% (new) block solution. The results from this experiment are shown in Figure 4.9. 
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Figure 4.9 Comparison of absorbance readings using different concentrations 5% (left) vs. 10% (right) of blocking solution. OD is optical density at 492nm. Includes two replicates of 
the sample (open and filled square markers) and two replicates of the mock (open and filled 
triangles) for each assay. 
iv) Comparing effect of different secondary antibody 
Investigated the use of a different secondary antibody in the specific assay as a possible 
reason for the low absorbance. Wilson et al [20] used Horseradish Peroxidase (HRP)- 
conjugated goat anti-human IgG as the secondary antibody for the RSV specific ELISA 
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with no documented reason for doing this. In this study HRP-conjugated rabbit anti-human 
IgG was used in both the capture and the specific assay. An experiment was performed to 
investigate the difference between the two secondary antibodies. Oral fluid samples taken 
from Kilifi adults were assayed and serum included as the standard. 
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Figure 4.10. Comparison of absorbance readings using two different secondary antibodies 
on both serum (right) and oral-fluid (left) samples. OD is optical density at 492nm. Dilution 
used was 1/2 - 1/64 for oral-fluid and 1/50- 1/1600 for serum (shown on the graph as 1-6). HRP-conjugated goat antihuman (filled (signal) and open box (noise) markers). HRP- 
conjugated rabbit anti-human (filled (signal) and open circles (noise) markers). 
From the example in Figure 4.10 above and in all samples analysed the HRP-conjugated 
goat anti-human IgG produced higher absorbance readings than the HRP-conjugated rabbit 
anti-human IgG [as used by Wilson]. Despite the fact that there is a difference in the results 
given by the different secondary antibodies, the HRP-conjugated goat anti-human also gave 
higher noise signal which seems to even out the overall effect. Still the HRP-conjugated 
goat anti-human was adopted for use. Subsequently, previously assayed paired serum and 
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oral-fluid samples were also tested using the new secondary antibody. It is now know that 
there was a problem with the antigen coated plates which has only recently been resolved 
by growing our own Ag and changing various aspect of the coating method (see discussion 
later). 
Results 
Similar dose response patterns were observed (some examples illustrated in Figure 4.11 and 
4.12). In most instances the absorbance readings of saliva were found to be roughly half the 
magnitude of that seen in serum. Note that the sample dilutions used for serum and oral- 
fluid were different. Signal to noise ratio for oral-fluid sample is in several instances almost 
1 i. e. no difference between antigen and mock. 
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Figure 4.11. Absorbance readings for paired serum (top) and oral-fluid (bottom) samples from a household child. First set of samples on the left taken on 20-05-03 (6.9 years) and 
second sample on the right taken on 10-09-03 (7.2 years). Dilution used was 1/50- 1/1600 for serum and 1/2 - 1/64 for oral fluid. OD is optical density at 492nm. Samples run 
in 
duplicate (signal -filled box and circle markers and noise- open box and circle markers). 
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d) Determination of the optimal coating concentration of RSV antigen 
With less than promising results, a review of the dilution of the antigen used was 
undertaken. Until this point, plates coated with 1/64 antigen dilution, the dilution that gave 
the best signal to noise ratio for serum had been used. Oral-fluid samples were titrated 
against antigen in a checker board analysis. The checker board analysis was done using the 
same previously used lysate grown at the Birmingham laboratory and new locally grown 
lysate. Results from this experiment show that the 1/64 antigen dilution used gives general 
low absorbance reading. The signal to noise ratio in most instances was -1 except at the 
neat and 1/2 antigen dilution. This may explain why we were getting such low absorbance 
readings in general. Using the lysates undiluted or at a 1/2 dilution was not feasible in 
terms of lysate production. 
4.4 Discussion 
The serological assays have the added potential for the identification of possible 
asymptomatic cases missed by routine clinical surveillance. This is especially important in 
older children and adults with typically more mild illness of short duration or who in some 
instances show no symptoms (Chapter 2). Previous work in children indicates 50% 
sensitivity for RSV infections through clinical surveillance [19,94,144]; even less in 
adults [125]. Though less informative than viral detection (Chapter, Section 3.4), oral-fluid 
ELISA determined infections identified by changes in antibody titers would have picked up 
infections missed by clinical surveillance for a number of reasons, including asymptomatic 
infection, IFAT sensitivity particularly in adults and older children [125,241]. However, 
we were unable to proceed with the oral-fluid assay due to unreliable signal the reasons for 
which are not clear. 
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Lower concentration of immunoglobulin in oral fluid makes the quality of the sample very 
important. The most important source of the IgG antibody in oral fluid is the crevicular 
fluid as previously indicated. It is therefore vital that the device used to collect oral fluid 
targets this fluid. There are various collection methods. A study [213] comparing several 
devices rated the Oracol sponge device the most comfortable and with significantly higher 
geometric mean titres of total IgG than for the other two devices (41.7 mg/L (95%CI 28.8- 
58.9) sponge versus 25.1 mg/L (18.2-35.5) OmniSal and 22.9 mg/L (18.2-28.8) OraSure). 
Assuming a direct relationship between virus-specific and total IgG, it is thus unlikely that 
the low signal in our experiments was as a result of the quality of the sample and the 
collection device used. 
A similar procedure was, at the time of writing, giving very low signal to noise ratio with 
sera from cohort children (by a PhD student colleague, Rachel Opiyo). Results from the 
serum assay will be essential in understanding the problem(s) with the oral-fluid assay. 
After consultations with other researchers who had previous experience with the use of OF 
samples a joint decision was taken between my supervisors and myself in consultation with 
my appointed Student Advisory Committee to terminate this line of work and to 
concentrate of other aspects of the project. At the time, the major reason underlying this 
decision was the poor results obtained with the serum assay (considered the "gold" 
standard). It was felt that given these results it was highly unlikely that better results could 
be attained with the OF assay within the time constraints for completion of the thesis. It is 
thought that several aspects of the previous protocol were flawed contributing to the poor 
results. The protocol was based on a previously published method. A new improved assay 
protocol has since been developed (February 2007) for the serum assay details of which 
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and an interpretation of the possible problems as well as prospects for future work using the 
OF samples collected are discussed below. 
Following several modifications to the experimental protocol the test signal-noise ratio for 
serum assay has improved significantly suggesting a similar result would be expected when 
used with oral-fluid samples. The modifications implemented include: 
i) the viral antigen recovery method was modified. Previously, recovery of virus from 
culture was by the addition of detergent and shaking to rupture the cells. The detergent acts 
by interfering with the cell membrane and therefore aids in the breaking up of the cell 
membrane. It is thought that this method did not efficiently break up epithelial cells. This 
method was found to limit the amount of virus antigen recovered. In addition, the added 
detergent was found to prevent binding of virus antigen to plates. The method of viral 
recovery was therefore changed and cell break up is now done by sonication. Various 
combinations were tested before one was selected: sonication alone, detergent plus 
sonication and using detergent only. No difference was observed between the two methods 
using sonication but there was a significant difference with the group using detergent only. 
Two main outcomes; 1) consistency of replicates was minimal with the detergent only 
antigen but the sonication greatly improved the consistency of replicates (CVs of 30% with 
detergent vs 6% with sonication) 2) the overall ODs were much greater with the sonicated 
virus even at quite high dilutions, supporting the notion of greater viral release through 
sonication. From these results it was evident that the improved difference was brought 
about by sonication. Sonication has the advantage of liberating more viral protein, and 
retaining its quality and ability to coat plates. 
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ii) Secondly, plates were previously left at room temperature overnight to allow the 
antigen to bind to plates. It has since been established that optimal antigen binding can be 
achieved at 37°C for 4 hours. 
No appreciable difference was detected after 4 hours. This reduction in incubation time 
results in more efficient coating of plates an aspect that will prove to be important 
considering the numerous OF samples that will need processing. 
iii) Formerly acetone was added to fix antigen onto plates (as used for malaria slides) to 
facilitate transportation of coated plates from the UK. Until recently lysate was grown in 
the UK. A culture laboratory has now been set up in Kilifi and the RSV lysate is grown 
locally thus it is no longer necessary to fix the antigen on plates using acetone. To my 
knowledge there is no obvious detrimental effect of acetone except that it is no longer 
necessary. 
iv) Previous results suggested that there might be some non-specific binding of general 
IgG to the plate. This would then mask any true anti-RSV antibody signal. This prompted 
the need for revisiting the blocking step. The blocking process acts to cover any exposed 
surfaces on the plate with another protein that does not react with sample antibody thus 
preventing non-specific binding to the solid phase. Milk (e. g. Marvel powder) an 
alternative protein that does not react with the sample is usually used and binds to places 
where Ag is not bound. In the previous protocol milk added to PBS-T was used. It has been 
suggested that the addition of Tween (a detergent) might hinder the effectiveness of the 
blocking. PBS with Tween is ordinarily used in plate washing to remove non-specifically 
bound particles on the plate but not to prevent non-specific binding. Thus is not necessary 
in the blocking process and has since been left out. In the new protocol plain PBS is used to 
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constitute the blocking solution. The specific reasons for high background in previous 
assays are still not clear as there is no known reason for mock (cells without Ag) to show 
non-specific binding. One possibility is that there may have been some cross contamination 
in previous culture or during the transportation of plates from Birmingham to Kenya. 
Presently background levels are consistently low as is desired. This will be important 
especially for OF samples which have a lower signal thus requires very low background to 
detect difference. 
v) Lastly, the protein adsorption of the plates in use currently is also higher by adopting 
plates with a high protein binding specification. Standard binding plates appears to result in 
scant attachment of the viral protein to the solid phase such that once the sample is loaded 
there is increased chance of unsuccessful binding. Specifically with regards to OF it is felt 
that this would be important given the low quantity of antibody present in the sample. With 
a saturated solid phase the chances of successful antigen-antibody binding are higher. 
Reluctantly the work on perfecting the oral-fluid method had to be curtailed. The 
serological element of this project was a key component of the study design insofar as was 
necessary in defining the contribution of re-infections (age-stratified incidence rates) in 
both children and older individuals to community transmission dynamics. The absence of 
these data means that a major aspect of the study has been compromised and results need to 
be viewed in the light of this omission. However, plans are underway to use this new 
protocol and assay optimisation with OF samples. If this proves successful we intend to 
proceed with the processing of all the OF samples collected within the Household study. 
Current results using the new protocol are shown in Figure 1. This shows the results of a 
standard checkerboard analysis, varying both antigen and antibody. The results show a 
clear shouldering effect. These preliminary results indicate that it will be necessary to use a 
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higher dilution of Ag to coat plates compared with that of there equivalent serum assay. It 
appears that the 1/4 Ag dilution and neat saliva will be optimal for use; this now requires 
the culture of large quantities of RSV antigen which is underway 
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Figure 4.13. Oral fluid checker board titration. Correct OD reading (Top panel). Bottom 
panel shows actual Ag and mock signals. 
The preliminary results of the oral fluid evaluation that have just been concluded are 
presented illustrating implementation and progress achieved at present. 
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Chapter Five 
Transmission within the household 
5.1 Introduction 
RSV transmission is known to occur rapidly within a population such that most (60% or 
more) children are infected during the first epidemic to which they are exposed and 
practically all have had at least one infection by the end of the third year of life. It therefore 
seems non-intuitive that RSV is transmitted by large droplets and contaminated materials 
(fomites) as opposed to aerosol transmission [55,77] suggesting the need for close contact 
for infection to occur. Furthermore although most of the disease is observed in young 
children (< 1 year) it seems unlikely that they are the main source of infection. This 
hypothesis is supported by evidence from previous community studies (Chapter 2 section 
2.7) and some adult studies [53,98,135,136,142] that report high incidence of re- 
infections and identify siblings, especially of school age, as an important risk factor 
(Chapter 2 section 2.8 & 2.11). Accordingly, susceptible individuals in the population can 
be classified as being of two types: fully susceptible (naive) children who have not had a 
primary infection and partially susceptible individuals i. e. those who have partial acquired 
immunity against RSV and can be re-infected (Figure 5.1. ) 
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Fomites/large droplets 
=> close contact 
Infants - few +full susceptible 
Short but skewed 
Figure 5.1. Transmission model of RSV. p is the probability of transmission taking place 
on contact, D is the duration of viral shedding, Y refers to infectious individuals in the 
population. There are two classes of susceptible individuals (X); fully susceptible infants 
and partially susceptible older children and adults. Incidence, I is a function of the number 
(density) of susceptible and the rate of infection per susceptible, also known as the force of infection. The force of infection is a function of the rate of infectious contacts (c YIN) 
scaled by the probability of transmission, p. Prevalence is a function of incidence, I, and 
average duration of infection, D (the inverse of the average rate of recovery). 
The epidemiological pattern as represented in the transmission model shows that close 
contact such as is evident in the home or school setting provides ample opportunity for 
spread and increased the risk of infection. This is in line with existing risk factors for 
fomite and close contact spread which include the proximity of child to mother and 
nearness between siblings in the home [113,144,194,198,257]. It seems important 
therefore to understand transmission patterns within the household as a means to 
understanding transmission at the population level. Examination of levels of mother to 
child transmission would also be a significant contribution to studies on the possibility of 
maternal vaccination as a means of reducing the risk of mother-to-child transmission (as 
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well as longer protection from boosted maternally derived antibodies), delaying primary 
infection and consequently reducing the risk of severe disease [257] . 
Based on the assumption that re-infected individuals are an important source of 
transmission and the presumed infectivity of re-infected children, the study aims to 
investigate the chains and modes of transmission within the household as a unit of 
investigation, identifying who is acquiring infection from whom and studying the 
relationship between past exposure and duration of shedding (Chapter 6). 
5.2 Chapter Aims 
This chapter will present the observational data and subsequent chapters will present 
analyses e. g. Chapter 6 estimate rates of shedding in relation to various risk factors and 
Chapter 7 estimate rates of transmission. The studies presented in this chapter mainly aim 
to identify the potential role of re-infection to RSV spread through investigation of re- 
infection patterns by age, family structure and environmental risk factors; relative 
contribution of different classes of individuals to transmission; secondary attack rate and 
factors influencing secondary transmission. 
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Table 5.1. Table of definitions 
Term 
,, Definition 
Household Individuals in a homestead who normally 
share the same meal. 
Sibling Any child less than 15 years old at the time 
of recruitment living in the household of the 
birth cohort child (may include cousins and 
step-siblings). 
Household index case The first case in a household and the first 
person to introduce the virus into the home. 
If more than one case appeared on the first 
calendar day of an introduction episode, 
both cases were considered as primary 
cases. 
Household contacts Persons living in the same household 
exposed to the primary case. 
5.3 Methods 
The method of intensive surveillance of a birth cohort and a household cohort was 
previously described in Chapter 3 and published [5]. In brief, study individuals were 
monitored through active household visits undertaken weekly during epidemic periods and 
every 4 weeks otherwise, and via passive referral to a research out-patient clinic or the 
paediatric wards at the District hospital, which operated throughout the study. The severity 
of respiratory disease was assigned on the basis of WHO criteria as described previously 
[5]. The definition of an epidemic was described previously in Chapter 3 with the gap 
between epidemics defined as the time interval between the end of one epidemic and the 
start of the next epidemic. 
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The interval between successive clinical cases in a household (Fig. 5.2) was calculated using 
the method defined by Fine [123). Briefly, let us assume person 1 transmits infection to 
person 2, both becoming symptomatic. The observations made are of the clinical onsets and 
not actual infection transmissions. The separation in time of these cases can be said to be a 
reflection of two things: i) the timing of infection transmission with regard to person 1's 
clinical onset (T1, defined as the time of infection transmission from person 1 minus the 
time of person 1's clinical onset), and ii) the incubation period of person 2 (12, being the 
time of person 2's clinical onset minus the time of person 2's infection transmission). 
Accordingly, TI is positive if transmission occurs after person 1's illness onset but it is 
negative if transmission occurs prior to person 1's illness (Figure 5.2). Using this 
definition, Fine states that: `the clinical case to case interval between persons 1 and 2 is 
calculated simply as (Tj + 12)'. This is a minimum if the transmission occurs early in 
relation (even prior) to person 1's clinical onset (i. e., T, is small or negative) and if person 
2's incubation period is a minimum (12 is small; Figure 5.2, part B). The maximum clinical 
onset interval will occur if transmission occurs late relative to person 1's clinical onset (Ti 
is thus a large positive number) and with a maximum incubation period for person 2 
(Figure 5.2, part A) [123]. 
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Transmission ' Clinical episode 
Incubation Case to case interval 
Infectious 4 10 
Figure 5.2. Relationship between successive clinical cases (adapted from paper by Fine 
[123]). In part A, (T1>O) as transmission from person 1 occurs relatively late in the course 
of l's infection and case 2's clinical onset occurs (T1+I2 time units) after that of case 1. 
In 
part B, the combination of early transmission, before case 1's clinical onset (T1<O), and a 
short incubation period for case B (12< (-Ti)) means that case B is symptomatic before case 
1. 
Ti and I2 are not directly observable in this study therefore evidence from previous studies 
[57,58] discussed in Chapter 2 was used to estimate the two intervals. From this controlled 
adult challenge study, a preclinical infectious period of 1-3 days and an incubation period 
of 3-7 days were observed. The range in days from infection to viral shedding was 2-5 
days 
with observed recovery of virus for 3 -4 days after clinical onset. 
The assumption made is 
that the start of infectious period is correlated to viral shedding (discussed in Chapter 6). 
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Using this method the case to case interval was estimated to be between a minimum of 0 
days (T1=-3; 12= 3) and a maximum of 11 days (T1=4; 12 = 7). With this estimated interval 
and actual observed data on the interval from primary case to subsequent cases (Figure 5.3) 
successive cases detected within households 2 days after the initial primary case were 
defined as secondary cases. Due to the limitations of the study design (sampling on 
presence of clinical symptoms) it was assumed that in a single epidemic, a household could 
have only one infection introduction. Cases identified after 11 days may be tertiary cases or 
reintroduction but no such differentiation is made. 
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Figure 5.3. Frequency distributions of the interval from primary case onset to the onset of 
subsequent cases in households within the space of one epidemic. 
5.4 Results 
Details on numbers of households and individuals recruited and losses to follow up (by 
year or epidemic) have been provided in the results section of Chapter 3. 
i) Description of Households 
Families in this study had between 2 to 13 members, Figure 5.2 with a median of 7 
members and an average of 5.3 members. During the follow up period some households 
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had new members introduced through births, Figure 5.2a (start of the study) versus b (end 
of the study). Individuals who were under 15 years of age at the time of recruitment were 
classified as children and are herein referred to as "siblings" to the birth cohort child. The 
study households had between 0 and 9 siblings as shown in figure 5.2 c (start of the study) 
and d (end of the study) with an average of 2.8 siblings. The birth cohort child was the only 
child in one replacement household. 
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Figure 5.4. Characteristics of households at the beginning and at the end of the study. a) Household sizes at start of study, b) household size at end of study, c) number of siblings 
in 
the study households at start, and d) number of siblings at the end of study. 
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ii) Age distribution ofparticipants 
At recruitment siblings of the birth cohort child ranged in age between 0 and 176 months 
(14.6 years). 55.9% of the siblings were five years of age or younger (Figure 5.3 a). The 
adults in the study were between 15 and 81 years of age with 80% being less than 35 years 
of age. 10% of the adults were less than 20 years of age (Figure 5.4 b). 
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Figure 5.5a. The age distribution of siblings in the household study 
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Figure 5.5b. The age distribution of the adults in the household study 
iii) Sex distribution 
Overall there were slightly more females than males in the household cohort. Within the 
child (sibling) and birth cohort categories there were equal numbers of males and females 
but there were considerably more adult females 75% than adult males 25 % in the study as 
shown in Table 5.2, consistent with the demography of the District (Figure 3.2). 
Table 5.2. Sex distribution of household individuals 
Cohort type 
Sex Adult Child Birth Total 
Female 99 115 43 258 
% 75.0 49.8 51.2 57.6 
Male 33 116 41 190 
% 25.0 50.2 48.8 42.4 
Total 132 231 84 447 
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iii) Epidemics 
The household cohort experienced three epidemics in the population, defined as epidemic 
1-3, within the dates 3/12/02 to 15/4/03,8/1/04 to 2/6/04 and 11/11/04 to 18/2/05, 
respectively. The interval between the successive epidemics (i. e. end of one and start of 
next) was 268 days (8.8 months) and 162 days (5.3 months), respectively. Recruitment of 
households started in the middle of epidemic one. 73 households were recruited in the first 
epidemic, with 400 participants. The denominator (number of households) at each 
successive epidemic was 67 and 62 households respectively with 367 and 353 study 
participants, respectively. 
5.4.1 Infection and re-infection patterns 
A total of 121 clinical infections were identified, and occurred in 53 out of 81 (54%) 
households. One replacement household is excluded from analysis involving introduction 
of infection into the household and transmissibility because the birth cohort child 
became 
infected before the household was recruited. The distribution of individual infections and 
household infections by weeks during follow-up is shown in Figure 5.4. 
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Figure 5.6 Distribution of individual infections (black) and household infections (red) by 
week 
In epidemic one, two birth cohort children from two households were infected. In the 
second epidemic there were 75 clinical infections identified in 43 households, while 
in the 
third epidemic 41 infections were identified in 27 households (Table 5.3). 20 (74%) of the 
27 households in epidemic three had previously been infected. Of the 75 infections 
identified in epidemic two, 42 were in the birth cohort children who were all less than 
1.5 
years old at the time. In this epidemic, only two re-infections were identified both arising 
in 
birth cohort children. In the third epidemic 17 infections were in birth cohort children and 
of these 11 were re-infections. Out of the 23 infections identified in the siblings, 7 (30%) 
were re-infections. Of these, 5 were infected in epidemic two while the other two siblings, 
one 3.8 years old and the other 1.2 years old, were infected twice in the third epidemic 
(Table 5.3). With the exception of two instances, the interval between the two RSV 
infections was less than 6 months the interval between epidemic two and three being only 5 
months. In those 2 exceptions there were spans of 22 and 23 months between the two 
145 
infections. Crude attack rates in birth cohort children was 60% and 27% in epidemic 2 and 
3 erspectively while that in siblings was 17% and 13% respectively. 
Table 5.3. RSV infection in the household study by epidemic 
Epidemic 2003 Epidemic 2004 Epidemic 2005 
households infected 2/73(3%) 43/67 (64%) 27/62 (44%)* 
individuals infected 2/306 75/326' 41/300& 
birth cohort child 2/76 42/70(2)$ 17/63(11)$ 
siblings(0-15 years at 0/230 33/199(0)$ 23/182(6)$ 
recruitment) 
adults 0 0/57 1/55 
7 new introductions $ (re-infected) 
& denominator includes adults under clinical surveillance 
43% (36/84) of birth cohort children were infected on one occasion only during the study 
compared to 19% (43/230) of siblings. 15% (13/84) of birth cohort children were 
infected 
on more than one occasion, 2 of whom were infected three times, compared with 3% 
(6/230) of siblings with re-infection, 1 of whom was infected 3 times. Hence in total 19/314 
(6%) children were re-infected with a total of 22 re-infections. 
i) Infection and re-infection patterns in relation to age 
The age stratification of all the infections identified during the household study is shown in 
Figure 5.5. The majority, 88%, of infections were in children less than 5 years of age. 67% 
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of the infections in children <5 years occurred in children 3 years of age or less. 13 (11%) 
infections were identified in children between the ages of 5 and less than 10.73% of 
reinfections identified during the study occurred in children <3 years, 68% (15/22) were 
in 
birth cohort children (i. e. <3 years), and 32% in siblings. 86% of sibling infections were in 
the age group 3 -<5 years. 
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Figure 5.7. First infections (blue) and re-infections (maroon) in relation to age in a 
household cohort. Adult is defined as individuals >_ 15 years at recruitment 
The data shown in Fig 5.7 are stratified as first and re-infection on the basis of observation 
during this study. However, it may be inferred from previous studies (see section 2.4 
Chapter 2) that all siblings who were 3 years of age or older were in fact most likely to be 
suffering from a re-infection (Table 5.4). This assumption is adopted for all subsequent data 
analysis in this Chapter. Thus, 76.8% of the infections observed in siblings were re-defined 
as re-infections. 75% of these re-infections were in children between 3 and less than 10 
years of age. 10.7% of the infections in siblings were in household children younger than 
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the birth cohort child (born during the study). Of the infected siblings, only 16% (9/56) 
were attending school. The age-specific incidence rates are described in Chapter 7. 
Table 5.4. Infections in siblings in the household cohort 
Age (years) Number Proportion Number attending 
(%) school 
1" Infection 
<1yr 4 7 0 
1-2 yrs 2& 4 0 
2.1-<3 yrs 7 13 0 
Re-infection 
3-<4yrs 17 30 
4-< gyrs 12 21 1 
5-< 10 yrs 13 23 7 
10+ 1 2 1 
Totals 56 100 9 
*all children 3 years of age or older assumed to be re-infected $ Proportion of all infections &1 re-infection 
ii) Infection and re-infection patterns in relation to family structure 
A comparison was made between households in which infection occurred, 52 (65%), and 
those in which no infection occurred, 28(35%), to identify household characteristics that 
may influence observed infection patterns. 8 households were lost to follow up before 
experiencing an epidemic and thus are excluded from this analysis. The number of children 
(<15 years), household size or number of adults in the home did not differ between the 
infected and non-infected households (x2 test, P>0.05). Similarly infected and non-infected 
households did not differ with regard to the classes of children present in the home: i) 
number of pre-school children ii) number of school children under 6 years and iii) number 
of school children 6 years of age or more (x2, P>0.05). 
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Comparison based on size of outbreak 
Data on the size of outbreaks (number of cases in a household) within different households 
are presented in Table 5.5. In examining if there are certain household and environmental 
factors that promote the transmission of RSV, several factors were tested. Households are 
classified according to both type of households and the number of cases. A comparison of 
the outbreak size for the different types of households is equivalent to testing the 
independence of the two types of classifications. Of the factors tested, only socio-economic 
status was found to affect the size of the outbreak in households ()2 (2) = 10.6, P= 0.005). 
Further analysis of individuals and household risk factors is reported in Chapter 8 and 9. 
Table 5.5. Factors that influence outbreak size (number of infections in a household) in the 
household cohort. 
Outbreak 
size 
Factors Categories 1 case 2 cases 3+ cases Totals P- 
value* 
household size 10+ 4 2 0 6 0.099 
5 to 9 22 19 7 48 
<5 15 4 0 19 
SES$ poor 25 23 7 55 0.005 
not poor 16 2 0 18 
pollution burn refuse 34 22 4 60 0.166 
don't burn 7 3 3 13 
cooking different house 22 12 4 38 0.678 
location@ 
same house 13 11 3 27 
outside 6 2 0 8 
fuel firewood 32 21 7 60 0.358 
other' 9 5 0 13 
sanitation no toilet 15 7 4 26 0.356 
latrine or flush toilet 26 18 3 47 
* x` test 
$ Socio-economic status (defined using asset index score (Chapter 8)). Households sorted 
by asset index and establish cutoff values for percentiles of the population. 
House location same as or different from sleeping area & Other - (paraffin/charcoal/mix) 
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5.4.2 Introduction of infections into families 
There was a suggested association between introduction of infection into the household and 
household size (Figure 5.8) with greater proportion of larger households infected. 
Borderline significant association between HH size and occurrence of an outbreak observed 
above (x2 , P=0.09). 
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Figure 5.8 Proportion of households into which virus introduced. Numbers above each bar 
show frequency of households of each size. 
Single primary cases occurred in 38 families in the three epidemics and co-primary cases in 
an additional 8 families. Within co-primary cases, two of the 8 cases included an infant. 
Secondary transmission occurred in 25 instances in two epidemics, 17 households in 
epidemic two with 5 having more than two household members infected and 8 in epidemic 
three. Table 5.6 shows the primary and subsequent case classification by age for epidemic 
two and three. 78% of primary cases were of pre-school age (< 5 years). Only 7 sibling 
primary cases were school attendees. Only 1 case of an adult introduction was documented 
out of the 41 households in which adults were also under routine clinical surveillance from 
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the middle of epidemic two. In 6 of these households the father worked and lived away 
from the home and was therefore not likely to introduce infection or be infected by other 
household members. 
Table 5.6. Characteristics of primary and secondary cases in RSV positive families with 
multiple infections stratified by age, cohort type and school attendance. 
Primary case Secondary cases 
Age group 
<1 year 8a 5 
1- <3 years 17b 12d 
&3-<5 years 12 12 
5-<10 years 8 (6)* 3(2)* 
10+ years 2c(1)* - 
Total 47 32 
a2 are siblings b4 are siblings °1 adult -mother °3 are siblings 
* Numbers attending school 
&All children 3 years of age or older are siblings to the birth cohort child 
The relative frequency with which various family members (birth cohort child or 
sibling/adult) introduce RSV infection into the home was investigated [258). Birth cohort 
children were most often the index case identified (Table 5.7); except in families of 6-9 
members where the siblings were more often identified as the index case. When households 
with a single case of infection were excluded, siblings were 1.4 times more likely to 
introduce the virus into the home. 
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Table 5.7 Relative frequency of introduction in households of different characteristics 
Household Relative risk of 
Characteristics introduction* 
HH size Number of No. RR* 
children in HH 
2-3 members 1-2 9/2 4.5 
4-5 members 2-4 17/8 2.1 
6-9 members 4-7 15/24 0.6 
10-13 members 8-9 5/2 2.5 
* Number of introductions by birth cohort child 
Number of introductions by siblings/adult 
5.4.3 Spread of RSV infection within the home 
The frequency of secondary cases that developed on each day after a primary case has been 
detailed in Figure 5.3. An index of the frequency with which spread occurs, the secondary 
attack rate (SAR), was defined as the number of secondary cases divided by the number of 
family children exposed to the index case(s). In Table 5.8 we first show the relationship 
between the age of index cases and age of secondary cases. Overall there was little 
evidence to suggest any relationship between age of index and age of secondary case. 
However, older primary cases (5-< 10 years) were observed to infect younger children 
more often than older children while the reverse was true for younger index case (<3 
years). It is expected that this result would particularly be evident in smaller HHs since the 
first case `uses up' one of the two groups (younger or older). Due to small numbers no such 
subgroup analysis was done. 
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Table 5.8 Matrix of age of primary case and age of secondary cases 
Age of secondary case (years) 
Age of index <1(%)* 1-<3(%) 3-<5 (%) 5-<10(%) Total 
case (years) 
<1 0(0) 3 (43) 3 (43) 1 (14) 7 
1-<3 2 (20) 0(0) 8 (80) 0(0) 10 
3-<5 0(0) 6(86) 1(14) 0(0) 7 
5-<10 3(43) 3(43) 1(14) 0(0) 7 
10+ 0(0) 1(33) 0(0) 2(67) 3 
Total 5 13 13 3 34 
*Proportion of secondary cases infected by age class of index case 
Interval between primary and secondary case 
The occurrence of subsequent infections after an introduction was explored in terms of the 
interval between the index cases and the secondary cases, Table 5.9. Median interval 
between index and secondary cases was 7 days with a mean of 12.4 days. The majority 
(59%) of secondary transmission appeared to take place within 8 days of introduction- most 
transmission taking place between 5-7 days. The youngest age group seemed to experience 
significantly shorter (t=-1.95, P=0.03) intervals thus appear to be infected preferentially or 
it may be the case that they have a shorter incubation period. There was only one primary 
case classified as severe RSV-LRTI with two others as RSV-LRTI. There were 4 cases of 
disease among secondary case; 2 classified as severe RSV-LRTI and 2 RSV-LRTI (in 
twins). Thus there were too few cases to assess the relationship between the time to 
secondary case and the severity of the first case, or the severity of the first case to the 
severity of the secondary case. 
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Table 5.9. Median interval between index and secondary cases of RSV infection in family 
children by age of the secondary case. 
age of secondary case Numbers median interval mean interval 
(years) (days) (days) 
<1 555.4 
1-<3 years 12 8 15.1 
3-<5 years 12 7.5 11.6 
5-<10 years 3 5 16.7 
10+ 0 no cases no cases 
Totals 32 7 12.4 
Secondary attack rate 
Secondary attack rates (SAR) appear to decline with increasing age of contacts. The mean 
SAR tended to be higher in younger children, those less than 3 years, than in older children 
3- <5 years (0.48 vs. 0.34, (t=1.87, P=0.07)) and 3-<10 years 0.48 and 0.35 (t=1.81, 
P=0.08) respectively although not significantly. Households of smaller size had 
significantly higher SAR. The mean SAR was 0.72 for households with 2 children 
compared 0.37 and 0.21 for larger households with 3 to 5 or 6 or more children respectively 
(t=3.34, P =0.004; t=4.70, P=0.002). The mean SAR was significantly higher for 
households with 3-5 children compared to those with 6 or more (t=2.51, P=0.021). Smaller 
households had on average younger children. The relationship between age-specific 
secondary attack rates and the age of the index case (Table 5.10) is presented for family 
episodes with a single index case of infection. There was evidence to suggest that the 
secondary attack rates were related to the age of the index case. The mean SAR following 
exposure to a child under 1 year of age was generally lower than if the index case was an 
older child (column 2 and 3 vs. 4). Older children (4+ years) tended to be more effective in 
spreading infection to younger children than to children of the same age (0.67 & 0.63 vs. 
0.41) though this was not significant. On average, older index cases seemed to spread 
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significantly more infection to younger contacts than younger index case (1-<4 years) to 
children the same age (0.63 vs. 0.35, t=-2.55, P=0.059). 
Table 5.10. Age-specific secondary attack rates according to the age of index cases, in 
episodes with a single index case 
Age of index case (years ) 
Age of contact <1 1-<4 4+ 
(years) 
<1 - 0.25 0.67 
1-<4 0.36 0.35 0.63 
4+ 0.33 0.40 0.41 
5.5 Discussion 
Several aspects of infection and transmission of RSV within the household and results 
concerning the introduction of infection and secondary transmission are presented. In 
general birth cohort children were more often the index case identified in the home more 
frequently than older siblings. In developed countries young children are exposed to a large 
group of non-household contacts through daycare and other pre-school activities, activities 
that are alien to this community, hence are more at risk of acquiring infection outside the 
home. The above result is therefore surprising given that most young children in this rural 
Kenyan community have limited contact with other community members. The result may 
well be a reflection of lower immunity in these young children leading to greater 
probability that infection is symptomatic accompanied by higher likelihood of dectection 
(increased viral shedding and longer duration of illness [62]). This is an issue explored in 
Chapter 6. However, when only households with multiple infections (i. e. secondary cases) 
were considered, siblings were found to introduce infection into these homes more often. 
This result is similar to reports from other studies [15,50] and is in line with the 
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expectation that older children have more potential contact infectious people in the 
community (e. g. school, and play areas). Nevertheless, only 7 index cases were associated 
with school attendance (discussed further below). Because of the general mildness of most 
respiratory infections specifically when they occur in older children and adults [16,118], an 
apparent introduction into the family may actually have been a secondary acquisition from 
an inapparent index case within the home. This possibility of sub-clinical infection to which 
our study is insensitive could also be an explanation for the near complete absence of (a 
single case only) of infection identified in adult participants; it is possible that symptomatic 
re-infection is very uncommon in this setting. 
Of the previous family studies carried out in developed countries only one study [15] used 
symptomatic identification of infection -16.8% of exposed adults (>17 years) were infected. 
All other studies used serologically identification (Table 2.9). As stated no information is 
available to qualify this. In this study we were unable to detect mild and/or sub-clinical 
infection due in part to the sampling interval and a large extent to the failure of the OF 
assay. Assuming some age-dependence of viral shedding it would imply that the study was 
less likely to have picked up infection in older children not because infection did not occur 
but because they were less easily detected. Hence it is likely that those infections 
indentified were probably measuring those cases shedding more virus - which is correlated 
to severity indicate more severe cases. However, these are the cases most likely to spread 
the infection - which is of epidemiological importance. 
Majority of the infections identified were in pre-school children. Thus the hypothesis that 
older children especially school children are more often than not those who bring infection 
into the home [15,16,128,144] in general did not hold true in this study as only a small 
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proportion (11%) of the infected siblings were attending school. 58% of the children in this 
study population were attending school. This increased chance of acquiring infection 
outside the home (from school contacts) would ideally be reflected in the number of index 
cases in this study who were in school. Indeed within the age class of potential school 
children (children 5 years of age and above), 67% of the index infections were from a child 
attending school (Table 5.6). These results are likely to be biased by the study design which 
favours detection of infection in younger children. Therefore, the observed reduced 
infection rates in older children in general may be a function of the clinical (symptomatic) 
case definition. Given results from previous studies the likelihood of missed sub-clinical 
infections in school children in this study cannot be ignored. 
There were eight instances of more than one index case with two additional cases occurring 
within a day of first case, also considered to be index cases. Simultaneous cases within 
household members are generally rare as such cases require common exposure and 
transmission as well as similar likelihood of disease in the hosts or increased virulence in 
the pathogen. For such cases it is possible that one of the index cases was infected first. The 
data necessary to validate this (i. e. exact duration of shedding prior to clinical symptoms) is 
not available in this study. However, instructions given to the family may also play an 
important role in the timely identification of illnesses and in this study the importance of 
presenting to the OP clinic immediately symptoms were detected was emphasized. Hence 
we are re-assured that most samples would have been collected towards the start of clinical 
symptoms. 
When dealing with a disease that is prevalent in the community as is the case with RSV 
during epidemics, it is not always possible to determine where an infection was acquired. 
157 
Accordingly identified cases of spread within the family may have been the result of 
independent exposure outside of the family and not from within the family. Nevertheless, 
documentation was made of several instances of secondary transmission in this study. 
Given the close contact occurring in families, it was expected that several family members 
would become infected once the virus was introduced as has been reported in nursery 
studies [119] and other family studies [15,50]. Rather surprisingly in most instances an 
index case(s) resulted in only a single secondary case. Households provide a special setting 
as "outbreaks" in households imply transmission of infection under particular intense 
conditions of contact as well as the issue of extended physical closeness. The infectious 
dose thus would be higher increasing the probability of transmission taking place adding 
weight to the suggestion of missed infections. 
The efficiency of transmission was investigated. The potential for spread is determined by 
probability of transmission taking place. This may in part be dependent on the level of 
susceptibility of exposed individuals, the contact patterns and to some extent the infectious 
dose. Thus, there are some contacts that are more likely to result in infection than others. 
Overall, several important patterns were observed i) infants in the family appeared to be 
infected earlier (significantly shorter interval between index and secondary case). As 
mentioned this may be the results of short incubation periods in younger child an aspect 
that remains unknown in the present study ii) SAR were higher for younger children as 
previously reported by Hall et al [15], and iii) older children seemed to be more effective at 
transmitting to younger children in the home than children of own age - older children 
preferentially infected younger children than similar aged children. Older children in this 
study seem to be less susceptible presumably due to previous history of infection (higher 
levels of antibody) but if infected are more effective at transmitting to younger children 
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who are more susceptible. Households of smaller size had significantly higher SAR 
presumably due to younger children. These households had a lower average age of children 
than did larger (6+ members) households (2-4 years vs. 5-7 years). As with all aspects of 
this section, these estimates are affected (biased) by possible age-dependence in detection 
of cases i. e. older cases less likely to be detected. 
Of siblings <15 years, 23% had evidence of infection with RSV. 17% of the infections 
identified during follow-up were re-infections and these were in younger children (<4 
years). The majority of these had re-infections identified in successive seasons. 
Interestingly, there were 4 instances where the re-infections occurred in the same epidemic 
implying that re-infection can occur within a short interval presumably an indication of 
short livid immunity discussed in Chapter 2 (Section 2.3.1) and published [110]. 
It is generally accepted that by three years of age most children have had a primary 
infection [12,19,25,90,111,114]. Thus infections occurring in children/siblings 3 years 
of age or older were assumed to be re-infections. Using this definition, 49% of the 
infections in this study were in effect re-infections. Clearly the contribution of re-infections 
to transmission in this community - though in fact underestimated in this study - is not 
negligible. This is explored further in Chapter 7 in which we calculate the age-stratified 
incidence estimates. Several factors (discussed in Chapter 2) may contribute to the 
occurrence of re-infections [18,19,101] and include individual age, viral antigenic 
variation, host neutralizing antibody and of course the time between challenges. At the time 
of writing this thesis there was incomplete data available concerning antibody levels or data 
on the circulating strains during the study. Those samples that were genotyped showed that 
Group A was the dominant strain in epidemic 2 and co-dominant in epidemic 3 
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(unpublished data, DJ Nokes; Figure 2.4). 68% of re-infections observed were in birth 
cohort children between the ages of 1- 2 years. Age thus appears to affect clinically 
observed re-infection; 68 % of the re-infections were in children younger than 5 years 
compared to 30% in 5 to <10 year olds and only 2% in those 10 years or older. This 
relationship of clinical versus sub-clinical infection and age can only be clarified using 
serological data. 
Infected and non-infected households in this study did not differ in terms of family 
structure. They both exhibited similar patterns of pre-school children and school attendees, 
hence there was no apparent explanation for why certain households did not get infected, 
other than a purely stochastic process of introduction. Similar results have previously been 
documented [9,151. It may be that certain socio-economic characteristics were different for 
households in this study or the location in relation to the epidemic was different. However, 
there does not appear to be spatial clustering; since, both infected and uninfected 
households were from similar locations. Differences by socio-economic class were 
considered. Infected households were found to have a higher proportion of households 
classified as poor (72%) than did the non-infected households (41.2%), a difference that 
was found to be significant (Pearson x2 test; p=0.022). A household's socioeconomic 
classification was also observed to influence the number of cases occurring after an 
introduction. Thus the reason for certain households being preferentially infected could be a 
predisposition effected by lower socio-economic status. Lower socioeconomic status has 
been associated with ARI morbidity; these households generally have poorer hygiene 
affecting the general health of members [259]. 
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Lastly, it is important to note at this point that the results presented here do not give a 
complete picture of household transmission because of various factors. First, not all 
families studied had all members under routine clinical surveillance and even those that did 
were not under routine surveillance for the entire period of the study. Thus most of the data 
presented here is limited to transmission relating to children in the family. Second, the 
study protocol limited sample collection to symptomatic infection. An important adjunct of 
this was to be the results of surveillance for sub-clinical infection using oral-fluid 
(described in Chapter 4). Renewed efforts to optimization the oral-fluid ELISA are 
currently underway. However information concerning asymptomatic infection or infection 
not detected by our diagnostics method is to this extent still incomplete. Only 121 
infections were identified in 373 participants followed up for two and half years with 56% 
of these being children <5 years and with only a single infection identified in an adult. 
Hence, it is likely that some RSV infections within this HH cohort were missed. Results 
presented in this chapter should be viewed in light of these limitations. 
The primary aim of the birth cohort study, within which this study is nested, was to assess 
the effect of past history of infection on the risk of re-infection. For this it was desired to 
make a comprehensive record of RSV infection in each child and in particular to maintain 
follow up long enough to ensure a large proportion of children experienced more than one 
RSV infection (to allow the computation of protective efficacy - Chapter 1). Consequently, 
the recruitment strategy was designed for this purpose rather than for the estimation of 
incidence - for which continuous recruitment throughout the year would have been more 
useful in the estimation of finely age stratified rate of infection. One interesting 
consequence of the adopted intermittent recruitment (i. e. roughly 6 months of each year) 
arose in the second phase of the cohort as a result of the RSV epidemic starting 3 months 
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earlier than the preceding epidemic. The result was that only a small proportion of children 
experienced an RSV infection in their first 6 months of life. However, this did facilitate 
estimation of relative risk of RSV disease by age following primary infection. While it is 
acknowledged that intermittent recruitment creates problems in incidence estimation, the 
effect can be largely overcome by a process of weighting for age-specific observation time 
within/between epidemics as detailed in Chapter 7. 
In spite of these deficiencies highlighted in the discussion, the data collected - which relate 
to clinically apparent infections only - have illuminated our understanding of various 
aspects of household transmission, and provided some thought provoking data regarding 
transmission patterns within the home. We identified substantial infection rates within 
households, documented infection introduction and defined interval between cases and 
SARs in relation to various factors. In the next chapter, analysis of these data also provides 
useful information on RSV transmission rates and risk of disease on primary and re- 
infection and the duration of shedding in relation to various factors. 
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Chapter Six 
Duration of Viral Shedding 
6.1 Introduction 
The infectious period is a key characteristic determining the transmission of infectious 
pathogens (see schema Fig. 5.1). In terms of RSV transmission dynamics it is important to 
quantify the infection / recovery process, and in particular to know how past infection 
modifies the infectiousness of individuals [60]. Because of the low average age at infection, 
the vast majority of the host population is in the category of `previously infected'. The 
contribution of subsequent re-infections to the total rate of infection within a community 
will be highly dependent upon their duration of shedding. Equally, the occurrence of long 
term shedding of RSV may have significant implications to viral persistence, viral genetics 
and continued transmission [41]. Prolonged excretion of RSV enhances the possibility of 
transmission and makes such individuals potential sources of community spread of 
infection an important consideration in the control and prevention of RSV infection in 
infants. An assessment of this issue requires improved data on the prevalence and duration 
of viral shedding. The aim of this study is to estimate the duration of infectiousness. There 
are three durations commonly recognized in viral infections: from infection to the start of 
infectiousness (often called latent period in infectious disease epidemiology), from 
infection to onset of clinical symptoms (often called incubation period in clinical literature), 
and from onset of infectiousness to cessation of infectiousness (often called infectious 
period in epidemiological literature). All of these periods will have a distribution, i. e. will 
vary between individuals and infectious episodes. In particular, there will be a distributed 
period between infection with virus and the start of infectiousness for which we cannot 
have direct information in an observational field study. Further, infectiousness can only be 
assessed indirectly, that is, generally through detection of virus in nasal sections. 
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Consequently, we must assume that shedding is closely related to infectiousness (see 
discussion) and consequently, we are estimating the duration of viral shedding as a 
correlate for the infectious period distribution (IPD). 
Estimation of the duration of shedding for perfectly observed data is straightforward. 
However, recognised in this study were two problems with the way the data were collected 
with a bearing on the estimation of shedding duration. First, recruitment into the study was 
based on a positive sample so that the date of onset of shedding is unknown, i. e. there is left 
censoring due to the recruitment protocol. The information we have defines an interval 
during which shedding started, i. e. the date of last known negative and the date of first 
positive. Second, the exact date of cessation of shedding is not known. The data defines the 
interval in which cessation of shedding occurred as samples were obtained at three day 
intervals. If cessation of shedding is defined as failure, then this is termed interval 
censoring. This was the case for all observations in this study except for one individual who 
died before end of shedding, i. e. was right censored. This individual's data was excluded 
from the analysis. As the intervals between sampling were relatively short, the interval 
censoring is not critical but to be correct should be accounted for in the analysis. However, 
some of the left censored intervals are large and their exclusion could substantially alter the 
analysis outcome and give rise to spurious results. It is acknowledged that there is a 
probable third problem that is the single negative indicating failure rather than confirmed 
by two negatives (see discussion). 
A review of previous studies on the duration of shedding has been given in Chapter 2. 
Typically, RSV has a short infectious period of approximately 6 days. However, the 
distribution of shedding duration is skewed with a small proportion of individuals shedding 
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for relatively longer periods. It is therefore interesting that the disease is able to persist even 
with such a short duration of infection. The hypothesis advanced to explain the dynamics of 
shedding is that infected individuals fall into two categories i) children suffering from a 
primary infection and who are potentially longer shedders but form a small proportion of 
the population and ii) those with a re-infection (majority of the population) but who are 
thought to shed virus for a shorter duration i. e. each re-infected person less important than a 
primary case (Fig. 5.1). It is not clear exactly which of the two groups is the major 
contributor and thus potentially more important in RSV transmission dynamics. Re- 
infection occurs frequently (Chapter 2), and is probably very important in overall 
transmission. If indeed re-infections have a shorter duration of shedding than primary 
infection, then the magnitude of this shedding reduction would greatly affect the total 
contribution of these re-infections to the pool of infection. An attempt was therefore made 
to quantify this. 
6.2 Chapter aims 
In contrast to much of the information available regarding shedding of RSV (from 
hospitalised patients), in this Chapter we give a report of the duration of shedding of RSV 
from infected individuals in the community, in relation to past infection history, i. e. 
primary or re-infection, by age, sex and by the severity of infection. 
6.3 Methods 
Study population and samples 
A study to determine the duration of shedding of RSV after infection was nested within the 
surveillance framework of the main birth cohort project and the household cohort study 
(described in Chapter 3). The study observation period reported for the duration of 
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shedding study is that from two epidemics between January 2004 and June 2004 and 
November 2004 and February 2005. Nasal washings were collected routinely from 
participants experiencing episodes of acute (rapid onset) respiratory illness which were 
screened for RSV by commercial direct immunofluorescent antibody test as described in 
Chapter 2. During 2004 and 2005 any child in the cohort identified (through either home 
visit surveillance or passive referral) as RSV positive was asked to enrol in the shedding 
study. Following the identification of RSV infection (day 1 or to), a further nasal washing 
was obtained as soon as possible, and thereafter every 3 days up to day 14. Individuals 
remaining RSV positive on their 4th sample were followed-up and sampled after a further 7 
and 14 days, and thereafter every 2 weeks up to 16 weeks (Figure 6.1). Follow up was 
discontinued following a single sample testing negative. 
RSV positive-ENTRY 
Negative sample- EXIT 
00101 0; 0 
[E] 
NW 
rDayl4 
Figure 6.1. Illustration of study design. Red arrows show sample collection. 
Data Analysis 
Data was analyzed using Excel (Microsoft Office) program and Matlab (Release 14, 
www. matlab. com). Relevant observations for each individual, i, are sample dates of most 
recent prior virus negative, first virus positive, last virus positive and first virus negative: t- 
i,; to, ti,; and t2,; respectively (Figure 6.2). The prior negative sample refers to the date of the 
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most recent sample collected which was antigen negative before the positive sample (first 
virus positive) that initiated shedding follow up in the individual. All data are in days, and 
we assume that all samples were taken at noon of each day. The time of first positive 
sample, to, is set to zero and so all observed times are relative to that time. For each 
individual, the start day of shedding, u;, and the day of cessation of shedding, v;, are defined 
by: t. 11 <_ u; _< to and t1 5 v, 5 t2,; respectively. Where the 
first prior observation was positive 
and not negative (occurring in 2 instances), t. 1,; is set to -200d. 
u to tý V 
Figure 6.2. The time line for each study individual. The reference time is to (day of first 
positive) which is set to zero for all individuals. ti, ti and t2 are the times of last negative, 
last positive and first negative result, respectively. Shedding starts at u (t. 1: 5 u: 5 to) and 
finishes at day v (tl<_ v: 5 t2). 
Figure 6.3 shows the numbers of individuals at each time point demonstrating the extent of 
left and interval censoring in the dataset. For each individual, the day on which shedding 
was first detected is taken as the reference time (to= day 0). The left hand distribution 
shows the number of individuals at each day prior to detection of shedding who might have 
been shedding on that day, i. e. between the last negative result and the first positive result. 
The right hand distributions show: i) the number of individuals at that time point known to 
still be shedding virus (a positive nasal wash after first positive (to); t: 5 t1- dark grey bars) 
ii) the number of people known to have stopped shedding (confirmed negative nasal wash 
after to; t: 5 t2 - light grey bars), iii) the number whose status is unknown (nasal washing not 
yet collected- illustrating the interval between sampling- yellow bars ). 
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Figure 6.3. The number of individuals at each time point. For each day is shown the 
number known to be shedding (dark grey), known to have stopped shedding (light grey), of 
uncertain classification due to interval censoring (interval between positive and negative 
samples) (yellow) and at risk of having started shedding, i. e. <day 0 (black bars). The 
horizontal axis is time in days, with t=0 as the reference for each individual. (left hand side 
of Figure has been modified). 
The two types of unobserved times (infection onset and cessation) need to be accounted for 
in the estimation. We assume that the rate of commencement of shedding is a constant, ?, 
so that the distribution of start times follows a truncated exponential distribution: 
Au; 
f(u; ýý)= e 2>0 
1-e 
=1 A=0 
- t_1, ß 
noting that with our definition of time t_1,, and u; are negative. For high values of 2 the 
probability of infection becomes increasingly concentrated towards to (Figure 6.4). 
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truncated negative exponential distribution and infection occurs before day 0. a) X =0.01; b) 
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The Weibull probability distribution function was used to estimate the probability density 
function of shedding duration. This distribution is sufficiently flexible to capture the 
important features of the observed shedding times, and relatively easy to handle 
computationally. The probability density function is given as 
P(t I a, ß) = aßtß-ie-atß, 
and the survival function as 
S(tI aßß)=e "'tß 
where a and (3 are two unknown parameters to be estimated. Figure 6.5 shows a particular 
Weibull distribution. 
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Figure 6.5. The Weibull probability distribution as the survivor function (blue) and the 
probability density function (black) (ß= 3 and a=0.002). As the shape parameter (ß) 
increases the survivor function becomes increasingly like a step function. 
The mean (m) and variance (Q2) of the distribution are given as 
m-l 
la 
r\l+/ 
/ý/ 
aZ -`ý1ý/6LI'`l+/ijý-I'`1+y)6)ZJ 
where ]Fis the gamma function. 
If the start of shedding (u; ) was perfectly observed, then the likelihood of observing 
shedding at ti,; and no shedding at t2j is: 
L, (u,, a, 9)={S( u, +t)-S( u; +t2,, )} 
We compute the full log-likelihood by integrating over all possible values of u;, and 
summing over all individuals: 
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La= In 
to 
utS -u+tl., -S -u+t2,, du 
I L1.1 
This likelihood was computed numerically in MatLab (Release 14, www. matlab. com) by 
Prof. Graham Medley. 
The relationship between duration of shedding and age, sex, severity of infection and 
history of infection was evaluated (Table 6.1 and 6.2). All factors considered had two 
categories. We compared models using the likelihood ratio test (LRT) based on the 
likelihood ratio statistic (LRS) = -2(Lo-L1). Table 6.1 shows the numbers of individuals in 
each category tested. 
6.4 Results 
A total of 193 RSV positive children were enrolled into the shedding study, 160 were birth 
cohort infants and 33 siblings from the household study. 192 failures (end of shedding) 
were observed, 1 child died before completing the study and was excluded from the 
analysis. The children were between the ages of 2 and 164 months (i. e. 0.2 - 13.7 years); 
9.5% were less than 1 year while 71.9% were 2 years of age or less. The median age of 
children in the study was 30 months, and 45.4% were male. Of the 193 RSV infections 165 
were classified as an upper respiratory tract infection (URTI), 20 as having mild LRTI and 
7 with severe LRTI, none with very severe LRTI. 
For 120 of the children, the day on which they were found to be positive was equal to the 
day of their last positive test (to = t1), indicating that the majority of children only shed 
virus for a maximum of 3 days (Figure 6.3). To get some insight into the data, Kaplan 
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Meier curves of survival assuming infection at to with failure as first negative were plotted. 
Only plots with highest significance are shown. 
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Figure 6.6. Kaplan Meier survival estimates for covariates with highest significance a) Age 
class (blue: 0-23months; maroon: 24+ months) b) Infection history (blue: never infected; 
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Figure 6.7 shows the results of estimating the Weibull distribution for predefined values of 
X. Lambda in this case is not the rate of infection, but a parameter describing the shape of 
the imputed distribution of shedding start times. The log-likelihood is maximised for very 
high values of ?. (i. e. shedding starting immediately prior to first positive sample) and 
changes dramatically for values between 0.01 and 1 per person per day (i. e. shedding 
commencing every 100 days to daily). The estimated IPD becomes more exponential - less 
like a step function - (ß goes from 2.9 to 1.02). The mean of the IPD goes from 7d to 2.5d 
and the standard deviation remains relatively constant. 
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Figure 6.7. Variation in results with model parameter (XI (X). a) the maximum log- 
likelihood (top left); b) the parameters of the Weibull IPD function relative to their 
maximum value (solid line: a; dashed line: ß); c) the mean (solid line) and standard 
deviation (dashed line) of the IDP (bottom left). 
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The two tables below (Table 6.1 - best fit model and Table 6.2) show the results for the 6 
binary variables that were investigated using two values of lambda (X=10 and 7. =0.01). 
None of the variables examined were found to significantly affect the duration of shedding. 
The estimation procedure was confirmed by adding a dummy variable to divide the data on 
the basis of the observed duration of shedding, and was found to be working. Although no 
formal power calculations have been performed, if there were a consistent, large effect of 
any of these variables it would be detected by this approach. 
Table 6.1. Infectiousness period distribution (IPD) estimated using survival analysis using 
data from 192 infected children from the best fitting model (X=10). 
Factors Categories Numbers Mean beta LL* LRS 
N=192 IPD 
History never infected 96 2.904 1.337 -163.469 2.964 
infected 96 2.362 1.106 
Sex male 88 
female 104 
Age class 0-11 months 20 
12+ months 172 
0-17 months 55 
18+ months 137 
0-23 months 121 
24+ months 71 
Severity of URTI 165 
infection 
2.495 1.166 -164.658 0.586 
2.760 1.245 
2.534 1.302 -164.859 0.184 
2.656 1.200 
2.652 1.277 -164.839 0.224 
2.634 1.179 
2.817 1.248 -164.103 1.696 
2.338 1.153 
2.502 1.202 -163.293 3.316 
LRTI 27 3.478 1.325 
LL- Log-likelihood 
The Log-likelihood for the full (saturated) model is -164.951 $1 df at 5% significance the chi-squared value is 3.84. Parameter values with LL above the 
line at 3.84 are not statistically signifcant 
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Table 6.2. Infectiousness period distribution estimated using survival analysis using data 
from 192 infected children with X=0.01. 
Factors Categories Numbers Mean IPD beta LL* LRS 
N=192 
History never infected 96 6.996 3.479 -407.499 1.458 
infected 96 6.69 2.636 
Sex male 88 6.634 2.768 -407.838 0.780 
female 104 7.078 3.209 
Age class 0-1lmonths 20 5.571 2.848 -406.965 2.526 
12+ months 172 7.076 3.075 
0-17 months 55 6.647 3.143 -408.071 0.314 
18+ months 137 6.984 2.899 
0-23 months 121 6.916 2.908 -408.185 0.086 
24+ months 71 6.816 3.099 
Severity of URTI 165 6.659 2.986 -407.162 
Infection 2.132 
LRTI 27 8.11 3.199 
LL- Log-likelihood 
*The Log-likelihood for the full (saturated) model is -408.228 
6.5 Discussion 
In contrast to much of the information available regarding shedding of RSV, in this thesis 
we give a report of the duration of shedding of RSV from infected community individuals, 
in relation to past infection history, i. e. primary or re-infection, by age, sex and by the 
severity of infection. 
Sensitivity of detection of shedding (infectiousness) is likely to be determined by intensity 
of shedding, which is expected to increase then decrease as the infection proceeds within 
the individual. It may be assumed at the early stages of virus replication, viral load in 
secretions will be low, and it has been shown [63] that as the days post (samples collected 
soon after admission) infection increase subsequent specimens tend to have lower RSV 
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viral load. Consequently sensitivity of antigen detection will change during the infectious 
period: individuals first assessed during the early or late stages of infectiousness will be 
less likely to be included (a potential bias in recruitment) into the study. The second bias is 
that of identification of failures which was assumed to arise after a single negative result. 
Given the nature of error in biological measurement -particularly at low level shedding 
towards the end of the infection, it is conceivable that children testing negative one day 
might subsequently be positive on the next. Ideally we would have used the criterion of 
two sequential negatives as indicative of a failure. However, given this argument (that we 
are dealing with the terminal part of the infection with low viral load) it is most likely that 
the probability of a false negative is low. Indeed in a sub-sample (102) we did change the 
criterion to double negative for a failure, and this gave rise to a risk of false negativity of 
4.9%. Future analysis planned will account for this small bias in the estimation procedure. 
These are additional to those which we have attempted to take account of in the analysis i. e. 
uncertainty of the exact times of onset and cessation of infection, u and v. Data on intensity 
of positives was not available, and hasn't been included. 
For a fuller analysis we would need to take account of additional information concerning 
the force of infection for RSV. Since the sampling interval was decreased during periods of 
high RSV activity (from 4 to 1 week) the enrolment is potentially biased towards an 
increase in estimated length of time elapsed from the point of infection to recruitment. This 
would arise for those cases occurring early in the epidemic. Also, if sub-groups of the 
population e. g. older children have shorter IPD, then they are less likely to be included in 
the study. This aspect will, also, potentially bias the analysis if it is not included. In 
particular, inclusion of calendar time and external information on RSV activity (i. e. from IP 
surveillance) will enable potential biases to be included in the analysis. In particular, the 
177 
duration of IPD is directly related to the probability of inclusion in the study, so that the 
analysis is biased against shorter IPD 
The estimated duration of shedding (Fig 6.7) is a few days (2.5-7days). This is in 
accordance with previous results [15,57-59]. The best fitting model was apparently for this 
duration to be exponentially distributed with mean approximately 3 days, There is little 
information in the left censored times to indicate what should be imputed. Given the 
invasive nature of sampling, there is little that can be done to improve the sampling 
intervals related to recruitment. The analysis shows that the best models are with a zero 
imputation (i. e. individuals start shedding when they are recruited). This is unlikely, but 
information to qualify this for this study is currently unavailable. 
Contrary to expectation [59,621, the tested co-variates provided no statistically significant 
evidence of an impact on duration of shedding. Transmission dynamic modelling [601 has 
demonstrated that shortened duration of shedding during second and subsequent infections 
with RSV can account for many of the population level dynamic patterns. However, it 
might be that there is an inherent bias in the data collection against detecting shorter 
shedding periods. The KM plots in Figure 6.6 give insight into the data. The patterns of 
shedding in general appear consistent with assumptions about increased shedding duration 
in primary versus reinfected children and in those more severely infected. This ought to be 
further investigated. 
Other methodological issues that might have affected the estimated duration include the 
assumption that all children not followed up from birth but who were over the age of three 
have had a previous infection. This assumption is warranted because by the age of three 
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years the great majority of children will have experienced a primary infection [12,19,25, 
90,111,114]. Only studies that take samples irrespective of symptoms potentially give a 
precise estimate of the duration of shedding [59]. In this study by Frank et al. [59], any 
samples taken 8 days pre-illness were used to compute duration of shedding. 
Encouragingly, most isolates of RSV were obtained during the first seven days after the 
onset of illness (i. e. very few pre-symptomatic samples are positive). Thus, the fact that 
samples are taken only when symptoms are present in this study is not a big concern. An 
improvement of the present study design would be to collect daily samples pre and post- 
infection something that we believe would be difficult to justify and even implement (in 
terms of participant refusal). A possible compromise would be to take samples at closer 
intervals. Also, more sensitive detection techniques such as PCR might be warranted - 
however, it would be less certain whether identification by PCR relates to viable virus 
compared with the IFAT diagnostic method used here (i. e. observation of infected cells). 
In conclusion, the duration of shedding of respiratory viruses in naturally infected persons 
with non-severe infection is important for understanding the spread of infection in a 
population and will contribute to the development of transmission dynamic models to 
investigate the impact of immunization. This chapter provides such estimates specifically 
taking account history of infection. Estimates of the duration of shedding remain 
conservative even though we have attempted to account for the left and interval censoring. 
There was no convincing evidence for an association between suspected risk factors and 
increased period of shedding. 
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Chapter Seven 
Age-stratified incidence of infection and disease severity 
7.1 Introduction 
The epidemiology of RSV is mainly about infection and re-infection, and how this relates 
to disease. Community and hospital-based studies have reported the importance of RSV as 
a cause of LRTI and severe LRTI [4-9,11,205]. However, there are few disease burden 
studies from developing countries [38]. RSV-LRTD (pneumonia and bronchiolitis) is 
almost entirely confined to children less than 3 years of age [12,16,19,35,90,94,101, 
260]. The risk of severe RSV infection is correlated with a number of factors, in particular, 
primary infection in early life, in children with underlying predisposing risk factors such as 
prematurity (presumably because of absence of maternal antibody), and with cardio- 
pulmonary disease. Some environmental factors such as exposure to smoke or socio- 
economic classification (explored in Chapter 8) have also been reported to increase the risk 
of RSV disease. 
Though largely overlooked, because of the importance of infection in children, RSV causes 
repeated infection throughout life. One of the main characteristics of transmission is the 
occurrence of re-infection. This occurrence of infection in older age groups discussed in 
section 2.6 (Chapter 2) has important implications for community transmission but has as 
yet not been comprehensively investigated, and particularly so in developing countries 
where no study has explored the contribution of re-infection in older age groups and thus 
forms the basis of this Chapter. 
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7.2 Chapter Aims 
This chapter aims to quantify the occurrence of ARI and RSV associated ARI by age, sex 
and child class (pre-school or school child) in the household cohort. The risk of disease 
following RSV infection is also investigated. 
7.3 Methods 
Study design 
A total of 73 families of birth cohort children within the DSS were recruited between 
February and May 2003. Sampling was purposive rather than random. A sub-sample of 
households of birth cohort infants with at least one sibling were selected. Within these 
families, all children up to and including those aged 14 years were monitored for ARI for a 
maximum of 26 months. From the end of January 2004 consenting adults were also 
included. Monitoring involved active and passive surveillance as described in chapter 3. 
Nasal specimens were tested for RSV antigen by Direct Immunofluorescence. There were 
25 households lost to follow up during the study, of which 8 were replaced before 
experiencing an epidemic (in 2004). Thus in total 81 (73+8) households were recruited. 
Data and definitions 
Data collected are the cases of ARI and RSV positive ARI (RSV-ARI) over the study 
period. At each active visit a record was made of absence from the District since the last 
visit. The presence of any respiratory symptoms was considered an illness episode (refer to 
Chapter 3). Due to the diverse aetiology of ARI, new ARIs were delineated if symptoms 
were present one week after the previous illness episode. Observation time was time at risk, 
that is, time present within the DSS during which episodes were potentially observable. 
Non-observational time was excluded from time at risk. Only children for whom a single 
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visit following recruitment arose were included as study participants. For a specified period 
following RSV infection (14 days) an individual was assumed not to be at risk of another 
infection hence this should be viewed as non-observational period and was excluded. The 
one week post infection was not excluded from observation time for ARI estimates. The 
last visit was treated as the exit date leading to the exclusion of observation time between 
the last visit and the documented exit time. 
The severity of respiratory disease was assigned on the basis of WHO criteria as described 
previously [5]. Severe ARI (LRTI) is defined as a history of acute cough or difficulty in 
breathing and ?1 of the following: (1) fast breathing for age (260 breaths/min if <2 
months old or 250 breaths/min if 2-11 months old or 240 breaths/min if 12+ months), (2) 
indrawing, or (3) low oxygen saturation (<90%) by pulse oxymetry or inability to feed (in 
practice defined as prostration or unconsciousness), and if accompanied by a clinical 
diagnosis of LRTI or bronchiolitis (this caveat applies only to the diagnosis of very severe 
LRTI). Severe LRTI was diagnosed when a child had LRTI meeting criteria 2 and/or 3 
above. 
Children were categorized as follows: a) attending school b) a pre-school child with a 
sibling(s) who attends school or c) a pre-school child with no sibling(s) who attend school. 
Individuals were combined into three age classes - infants, young non-school children (1-5 
years), older school age children (6-14 years), and adults to calculate adjusted independent 
estimates. The definitions of an epidemic and inter-epidemic periods have been described 
previously in Chapter 3. 
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Analysis 
Analysis was carried out using STATA 8. Incidences were estimated as the number of 
cases of ARI and of RSV-ARI per 1000 person years of observation. Poisson regression 
commands were used. Incidence rates and 95% confidence intervals for ARI and RSV-ARI 
and RSV-LRTI were calculated by age, sex and class of children in the household. To 
account for repeated episodes of ARI within individuals (significant within individual 
clustering), Poisson regression accounting for clustering using a random intercepts model 
was used. The same was not done for RSV infection since there very few reinfections. 95% 
confidence intervals for the incidence estimates were calculated using the quadratic 
approximation to the Poisson log-likelihood for the log-rate parameter. Adjusted (for age, 
sex and/or child class) incidence rate ratios (IRRs) (estimated by use of Poisson regression) 
between groups (95% CI) were calculated. Wald test (i. e. log (rate/SE)) of the null 
hypothesis that a particular rate ratio is 1 was used to assess for significance within groups 
and is based on the quadratic approximation to the log-likelihood ratio at the maximum. 
The Likelihood Ratio Test (LRT) was used to assess the presence of interactions between 
variables and to test the significance of a variable while controlling for others. 
For the analysis of incidence of RSV infection and disease the follow-up time was split 
according to epidemic and non-epidemic periods. The nature of recruitment (restricted to 6 
months and not all year round, a factor of the study design - see section 3.3.1 Chapter 3) 
resulted in a bias in observation time during epidemic and non-epidemic time periods in the 
different age classes. As a result time at risk of RSV infection was uneven between age 
strata. To account for this, the observation time was weighted by a ratio calculated using 
the actual and expected child years of observation (cyo) within and between epidemics, as 
follows: 
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Let the actual period of observation (days), Y (i), for age class i=1, m be the summation of 
observation in age class i, for epidemic, k=e, and non-epidemic, k=n, periods 
Y(i) = Y (l) +Y (1) = IkYk (i) 
The expected observation time in days, Ek (i) for age class, i, is calculated for non- 
epidemic, k=n and epidemic, k=e periods as 
Ek (i) = Pk. Y(i) 
where Pe is the expected proportion of a year with epidemic and P is expected proportion 
of year without epidemic. 
Hence, weights by age class i applied to data from within (e) and between (n) epidemics, 
Wk(i), are the ratio of expected to observed child years of observation for each age class, i, 
Wk (r) Er(t)pt(l) 
The expected proportions of the year within and without epidemic (Pk) were estimated to be 
32% (16.3/52) and 68% (35.3/52) respectively. Using this weighting incidence was 
calculated with respect to age class and time as detailed in Appendix 0 (p 351). 
7.4 Results 
There were 73 families with 373 members who had more than one visit who are considered 
in this analysis. This included 314 children under the age of 17 years (<15 years at the start 
of the study) with a median age of 4 years. Most of the adults were females (50 of the 59). 
Participants numbering 87 (78 from whole HHs) dropped out from 25 families before the 
end of the study; 51% refused (i. e. withdrew consent), 44% moved out of the study area 
while the remaining 5% either died or were requested to exit the study. Those requested 
were as a result of a split in one polygamous household. 8 households were replaced. The 
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age and sex distribution of study participants at recruitment is given in Table 7.1. There 
were 137 children attending school, 4 of whom were classified as adults (i. e. > 14 years at 
recruitment), 133 pre-school children with one or more siblings attending school and 48 
pre-school children with no sibling(s) in school. 
Table 7.1. Age and sex distribution of study participants at recruitment 
Sex 
Age (years) Female Male Total 
<1 50 45 95 
1 7 6 13 
2 20 20 40 
3 12 12 24 
4 7 12 19 
5 11 9 20 
6 10 10 20 
7 9 7 16 
8 3 3 6 
9 4 9 13 
10 10 10 20 
11-14 -14 14 28 
15+ (adults) 50 9 59 
Total 207 166 373 
7.4.1. Incidence of all respiratory illnesses 
A total of 2,566 ARIs were recorded from a total observation time of 537.3 years with an 
average of 477 respiratory illnesses per 1000 person-years (95% CI, 459 -499 illnesses/ 
1000 person-years). There were 203 cases of LRTI identified in the household cohort with 
an incidence of 378 per 1000 person-year (CI 330-430). 
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i) Age-specific incidence rates (IR) 
There was a general decline in all-cause respiratory illness rates with age (Table 7.2). There 
was a general reduction in the rate of illness from 2 years of age except for a slight increase 
observed in children aged 3 years. Adults had fewer attacks compared to children, with 
higher rates observed in women (1.59 (95%CI 0.98,2.60) vs. 0.79 (0.30,2.06)). The 
estimate of the incidence of LRTI in <5 was 679 cases/1000 cyo (95% CI, 550-839), that 
in < 15 was 410 cases/1000 cyo (95% CI, 327-514). 
Table 7.2 Incidence of respiratory illness according to age 
Age # of Person years of ARI per person- ARI per person-year 
(years) illnesses observation year (95% CI)* (95% CI)* adjusted for 
clustering of episodes 
<1 596 75.7 7.87 (7.26,8.53) 7.62 (6.71,8.66) 
1 662 67.6 9.79 (9.07,10.57) 9.41(7.39,11.99) 
2 202 38.6 5.68 (4.94,6.51) 5.29(3.80,7.37) 
3 328 47.3 6.92 (6.22,7.72) 6.60 (4.77,9.13) 
4 186 40.1 4.64 (4.02,5.36) 4.74(3.34,6.72) 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
106 
103 
79 
59 
26 
31 
21 
28 
35 
17 
29.8 
31.2 
30.1 
22.2 
14.9 
18.8 
22.2 
16.5 
15.2 
9.1 
3.56 (2.94,4.30) 
3.30 (2.72,4.00) 
2.62 (2.10,3.27) 
2.66 (2.06,3.44) 
1.74 (1.19,2.56) 
1.65 (1.16,2.34) 
0.95 (0.62,1.45) 
1.69 (1.17,2.45) 
2.31 (1.66,3.21) 
1.87 (1.16,3.00) 
1.43 (1.16,1.76) 
3.44 (2.33,5.09) 
3.46 (2.32,5.15) 
2.74 (1.80,4.18) 
2.56 (1.62,4.04)) 
1.78 (1.00,3.17) 
1.72 (0.99,2.96) 
0.97 (0.53,1.78) 
1.61 (0.92,2.83) 
2.36 (1.37,4.07) 
2.10 (1.05,4.20) 
adults 87 60.9 1.45 (0.97.2.19) 
Total 2566 537.3 4.77 (4.58,4.96) 4.53 (4.11,5.00) 
*95% confidence intervals for ARI incidence are calculated using the quadratic 
approximation to the Poisson Log likelihood for the log-rate parameter. 
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ii) Incidence of respiratory illness by age and gender 
Infection rates were compared by age and gender. Among children 1 year old or younger, 
the incidence rates were higher in male children than in females (Figure 7.1). IRR with age 
class and sex were calculated. There was a significant age effect in some age classes and 
not in others suggestive of an interaction. The results show that the interaction between sex 
and age is not significant (lrtest, p=0.122). School children (6-14 years) and adults had 
significantly lower rates after adjusting for sex; 0.41 and 0.24 respectively. The rate in pre- 
school children (1-5 years) was the same as that observed in infants (IRR 1.06, p=0.246). 
Although sex does not appear to be significantly associated with respiratory infection rate, 
among adults the rate was twice as high in females (IRR =0.49) but this was not significant. 
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Figure 7.1. Incidence (95% CI) of all-cause respiratory illness among children in the 
household cohort by age and sex. 
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iii) Incidence of respiratory illness by child class 
The relationship between school attendance and the incidence of respiratory infection was 
studied. Children were classified as detailed in the methods section of this Chapter. Figure 
7.2 shows the age specific incidence rates in each of the three age classes. The influence of 
school children on respiratory illness among siblings is shown. For comparable ages, the 
rates tended to be higher in pre-school children with siblings who were going to school than 
those pre-school children without sibling(s) in school. Except for one age group, school 
children 3 years of age, the rates of infection in children attending school were lower than 
the rates for either class of pre-school children. The incidence rates are poorly established 
for 3 year-old school children because of limited data as few children of this age attend 
school. The crude IRR for pre-school with school siblings and for school siblings relative to 
baseline of pre-school no siblings was 1.20 and 0.36 (P= 0.144 and <0.00 1), respectively. 
The age adjusted estimates were 1.17 and 0.79 but these were not significant. 
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Figure 7.2. Incidence estimates of respiratory illness by age and child class: Pre-school 
children with no school child in the HH (open diamonds), pre-school child with sibling(s) 
in school (black boxes), school children (red triangles) and school-aged children not in 
school (black box dashed line). The 95% Cl are given in Appendix P (p 353). 
The importance of school children in increasing ARI rates in adult household members was 
demonstrated comparing rates in adults in households with and without school children 
(IRR=1.40) although this difference was not significant (Wald test, P=0.37 ). 
7.4.2 RSV infection and disease 
As only one adult had an identified clinical infection, these analyses were restricted to 
children (i. e. those < 15 years at recruitment). Details of child years of observation (cyo) 
and adjusted (weighted) cyo are summarized in Table 7.3 as are the cases of RSV infection 
and re-infection identified during the study by age and gender. In children 2 years of age or 
less there is no difference in numbers infected by gender. In children 3- <5 years of age 
there were almost as many male children infected as females. 
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Table 7.3. Observed and weighted years of observation, by age class, and RSV cases by 
sex and age class for children within the household cohort 
Age class Child years of observation Cases 
Observed Adjusted Gender 
Epidemic Non- Epidemic Non- Female Male 
epidemic epidemic 
0-11 mths 19 55 24 51 14 14 
12-17 mths 15 19 11 23 12 12 
18-24 mths 17 19 12 24 10 8 
25-36mths 9 27 11 24 7 4 
37-59mths 31 51 26 56 9 16 
5-9yrs 42 73 37 78 8 5 
>9yrs 36 63 32 67 1 0 
Total 169 307 153 323 61 59 
There were 22 repeat RSV infections (re-infections) identified during the study. As the 
history of infection was not known for the siblings in the household study, it was assumed 
that all RSV infections identified in children over two years of age were classified as re- 
infections and those infections in siblings 2 years of age or younger (5 children in total) 
were primary infections. Most of these are siblings born during the follow up period. Using 
this re-assignment, the number of primary and re-infections identified in this study by age 
class is shown in Table 7.4. Thus there were 54 primary infections identified in the 
household cohort and 66 re-infections. 59 % (39/66) of the re-infections were in children 
over 3 years of age. 
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Table 7.4. RSV disease risks after primary and re-infection stratified by age 
Primary Infection Re-infection 
Age class URTI LRTI URTI LRTI Total 
(risk %) (risk %) 
0-11m 24 2(8) 1 0(0) 27 
12-17m 12 4(25) 2 0(0) 18 
18-24m 5 1(17) 9 2(18) 17 
25-36m - - 10 I (q) I1 
37-59m - - 25 0 (0) 25 
5-9yrs - - 13 0 (0) 13 
>9yrs - - 1 0(0) 1 
Total 41 7(15) 61 3(5) 112 
Note: Fisher's Exact test by age: P= 0.202, for LRTI following primary infection; P 
=0.207, for re-infection. 
The risk of developing disease after a primary infection and after re-infection was 
investigated. Data from twins (3 sets) was excluded from this analysis (total of 8 infections 
excluded). There was no significant difference in risk of disease by age after primary 
infection; 0-11m vs. 12+ months (RR=1.72, P=0.1414). There was borderline association 
(RR=0.41, p=0.055) between age and risk of disease following re-infection; 0-24 month vs. 
25+ months. 15% of children <25 months getting an LRTI compared only 3% in older 
children (Table 7.4). However, there is little confidence in the age-stratified data as there 
are not many cases of LRTI. Thus an estimate for the total across age groups (more 
reliable) was made. The risk of disease following primary infection was higher (borderline 
significance) than after re-infection (RR= 0.32, P=0.069). There was little overlap in age 
classes of primary and secondary cases to enable a comparison. No difference in disease 
risk by sex was observed (RR =1.03, P=0.953). LRTIs were further subdivided to identify 
cases of severe RSV-LRTI. The risk of severe disease after primary infection was limited to 
children less than 18 months. There was no significant difference in risk of severe disease 
in the two age groups (Figure 7.3); 9.1% in children 0-11 months and 13% in children 12- 
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17 months (Fisher's Exact test, P= 1.000). There were no cases of severe LRTI resulting 
from re-infections. 
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Figure 7.3. Proportion of RSV primary infections resulting in disease (Risk) stratified by 
age class. RSV-LRTI (black bars), severe RSV-LRTI (red bars). 
7.4.3. Incidence of RSV infection 
The incidence of RSV infection was 218 cases/1000 cyo (95% Cl, 182- 264 cases/1000 
cyo). The incidence of primary RSV infection was 476 cases/1000 cyo (95% Cl, 361-630 
cases/1000 cyo) and the incidence of re-infection was 147/1000 cyo (95% Cl, 115-189 
cases/1000 cyo). 
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Figure 7.4. Incidence (logio scale) of RSV associated ARI (open bars), LRTI (light blue 
bars) and severe LRTI (dark blue bars) by age class in the household cohort. Bars indicate 
95%CI. 
Figure 7.4 shows the incidence of RSV infection and disease in this study population. 
Estimates are inclusive or nested i. e. RSV-LRTI means RSV-LRTI and sLRTI. The actual 
incidence estimates are given in Appendix Q (p 355). Note that an RSV infection on 
its 
own must at least indicate an URTI. The estimates are inclusive or nested i. e. RSV-LRTI 
means cases of RSV LRTI or sLRTI. No appreciable decline was seen in infection rates of 
RSV until after 3 years of age where the rate of infection is significantly lower than for 
children 0-11 months (254 compared to 459/1000 cases)). LRTI occurred in children 3 
years of age or lower while cases of severe disease were confined to children below 18 
months. The IR of all-cause LRTI was 354 cases/1000cyo (95% CI, 282-444), that of RSV- 
LRTI was 22.5 cases/1000 (95% CI, 13 - 39 cases /1000 cyo). 
The IR of all-cause severe 
LRTI was 132 cases/1000 cyo (95% Cl, 94-185), that of RSV- associated severe LRTI was 
7.6 cases/1000(95% Cl, 2.7-20.9 cases /1000 cyo). 
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The incidence rate of primary RSV infection by age is shown in Figure 7.5. The IR of 
primary infection in children <1 year was 406 cases/1000 cyo (95% CI, 270- 612 cases 
/1000 cyo). IR was significantly higher in children 12-17 months of age, 873 cases/1000 
cyo (95% CI, 315 - 2,414 cases /1000 cyo, IRR 1.93; P=0.03) and was 266 in children 18- 
24 months (95% CI, 72 - 995 cases /1000 cyo). IR of LRTI after primary RSV infection by 
age is shown in Fig. 7.5. The IR was the same for RSV-LRTI and RSV- associated severe 
LRTI in children <1 year, 35 cases/1000 cyo, was higher 349 and 87 cases/ 1000 cyo, 
respectively in children aged 12- 17 months. This difference was significant for RSV-LRTI. 
The IR was 45 cases/1000 cyo (95% CI, 1- 1969 cases /1000 cyo) for RSV-LRTI in 
children 18-24 months with no cases of severe disease identified in this age group. There 
were no cases of hospital admission in the household cohort. One child died within a week 
of a positive RSV diagnosis (age 2 years 10 months with a mild LRTI) but the cause of 
death was unknown. 
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Figure 7.5. Incidence (loglo scale) of primary RSV associated ARI (open bars), disease 
(light blue bars) and severe disease (dark blue bars) by age class in the household cohort. 
Bars indicate 95%CI. 
The age specific incidence rate ratios (IRR) of all RSV infections and disease are shown in 
Table 7.5. The comparison group is children 0-11 months of age. Adjustments for sex does 
not change the estimates significantly (lrtest, p>0.05). Incidence of infection declined with 
age significantly at age >3 years. There was only one child infected over the age of 10, a 14 
year old girl with an RSV ARI. The IRR of RSV-LRTI in age class 12-17 months was 5 
times that of children 0-11 months, this difference was significant (P=0.041). That of 
children in 18-24 months and 25-36 months was 1.8 times and 1.1 times that of the 0-11 
month-old children, respectively (not significant). The IRR of RSV-associated severe 
LRTI in children 12-17 months was 1.25 times that of infants. This increased incidence was 
not significant. There was no case of RSV-associated severe LRTI in children older than 17 
months. 
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12-24m 
Table 7.5. IRR of RSV-ARI, RSV-LRTI and RSV-associated severe LRTI by age class in 
the household cohort 
Age class (months) RSV ARI RSV-LRTI Severe RSV- LRTI 
0-1 Im - -- 
12-17m 1.08 (0.62,1.87) 5.03 (1.07,23.75) 1.26 (0.18,8.96) 
18-24m 0.76 (0.42,1.37) 1.76 (0.29,10.56) - 
25-36m 0.89 (0.44,1.80) 1.14 (0.10,12.55) - 
37-59m 0.55 (0.32,0.95) -- 
60-108m 0.22 (0.11,0.42) -- 
109+m 0.02 (0.00,0.14) -- 
0-11m is the baseline group 
Significant estimates in bold (Wald test, p< 0.05) 
Similar to that observed with all-cause ARI (Fig 7.2), the incidence of RSV infection was 
highest in pre-school children with siblings in school (Fig 7.6). All the cases of RSV-LRTI 
identified were also in pre-school children with one or more siblings in school. 
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Figure 7.6. Incidence estimates of RSV infection by age and child class. The lines 
correspond to pre-school children with no school child (open diamonds), preschool child 
with sibling in school (black box) and school child (red triangles). 95% CI are provided in 
Appendix P (p 353). 
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The IRR of infection was stratified by age and gender. Differences by gender were not 
statistically significant. The incidence of RSV infection was compared within and between 
seasons for each quarter of each year of follow-up. The overall incidence of infection 
within each epidemic (468 cases/1000 cyo 95% CI 392-560) did not differ between 
epidemics with no transmission observed outside the main epidemic season (Wald test, 
p>0.05). 
7.5 Discussion 
This is the first household study of RSV from a Less Developed Country (LDC). During 
the study of 28 months duration and spanning two and a half epidemics, we detected an 
RSV infection in 31% of the children in the household cohort. 45% of the RSV infections 
were identified to be primary infections, 15% of the primary cases were LRTIs. The 
incidence of RSV primary infection in the household cohort was 476 cases/1000 cyo (95% 
CI, 361-630 cases/1000 cyo), that for re-infection was 147/1000 cyo (95% CI, 115-189 
cases/1000 cyo). This compares well with previous data from Kilifi [5] where the incidence 
of primary infection was 487/1000 in infants while that for re-infection was 192/1000. 
In line with previous data from Kilifi, the incidence of all-cause LRTI in infants in this 
study was 863/ 1000 cyo (95% CI, 633-1175), slightly lower than previous estimates from 
another community study [6]. The estimate of the incidence of all-cause LRTI in <5 year 
olds (679/1000 cyo, CI 550-839) is in accord with reports from other studies [11,40,127]. 
Incidence of RSV-LRTI in infants was lower 33 cases/1000 cyo compared to reports from 
other community studies from developing countries, 100-220 cases/1000 cyo [5,6,11] but 
similar to that reported from the study from Indonesia [11]. However, the incidence of 
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RSV-LRTI in under 5s was 45 cases/1000 cyo, lower than in Nigeria but similar to that 
reported in Indonesia [11]. 
The data show high incidence of RSV infection (ARI) well into young childhood, with no 
appreciable decline until >60m of age. High rates of RSV infection beyond infancy is 
neither unusual nor epidemiologically unexpected. The study by Glezen et al [ 12] showed 
high rates of RSV in year 2 of life and reasonably high rates in year 3 and 4. Similar results 
of significant incidence rates of RSV ARI in older ages and even into adulthood have also 
previously been reported from the family study by Hall et al [15]. Mixing patterns in this 
community would suggest high rates of contact in large households and school attendance 
suitable for RSV transmission. However, the data also show a higher rate of RSV disease 
in the second year of life. This is unexpected and is probably influenced by methodological 
issues. Only two clinical infections were identified in the first epidemic as a direct result of 
timing of recruitment in relation to the first epidemic in the HH cohort (i. e. it occurred 
earlier than had been anticipated). Thus most first infections in infancy were found in 
children with an average age of I lm that is nearing the end of their first year of life. Many 
of the child years of observation in infancy would therefore have been at the tail end of the 
first epidemic when the infants were very young with highest levels of maternal antibody 
and thus would be afforded protection from disease. Thus the higher rate of disease in older 
children is an artifact of the temporal incidence and cohort age, which has greater impact on 
the incidence of disease estimates rather than the incidence of infection. Data from the full 
birth cohort data was able to adjust for this because of the two cohorts. Results from this do 
nevertheless still indicate that significant risk of disease does exist beyond the first year of 
life (Nokes et al, in press). Notably a quarter of all re-infections were associated with LRTI. 
An attempt was made to account for this study design in the calculation of incidence 
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estimates by the weighting procedure detailed herein. Although we have attempted to 
overcome the design problems by weighting admittedly data from the household study and 
specifically the disease results are probably still influenced by this problem. 
This study demonstrates quite considerable RSV infection levels in families (i. e. re- 
infection rates) as has previously been described in studies from developed countries [15, 
16,50]. In this study the incidence of clinical infection was drastically reduced after nine 
years of age; 101 cases in children 5-9 years to 9 cases/1000 cyo in older children. In the 
Tecumseh study in the US the highest rates (determined by serology) were observed in 
children 5-9 years [16]. Several factors may explain this. It has been observed in this and 
other studies that the incidence of ARI decreases with age. It is probable that there were 
missed asymptomatic RSV infections or infections with very short symptomatic periods. 
Nevertheless, several studies have reported that asymptomatic carriage of RSV is 
uncommon [261,262] but not impossible [50,101]. In order to consider asymptomatic 
infection, samples would have to be taken even in the absence of symptoms but justifying 
this might prove difficult. In addition, studies have shown that rapid antigen detection tests 
for the diagnosis of RSV respiratory illness in older individuals and adults are less sensitive 
than for diagnosis in children [125,241]. Thus it is likely, as a result of the diagnostic 
method, that some infections may have been missed in older individuals. 
The incidence rates of all-cause ARI reported here are similar (7.1 per child-year) to that 
from other studies, 6.1 per child-year in children <5 years in Manila [127]. As expected, 
respiratory infections were more common among female adults than male adults; a likely 
result of the closeness and length of contact that mothers have with children relative to 
fathers. Pre-school children with siblings in school had higher infection rates than pre- 
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school children without siblings in school. Presumably the former group is exposed to 
infection from their brothers and sisters who are attending school. Several studies done in 
developed countries provide evidence that younger children acquire infection from school- 
aged children within the household [15,16,50,145]. 
Epidemics were characterized by periods of fadeout. To elucidate the mechanism of RSV 
persistence the possibility of the persistence of infections in the inter-epidemic period was 
considered. No clinical infections were identified between epidemics. Again it is possible 
that sub-clinical infections were taking place but such information would only be available 
from serological data which is presently not available. Several factors have been suggested 
as possible triggers of epidemics [39,49,60] from climatic factors to behavioural changes 
to loss of immunity and geographical position. In this environment it is still not clear what 
triggers epidemics as the intervals are variable (see Fig2.3, KDH IP data) with no clear 
relationship to climatic indicators or known behavioural changes related to weather 
patterns. Continued surveillance may shed further light on this issue in the future. 
Certain methodological issues need to be qualified. New ARIs were delineated if 
symptoms were present one week after the end of the previous illness episode. Given that 
the aetiology of all cause ARI is diverse, there is justification for using only one week. 
Separate from this, the first 14 days following an RSV infection were excluded from the 
denominator since one was considered to be at no risk during this period. This was not done 
for ARI. It is rational to do this for RSV where repeat infections in the same child are 
relatively infrequent. However, for infections that are very common (all cause ARI), this is 
not practical as most observational time could potentially be excluded e. g. at the extreme 
case where children are getting a new ARI very frequently, there would be no observational 
time left and an incidence estimate can thus not be made. RSV Incidence was calculated 
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using weighted observation time (discussed in the methods). To illustrate the significance 
of this weighting a comparison of weighted and un-weighted incidence estimates was 
carried out (Table 7.6). Observed differences in estimates indicate that un-weighted 
observation time would result in either over or under estimation of the age-stratified 
incidence. This was not done for all-cause ARI based on the reasoning that ARI is less 
seasonal and therefore the age bias seen with RSV epidemic and non-epidemic observation 
time was likely to be less important. When age classes are combined this weighting effect 
ceases to be as important (Appendix R, p 356) 
Table 7.6. RSV incidence (/1000 cyo) estimates comparing weighted and un-weighted 
observation time, for the household cohort 
Age class Infection RSV-LRTI severe LRTI 
(months) 
weighted unweighted weighted unweighted weighted unweighted 
0-11m 459 371 33 26 33 26 
12-17m 495 689 165 229 41 57 
18-24m 346 494 58 82 0 0 
25-36m 409 309 37 28 0 0 
37-59m 254 300 0 0 0 0 
60-108m 100 113 0 0 0 0 
109+m 9 10 0 0 0 0 
In conclusion we have demostarted an important burden of RSV infection and associated 
disease in relation to age in a rural community in Kenya and in Africa. We have 
documented the risk of disease and severe disease resulting from both primary infections 
and re-infection an aspect that has not been comprehensively studied. Thus these data 
attend to the need for more information from developing countries. In subsequent chapters, 
we explore factors in this population that are associated with increased risk of RSV 
infection and RSV-LRTI. 
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Chapter Eight 
Risk Factor Survey 
8.1 Introduction 
There are three possible avenues of control for respiratory disease: prevention through 
vaccination, case management and supportive treatment for those who are already infected 
and lastly the identification and removal or avoidance of risk factors [194,263]. It may be 
desirable to implement one or more or all of the three control methods. However, which of 
these will be of most use in the resource poor settings will depend on numerous factors, but 
of particular concern in the case of viral associated respiratory disease is the near absence 
of effective vaccines. The use of therapy in the form of anti-viral agents is unlikely to be an 
affordable wide-scale option, and proper case-management such as the use of oxygen or 
cohorting to prevent nosocomial spread are beyond the resources of the typical District 
Hospital in the sub-Saharan setting. Thus while immunization and case management are, or 
could be, partly effective in ARI [264], it is possible that the long term solution in 
developing countries will depend on the control of risk factors. It has been estimated that up 
to 25% of moderate and severe ARI might be preventable through addressing certain 
factors, namely exposure to wood smoke, nutritional factors, all of which are known risk 
factors for all-cause ARI [166,194]. 
Respiratory infectious disease accounts for much global morbidity and mortality [21,22, 
25,265,266], and a significant proportion of ARI morbidity is due to RSV [27,28]. 
Despite 40 years of research on RSV, we are really not anywhere near to licensing a 
vaccine, and oxygen therapy, taken for granted in industrialized countries, for supportive 
therapy for RSV, is not affordable in most resource poor settings. 
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Risk factor studies on disease caused by RSV from developing countries are few [126,194, 
200] and also none as yet has investigated risk factors for possible non-hospitalised severe 
disease occurring in the community [5]. The birth cohort (Chapter 3) provides a frame work 
for the comparison of risk factors for mild RSV infection and disease as well as comparing 
risk factors for non-specific LRTI (defined in chapter 9) with those identified for RSV- 
LRTI. 
8.2 Chapter Aims 
This chapter describes in detail the methodological approach adopted to collect the 
household and individual level risk factor data for RSV infection and RSV-LRTI and for all 
cause LRTI. This was a cross-sectional survey conducted towards the end of longitudinal 
follow up study of a birth cohort. The study design, data collection procedures and data 
management processes are described. The statistical background for the methods used in 
the analysis of risk factors (Chapter 8) and some general results are described. Issues 
arising from the study design, the appropriateness of the questionnaire and the computation 
of the socio-economic asset index are discussed. 
8.3 Survey 
8.3.1 Study Design and Ethical Considerations 
A total of 635 children recruited at birth were monitored over 2 and half years between 
2002 and 2005 for episodes of RSV infection through a process of passive referral and 
active surveillance as described in Chapter 2. Within this framework, a cross sectional risk 
factor survey was carried out on families of all children from this cohort to investigate the 
association between exposure to putative risk factors for RSV specific infection/disease and 
all cause LRTI both in the individual and in the household. The survey was carried out 
between June 2004 and November 2004, that is at the end of the third epidemic season just 
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before follow up of cohort 1 ended and before the last year of follow up of cohort 2. All 
children in the main birth cohort were eligible to take part in the survey as long as they 
were still being followed up at the time of the survey. At the beginning of the interview 
visit, the purpose of the study was explained to the parents or guardians and verbal consent 
sought before the interview commenced. The field worker conducted the interview, reading 
out and explaining the questions to the respondent and then filling in the questionnaire. 
Ethical permission was given within the main proposal by the Kenya Medical Research 
Institute/National Ethical Review Committee and Coventry Research Ethics Committee, 
UK. 
8.3.2 Questionnaires 
A questionnaire (Appendix S, p 358) was filled out for all the children enrolled. The 
questionnaire addressed household characteristics, demographic, socio-economic and 
environmental factors. These were fashioned on the basis of previous work done on risk 
factors for RSV and other risk factor surveys conducted in sub-Saharan Africa [ 167,175, 
194,267-269]. The questions on socio-economic status and household characteristics were 
used to classify households into different socio-economic classes based on an asset index 
described herein. 
A pilot risk factor survey was initially conducted in collaboration with a student intern 
(Nicodemus Kisengese). The first pilot study was mainly used as a tool for accessing the 
appropriateness of questions included. Results from this pilot study were used to modify 
and inform the main survey questionnaire with certain questions being weeded out or 
modified and new questions included as necessary. It was also used to design an 
appropriate database to facilitate data entry. Most of the questions were multiple choice 
204 
with one or two applicable answers being marked with a circle. Several questions required 
a number to be entered into the box (e. g. how many children live in your household? ) The 
question on occupation of the major income provider (MIP) was the only one to require a 
written answer. Each field worker was provided with a rubric (Appendix T, p 364) in 
English giving details of the questions in the questionnaire as well as details on what sort of 
responses were expected for each question. A field worker training session was 
subsequently conducted. The questionnaire was in English but questions were translated 
into the local Giriama or Kiswahili language at the time of the interview. 
8.3.3 Data Management 
Data from the questionnaires were double entered by two independent data entry clerks 
onto a FileMaker (FileMaker Pro Developer Version 5.5) database with several internal 
consistency checks. The two data sets were then compared using a specially designed 
verification program in FoxPro (Version 6) that generates a text file document detailing the 
discrepancies, which were resolved by consulting the original paper questionnaires. 
8.3.4 Description of data set 
Longitudinal data on infection history from active and passive surveillance was combined 
with cross-sectional data from the risk factor survey. The dataset consisted of individual 
subjects with observations recording the start and end of each observation period and the 
infection status at the end of that observation period resulting in survival time data. Each 
child had multiple record visit data over the follow-up period. A total of 529 questionnaires 
were completed including 60 from infants recruited form IP or OP. Information on 
household and individual demographic and social characteristics was available from the 
questionnaire data. The outcome variables were (i) LRTI (ii) RSV-ARI and (iii) RSV- 
LRTI, all identified by clinical surveillance methods using modified WHO criteria as 
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previously described (Sec 7.3, Chapter 7 ), and in the specific case of RSV identified by 
antigen assay (IFAT) of nasal washings. These three outcomes will be referred to as all- 
cause LRTI, RSV infection (RSVI) and RSV disease (RSV-LRTI) respectively in the 
following text of this and the next chapter. 
8.3.5 Response rate 
Out of a total of 635 birth cohort children who had at least one visit, data on risk factors 
was obtained from 469 children (74%). Most (75%) of the 166 children for whom no data 
was available had dropped out of the study before the start date of the risk factor survey. 
469 children were used in this analysis with 60 children being excluded because they were 
recruited into the cohort from either the IP or OP and thus did not have records from birth. 
8.4 Analysis 
The analysis used for generation of the results presented in Chapter 8 are presented here. 
8.4.1 Descriptive analysis 
Standard descriptive statistical analyses (means, frequency tabulations) were conducted to 
explore the dataset. The distribution of each of the variable was examined to find outliers 
and to get a good understanding of the characteristics of the study population with respect 
to the risk factors. Single variables were investigated in relation to RSV infection/disease 
and all-cause LRTI incidence. Data reduction procedures were then carried out. Only 
variables with substantial variability within categories were included. Variables with 
categories that had small numbers of observations were combined. Categories were created 
after complete exploration of variables to ensure no effect was masked and check for non- 
linearity. Correlation and interaction between variables was explored creating new 
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variables that best captured the essence of the data. The means, ranges and distributions of 
these variables are in Appendix U with a description of social and demographic 
characteristics of the population can be found in Table 7.4. 
8.4.2 Creation of an asset based wealth index to estimate household socio-economic 
status 
In most African settings information on income and expenditure is difficult to collect 
because most people engage in subsistence farming, barter or petty trade and therefore 
information on income and expenditure is often unreliable. In the absence of information on 
household income and expenditure several alternative methods have been developed that 
rely on assets owned and housing quality as well as occupations of household members. In 
this study I used data on asset indicators or asset variables to construct an asset index based 
on the method described by [270]. This asset index does not reflect current consumption; 
rather it is viewed as a proxy for a household's long running economic status. This is done 
by creating a proxy for wealth by constructing a linear index from asset ownership 
indicators, using principal components analysis (PCA) to derive weights. Principal 
components analysis is a statistical technique for data reduction and provides a method of 
identifying those factors that most contribute to the variance of each composite wealth 
index. The objective is to find unit-length linear combinations of variables that contain the 
most information (greatest variance) and the weighting of the variable is based on the value 
of its principal component [270-272]. The first component (PCI) gives the minimum 
perpendicular distance between it and all the data points; minimising the perpendicular 
error is the same as maximizing the variation in the predicted i. e. the PC. Thus the PC1 
maximizes the differences between households and is typically assumed to be the asset 
index. The result obtained from the first principal component is usually used to develop the 
asset index AA based on the following formula: 
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Aj =fl * (aii-«i) /(Si)....... + fN * (ajN-aN) /(srr) 
In the above formula: 
"f is the `scoring factor' for the first asset as determined by the procedure; 
" aj 1 is the jth household's value for the first asset; and 
" al and sl are the mean and standard deviation of the first asset variable over all 
households [270]. 
i) Construction and validity of the asset index 
The classification was based on the computation of asset indices that take into account a set 
of asset-based and health-related variables for each household: 
" whether the household has electricity, radio, a television or video, any bicycles, any 
motorcycles, or a telephone (each coded as 1= Yes, 0= No); 
" the main household source of drinking water (5 categories); 
" the main type of cooking fuel (three categories). 
" the main type of toilet facility used by the household (three categories); 
" the main type of housing material in the household (two categories); and 
" the home ownership (three categories). 
The percentage of the variance explained by the first principal component is 24%, Table 
8.1. The first eigenvalue is 6.096; the second eigenvalue is 2.36. 
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Table 8.1 Eigenvalues from the PCA. Showing the variance explained by the first 13 
components. 
Component Eigenvalue Difference Proportion Cumulative 
Comp l, 6.09621 3.73503 0.2438 0.2438 
Comp2 2.36118 0.390062 0.0944 0.3383 
Comp3 1.97111 0.199366 0.0788 0.4171 
Comp4 1.77175 0.098659 0.0709 0.488 
Comp5 1.67309 0.309788 0.0669 0.5549 
Comp6 1.3633 0.160906 0.0545 0.6095 
Comp7 1.2024 0.094942 0.0481 0.6576 
Comp8 1.10745 0.092685 0.0443 0.7019 
Comp9 1.01477 0.042767 0.0406 0.7425 
Comp10 0.972002 0.147344 0.0389 0.7813 
COMP 11 0.824659 0.037738 0.033 0.8143 
Comp12 0.78692 0.064033 0.0315 0.8458 
Comp13 0.722888 0.060349 0.0289 0.8747 
The first component has negative loadings for having no toilet, house walls made of mud, 
using fire wood as the main cooking fuel, owning the house in which you live, obtaining 
water from a well that is open to the public and owning an animal (cows, goats or sheep) 
thus can be interpreted as distinguishing the "poor" households from those that are better 
off households, Table 8.2. Owning a house usually implies living in your rural homestead 
and thus entails very little financial input (as most of them are makuti (palm leaves) 
thatched, mud-walled houses). 
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Table 8.2. First six components from the principal components analysis. 
Variable Compl Comp2 Comp3 Comp4 Comp5 Comp6 
phone 0.2169 0.2564 0.0248 0.183 -0.0364 0.0734 
radio 0.1282 0.1701 0.1863 0.2055 0.0286 0.1963 
Motor bike 0.0079 0.0950 0.0985 0.1516 -0.0768 0.0289 TV or video 0.2191 0.2477 -0.0852 0.1395 0.0486 0.1604 bicycle 0.0378 0.2250 0.2480 0.2616 -0.0571 0.1677 Electricity 0.2529 0.1139 -0.1901 -0.0145 0.1123 -0.0277 Cows -0.0066 0.2124 0.1553 0.1404 -0.2118 -0.2150 Goats -0.0213 0.2894 0.4463 -0.4056 0.1541 -0.0478 Sheep -0.0044 0.2327 0.4106 -0.4572 0.2136 -0.0354 Block walled house 0.3202 0.0379 0.1082 -0.0952 -0.0808 0.1645 Mud walled house -0.3202 -0.0379 -0.1082 0.0952 0.0808 -0.1645 Owned house -0.2797 0.2662 0.0504 0.2371 -0.0201 0.1803 Rented house 0.2629 -0.2775 -0.0446 -0.2369 0.0340 -0.0709 Not rented not owned 0.0752 -0.0097 -0.0197 -0.0318 -0.0288 -0.2722 Flush toilet 0.1836 0.2752 -0.2713 0.0077 0.2148 0.1273 Latrine 0.1333 -0.3571 0.3539 0.1239 -0.2552 0.1661 No toilet -0.2313 0.2291 -0.2278 -0.1320 0.1545 -0.2366 Main fuel firewood -0.3228 0.1336 0.0484 0.0953 -0.0643 -0.0038 Main fuel charcoal 0.3021 -0.1179 -0.0754 -0.0981 0.0741 -0.0848 Main fuel non biomass 0.0668 -0.1027 0.1165 0.0364 -0.0608 0.1865 Dw well -0.0848 0.1206 -0.2025 -0.3399 -0.4656 0.286 Dw piped 0.0944 -0.1428 0.2207 0.3341 0.4718 -0.2463 Ws owned 0.2310 0.1873 -0.2355 0.0057 0.1698 0.1324 Ws public -0.2636 -0.2208 0.0682 -0.0628 0.2365 0.3496 Ws shared 0.1437 0.1437 0.0877 0.0662 -0.4140 -0.5110 
Table 8.3 reports the scoring factors from the PCA of 25 variables. Scoring factors are the 
"weights" assigned to each variable (normalized by its mean and standard deviation) in the 
linear combination of the variables that constitute the first principal component. When 
using a correlation matrix the PCs are in standardized units (mean 0, variance 1). In such a 
case the scoring coefficients/ factors and the eigenvectors (PCs) will be the same. 
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Table 8.3. Scoring factors for variables entering the computation of the first four principal 
components. 
Variables* Means 
Poorest Middle Richest 
scoring mean std. dev. scoring 34% 33% 33% 
factors (sd) factor/sd 
own phone 0.217 0.225 0.418 0.519 0.017 0.155 0.509 
own radio 0.128 0.664 0.473 0.271 0.406 0.776 0.817 
own motorbike 0.008 0.009 0.097 0.082 0.000 0.011 0.017 
own a TV or video 0.219 0.134 0.341 0.642 0.000 0.063 0.343 
own bicycle 0.038 0.484 0.500 0.076 0.311 0.615 0.531 
electricity in home 0.253 0.074 0.262 0.967 0.000 0.000 0.223 
Number of cows owned -0.007 0.76 2.169 -0.003 0.739 0.759 0.783 
Number of goats owned -0.021 3.155 9.839 -0.002 2.750 4.150 2.580 
Number of sheep owned -0.004 0.386 6.593 -0.001 0.028 1.011 0.131 
house made of block wall 0.320 0.363 0.481 0.665 0.000 0.195 0.903 
house made of mud wall -0.320 0.637 0.481 -0.665 1.000 0.805 0.097 
owns house you live in -0.280 0.784 0.412 -0.680 1.000 0.931 0.417 
rent house you live in 0.263 0.185 0.389 0.676 0.000 0.046 0.514 
not rented not owned 0.075 0.03 0.171 0.439 0.000 0.023 0.069 
HH owns flush toilet 0.184 0.062 0.242 0.758 0.000 0.006 0.183 
HH owns latrine 0.133 0.594 0.492 0.271 0.646 0.206 0.800 
HH has no toilet -0.231 0.344 0.476 -0.486 0.794 0.207 0.017 
Cooking fuel is firewood -0.323 0.745 0.436 -0.740 1.000 0.920 0.309 
Cooking fuel is charcoal 0.302 0.242 0.429 0.705 0.000 0.086 0.646 
Cooking fuel gas or 0.067 0.03 0.171 0.390 0.000 0.017 0.074 
kerosene 
drink water from well -0.085 0.059 0.235 -0.361 0.133 0.023 0.017 
drink water from piped 0.094 0.896 0.306 
source 0.309 0.778 0.948 0.966 
water source owned 0.231 0.083 0.276 0.836 0.000 0.006 0.246 
water source public -0.264 0.775 0.418 -0.631 0.978 0.885 0.457 
water source shared 0.144 0.147 0.355 0.405 0.022 0.109 0.314 
Economic Status Index -2.16 -0.82 3.03 
*The means, ranges and distributions of these variables are in Appendix U (pg 367). 
The index is essentially the sum of included variables, weighted by the elements of the first 
eigenvector. Because majority of the asset variables are binary (0/1), the assigned weights 
have an easy interpretation: a move from 0 to I changes the index by fl; /s; (column 4). An 
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asset that doesn't vary across households gets a weight of zero for instances as it explains 
none of the variation across households. 
The difference in the average index between the poorest and the middle group is 1.34 units. 
One example of a combination of assets that would result in this difference is owning a TV/ 
video (0.642), using charcoal as your main cooking fuel (0.705) and owning a cow(s) (- 
0.003). The average asset index in richest group is 3.85 units higher than for the middle 
group. This difference is equivalent to owning a radio (0.271), TV or video (0.642) and 
phone (0.519), having electricity (0.967) and flush toilet (0.758), using charcoal as cooking 
fuel (0.705) and owning a cow(s) (-0.003) and goat(s) (-0.002). 
Table 8.3 shows a consistent pattern in the asset variables used in the model. The assets that 
are likely to be owned by the better-off households have a positive value, which increases 
the household's asset index. In contrast, those that characterise poor households (e. g. no 
toilet or mud wall and an open well) have the expected negative value, which results in a 
decreased asset index. A household that owns a flush toilet has an asset index higher by 
0.76 than one that does not; owing a radio raises a household's asset index by 0.27 units; 
drinking water from a well lowers the asset index by 0.36 [270]. 
Households were sorted by the asset index and grouped into percentiles. For expository 
convenience the top 33% are referred to as "rich" the next 33% as "middle" and the bottom 
34% as "poor". This classification does not, and is not intended to, follow any of the 
standard definitions of poverty. The last three columns of Table 7.3 compare the average 
ownership of each asset across different types of households. Large differences are 
observed across groups showing the internal coherence of the asset index, radio ownership 
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is 40% for the poor versus 82% for the rich. Along the same line, houses with block wall 
are 0% for the poor and 90% for the rich. Households with no toilet are 79% in the poor 
compared to 1.7% in the rich households. Certain variables don't vary across the groupings 
(such as number of cows) while interestingly other variables have a non-linear pattern (such 
as number of goats and sheep or bicycle ownership). 
8.4.3 Calculation of anthropometric indicators based on WHO child growth standards 
Anthropometric measurements were obtained at birth and at three month intervals 
thereafter. We used a WHO macro in STATA (igrowup_STATA macro [273]) to calculate 
z-scores for three anthropometric indicators, weight-for-age, length/height-for-age, weight- 
for-length/height (Appendix V, p 368). Z-score is the deviation from the median of a 
reference population (the WHO Child Growth Standards) expressed in multiples of the 
standard deviation [274]. Any extreme (i. e. biologically implausible) z-scores were flagged 
up for each indicator according to the following system: weight-for-age z-scores of < -6 or 
> 5, length/height-for-age z-scores of < -6 or >6 and weight-for-length/height z-scores of < 
-5 or> 5. These were marked as missing and were excluded. 
For children aged below 24 months (< 731 days) and measured standing, the macro 
converts the height to recumbent length by adding 0.7 cm; and for children aged 24 months 
or above who are measured in recumbent position, the macro converts the length to 
standing height by subtracting 0.7 cm. In other words, all the z-scores for children below 24 
months are length-based, and height-based otherwise. The macro imputes any missing data 
on whether measurement was of recumbent length or for standing height according to the 
following algorithm: a) If age is given, then it is recumbent length if the child's age is 
below 24 months (< 731 days), and standing height if the child's age is 24 months or above. 
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b) If age was missing, then it was assumed to be recumbent length if length/height < 87 cm 
and standing height if length/height 2: 87 cm (Appendix V). 
8.4.4 Regression models for cohort studies 
In longitudinal studies risk factors and exposures are not constant and change with time and 
this variation must be taken into account. This is usually done by breaking the individual 
follow-up times into segments specific to the time changing variable and is known as Lexis 
expansion. Within each segment the rate is assumed to be constant. The individual follow- 
up time is split into bands of the time changing variable and then the Poisson regression is 
used [275]. The simplest model for cohort studies is the Poisson model. 
Cox's method is very similar to the Poisson regression but is based on a much finer 
subdivision of time [275]. Cox regression is a Poisson model with very narrow time bands 
such that each time band only has one event. This is also known as a proportional hazard 
model and is based on the proportional hazard assumption which states that given two 
observations with different values for the independent variable, the ratio of the hazard 
functions for those two observations does not depend on (constant over) time. Cox 
regression is used if the hazard rate is thought to vary rapidly with time and also to evaluate 
the effects of explanatory variables or covariates on the hazard rate, i. e. expressed as a 
function of both the time and the covariate X (t, x) where X is the hazard rate, t is time and x 
is the covariate(s). The hazard rate is modeled to represent dependence on variables 
recorded for each subject as well as on time. The form of the baseline hazard is not 
specified, and the model is therefore nonparametric with respect to time but parametric in 
terms of covariates [276]. 
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The Cox model only operates on times when failures actually occur. Consequently in Cox 
regression the results are based on forming, at each failure time, the risk set and then 
maximizing the conditional probability of failure [275,277]. The risk set is the collection of 
subjects who are at risk of failure at the time of the event. Different time scales can be used 
to compute risk sets. With a Cox model the choice of the time scale (i. e. time since entry 
into study or time as age or calendar date) determines the composition of the risk sets 
associated to each failure [277]and results produced are critically dependent on the choice 
of timescale. Time should be interpreted in the way that is most appropriate for the analysis 
to be carried out [275], i. e. the time scale with the strongest relationship to the failure rate, 
and in this case calendar time, will be used. This eliminated the potential confounding 
effect of seasonality as the resulting risk sets were defined at the calendar date of each 
event (children under the same level of exposure) (Figure 8.1). 
When subjects are tied (i. e. failures that occur at the same time) and the exact ordering of 
failure is unclear, the partial likelihood needs to be modified. The Breslow approximation 
used in this analysis to deal with tied failures states that since the order of failure is not 
known, the largest risk set for each of the tied failure events is used. It is an approximation 
to the exact marginal likelihood, in which the likelihood reflects the marginal probability 
that the tied failure events occurred before the non-failure events in the risk pool, and the 
order in which they occurred is not important [278]. 
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Figure 8.1. Follow up of cohort children by calendar time. Lines indicate individual 
follow-up of children. Time starts on date first study subject visited and ends on last visit 
date of follow up. The red lines at the bottom of the graph show the four epidemics that 
occurred during the study. These were between 12/03/02 - 01/07/02,03/12/02 -15/04/03, 
08/01/04 - 02/06/04 and the last between 11/1104 -18/02/05. 
Time Dependent Variables 
These are handled automatically by the Cox model in STATA. Since the risk set is indexed 
by the failure time associated with it, the model simply takes the value of the covariate at 
that time [279]. The premise is that the instant the value of the variable changes the hazard 
of risk changes [277]. In STATA when the time-varying nature of the covariate(s) is not 
spelled out in multiple observations per subject, the time varying covariates are specified 
using the tvc option [278] used when one wants a covariate to change as a continuous 
function of time, i. e. 
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time-varying covariate = (constant covariate in my data) * f(t) 
where f(t) is a function of time, with f(t) =t by default and settable via the option texp 0 in 
STATA [279]. 
Clustering of Data 
For clustered data, i. e. repeated measurements within individuals, a shared frailty model 
should be used. This is the survival data analog to regression models with random effects 
[277]. A frailty is a latent random effect that enters multiplicatively on the hazard function. 
A Cox model with shared frailty is therefore simply a random effects Cox model used to 
model within group correlation. Observations within a group/individual are correlated 
because they share the same frailty and this extent of correlation is measured by the 
parameter 0, and when zero the Cox shared frailty model simply reduces to the standard 
Cox model [278]. An alternative to fitting a shared frailty model is to fit the standard Cox 
model and adjust the standard errors of the estimated parameters to account for possible 
correlation using the cluster option in STATA. Both methods were used in the analysis as 
detailed in Chapter 8. 
Testing the Proportional Hazard Assumption 
One of the main assumptions of the Cox proportional hazard model is proportionality. 
Shoenfeld and scaled Schoenfeld residuals were used to test the proportionality assumption. 
This test for non-zero slope is the generalized linear regression of the scaled Schoenfeld 
residuals on functions of time. A non-zero slope is an indication of a violation of the 
proportional hazard assumption [280]. The regression graph was assessed using the stphtest 
command in STATA and a test of non-zero slope carried out. Log-log plots were also used 
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to assess the relationship, in which parallel lines indicate that predictors do not violate the 
proportionality assumption. 
Assessment of Model Fit 
The goodness of fit of the model can be evaluated using the Cox-Snell (cs) residuals. If the 
model fits the data well then the true cumulative hazard function conditional on the 
covariate vector has an exponential distribution with a hazard rate of one [277]. With 
multiple observations per subject, a residual that is subject specific, in this case summed 
over the observations within the subject is required: cumulative Cox-Snell residuals [277]. 
Under a good-fitting model, the cumulative hazard of the Cox-Snell residuals should be a 
straight 45° line [277,281]. The model fit can be verified by estimating the empirical 
Nelson-Aalen cumulative hazard function, with the Cox-Snell residuals as the time variable 
along with the data's original censoring variable. 
8.4.5 Univariate Analysis 
First the data was declared to be survival-time data using the stset (st-survival time) 
command in STATA. Initial univariate analysis was carried out using Kaplan Meier (KM) 
curves and log rank tests [282]. KM curves were used to assess proportionality. Tests of 
equality of survival distribution across strata were performed using the log-rank test for 
categorical variables. Univariate Cox proportional hazard regression was used for 
continuous variables. These were done to explore whether or not to include the risk factor 
in the final model. The risk factor was included if either test gave a P-value of 0.25 or less. 
This way, only those variables that had an unconditional association with the outcome were 
Potentially to be included in the final model. I used this elimination scheme because all the 
risk factors in the data set are variables that could be relevant to the model, but by 
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convention if the predictor has a P-value greater than 0.25 in a univariate analysis it is 
highly unlikely that it will contribute anything to a model which includes the other risk 
factors [283]. 
8.4.6 Multivariable Analysis 
Some variables (e. g. age) were included in the model as they were believed a priori to be 
potential confounders. The hazard ratio (HR)/Relative risk (RR) is the hazard rate among 
children at the higher risk level divided by the hazard rate among those at the lowest-risk 
level. Subsequent variables were included in the model using a non-automated forward 
stepwise regression [283]. Variables with P-values < 0.25 in the univariate analysis were 
selected using a forward selection procedure starting with the variable with the highest test 
statistic. A variable was retained in the model if any category of the variable had a P-value 
of < 0.05. After addition of any variable a backward elimination procedure was applied to 
each variable already in the model. Throughout the model building process changing effect 
estimates and possible variable interactions were monitored. New combination variables 
were created where appropriate. In relation to highly correlated variables, i. e. correlation 
coefficient of > 0.9, only one of the variables was included. To make certain that no effect 
of eliminated variables had been masked, after the maximum model was fitted, the 
eliminated predictors were added back in one at a time to the final model. 
8.5 General Results 
There were a total of 29,979 observations from 469 children. The characteristics of the 
study population are shown on Table 8.4. Figures 8.2 to 8.4 show the different nutritional 
indices by age of children progressively through follow up computed using the WHO child 
growth standards. 
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Table 8.4. Characteristics of population studied 
Characteristics Number Percentage 
(all) (all) 
Age of PCT * 13-20 years 70 14.93 
21-30 years 229 48.83 
31-40 years 130 27.72 
41-50 years 31 6.61 
51-63 years 9 1.92 
Educational level of PCT No schooling 199 25.37 
1-7 years of schooling 184 39.23 
8-12 years of schooling 146 31.13 
>12 ears of schooling 20 4.26 
Literacy of PCT Able to read 302 64.39 
Unable to read 167 35.61 
Occupational class: Professional 50 10.66 
Skilled 166 35.39 
Non-skilled 174 37.31 
Trade 78 16.63 
Receive outside financial assistance Yes 91 19.40 
No 378 80.6 
Household assets (Number that have) Phone 111 23.67 
Radio 317 67.59 
Motor bike 5 1.07 
Bicycle 233 49.68 
TV video 69 14.71 
Electricity 37 7.91 
(One or more) Cows 92 19.62 
Goats 220 46.91 
Sheep 10 2.13 
Housing Owner occupied 362 77.19 
Rented/Other 107 22.81 
House type Block wall 181 38.59 
Mud wall 288 61.41 
Cooking Fuel Mainly firewood 329 70.15 
Mainly charcoal 110 23.45 
Both 12 2.56 
Non-biomass 18 3.84 
Cooking location Outside 36 7.68 
Same house as you sleep in 175 37.31 
Different house from where you sleep 258 55.01 
Water source Open/closed well 24 5.12 
Piped 423 90.19 
Both 22 4.69 
Water Site Owned 42 8.96 
Public 359 76.55 
Shared 68 14.50 
Toilet type No toilet 155 33.05 
Flush toilet 32 6.82 
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Latrine 282 60.13 
Number of children in the household I child 53 11.30 
2-3 children 154 32.84 
4-6 children 175 37.31 
7+ children 87 18.55 
Household size 1-4 members 108 23.03 
5-9 members 242 51.60 
10+ members 119 25.37 
*PC1'-Primary care taker 
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Figure 8.2. Height for age of children in the study by sex and age. The box plot depicts the 
interquartile range as a box and the median as a line in the box. Bars, upper and lower 
adjacent values. 
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Figure 8.3. Weight for age of children in the study by sex and age. The box plot depicts 
the interquartile range as a box and the median as a line in the box. Bars, upper and lower 
adjacent values. 
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Figure 8.4. Weight for height of children in the study by sex and age. The box plot depicts 
the interquartile range as a box and the median as a line in the box. Bars, upper and lower 
adjacent values. 
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8.5.1 Lower Respiratory Tract Infection 
There were 857 episodes of a LRTI in this data set from a total time at risk of 940.2 years 
(343,400 days). There were 429 LRTI episodes in females compared to 428 in males. The 
incidence of LRTI was 911.5 cases per 1000 child-years (95% CI 852.5- 974.6). The 
incidence of LRTI was 354 cases/1000 cyo in the household cohort (Chapter 7). Many 
children had multiple episodes of LRTI as shown in Table 7.4. Of those children who had 
a LRTI, 128 (37%) children had only one episode of LRTI, 216 (63%) had 2 or more 
episodes. There were 535 events in cohort one and 322 events in the second cohort. The 
number of observations per child was between 23-104 with a mean of 71 observations and 
a median of 71 observations. 22 children who had 8 or more episodes of LRTI (Table 8.5) 
had between 76- 101 visits i. e. higher than the average number of visits. This seems to 
suggest that these are children who were frequently ill and came to hospital more. 
Table 8.5. Frequency of episodes of LRTI in cohort one and two 
Number of 
LRTI infections 
RSV 
cohort 
first second Total 
1 185 159 344 
2 131 85 216 
3 79 39 118 
4 48 15 63 
5 28 12 40 
6 21 6 27 
7 13 2 15 
8 10 2 12 
9 7 2 9 
10 5 0 5 
11 3 0 3 
12 2 0 2 
13 1 0 1 
14 1 0 1 
15 1 0 1 
Total 535 322 857 
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8.5.2 RSV infection and RSV specific Lower respiratory tract infection (RSV-LRTI) 
There were 362 episodes of clinical RSV in the data set from a total time at risk of 936.7 
years (342,144.4 days). 283 single infections, 79 children infected more than once (68 
twice, 8 three times, two four times and one five times). The incidence of clinical RSV 
infection was 348.6 (95% CI 349-428) cases per 1000 child-years. There were 92 episodes 
of RSV-LRTI in the dataset. There were 86 single episodes of RSV-LRTI, 6 children had 
two episodes of RSV-LRTI. The overall incidence of RSV-LRTI in this study population 
was 98.2 (95% CI 80-12 1) cases per 1000 child-years. 
8.6 Discussion 
8.6.1 Advantages and limitation or the study design and questionnaire 
The cross-sectional survey was done within a birth cohort study. Because the survey was 
carried out within a longitudinal study, comprehensive data on infection history was 
available for all children and therefore yields more information. The survey was carried 
out in 2004 just before the end of follow up of cohort one. This meant that some children 
had been lost to follow up before the risk factor study and data on their risk factors was 
unavailable. Out of a total of 635 birth cohort children who had at least one visit, 469 
(74%) children were part of the survey. 
The survey was done at one point in time with some of the data being collected 
retrospectively. As some risk factors studied changed over the follow up time, an improved 
study design would be a prospective study collecting risk factor data at the beginning of the 
study and have this updated periodically through out the study period. In this way the recall 
bias would have been reduced. One important point to note is that during the RSV 
epidemics (around which the survey questions were structured; Appendix S, p 358) the 
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active surveillance was by weekly home visit, thus mothers were more likely to recall 
events of that particular time period thus potentially reducing the level of recall bias. 
Even though the questionnaire had been piloted, several questions were found to be 
redundant at the time of analysis: sex of the primary care taker; 99% were female, owning a 
motorbike (1%), obtaining drinking water from an open source (river) <1%. Thus these 
could have been excluded from the questionnaire, although they were considered to be 
variable prior to analysis of results. These questions may not be considered necessary in 
subsequent surveys. In addition, an improved definition of the duration of breastfeeding is 
recommended clarifying exclusive breastfeeding from weaning and breastfeeding. 
Similarly, several other socio-economic questions ought to be included to improve 
computation of the index e. g. land ownership, type of floor and type of roofing material 
used, measure of crowding index. Overall we were able to capture adequate information 
based on the questions included in the questionnaire. 
There are three outcomes for which this survey was conducted; clinical RSV infection, 
RSV-LRTI and all cause LRTI. Outcome was ascertained based on recommended methods. 
LRTI was defined according to modified WHO guidelines adjusted for low specificity 
particularly in children <2 months [5]. The incidence of LRTI in this study is similar to 
results from other studies from developing countries; discussed previously (see Chapter 6), 
implying an adequate detection of cases in this study. The method of detection of RSV 
antigen in nasal specimens and its limitations has been discussed in Chapter 3. The IFAT 
test used for RSV diagnosis is the recommended diagnostic method for samples from 
children [242]. It is still possible that sub-clinical RSV infection may have occurred 
resulting in lower incidence of RSV infection and disease. Serological assays currently 
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underway will shed more light on this concern. Consequently, assessment of risk factors in 
this thesis was limited to clinical infection, Chapter 8. 
8.6.2 Validity of asset index 
There is a lack of clarity in the determination of how many components to retain. Usually 
one weighs the cost of using additional components in subsequent analysis against the 
benefits of the additional variance for which they account. However, in the computation of 
asset indices it is generally assumed that the first component captures an adequate measure 
of welfare of a household [284,285]. To test this assumption and the robustness of asset 
index we use the rank correlation coefficient, which compares the degree to which two 
methods (i. e. index computed using the first component and that computed using 3 
components, Table 8.6) produce the same ranking of households. The correlation between 
these two indices was 0.78; p< 0.001. Thus only one component was retained. 
Table 8.6. Classification differences of the study population using different indices 
3 Quantiles computed 
from first component 
3 quantiles computed from first 
3 PCs 
1 2 3 Total 
1 147 31 2 180 
% 77.78 18.9 1.14 34.03 
2 38 101 35 174 
% 20.11 61.59 19.89 32.89 
3 4 32 139 175 
% 2.12 19.51 78.98 33.08 
Total 189 164 176 529 
100 100 100 100 
A possible problem with the asset index is the possibility that it may tend to reflect 
community variables especially locally available infrastructure rather than actual variables 
that are specific to households [270], or specific risks to the outcomes. It is reassuring then 
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to know that there is a clear difference in variables not related to infrastructure like the use 
of blocks in building homes or in actual household consumables like phones and radios. 
However, a comparison of results obtained from the asset index with income and 
expenditure or consumption data of each household would be the ideal means of comparing 
the correlation of the asset index. Thus to further validate the asset index, we compared the 
occupational category of the major income provider (MIP) in the three socio-groupings, 
Table 8.7. There was significant association (Pearson's x2, P< 0.001) between the index 
and the profession of the MIP. "Rich" households had a higher proportion of MIPs in the 
professional and skilled category. Individuals in these professions have higher earnings thus 
are considered to be better off. "Poor" households had a high proportion of un-skilled MIPs 
who were mostly manual laborers with minimal and inconsistent income. This result thus 
adds weight to the validity of the asset index. 
Table 8.7 Comparison between the asset index and the profession of a household's major 
income provider. 
Poverty Classification 
Job description of poor middle rich Total 
MIP 
non-skilled 83 52 40 175 
% 47.43 29.71 22.86 100 
trade 20 33 25 78 
% 25.64 42.31 32.05 100 
skilled 46 54 66 166 
% 27.71 32.53 39.76 100 
professional 1 13 36 50 
% 2 26 72 100 
Total 150 152 167 469 
31.98 32.41 35.61 100 
MIP-major income provider 
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Some of the assets were found to follow a non-linear relationship (Table 8.3). These are the 
assets that one would say are somewhat affordable but still out of reach for the very poor 
households and include owning a bicycle or owning goats and sheep. Most homesteads in 
this community will own a few goats and/or sheep especially those that are out of the main 
township area. Furthermore, most of the public transport is restricted to the main highway 
thus owning a bicycle is convenient in terms of facilitating movement internally thus 
becomes almost a necessity. A bicycle is a relatively cheap mode of transport and requires 
only a single initial investment. 
The children in this study were for the most part well-nourished. Boys had consistently 
lower median z-scores than girls. As is usually the case at birth and up to the age of 1 year, 
the children in this study were within the limits considered to be well nourished (z-score 
>1) [286]. Although weight-for-age (underweight) and height-for-age (stunting) scores 
reduced in older children in comparison with the WHO standard, this decline was moderate 
with very few children being classified in the severely underweight or stunting categories 
(5-3). This fall was more pronounced for stunting (Figure 8.2). The decline in the weight- 
for-height was less pronounced. From this data we can conclude that the incidence of 
malnutrition in the birth cohort was generally low. However, it is worth mentioning the 
likely inadequacy of the current measurements. The anthropometric measurements were 
obtained every three months, which is considered to be inadequate to describe the rapid and 
changing rate of growth in early infancy [274]. Ideally, measurements should be taken at 
shorter intervals to capture this rapid growth. 
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Chapter Nine 
Determinants of Respiratory Disease at Household and Individual level 
9.1 Introduction 
The focus of the study in these risk factors chapters is the infant i. e. birth cohort child - as a 
key group for prevention of disease. Variations in disease incidence [5,6,11,40,126,127] 
that cannot be accounted for by methodologically differences can probably be associated to 
existing differences in socio-economic-cultural risk factors for infection and disease for 
example family size and structure, schooling, religious practices [11], environmental 
pollution, nutritional status, co-infection [41,207] and host genetics [40] (detailed in sec 
2.9, Chapter 2). These risk factors are of considerable intrinsic interest and some of these 
were explored in this population. 
9.2 Chapter aims 
In this chapter, the birth cohort data presented in Chapter 8 are initially used to determine 
the risk factors for RSV infection (RSVI). Since it is well-known that every child gets RSV 
in the first couple of years of life this was specifically to identify risk factors for clinical 
infection (ARI). Those risk factors identified for clinical RSVI were then used as a template 
to characterize the risk factors for RSV specific lower respiratory tract infection (RSV- 
LRTI). The identified risk factors for RSV-LRTI are then compared with those determined 
for all-cause LRTI. 
9.3 Age-stratified incidence estimates 
Age-stratified incidence of RSVI and disease (RSV-LRTI) 
The age-stratified incidence of RSVI and disease (RSV-LRTI and severe RSV-LRTI) is 
shown in Figure 9.1. There were no observed differences in RSV infection and RSV-LRTI 
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rates by age. The incidence of severe RSV-LRTI appears to start declining from the age of 
9 months onwards, reaching a significant decline at 12-17 months and beyond (Wald test, 
P-value < 0.05). 
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Figure 9.1 Age-stratified incidence of RSV infection (open bars), RSV-LRTI (light blue 
bars) and severe RSV-LRTI (dark blue bars). 
Age-stratified incidence of all-cause LRTI 
Figure 9.2 shows the age stratified incidence of all-cause LRTI cases. The incidence of 
LRTI did not significantly differ by age group. The peak incidence was in children less than 
6 months and 12-17 months of age. 
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Figure 9.2. Incidence of all-cause LRTI by age class with 95% Cl 
9.3.1 Interactions between age and gender, poverty level and HH density 
Interactions between age and gender, age and poverty classification and age and household 
density were investigated for all three outcomes; RSVI, RSV-LRTI and all-cause LRTI. No 
differences in infection and disease rates were observed between boys and girls for all 
outcomes. The incidence by age and poverty classification for the three outcomes together 
is shown in Figure 9.3. Slightly higher rates of disease were observed in certain age groups 
in poorer households. The incidence of RSVI and LRTI was generally the same in the 
different households (Wald test, P>0.05). The incidence was lower (borderline 
significance) in children 12-17 and 18+ months old (Wald test, P=0.089 and 0.065) 
respectively in households classified as rich. 
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Figure 9.4 shows the incidence rates by age class for households of different size. 
There were no significant differences observed in the incidence rates for RSVI and LRTI in 
the different ages in the different households. However, there was a suggestion of 
decreased rates of RSV-LRTI in older children: 6-11 months (P=0.035), 12-17 months 
(P=0.063) and 18+ months (P=0.029) in larger households (11+ people). 
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Figure 9.4. Age-stratified incidence of RSV-LRTI, RSVI and LRTI by household density 
9.4 Exploring data for RSVI, RSV-LRTI and all-cause LRTI outcomes 
Screening was done using a log rank test to test for equality of survival function across 
strata (described in Chapter 8) for all the outcome variables. Those variables that gave ap 
value <0.25 (conventional cutoff) had potential to be included in the final model. Tobacco 
exposure was defined as being present if any person living in the household smoked. 
Breast-feeding was defined as being present if the subject was fed by breast at all. 
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9.5 Univariate Analyses 
Subject and household factors were analyzed to assess their association with disease. 
Univariate analysis of risk factors for clinical infection and disease was performed using 
Cox regression taking account of clustering of infection within individuals. Three different 
outcomes were assessed: RSVI, RSV-LRTI and all-cause LRTI. Univariate analysis 
revealed several factors associated with RSVI, RSV-LRTI and all-cause LRTI (see 
Appendix W, p 375). 
9.6 Summary of associations between variables 
Where possible especially in the case of RSV-LRTI where events were few, categories with 
small numbers of observations were combined or redefined to achieve stable estimates in 
the multivariate model. This included the PCT age classification where the baseline age 
class was changed from 13-20 to 13-22 and the two higher age classes were combined 
creating one class of PCTs aged 41-63'. The two lower categories defining birth weight 
were also combined to have <2.5 kg as the baseline. The baseline category for main fuel 
used for cooking was changed from non-biomass to charcoal as there were no RSV-LRTI 
events in the non-biomass category. Ownership of water site was also changed from three 
categories to having only two categories; owned/shared water source and public water 
source. For some variables this was not possible as the categories within the variables 
define different effects (e. g. that of care giver) and thus were left unchanged. 
Certain variables were found to be associated with each other some of which were found to 
be highly correlated creating problems of collinearity which caused difficulties in 
distinguishing individual effects. By their definition variables illustrating contact intensity 
within the household such as the number of siblings sleeping in the same bed were 
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inherently collinear. The number of siblings of a certain age sleeping in the same bed was 
conditioned by the number of siblings of that age sleeping in the same room (variable 
denoting numbers sleeping in bed could only be equal to or less than number of siblings 
sleeping in the same room). In terms of transmission one would expect that closer contact 
would make transmission more likely to take place. Possible differences in risk between 
sleeping in same bed and/or in room with siblings were investigated. For these variables; 
siblings 6+ years sleeping in same house, room or bed and siblings <6 years sleeping in 
same house, room or bed, it was decided to include, after fitting each separately, the 
variable that was most significant and use this to capture the effect of the other variables. 
Over 50% of the siblings who are 6 years of age or older, though sleeping in the same 
house are sleeping in a different room from the cohort child which precludes sleeping in the 
same bed. 
Certain socioeconomic variables were found to be associated with each other; type of 
cooking fuel, house ownership, water site location and ownership, type of house and type 
of toilet. A new variable combining the type of house and sanitation was created. Majority 
of owned houses are mud walled. Ordinarily owning a home would imply higher socio- 
economic status but in this environment this usually refers to the local rural homestead thus 
in a majority of the situations there is no financial investment associated with ownership 
evidenced by the fact that 41% of the owner occupied homes were classified as "poor". 
Those that are rented are mostly block walled and are households that are better off; 91% 
classified as "rich". Moreover, interaction between the composite variable denoting poverty 
class and those variables used in its computation was observed. For these, only those that 
were associated with infection or disease in the univariate Cox model were assessed for 
inclusion into the final model. Each of these socioeconomic predictors was first assessed in 
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the multivariate model separately and then in combination with the other variables and 
those still remaining significant were included in the final model 
There was a highly significant correlation between number of children in the household and 
family size (r=0.9), thus only one of these was included in the multivariate model as was 
the case between literacy and number of years of education (r=0.8) of the primary care 
taker (PCT). We chose to keep family children and education as each one automatically 
explains the other and these remained significant in the multivariate model. We evaluated 
possible interaction between family children, family size and poverty classification, Figure 
9.5. There does not appear to be an interaction just potential for confounding i. e. the nature 
of the association (slope) of family children and family size does not seem to alter for 
different poverty class, the linear relationship for each poverty status has similar slope and 
the lines do not cross over. 
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Figure 9.5. Correlation between family density and number of children in the household 
(y-axis) for households of difference socioeconomic class. 
9.7 Analyses of Independent Effects 
Independent predictors of disease were analyzed using multivariate models using a forward 
stepwise approach. Out of 42 variables 12,21,33 had a significant log-rank test of equality 
across strata for clinical RSVI, RSV-LRTI and LRTI respectively, Table 9.1 and 9.2. These 
variables were included as potential candidates for the final model for the three outcome 
measures respectively some being excluded as discussed above. In this analysis we used 
forward stepwise regression to build the maximum model always keeping in mind 
biologically plausible relationships. A shared frailty model was used for all-cause LRTI 
outcome with significant within-child correlation. This was not the case for RSVI or RSV- 
LRTI for which robust standard errors adjusted for clustering of measurements within-child 
were calculated. The risk factors that independently predicted increased risk of disease are 
shown and discussed below. In each analysis, P-values are for the tests of the null 
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hypothesis that each hazard ratio is one. Significant P-values are in bold whereas those of 
borderline effects are underlined. 
Table 9.1. Estimated hazard ratios for factors associated with clinical RSV infection. 
Risk Factor Categories (events) cyo Hazard Ratio P>z 
(95% CI) 
PCT age group 13-20 years (49) 137 - - 
PCT age group 
_1 
21-30 years (186) 465 1.15 (0.87,1.52) 0.316 
PCT age group 2 31-40 years (92) 263 1.09 (0.79,1.49) 0.600 
PCT age group 
_3 
41-50 years (23) 63 1.02 (0.66,1.57) 0.925 
PCT age group 
_4 
51-63 years (12) 19 2.13 (1.27,3.59) 0.004 
care giver 
-O 
Mother (300) 767 - - 
care giver_1 other family member 115 0.77 (0.54,1.08) 0.130 
(41) 
care giver _2 
House help (7) 22 0.54 (0.30,0.99) 0.047 
care giver_3 School (1) 2 1.06 (0.87,1.30) 0.571 
care giver_ 4 mother / other family 1.28 (0.80,2.05) 0.312 
member(13) 38 
smokers in HH_0 None (255) 657 - - 
smokers in HH 
-1 
1 (83) 222 0.92 (0.74,1.15) 0.477 
smokers in HH_2 2 or more (24) 44 1.40 (1.07,1.84) 0.016 
family assisted No (273) 767 - - 
family assisted Yes (89) 183 1.20 (0.98,1.46) 0.084 
house-toilet 0 mudwall no toilet 274 - - 
(124) 
house_toilet 1 blockwall no toilet 30 1.03 (0.73,1.46) 0.870 
(15) 
house toilet 2 mudwall latrine (121) 301 0.98 (0.79,1.21) 0.826 
house-toilet 3 blockwall latrine (88) 268 0.83 (0.65,1.06) 0.141 
house toilet 4 mudwall flush toilet 5 0.53 (0.19,1.47) 0.221 
1 
house toilet 5 block flush toilet 57 0.60 (0.40,0.91) 0.016 
(13) 
Notes (apply to all subsequent tables) 
Underlined values mean borderline significance 
Bold co-variates indicate significant results 
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Increased age of the PCT (>50) was the strongest predictor of increased risk of RSVI, also 
thought to be related to household size. Other factors not related to PCT but associated with 
increased risk of RSVI were exposure to tobacco smoke and two potential indicators of 
higher socio-economic status (SES): house type and toilet (block walled house with a flush 
toilet) and the birth cohort child's care giver (hired house help). Other SES indicators that 
were significant in the univariate e. g. profession of the major income provide (MIP) and the 
variables representing crowding and intensity of contact (Appendix W, p 375) were not 
independently correlated to RSVI. The significant variables i. e. those that predict the risk 
of infection were included in the RSV-LRTI multivariate analysis as the baseline. 
Additional variables were then fitted in an attempt to explain the difference between 
infection and disease. Results from this multivariate regression are shown in Table 9.2. 
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Table 9.2. Risk factors independently predicting increased hazard of RSV-LRTI / disease 
Risk Factor Categories cyo Hazard Ratio 
(95% C 
P>z 
child's care-0 mother (73) 767 - - 
child's care 1 another family 0.95 (0.53,1.71) 0.872 _ member (13) 115 
child's care 
_2 
house help (3) 22 1.49 (0.56,4.00) 0.424 
child's care 
_3 school 
(0) 2 0.00 (-) 
child's care 4 mother / family 1.26 (0.47,3.37) 0.646 _ member (3) 38 
PCT*_agegroup_0 13-24 years (26) 329 - - 
PCT agegroup_1 25-30 years (24) 274 1.03 (0.58,1.82) 0.928 
PCT agegroup_2 31-40 years (28) 263 1.49 (0.88,2.53) 0.137 
PCT agegroup 3 41-63 years (14) 82 2.19 (1.13,4.25) 0.021 
smokers in HH 
-0 
None (66) 657 - - 
smokers in HH 1 1(21) 222 0.87 (0.53,1.45) 0.597 
smokers in HH 2 2 or more (5) 44 0.81 (0.36,1.84) 0.621 
height for age z-score >-1 (38) - - 
0 465 
_ height for age z-score -1.99 to -1 (26) 1.34 (0.83,2.17) 
0.227 
_1 
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Height for age z- < -2 (28) 1.73 (1.08,2.76) 
0.022 
score 2 233 
family assisted No (69) 767 - - 
family assisted Yes (23) 183 1.34 (0.86,2.09) 0.195 
house toilet 
_0 mudwall no 
toilet (26) 274 - - 
house_toilet 1 blockwall no toilet 3.62(1.53,8.88) 0.003 _ 7 30 
house_toilet_2 
mudwall 
latrine (34) 301 1.57 (0.96,2.57) 0.074 
house_toilet_3 blockwall latrine (24) 268 1.41 (0.79,2.53) 0.248 
house toilet 4 mudwaIl flush toilet 0.000 
(0) 5 
house toilet 
_5 
block flush toilet (1) 57 0.25 (0.03,2.11) 0.203 
family_children_0 1-5 children (60) 684 - - 
family_children_1 6-10 children (26) 230 0.97 (0.57,1.66) 0.920 
family_children 2 11+ children (6) 27 2.58 (1.03,6.50) 0.044 
siblings under 6 no siblings< 6 yrs (16) - - 
Years 0 263 
siblings under 6 1-2 siblings<6 yrs 2.00 (1.17,3.42) 0.011 
years 
_1 
(58) 548 
siblings under 6 3-4 siblings<6 yrs (15) 1.99 (0.81,4.91) 0.133 
Years 2 120 
siblings under 6 5+ siblings<6 yrs (3) 21 1.74 (0.54,5.63) 0.356 
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years 
_3 job description of non-skilled (35) -- MIP0 356 
job description of Trade (21) 1.64 (0.98,2.73) 0.058 
MIP_1 156 
job description of Skilled (27) 0.91 (0.56,2.09) 0.701 
MIP 2 329 
job description of Professional (9) 1.04 (0.48,2.27) 0.916 
MIP_3 99 
Of the predictors of RSVI, increased age of PCT (>40 years) and house and toilet type were 
also correlated with an increase in risk of RSV disease. Of the traditional risk factors for 
RSV disease - crowding (number of children in the home) and characteristics of contact 
person (number of children <6 years in the home) were found to correlate with increased 
risk of RSV-LRTI. Stunting (height-for-age z-score (haz <_ -2) was a significant 
independent predictor of RSV disease. Other factors found to be associated with increased 
risk of disease in the univariate model (Appendix W, p 379) were not confirmed as 
independent predictors of RSV-LRTI indicating their probable association with other risk 
factors (e. g. number of children in the home and house/toilet type), house ownership, 
profession of MIP (both SES indictors) and other variables also related to crowding; 
number of siblings of different ages were not found to be independent predictors of 
increased risk of RSV-LRTI. In an attempt to compare differences in the risk factors for 
RSV-LRTI and those for all-cause LRTI we sought to determine predictors of LRTI in this 
study population, Table 9.3. 
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Table 9.3. Risk factors independently predicting increased hazard of all-cause LRTI 
Potential risk factors Categories 
(number of events) 
cyo Hazard Ratio 
(95% CI) 
P>Iz) 
current age_0 0-5 months (245) 200 - - 
current age j 6-11 months (120) 214 0.55 (0.41,0.74) 0.000 
current age 2 12-17 months (290) 211 1.72 (1.31,2.25) 0.000 
current age_3 18+ months (202) 329 0.74 (0.52,1.04) 0.082 
multiple babies-0 1 child (790) 876 -- 
multiple babies 
_1 
Twins (50) 55 0.80 (0.54,1.19) 0.275 
multiple babies 
_2 
Triplets (17) 5 4.12 (1.55,10.99) 0.005 
education-0 no schooling (249) 241 -- 
education 
_1 
1-7 years (353) 383 0.95 (0.76,1.19) 0.675 
education 2 8-12 years (241) 301 0.81(0.64,1.19) 0.092 
education 3 >12 years (14) 38 0.40 (0.21,0.76) 0.005 
Height-age-z score 0 >-1 (363) 465 - - 
height-age-z score 1 -1.99 to -1 (239) 246 1.27 
(1.06,1.52) 0.010 
height-age-z score_2 <_ -2 (255) 235 1.38 
(1.12,1.70) 0.002 
family_children 0 1-4 children (598) 684 - - 
family_children_1 6-10 children (214) 230 0.96 (0.77,1.19) 0.696 
family_children 2 11+children (45) 27 1.68 (1.07,2.63) 0.023 
main_fuel 0 gas/paraffin (16) 36 - - _ 
main_fuel 1 Charcoal (158) 211 1.34 (0.74,2.44) 0.339 
_ 
main_fuel 2 Firewood (660) 657 1.71 (0.96,3.05 0.071 
main fuel_3 firewood/charcoal(23) 23 2.11 (0.97,4.60) 0.060 
# siblings <6yr sleeping in no siblings <6 yrs 520 - - 
same room as index 0 (411) 
_ # siblings <6yr sleeping in 1 -2 sibling <6 yrs 411 1.19 
(0.99,1.43) 0.067 
same room as index 1 (408) 
- # siblings <6yr sleeping in 3 siblings <6 yrs (11) 11 1.69 (0.81,3.51) 0.162 
same room as index 2 
- # siblings 6+ years sleeping no siblings 6+ years 630 - - 
in same room as index 0 (535) 
_ # siblings 6+ years 1 siblings (194) 183 1.29 (1.04,1.61) 0.021 
sleeping in same room as 
index 1 
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# siblings 6+ years sleeping 2-3 siblings (88) 110 0.83 (0.62,1.11) 0.213 
in same room as index 2 
_ # siblings 6+ years sleeping 4 siblings (13) 18 0.63 (0.31,1.28) 0.205 
in same room as index 3 
# siblings <6yr going to no siblings <6 yrs 794 -- 
school 0 going to school (709) - # siblings <6yr going to 1 sibling <6 yrs 131 0.80 (0.62,1.05) 0.107 
school_i going to school (86) 
# siblings <6yr going to 2-3 siblings <6 yrs 27 1.52 (0.98,2.33) 0.059 
school 2 going to school (35) 
Age was an independent predictor of LRTI. The effect of age was mixed, associated with 
protection in those 6-11 months and increased risk in those 12- 17 months. Being a child of 
a multiple birth was the strongest independent predictor of LRTI probably reflecting its 
association with lower birth weight which was not found to be associated with LRTI in this 
study. Other factors found to be associated with increased risk of LRTI were height-for- 
age z-score <_-1, crowding (number of children in the home), intensity of contact with 
siblings <6 years of age (number sleeping the same room as cohort child). Borderline 
significant factor was having 2-3 siblings <6 years attending school. Two factors were 
found to be associated with protection from LRTI, having a care taker with a college 
education (>12 years of schooling) and having a young sibling (<6 years) attending school. 
Reflecting the possible association of these variables with each other and with other 
variables already in the model, certain variables that were significant at univariate analyses 
did not make it into the multivariate model (Appendix W, p 375). These include weight-for- 
height z-score (related to height for age z-score), house and toilet type, the cohort child's 
care giver (related to SES), number of siblings <6 years and number of male siblings 
(related number of children in the home). These variables are related and probably 
ultimately related to socioeconomic status. Because of the small number of multiple births 
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in these data, the LRTI multiple regression model was re-fitted excluding this variable to 
achieve more stable estimates. There was minimal difference in the effect estimate, results 
not shown. A summary table comparing individual risk factors across the different 
outcome groups is provided below (Table 9.4). 
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Figure 9.4 Summary table comparing individual risk factors across the different outcome 
groups is provided below 
Risk Factor Categories RSV LRTI RSV-Infection All cause -LRTI 
HR (95% CI) HR (95% CI) HR (95% CI) 
Current age 0-5 months --- 
6-11 months --0.55 (0.41,0.74) 
12- 17 months --1.72 (1.31,2.25) 
18+ months --0.74 (0.52,1.04) Multiple babies 1 child --- 
Twins --0.80 (0.54,1.19) 
Triplets --4.12 (1.55,10.99) Education level of no schooling --- PCT 
child's care 
PCT* age group 
Number of smokers in HH 
height for age z- 
score 
1-7 years 
8-12 years 
>12 years 
mother 
another family 
member 
house help 
school 
mother / family 
member 
13-24 years 
25-30 years 
31-40 years 
41-50 years 
51-63 years 
None 
1 
2 or more 
>-1 
0.95 (0.53,1.71) 
1.49 (0.56,4.00) 
0.00 (-) 
1.26 (0.47,3.37) 
1.03 (0,58,1.82) 
1.49 (0.88,2.53) 
2.19 (1.13,4.25)8' 
0.87 (0.53,1.45) 
0.81 (0.36,1.84) 
- 0.95 (0.76,1.19) 
- 0.81(0.64,1.19) 
- 0.40 (0.21,0.76) 
0.77 (0.54,1.08) 
0.54 (0.30,0.99) 
1.06 (0.87,1.30) 
1.28 (0.80,2.05) 
1.15 (0.87,1.52) 
1.09 (0.79,1.49) 
1.02 (0.66,1.57) 
2.13 (1.27,3.59) 
0.92 (0.74,1.15) 
1.40 (1.07,1.84) 
-1.99 to -1 1.34 (0.83,2.17) - 1.27 (1.06,1.52) 
< -2 1.73 (1.08,2.76) - 1.38 (1.12,1.70) family assisted No --- family assisted Yes 1.34 (0.86,2.09) 1.20 (0.98,1.46) - 1louse and toilet type 'mud wall no toilet --- 
block wall no toilet - 3.62(1.53,8.88) 1.03 (0.73,1.46) 
'. ý mud wall latrine 1.57 (0.96,2.57) 0.98 (0.79,1.21) - 
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block wall latrine 1.41 (0.79,2.53) 0.83 (0.65,1.06) - 
mud wall flush toilet 0.00(-) 0.53 (0.19,1.47) 
block flush toilet 0.25 (0.03,2.11) 0.60 (0.40,0.91) - 
main fuel used for gas/paraffin -- 
cooking 
Charcoal --1.34 
(0.74,2.44) 
Firewood --1.71 
(0.96,3.05 
firewood/charcoal 2.11 (0.97,4.60) 
job description of non-skilled --- 
MIP 
Number of family 
children 
Number of siblings 
under 6 years 
Trade 1.64 (0.98,2.73) -- 
Skilled 0.91 (0.56,2.09) -- 
Professional 1.04 (0.48,2.27) -- 
1-5 children -- 
6-10 children 
11+ children 
no siblings< 6 yrs 
0.97 (0.57,1.66) - 0.96 (0.77,1.19) 
2.58 (1.03,6.50) - 1.68 (1.07,2.63) 
# siblings <6yr 
sleeping in same 
room as index 
# siblings 6+ years 
sleeping in same 
room as index 
1-2 siblings<6 yrs 
3.4 siblings<6 yrs 
5+ siblings<6 yrs 
no siblings <6 yrs 
1 -2 sibling <6 yrs 
3 siblings <6 yrs 
no siblings 6+ years 
2.00 (1.17,3.42) -- 
1.99 (0.81,4.91) -- 
1.74 (0.54,5.63) -- 
1.19 (0.99,1.43) 
1,69 (0.81,3.51) 
1 siblings - - 1.29 (1.04,1.61) 
2-3 siblings - - 0.83 
(0.62,1.11) 
4 siblings - - 0.63 
(0.31,1.28) 
# siblings <6yr going no siblings <6 yrs - -- to school going to school 
1 sibling <6 yrs - - 0.80 
(0.62,1.05) 
going to school 
2-3 siblings <6 yrs - - 1.52 (0.98,2.33) 
going to school 
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9.8 Testing the proportional hazard assumption (PHA) 
The fundamental assumption of the Cox regression model is that the effects of the 
parameters included in the model do not change during the time covered by the study. The 
Schoenfeld and scaled Schoenfled residuals were used to test that the model satisfied the 
proportionality assumption. This involves testing for a non-zero slope in a generalized 
linear regression of the scaled Schoenfeld residuals on functions of log time. A non-zero 
slope is an indication of a violation of the proportional hazard assumption. Results are 
shown in Appendix X (p 389). The proportionality of the model as a whole as well as for 
each predictor was tested. If the individual predictor tests are not significant (P->0.05) we 
cannot reject proportionality and we assume that the model does not violate the 
proportional hazard assumption. 
Although the global PHA test was non-significant, 3 predictors in the LRTI model had a p- 
value of less than 0.05. These results were cross-checked by obtaining a graph of the 
regression, Figure 9.6 and 9.7. A horizontal line in the graph of the residuals is an 
indication that we do not have a violation of the proportional assumption. Both lines are 
horizontal so predictors were left in the model. Thus the PHA was held for all multivariate 
models used. 
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9.9 Goodness of fit of the Models. 
The model fitness was evaluated using the Cox-Snell residuals as described in Chapter 8. 
When compared in all instances the hazard function follows the 45 degree line (see 
Appendix Y, p 392). This means that it approximately has an exponential distribution with 
a hazard rate of one and that the model fits the data well. This is true except for high values 
of time which is essentially because of censoring. 
9.10 Discussion 
It is apparent that the child's nutritional status plays an important role in the risk of disease 
(RSV-LRTI and LRTI). Mild to moderate and severe stunting (height-for-age z-score <_ -1) 
was associated with increased risk of disease. This finding is consistent with only one other 
study in South Africa reviewed by Vardas et al [287] that reported increased risk of RSV- 
LRTI in admissions with malnutrition. All others observed a negative association or 
suggested a protective effect of malnutrition on RSV [38]. Thus this is an interesting 
finding. On the other hand, malnutrition is a widely know risk factor for ARI and LRTI [27, 
157,159,176]. It is generally thought that malnourished children are susceptible to 
opportunistic infections (although RSV and co-bacterial infections are uncommon [28,116, 
205,206]). This is based on results from several studies indicating a deficiency in the 
immune response in malnourished children. From T- cell dysfunction [288] to the effects of 
micronutrient deficiencies which have been reported to cause increased susceptibility to 
respiratory infection through defects in the immune system [289-291]. In addition, zinc 
deficiency which has been associated with stunting [292] may also contribute to impaired 
function of the immune system. Vitamin A deficiency caused by prolonged dietary 
deprivation is also said to decrease the functional integrity of the mucociliary system lining 
the respiratory tract [157]. Children in Kenya as a national policy routinely get vitamin A 
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supplements free of charge. Still, not every mother brings their children to the MCH clinic 
however children in this study were routinely remind about their vaccination appointments 
(implemented a policy of checking road to health cards at each visit). Stunting as an 
indication of long term malnutrition seems to be a more significant risk factor for all cause 
LRTI than acute (short term) malnutrition (wasting) in this study and in an earlier study 
done on Kenyan children [157]. Several studies have reported no association or negative 
association between malnutrition and incidence of RSV disease [8,200,202,205,208, 
209]. The difference in results observed may be due to the inconsistency of the definition of 
malnutrition used and different reference standards used in the calculation of the 
malnutrition indices. Until recently the NCHS/WHO international reference used were 
based solely on US children who as infants were predominantly formula fed thus not 
comparable. The reference standard used in this study is from a recent WHO multi-centre 
study initiative using a reference computed from children in both developing and developed 
countries [274] and is thought to be more applicable in this setting. Similarly, the different 
indicators and cut offs used in studies (weight-for-age, oedema, weight-for-height, mid 
upper arm circumference) make direct comparison difficult. Stunting is also associated with 
Trickuris infection. Previous data from Kilifi [293] show the population to be highly 
parasitized with documented incidence of Trichuris infection of between 15-20% in 
children <5 years. However, the incidence of Trichuris infection in the study participants is 
unknown thus an assessment of this interaction was not possible. 
To further explore this relationship, we investigated the association between the three 
malnutrition indicators and SES, Figure 9.8. There was no evidence of an association 
between malnutrition and SES although there appeared to be a suggestion that "richer" 
households had a higher median height-for-age z-score. 
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Figure 9.8 Association between malnutrition indicators and SES. X-axis denotes socio- 
economic classification - 1-poor, 2- middle (top) and 3- rich class (bottom). 
As expected, crowding was associated with increased risk of disease both RSV specific and 
all-cause LRTI. It is hypothesized that this restriction of observed effect to disease is in line 
with the increase in inoculum in households of higher density known to produce greater 
disease [162,294]. Having more children in the home is also expected to relate to an 
increased chance of virus introduction. The number of children in the home was highly 
correlated to number of persons in the home in this study population. Crowding also 
increases the potential for transmission taking place as a result of the increased chance and 
intensity of contact. Several recent studies (reviewed by Simoes [189]) observed a positive 
association between crowding and number of siblings and occurrence of RSV-LRTI. In this 
study, the age category (siblings <6 years) of children in the home was found to be 
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associated with RSV disease (Table 9.2). This would imply that not only does the number 
of children in the home matter but also the age of these children. A possible explanation for 
this is that younger children are more susceptible to infection thus more likely to acquire 
the infection in the first place and in turn transmit to the young child. 
We investigated several factors related to intensity of contact between other children in the 
home and the cohort child for all the three outcomes. An association was found between the 
intensity of contact (number of sibling sleeping in the same room) and increased risk of all- 
cause LRTI, Table 9.5. This correlates with the higher probability of transmission taking 
place due to prolonged exposure. A large number of studies as reviewed by Simoes [189] 
have shown an association between RSV-LRTI and number of people sleeping in the same 
room with the child or with siblings in school, none of these studies explored differences 
between sleeping in same room and more specifically in same bed as the child. Many 
studies [113,162,163,170] have found an independently significant association between 
LRTI and increased numbers of others sharing the room. We investigated the potential 
effects of these different dynamics; number of siblings sleeping in the same house, room 
and bed. However, a similar association was not observed for RSV-LRTI possibly due to 
the reduced power to detect a difference given the small number of events. 
The risks for RSV-LRTI can only really be interpreted in relation to those for RSVI in that 
it is not known if identified independent associations are for infection or disease, given that 
infection occurs in everyone. Thus factors identified to be independently associated with 
clinical RSVI were included in the model to determine factors that predict disease. It is 
clear that socio-economic classification (indicated by house and toilet type) plays an 
important role in the infection and disease in these data. In this study, living in a blocked 
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walled house with flush toilet ("richer" HH) was protective from RSVI whereas living in a 
block walled house with no toilet ("poor" HH) was independently associated with increased 
risk of RSV-LRTI. Though only of borderline significance, this finding is further supported 
by results indicating that children in households that receive financial assistance from an 
outside party/relative and those in households where the MIP is in trade had an increased 
risk of RSVI and disease respectively. This finding is inconsistent with findings from the 
study by Weber et al [194] where rather surprisingly case households more frequently had 
tap water and a flush toilet. They attribute this finding to differences in care seeking 
behavior by SES with parents of higher status being over represented in hosipitalised cases 
i. e. seeking treatment more effectively. In this study all children were under the same 
method of surveillance in addition to having their medical costs covered during the study. 
A rationalization of the effect of socioeconomics is that it is a determinant of factors that 
may influence health e. g. nutritional status and exposure to environmental smoke. 
Households that have a flush toilet and block wall in this population have a higher standard 
of living reflecting an economic advantage which is in turn reflected on their general health 
status. 
Along the same line, having a hired care giver was independently associated with 
protection from RSVI. Very few households in this study population are able to afford 
hired help. Thus a child who is cared for by a house help is most likely living in a 
household that would be categorized as being better off financially. We assessed for an 
association between having a house help and a household's socio-economic classification 
and found that 80% of households that had hired help were classified as "rich" with the 
remaining 20% classified as "middle" class households. None of the poor households had 
hired help. Thus we can conclude that this observed protective effect is almost certainly a 
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proxy for socioeconomic effect. The pathway by which SES might affect risk of disease 
include: higher crowding index- more people fewer rooms -increases the likelihood of 
infection, poor general state of health a refection of poor quality of environment (poor 
sanitation, dirty water among other things [162]) and nutritional status (lower buying 
power-long term undernourishment). Also people of lower SES have been reported to have 
poor access to health care and also tend to seek healthcare late [295]. From this study it is 
not possible to discern what the SES effect is due to. 
From this study it emerged that the age of the child's care taker plays a significant role in 
the risk of RSVI and RSV disease signified by an increased risk of infection and disease in 
children having older PCTs. There have been differing results on the effect of maternal age 
on LRTI, thus this finding though not surprising was unique for RSV infection and disease. 
In crude analysis of the Bostid studies [27] no consistent association was seen between 
maternal age and incidence of A(L)RI. With the exception of a few instances where the 
PCT was the grandmother, in most instances the PCT was the mother of the child. This 
finding may be related to or may be a proxy for family size with older mothers having had 
more children thus have generally more children to care for. It is also possible that older 
PCT are really grandparents looking after children whose mothers are working away, both 
of which are factors which may in turn affect the child's overall health translating into 
increased risk of RSV infection and disease. 
Exposure to tobacco and to environmental smoke (cooking fuel) was associated with RSVI 
and all-cause LRTI respectively in these data, evidenced by increased risk of infection and 
disease. This result is similar to reports from other studies showing an excess risk of ARI 
and or RSV disease due to indoor air pollution and exposure to smoke[ 144,164,166,169, 
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195]. It is widely known that environmental smoke contains significant amounts of 
pollutants (carbon monoxide, hydrocarbons) and also that the pathogenesis of ARI from 
biomass fuel has been shown to be similar to that of environmental tobacco smoke [296]. 
Still, the measurement of the independent variable, extent and length or intensity of 
exposure are issues to consider in assessing the effect. In this community female/maternal 
smoking is almost non-existent but exposure to cooking smoke is very prevalent. Most 
mothers tend to carry their young children on their backs while attending to household 
chores like cooking. Burning refuse was not associated with increased risk in any of the 
outcomes. 
In this study, we observed evidence of an association between age and risk of LRTI. The 
risk of LRTI was decreased in the subgroup of children aged 6-11 months with an observed 
increase in children 12-17 months. A similar effect was not observed for RSVI and RSV- 
LRTI. Thus, this effect may be a reflection of disease by other causes (bacteria, other 
viruses) of LRTI in this population. This increase at 11 months is presumably co-incident 
with introduction of solid food and independent motility. Declining nutritional status 
(Chapter 8) is also an important influencing factor as the nutritional status of children in 
this population was observed to start deteriorating at around 9 months of age. Furthermore, 
except in the case of RSV (conflicting results), maternal antibody is usually known to be 
protective in the first few months of life, a possible explanation for the protective effect 
seen at 6-11 months waning as the child gets older. There was no evidence of association 
between age and RSV-LRTI. Several studies have reported a relationship between age and 
RSV disease with most disease occurring in infancy specifically in children <6 months 
[132,133,191-193]. It has been suggested [189,294] that this is as a result of several 
effects; immature immune systems in younger child which improves with age, narrower 
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airways, hyper-responsiveness among others factors. The effect of age on disease may be 
limited to severe disease; published studies are cases of RSV-LRTI requiring 
hospitalization and are not similar to those in this study. We observed such an effect in this 
study looking at the incidence of severe RSV-LRTI by age. In this study, there appeared to 
be protection from severe RSV-LRTI with increasing age (Figure 9.1). 
Educational level attained by mothers is also an important social factor determining child 
health. The mothers' educational level was associated with protection from all-cause LRTI. 
There are several ways through which maternal education is thought to influence child 
survival [264] and by extension the risk of disease: i) education alters the traditional 
balance of power within the family allowing the mother to take independent decisions 
concerning child health ii) Education also modifies beliefs and knowledge about disease 
causation, prevention and cure and this has an influence on health care practices iii) 
educated mothers bring their children much earlier and much more frequently for treatment 
iv) Schooling causes changes in behavior such as improved cleanliness which are likely to 
persist into adulthood with implications for the general health of the child [264]. A study 
done in Kenya to assess the knowledge, attitude and practices (KAP) of mothers regarding 
ARI found that formal education had a positive influence on the KAP of the mothers [297] 
In this study, there was a gradual increase in the level of effect with increasing number of 
years of education (Table 9.3), indicating that the better educated the mother is, the bigger 
the effect of education on reducing risk of disease, lending credence to some of the 
mechanisms of action of the education effect listed above. Nonetheless, it is worth 
mentioning that less than 5% of the mothers in this study had higher than a high school 
education with 25% having had no schooling at all. 
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Multiple births (triplets) were associated with increased risk of LRTI in this population. 
There were very few multiple births in these data, 2 triplets and 27 twin births. These 
children as is typical had lower birth weight, which is probably the underlying effect 
explained by this result. Several studies from different developing countries have shown 
low birth weight to be a risk factor for LRTI [166,170,179]. Nevertheless, the results 
reported are not consistent as some studies have refuted the effect of low birth weight [ 163, 
170]. Low birth weight did not correlate with increased risk of LRTI in the multivariate 
model in these data, although there appeared to be a protective effect in heavier children in 
the univariate analyses for all the three outcomes. This effect however did not achieve 
significance. Another underlying factor is that children of multiple births are rarely carried 
to term and pre-maturity is a well known risk factors for ARI. 
Having siblings in school doesn't seem to be a risk factor for infection or disease in these 
data despite studies [15,16,50,144] showing that they are the most likely introducer of 
infection into the home. However, all these studies were done in developed countries which 
have markedly different household sizes and community structures, factors which may 
undoubtedly influence this effect considerably. An association between number of siblings 
in school and the risk of infection and disease was not observed in this study, although 
there appeared to be a borderline association between number of siblings <6yrs in school 
and increased risk of all-cause LRTI. The risk of transmission is thought to be higher in 
settings such as schools, therefore having older siblings who are more likely to be exposed 
to external infection and consequently facilitate infection in the birth cohort child, 
translating into higher risk of infection/disease in the cohort child. In fact in the household 
study, the rates of respiratory infection were found to be higher in pre-school children with 
siblings in school than in those without siblings in school (Chapter 5). However, the cohort 
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child in the household study was more often the primary case, possibly a result of 
undetected sub-clinical infection in other family members as has previously been discussed. 
For all three outcome measures, the sex of the child had no observable effect despite the 
fact that younger male children are known to have more severe respiratory infection than 
girls due to their narrower and shorter airways [189,298]. To investigate potential 
interaction between age and sex we looked at age-stratified incidence of infection by sex. 
There was no evidence for a difference in incidence of infection between males and females 
in the different age classes. 
The differences observed in this and other studies may be related to the fact that: i) in this 
case one of the outcomes was clinical RSV infection. There have been few studies with 
RSVI as an outcome presumably because every child gets infected. Still, RSVI is the most 
important risk factors for RSV-LRTI. The comparison between predictors of clinical 
infection and disease in this study is new. It appears that the risk factors for each are 
markedly different with only two factors identified to be common to both: increasing age of 
PCT and house and toilet type (possible surrogate for SES). Malnutrition and crowding 
were associated RSV-LRTI. ii) Common knowledge on risk factors for RSV disease 
typically stems from studies done on hospitalized cases which are in all probability more 
serious requiring hospitalization, than most of the cases in these data. Published data from 
Kilifi showed that hospitalisations due to RSV-LRTI represent only a small fraction 
(perhaps 15%) of all severe RSV-LRTI in the community [5]; there were very many severe 
RSV cases that were not admitted adding weight to the theory that hospitalized cases 
maybe more severe. A comparison of results from the present study with those from other 
studies with differences in design may account for some of these differences. iii) there is 
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also a lack of precision in the specification of independent variables in the different studies 
with different definitions, sample collection methods and diagnostic methods used in 
different studies. 
In this study nasal specimens were collected using the bulb washing method and tested by 
IFAT, the recommended method for diagnosis of RSV in samples from children. 
Nonetheless, diagnosis on the basis of immunofluorescent antibody test alone is not as 
sensitive as that by assay combinations [19] or by molecular methods. As previously 
discussed a study done in Kilifi showed the nasal wash bulb method to provide simple and 
effective alternatives to NPA (used in most hospital studies), with the NW being more 
acceptable and convenient for use in resource poor and home settings. In addition, there 
was no difference in the number of epithelial cells in the samples collected by the two 
methods [243]. The definition of LRTI used in this study was based on modified WHO 
guidelines specifically to capture LRTI in children <2 months and in cases of malaria co- 
infection. However, cases of RSV sero-conversion without an equivalent antigen positive 
result have been identified in this population (unpublished data-on going work) so it is 
possible and indeed probable that certain risk factors remain hidden due to reduced number 
of RSV-LRTI events. 
In conclusion, the factors that increase the risk of RSV-LRTI and LRTI in the published 
literature generally vary possibly because of inherent differences in other factors like 
cultural and traditional practices, poverty levels, climatic conditions, political structure that 
influence health systems among other things. Thus there may not be a homogenous effect 
of risk factors on the incidence of respiratory tract infections the world over. In addition, 
some risk factors identified are not changeable: family size, exposure to siblings, 
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socioeconomic assets. Even though a causal relationship can only be demonstrated in a 
controlled trial, some of the risk factors identified can be modified by what would be 
considered relatively easy interventions. For instance, nutritional status of children can be 
improved by nutritional supplements (vitamin supplements or fortified milk) or 
encouraging longer breastfeeding ensured by better family planning methods i. e. well 
spaced out children which can be implemented through pre-natal education. 
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Chapter Ten 
Overall Discussion 
10.1 Introduction 
The work presented in this thesis is an attempt to improve understanding of the infection 
dynamics of RSV within the community, and more specifically within the household. Most 
severe cases of RSV arise as primary infection in early infancy; for which the household 
contact is presumed to play a major role. Given the requirement for close contact to effect 
RSV transmission [299], the household within which intimate contact is undeniable 
presents a suitable unit of study to quantify community transmission rates. Presently, there 
is limited data on RSV in the resource poor settings and differences in family structure and 
contacts patterns may result in markedly different transmission dynamics to those identified 
in industrialized settings. 
This thesis thus presents an account of highly detailed investigations of the transmission 
patterns of RSV within households in the setting of a rural developing country community: 
Kilifi District, coastal Kenya from 2003 to 2005. RSV infection was sought in both 
children and adults using clinical and serological surveillance. Routine active and passive 
visit records were analyzed to address each of the study objectives. Data on the follow-up 
of birth cohort children in the main project was used to investigate risk factors. A detailed 
discussion of objectives of the study, including comparison of findings with those 
published and the study limitations can be found at the end of each result chapter. The aim 
of this Chapter is to summarize findings and make recommendations for future work. 
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10.2 Findings and evidence to support findings 
The source of infection to infants is not well documented. Thus, introduction and 
transmission of the virus within families was studied. This data is unique in resource poor 
settings and has not been collected anywhere since the 1970s. Surprisingly, the data 
indicate that introduction into the home was more often by the birth cohort child, although 
infants and young children mostly stay at home, so that a priori it would seem unlikely that 
they are the primary source of infection in households [15,16,61]. In fact, in households 
with documented secondary transmission in this study, older siblings were found to be the 
more likely introducers. It is epidemiologically plausible to expect that children in school 
are more likely to be infected externally (contact with other children) and in turn bring 
infection into the home. Moreover, infection rates were also found to be higher in pre- 
school children with siblings in school (discussed below). It is possible that an apparent 
introduction by a birth cohort child may in fact be a secondary case resulting from an 
inapparent asymptomatic primary case in a school-attending sibling. Due to the ethically 
constrained study design, where samples were collected only in the presence of symptoms, 
such a case would be unidentified. 
Older children were also observed to transmit more effectively to younger household 
members relative to transmission among themselves; a likely reflection of the increased 
susceptibility of younger children. Overall, there was minimal secondary transmission 
observed to be taking place, but the number of people infected in a family in an epidemic 
was influenced by a household's socio-economic status (SES). It is not possible in the 
current study to say exactly how the SES effect actually manifests itself, but one could 
speculate that this effect could be due to higher crowding in poorer households. This would 
result in greater intensity of contact potentially increasing the likelihood of transmission 
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perhaps through multiple exposures or increased dose. However, family size was not shown 
to be related to size of outbreaks in infected households. Alternatively it may reflect the 
generally poorer health status of individuals in these families. These results are of course 
exclusive of possible missed asymptomatic infection, although appreciable levels of re- 
infection were documented. 
It was hypothesized that re-infections have important influence on community transmission 
and persistence hence an attempt was made to estimate the age-stratified incidence of 
infection. This study demonstrates quite considerable infection levels in families, most of 
which is re-infection. Infections in older children and adults have largely been ignored by 
previous investigations. This study is unique in that previous studies have all been carried 
out in the developed world where social dynamics such as family sizes, living 
arrangements, and contact patterns are qualitatively different from those in developing 
countries. This confirms that infection in the older population can have important 
implications for transmission, infection, and disease in infants as possible reservoirs of 
infection. 
Infection rates appear to be similar in the first 3 years of life and only start to decline after 3 
years of age (Fig. 7.4). As expected, incidence of disease in this study was documented 
only in children younger than three years. Infection and disease rates were observed to be 
similar in both sexes. No cases of clinical infection were identified in adults (individuals 
over 15 years). In this study there were no cases identified of malaria (presence of 
parasites) co-infection in RSV cases. In areas of endemic malaria such as Kilifi, cases of 
malaria may be misdiagnosed as LRTI or ARI, hence giving an inaccurately high diagnosis 
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rate, so the fact that these patients were malaria negative gives strength to the diagnosis of 
respiratory disease 
There is a paucity of disease risk data for LDCs and the only other published study is by 
Nokes et al involving children in the first year of life from the same birth cohort as in the 
present study [5]. The household study was nested within the birth cohort project in which, 
for a subgroup of families, follow-up was extended to all family members (Chapter 3). As 
expected [12], risk of disease was found to be greater after primary infection than re- 
infection. Severe disease was observed to occur only during primary infection and only in 
children less than 18 months old. The risk of disease after re-infection was significantly 
higher in younger children. Interestingly, the highest risk of disease in this population was 
documented in the age group 12-17 months. This demonstrates that significant disease can 
occur following a primary infection even at this older age group, an observation which has 
not been previously documented. 
Infection rates (ARI and RSV specific ARI) were highest in pre-school children with 
siblings in school. These children seem to be playing a part in bringing the infection into 
the home. This has important implications when considering possible vaccination 
strategies. Until recently [2], attempts at vaccinating infants have met several obstacles. 
The principal barriers have been the need to vaccinate in the first months of life, at a time 
of interference by maternal antibodies as well as immunologic immaturity observed in 
infants. Additionally, the formalin inactivated vaccine that was tested in the 1960's failed to 
protect and resulted in enhanced disease in vaccinated infants during naturally occurring 
RSV infections [91,300]. Eliciting indirect disease protection in infants by vaccinating 
school children/siblings who are bringing infection into the home could potentially 
circumvent these problems. Reducing infection in school age children would reduce the 
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risk of infection in the vulnerable infants and young children and thus defer first infection 
to an older age where the risk of disease is significantly less - though as this study shows - 
not negligible. A comparable working model is the case with measles vaccine where the 
vaccine is given at 9 months. This does not directly protect the very young but might delay 
first infection by indirect protection conferred from less circulating virus in the community 
i. e. through the indirect effects of vaccination [86,3011. Given that natural infection does 
not prevent re-infection, it is hypothesized that a vaccine would provide at least partial 
protection from re-infection but might need to be given repeatedly (e. g. every year) for a 
sustained effect sufficient to protect infants. Whether this would be acceptable (recipients 
of the vaccine would not be those to benefit most) is not entirely clear but has the potential 
of substantially reducing incidence of disease in infants, which may outweigh the cost of 
repeated vaccination. An additional problem with this approach is to provide protection in 
the very young (<3m), requiring attenuation to a degree that the vaccine immunogenity is 
compromised [2]; there is currently no attempt to produce a more immunogenic (and 
possibly reactogenic) vaccine for use in individuals who have already been exposed to a 
natural infection. A further problem would be that after a period of approximately 5 years 
of a programme vaccinating school-children to protect infants, if the programme is 
successful, individuals would potentially join the targeted age-groups without having been 
infected naturally. 
Transmission is constrained by the duration of infectiousness inter alia. Thus an attempt 
was made to estimate the duration of viral shedding in this population. The longer the 
duration of shedding the greater the chance that transmission takes place (although account 
needs to be made of the shedding load which was not done in this study). Thus, any factor 
that affects this duration has important implications for disease incidence. The relationship 
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between past exposure, age, severity of infection, and sex and duration of shedding was 
explored. For some there was a suggestion of a risk (e. g. KM curves, Fig 6.6) but these 
were found to be statistically non-significant after accounting for some of the uncertainty in 
the data. The limitations of the data used (which may influence the results) have been 
discussed in Chapter 6. Further analysis of these data is required to tease out the possible 
relationships. 
Finally, the main purpose of the risk factor survey was to determine the independent effects 
that certain factors have on the risk of RSV-LRTI in cohort children. To this effect, a total 
of 469 children followed up from birth were compared i. e. infected and non-infected for 
possible risk factors for RSV-LRTI. These were then compared with those factors 
identified to be associated with all-cause LRTI and thereby identify factors solely related to 
RSV disease. Only two factors were found to be independently associated with both RSV- 
LRTI and LRTI; stunting (a marker of long term under nutrition) and crowding (as 
indicated by number of children in the home). Those that were common to both RSV 
infection and RSV-LRTI and associated with increased risk of infection and disease were 
increased age of the PCT and socio-economic status. All other independent factors were 
unique to each outcome. House type and sanitation was associated with increased risk of 
RSV disease but not with LRTI as was having a sibling under the age of 6 years. The only 
risk factor that was unique to infection with RSV was the number of smokers in the home. 
Age at infection and multiple births were found to be associated with increased risk of 
LRTI while a higher level of maternal education was associated with protection. 
Crowding (discussed above) and nutritional status are both directly influenced by SES; 
nutritional status is affected by a families' long term ability to purchase food. Educational 
266 
level can also be linked to SES. It is speculated that education may permit better 
employment opportunity facilitating stability through a regular income. A study done in 
Kilifi [295] observed that poor families tended to access health services later, i. e. they had 
other pressing priorities or little or no disposable income and faired worse than their 
wealthier counterpart in the event of an illness episode in the family. Nonetheless, to 
demonstrate a causal relationship between an observed, putative risk factor and disease 
outcome, an intervention through a controlled trial or by comparison would be necessary. 
However, nutritional supplementation and education are both already acknowledged to 
have significant positive benefits on all outcomes (not just RSV associated disease), so that 
such an intervention study is unlikely to be possible just based on RSV. 
In this study there were three epidemics observed in the household cohort, one at 
recruitment and two occurring in close succession almost a year later (Fig. 2.3), seemingly 
having a similar pattern to that seen in Finland [44]. However, more surveillance data is 
required to state this conclusively. The peak season for RSV was correlated with the 
absence of rainfall (Fig. 3.10). No re-infections were identified during the inter-epidemic 
period leaving the question of persistence unresolved. Although this data adds to the global 
knowledge on seasonality of RSV, it does not provide an explanation for the observed 
seasonal dynamics. 
10.3 Generalisability of study findings 
It is 50 years since RSV was discovered and as yet, information on RSV from developing 
countries is remarkably lacking. The WHO recognised the importance of RSV disease 
burden data in developing countries, supporting a generic surveillance protocol and funding 
a group of studies on RSV disease burden [11,117]. The present study provides data that 
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will contribute further to the knowledge base on RSV in developing countries and 
worldwide. Such a study is desirable as it provides information about the spread of RSV in 
the community, information that is vital in relation to the future of vaccine trials and 
interventions [2]. These series of studies have provided reliable estimates (albeit 
underestimated) of the amount of infection in certain age groups in the community and has 
shown that RSV poses a significant burden in this rural African population - not just to the 
infant but older age groups. This is the first such study from a developing country. 
Risk factor data on RSV from developing countries is also limited [126,194]. These results 
thus add to the body of knowledge on risk factors for RSV disease. Different study designs 
and population dynamics will ultimately affect observed findings. Nevertheless, other 
studies in similar settings such as this (rural community in a developing country) should 
ideally provide comparable results. 
A series of studies conducted in the 1970s and early 1980s in USA contributed to the 
understanding of the pattern of RSV shedding in hospitalized young infants without 
underlying conditions [61-63] and in the community [15,59]. It is only in these studies 
that the duration and titres shed by infants and young children have been classically 
reported. Thus this study of non-hospitalised young and older children in relation to history 
of infection provides important additional information relative to the data available. 
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10.4 Study Limitations 
Generally, serological information on infections, based on repeated serum or oral-fluid 
sampling, would have greatly improved the precision of the incidence estimates. In 
particular, supporting data from serological confirmed cases would have overcome the 
difficulty of collecting nasal washes and assay sensitivity in older children and adults. 
Collection of oral fluid is arguably a more acceptable alternative to serum. In particular, it 
is felt that results from the oral-fluid assay would have enabled a truer estimation of 
incidence and made possible the documentation of transmission in the non-epidemic period 
possibly shedding light on viral persistence. In addition, it would probably have influenced 
the apparent result that primary cases on infants fed infection in the household rather than 
re-infections from older siblings. However, a qualitative alteration of our findings of higher 
incidence in 12-18m olds and risk of disease estimates is unlikely as most primary 
infections are symptomatic. 
There were additional limitations of the surveillance methods in general. A severe 
limitation was that samples were only collected from individuals with symptoms. Without 
collecting specimens frequently and routinely in the absence of symptoms, there was a high 
potential for missing many infections, and the less frequent sampling of oral fluid (or 
serum) for serological confirmation has the drawback of not pin-pointing when the 
infection arose precisely in time and so cannot be used to identify transmission routes, thus 
the potential beneficial ability of active and passive methods to identify all cases at the time 
they arise. However, this is not necessary to determine infection in the inter-epidemic 
period but is crucial for transmission network studies. Another limitation of the present 
study was our inability to collect nasal specimens from adults pointing to the need for a 
more suitable method of collecting nasal specimens. Following on from this, a less 
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`invasive' yet sensitive method that would allow collection of samples irrespective of 
symptoms would be extremely beneficial to future studies. 
Prolonged shedders (shedding virus for more than 2 weeks) have been identified in other 
studies [302], but are likely to have been missed in this study because the duration of 
shedding was curtailed by taking the first negative test after positive as cessation of 
shedding interval. For those individuals from whom samples were collected until two 
consecutive negatives, only 4.9 % were identified as being falsely negative, so this is 
unlikely to seriously influence our estimates of duration of infection, but would potentially 
result in missing a small number of individuals with prolonged shedding, which might be 
discontinuous or variable. RSV infections have been detected throughout the year in HIV 
infected children [41] suggesting the possibility of prolonged shedding in immuno- 
compromised individuals [302]. The HIV status of children included in this study was not 
available, in part because HIV VCT (voluntary counseling and testing), hospital Diagnostic 
CT, and accompanying support infrastructure were at an early stage of implementation. 
Moreover, possibly more objective data by which to judge severity may be necessary 
although this could prove difficult in resource poor settlings. 
10.5 Recommendations for Further work 
There are several areas relating to re-infection and community transmission which still need 
to be explored. First it may prove necessary in future studies to visit households at shorter 
intervals possibly twice a week i. e. every 3-4 days. Furthermore, the question still remains 
open regarding how much infection is actually taking place in adults in this community and 
in turn relating this to infection in children. Given the improvement observed in results 
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from the present serum ELISA the possibility of reviewing the oral-fluid assay with better 
results seems likely and can be used to shed light on this issue. 
Genotypic profiling of the genotypes circulating within the family members during 
epidemics would provide information on who infects whom within the household structure. 
In no instance has the transmission within families been investigated with respect to the 
different genotypes circulating. It would be important therefore to establish whether the 
strains circulating in other members of the family especially the school aged siblings are 
similar to that found in the infant thus confirming possible association for the source of 
infection. Thus future work would need to include this. 
Future studies to determine the duration of shedding would need to continue sampling for 
at least one more occasion after the first negative sample. Additionally, there might be an 
inherent bias in the way the data was collected against detecting shorter shedding periods. 
Thus the possibility of regular sampling with shorter interval even in the absence of 
respiratory symptoms should be explored. Regular sampling in the absence of symptoms 
would also identify infections that may not elicit symptoms. Although this may be difficult 
to justify it seems necessary. Lastly, it is possible that transmission and sequelae of 
infection depend in part on the amount of RSV inoculum transmitted [3031. Thus, future 
reports on duration of RSV shedding should include a quantitation of the amount of virus 
shed. 
Lastly, there has been so little success in the current main approach to vaccination he. direct 
protection of infants in first few months. Other strategies such as maternal antibody 
boosting to provide longer duration of protection in first 6 months need exploration. 
271 
However, given the rate of catabolism of maternal antibodies, and resultant half life of 1 to 
3 months [88,89,304,305], this strategy may not substantially decrease the proportion at 
risk in first 6 months. Alternative strategies may therefore include immunization of those 
with partial immunity e. g. school children or all children within households of a newborn 
(discussed above) delaying the first infection thus potentially reducing the risk of severe 
disease in early life. 
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Appendices 
1. Field Procedures Appendices 
The attached appendices give details of field and sample collection procedures used during 
follow up for both the main cohort and the household study. Appendix A is the 
questionnaire used in the MCH clinic exit poll, a tool that was used to select the study area 
(Chapter 3). Following this is a series of all the consent forms used during the study 
(Appendix B-E). The next few appendices (F & G) provide specific details on field and 
research Out Patient clinic study procedures including the standard operating procedures 
(SOPS) for sample (nasal, oral-fluid and blood) collection and the limitations of cost 
covered during the study. 
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Appendix A: Exit Poll Questionnaire 
EXIT POLL QUESTIONNAIRE, Date 
Where did you give birth? Home, KDH, HC. Other 
If Other specify 
Date of birth? (RE: Road to Health Card or RHC) 
How old is the baby now? Months 
JWeeks 
How old was the baby at the first clinic visit? months Pi weeks 
What date was that? (RE: RNc) 
[III ATTIT 
What is the reason for your visit? 
Immunisation (list if more than one) /Other (specify) 
Where do you live? Name of village 
Location 
Sub-location 
Bus fare from home to the hospital (one way) [I 
How long does it take you to get to the hospital (<15mins, 15-<30mins, 
3 0-<60mins, >_6Omins) 
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Consent Forms 
The following is a listing of the consent forms that will follow 
1. RSV Birth Cohort consent form - this is the consent form used to recruit cohort 
infants at birth into the main RSV birth cohort (Appendix B). 
2. Household study consent form - this is the consent form used to recruit household 
members of cohort infant into the household study. In this initial household consent 
form only siblings < 15 years were recruited into clinical surveillance similar to that 
for the cohort child. This form is almost exactly the same as the RSV Birth Cohort 
consent form except that it is used in reference to all children in the home who were 
under 15 years at the time of recruitment. Differences between consent forms are 
underlined. The involvement of adults (household member 15 years or older) was 
limited to having 3-monthly oral-fluid samples collected (Appendix Q. 
3. Adult consent form - after receiving approval form the various ethical and scientific 
committees, adult household members were asked to consent to routine clinical 
surveillance as for the children in the home using this consent form. Consent form is 
same as that used for household children but changed to reflect reference to adult 
family members (Appendix D). 
4. Follow of study children and households had to be extended for an additional year 
(explained in chapter 3). Appendix E is the consent form used to request an extension 
of follow of study households. 
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Appendix B: Information and consent form for birth cohort child. 
STUDY OF A MAJOR CAUSE OF PNEUMONIA IN KILIFI DISTRICT 
Information and consent form far birth cohort child. 
PURPOSE OF STUDY 
Chest infections are one of the biggest health problems for children in Kilifi District. We know the cause and the right treatment for many of these, but in some cases this is not yet known. 
We are investigating an infection caused by a germ (virus) that is known to be a major cause 
of chest infections throughout the world. The virus is called Respiratory Syncytial Virus or 
RSV. For infants who are infected in their first year of life the symptoms can be severe 
enough for the parents to feel a need to take the child to hospital. This condition is distressing both to the infant and to the family, although is rarely life threatening. There are 
no drugs in routine use for reducing the symptoms, and currently no vaccine to prevent infection. However, much work is being carried out to develop a vaccine to prevent infection. 
The purpose of this study is to identify how important is RSV in Kilifi District, and to find out how the virus is transmitted and maintained within the population. Results of both would 
be 
of great value in developing and eventually implementing a vaccine against this disease. 
WHO IS ORGANISING THE STUDY 
The study is organised by the Kenya Medical Research Institute (KEMR1) CGMRC, Kilifi District Hospital (KDH) in collaboration with groups from outside Kenya (Universities 
in 
England) who have specific knowledge of the disease under study. 
YOUR INVOLVEMENT 
You are already enrolled in a Birth Cohort Study of Malaria and Pneumonia (pneumococcal) disease run by KEMRI CGMRC. We are asking you to involve your newly born child in 
another study of pneumonia in which we will monitor the child for infections of the nose and lungs that may be due to RSV. The method of monitoring is EITHER through you bringing 
your child to the hospital when he / she has symptoms of a cold or a chest infection, OR through weekly visits during the outbreaks of these problems (which occur each year) of our 
survey staff to your house to check on the child's health. If you decide to enroll we will record information on your pregnancy, details of your child (weight, length), and household information (location, number of siblings, household details). 
We will monitor your child until the end of year 2004 which is a period of three years 
{insert 2 
years as appropriate). 
If the child has signs of nose or chest infection that might be due to RSV we will collect a 
nasal specimen (fluid from the nose) in which we will check for the virus. If our tests confirm that the child is infected with RSV we will request a small sample of blood (less than half a teaspoon) and saliva soon after and again after 3-4 weeks by which to see how the child's immune defenses are reacting. 
Additionally, every 3 months we will collect a sample of saliva. You have already agreed for blood samples to be collected from your child every three months as part of the malaria and 
pneumococcal pneumonia study. For this RSV study, we would like to use a small amount 
of these blood samples and (where appropriate) we would also like you to continue to bring 
Your child in for 3 monthly blood sampling until the end of the study period. The samples are to look for evidence of the infection. 
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{Where appropriate} We will also ask for a swab from the nose and throat each week in the first year during the main season of RSV, to assist in identifying the disease. 
HOW DO WE COLLECT SAMPLES 
Nasal specimens will be collected by washing out the nasal passage with some harmless fluid. The fluid is squirted into one nostril using a syringe [demonstrate device] and collected 
as it returns through the same or the other nostril. This procedure, conducted by trained 
staff, causes no harm to the infant, and whilst being a little uncomfortable, should clear the 
nasal passage making breathing more easy. 
We collect saliva using a small clean sponge on the end of a plastic stick [show the device]. The sponge is brushed around the teeth and gums for half a minute - like using a toothbrush. This is painless, and without risk. Our staff will show how It is done. 
Blood collection is by trained personnel. We will collect a sample of 2ml as much as will fit In this tube [demonstrate a 2ml tube]. 
(Where appropriate) Nasal and throat swabs are collected using cotton buds on the end of a 
wire support. This brushed against the back of the throat (throat swab [show device]) or Inserted into the nose and brushed against the wall of the Inner nose (nasal swab [show device]). 
RISKS AND BENEFITS OF THE STUDY 
AU of the tests described above (taking blood or collecting fluid from the nose or mouth) are 
commonly used tests in clinics in many countries. They carry no danger for your child. Some 
of the procedures may be slightly uncomfortable, we try to ensure that this Is not a problem by using highly trained staff to perform the tests. 
Your child will benefit from having coughs, chest Infections and fever Investigated more 
quickly than would usually be the case because they are being seen more often. If your 
child is unwell at any time during the study, s/he can attend the research clinic at KDH and 
we will provide, without charge, examination and routine investigations (such as malaria tests) and medications (such a treatment for malaria, chest, skin or ear infections). Throughout the study period if our field worker asks you to attend the clinic with the child because s/he is unwell, or you bring the child to the clinic because you yourself have Identified signs of nose or lung Infection In the child (signs that we will explain), we will refund 
reasonable costs of your return travel fare. Because our funds are strictly limited we can 
only offer these benefits to the child involved in the study. 
The other main benefit of research studies Is in helping to improve understanding of disease, 
which may lead to better ways of preventing and treating these diseases. This benefits 
children and families in Kilifi District as a whole, as well as In other parts of Kenya. 
The samples are sent to the laboratory at Kilifi Hospital where they will be tested to identify If 
your child is infected with RSV, or has had the Infection in the recent past. To protect the 
privacy of your child, we will keep the records of this study under a code number rather than by name. We will keep the records in locked files and only study staff will be allowed to look at them. The name of your child or other facts that might point to him/her will not 
appear when we present this study or publish its results. 
We would also like to store any blood/saliva/nasal washings that are left over after we do 
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your tests. We plan to use these samples for studies we may do in the future. The 
samples will be labeled with a number, not a name, and if further information is required, 
e. g. to identify that this sample comes from your child, this information will only be 
provided to the researchers if the new study has been scrutinised and approved by the 
National Ethical Committee in KEMRI. You can decline to let us store your child's blood 
and saliva for use in other research projects and still be in this study. 
MORE INFORMATION 
Please feel free to ask any questions about the study. You are free to join in the study or 
not. You may also decide to withdraw your child from the study at any time, for any reason. If, after discussing this with us, you decide to allow your child to join the study we would like you to sign this form. 
We have given you a copy of this consent form. When you sign below, it shows that you 
agree to join the study. If there is any part of this form which you do not understand be 
sure to ask questions about it. Do not sign until you have full answers to all your questions. When you are ready to be part of the study, please tick one of the two boxes and print and 
sign your name on the lines below. 
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Consent form for infant cohort study. 
STUDY OF A MAJOR CAUSE OF PNEUMONIA IN KILIFI DISTRICT 
To Mother 
" Have you read, or had read to you, the invitation letter? 
" Have you had an opportunity to ask questions and discuss this study? 
" Have you received satisfactory answers to those questions? 
" Have you received enough information about the study? 
" Do you understand that you are free to withdraw your child from the study 
- at any time 
- without having to give a reason why 
- without affecting your child's access to medical provision 
I wish my child [name] to take part in the study 
QI also give consent for my child's blood/saliva/nasal samples to be stored at KEMRI 
under the conditions above 
I do not give consent for my child's blood to be stored at KEMRI for future research 
Print Name: 
Signature Date 
Household number/registration 
Witness 
I observed the process of consent. The parent/guardian of the prospective participant read 
this form, was given the chance to ask questions, appeared to accept the answers, and 
signed to enroll his/her child in the study. 
Name: 
Signature Date 
The study co-ordinator is Dr James Nokes. If you have any questions about the ethics of 
this study you can contact Dr Charles Mbogo, at KEMRUWellcome Trust, Kilifi District 
Hospital or telephone Kilifi 22535. 
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Appendix C: Information and consent form for household study participants. 
HOUSEHOLD STUDY OF A MAJOR CAUSE OF PNEUMONIA IN 
KILUF1 DISTRICT 
Information and consent form. 
PURPOSE OF STUDY 
Chest infections are one of the biggest health problems for children in Kilifi District. We know the cause and the right treatment for many of these, but in some cases this is not yet known. We are investigating an infection caused by a germ (virus) that is known to be a major cause 
of chest infections throughout the world. The virus is called Respiratory Syncytial Virus or RSV. For infants who are infected in their first year of life the symptoms can be severe 
enough for the parents to feel a need to take the child to hospital. This condition is distressing both to the infant and to the family, although is rarely life threatening. In older 
children and adults the infection is usually less severe. There are no drugs in routine use for 
reducing the symptoms, and currently no vaccine to prevent infection. However, much work is being carried out to develop a vaccine to prevent infection. 
The purpose of this study is to identify how important is RSV in Kilifi District, and to find out how the virus is transmitted and maintained within the population. Results of both would be of great value in developing and eventually implementing a vaccine against this disease. 
WHO IS ORGANISING THE STUDY The study is organised by the Kenya Medical Research Institute (KEMRI) CGMRC, Kilifi District Hospital (KDH) in collaboration with groups from outside Kenya (Universities in England) who have specific knowledge of the disease under study.. 
YOUR INVOLVEMENT 
Your newborn child has been recruited into a study of pneumonia in which we will monitor the child for infections of the nose and lungs that may be due to RSV. There will eventually be around 600 other newborns in this study from Kilifi District. The method of monitoring your child is EITHER through you bringing your child to the hospital when he / 
she has symptoms of a cold or a chest infection, OR through visits every month at least and weekly during the outbreaks of the virus (which occurs each year) of our survey staff to your house to check on the child's health. We are now askin you and your whole famil, 
are under 15 years of ae. Will be monitored in the same way (mentioned above) as the infant. In addition as for your infant we will request routine saliva samples from all 
This study will continue until the end of year 2004, that is, a period of up to two years. 
During this period if any of your children (those under 15 years) has signs of nose or chest infection that might be due to RSV we will collect a nasal specimen (fluid from the nose) in which we will check for the virus. If our tests confirm that the child is infected with RSV we will request a small sample of blood (less than half a teaspoon) and saliva soon after and again after 3-4 weeks by which to see how the child's immune defenses are reacting. We will also increase the number of oral-fluid samples collected over the next 3 months, with a 
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sample every week. These samples will assist in understanding how you develop your 
protection to RSV infection. 
{if appropriate} From 40 of the 70 households recruited we will ask to take blood samples 
the saliva results Before taking any such blood we will remind you about why it is required. 
(households selected for intensive sampling) Firiallysome of your household (this will be known by the field worker at that time) will be requested to be involved in an intensive 
study of oral fluid At the time of this study we will ask for one oral-fluid sample and for the subsequent 13 weekly visits This will assist us to understand more accurately how each person responds to RSV infection and re-infection 
HOW DO WE COLLECT SAMPLES Nasal specimens will be collected by washing out the nasal passage with some harmless fluid. The fluid is squirted into one nostril using a syringe [demonstrate device] and collected as it returns through the same or the other nostril. This procedure, conducted by trained staff, causes no harm to the infant, and whilst being a little uncomfortable, should clear the nasal passage making breathing more easy. 
We collect saliva using a small clean sponge on the end of a plastic stick [show the device. The sponge is brushed around the teeth and gums for half a minute - like using a toothbrush. This is painless, and without risk. Our staff will show how it is done. 
Blood collection is by trained personnel. We will collect a sample of 2ml as much as will fit in this tube [demonstrate a 2ml tube]. 
RISKS AND BENEFITS OF THE STUDY All of the tests described above (taking blood or collecting fluid from the nose or mouth) are commonly used tests in clinics in many countries. They carry no danger for you or your children. Some of the procedures may be slightly uncomfortable; we try to ensure that this is not a problem by using highly trained staff to perform the tests. 
Your children will benefit from having coughs, chest infections and fever investigated more quickly than would usually be the case because they are being seen more often. If your children are unwell at any time during the study, they can attend the research clinic at KDH and we will provide, without charge, examination and routine investigations (such as malaria tests) and medications (such as treatment for malaria, chest, skin or ear infections). Throughout the study period if our field worker asks you to attend the clinic with a child because s/he is unwell, or you bring the child to the clinic because you yourself have identified signs of nose or lung infection in the child (signs that we will explain), we will refund reasonable costs of your return travel fare. Because our funds are strictly limited we cannot afford to provide this service for anyone who is not in the study. 
The other main benefit of research studies is in helping to improve understanding of disease, which may lead to better ways of preventing and treating these diseases. This benefits children and families in Kilif District as a whole, as well as in other parts of Kenya. 
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WHAT HAPPENS TO THESE SAMPLES AND THE INFORMATION COLLECTED 
The samples are sent to the laboratory at Kilifi Hospital where they will be tested to identify if 
your child(ren) is infected with RSV, or has had the infection in the recent past. To protect the privacy of your family, we will keep the records of this study under a code number 
rather than by name. We will keep the records in locked files and only study staff will be 
allowed to look at them. The names of your family members or other facts that might point to them will not appear when we present this study or, publish its results. 
We would also like to store any blood/saliva/nasal washings that are left over after we do 
your tests. We plan to use these samples for studies we may do in the future. The 
samples will be labeled with a number, not a name, and if further information is required, e. g. to identify that this sample comes from your child, this information will only be provided to the researchers if the new study has been scrutinised and approved by the National Ethical Committee in KEMRI. You can decline to let us store leftover blood and 
saliva samples for use in other research projects and still be in this study. 
MORE INFORMATION 
Please feel free to-ask any questions about the study. You are free to join in the study or not. You may also decide to withdraw from the study at any time, for any reason. If, after discussing this with us, you decide to allow your family to join the study we would like you to sign this form. 
We have given you a copy of this consent form. When you sign below, it shows that you agree to join the study. If there is any part of this form which you do not understand be sure to ask questions about it. Do not sin until you have full answers to all your questions. When you 
are 
ready to be part of the study, please tick one of the two boxes and print and sign your name on the lines below. 
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Appendix D: Information and consent form for Adults in the Household study. 
HOUSEHOLD STUDY OF A MAJOR CAUSE OF PNEUMONIA IN KILIFI 
DISTRICT 
Information and consent form for Adults 
,. 
ý_ 
PURPOSE OF STUDY 
As you know we are investigating an infection caused by a germ (virus) that 
is known to be a 
major cause of chest infections throughout the world. The virus is called Respiratory 
Syncytial 
Virus or RSV. For infants who are infected in their first year of life the symptoms can 
be severe 
enough for the parents to feel a need to take the child to hospital. This condition 
is distressing 
both to the infant and to the family, although is rarely life threatening. In older children and 
adults the infection is usually less severe. There are no drugs in routine use 
for reducing the 
symptoms, and currently no vaccine to prevent infection. However, much work 
is being carried 
out to develop a vaccine to prevent infection., 
The purpose of the household study in which you are already involved 
is to identify who is 
bringing the infection into the home. Results of this would be of great value in protecting the infant in whom (as stated above) this infection is most dangerous. 
YOUR ADDITIONAL INVOLVEMENT 
Your whole fam been recruited into the household study of RSV. 
In this study your 
children those of whom are under 15 years of age are monitored by EITHER you 
bringing 
your children to the hospital when they have symptoms of a cold or a chest 
infection, OR 
through visits every month at least and weekly during the outbreaks of the virus 
(which occurs 
each year) of our survey staff to your house to check on your children's 
health. We are also 
taking saliva samples from all members of your family every three months. 
We are now 
Inviting older members within the family to be involved in a similar monitoring system. 
Durincl 
this period if you (or other adult famil member) have signs of nose or chest infection 
that 
mi ht be due to RSV we will col ect a nasal specimen fluid from the ose) 
in which we will 
check for the virus, If our tests confirm that you (or other family member) are 
infected with 
r,. -a -r 
This study will continue until the end of year 2004. 
HOW DO WE COLLECT SAMPLES Nasal specimens will be collected b washing out the nasal passage with some 
harmless fluid. 
The fluid is squirted into one nostril using a bulb syringe [demonstrate device] and collected as it returns through the same or the other nostril. This procedure, conducted by trained staff, causes no harm to the infant, and whilst being a little uncomfortable, should clear the nasal passage making breathing more easy. 
RISKS AND BENEFITS OF THE STUDY All of the tests described above (taking blood or collecting fluid from the nose or mouth) are commonly used tests in clinics in many countries. They carry no danger 
for you. Some of the 
procedures may be slightly uncomfortable; we try to ensure that this is not a problem 
by using 
highly trained staff to perform the tests. 
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You will benefit from having coughs, chest infections and fever investigated more quickly than 
would usually be the case because you are being seen more often. If you are unwell at any time during the study, you can attend the research clinic at KDH and we will provide, without 
charge, examination and routine investigations (such as malaria tests) and medications (such 
as treatment for malaria, chest, skin or ear infections). Throughout the study period if you 
present at the clinic because you have identified signs of nose or lung infection in the child (signs that we will explain), we will refund reasonable costs of your return travel fare. Because 
our funds are strictly limited we cannot afford to provide this service for anyone who is not in the 
study. 
The other main benefit of research studies is in helping to improve understanding of disease, 
which may lead to better ways of preventing and treating these diseases. This benefits children 
and families in Kilifi District as a whole, as well as in other parts of Kenya. 
WHAT HAPPENS TO THESE SAMPLES AND THE INFORMATION COLLECTED 
The samples are sent to the laboratory at Kilifi Hospital where they will be tested to identify if 
you are infected with RSV, or have had the infection in the recent past. To protect your privacy, 
we will keep the records of this study under a code number rather than by name. We will keep the records in locked files and only study staff will be allowed to look at them. Your 
name or that of any family members or other facts that might point to them will not appear 
when we present this study or publish its results. 
We would also like to store any specimens that are left over after we do your tests. We plan to use these samples for studies we may do in the future. The samples will be labeled with a 
number, not a name, and if further information is required, e. g. to identify that this sample 
comes from your child, this information will only be provided to the researchers if the new 
study has been scrutinised and approved by the National Ethical Committee in KEMRI. You 
can decline to let us store leftover blood and saliva samples for use in other research projects 
and still be in this study. 
MORE INFORMATION 
Please feel free to ask any questions about the study. You are free to join in the study or not. You may also decide to withdraw from the study at any time, for any reason. If, after discussing this with us, you decide to allow your family to join the study we would like you to 
sign this form. 
We have given you a copy of this consent form. When you sign below, it shows that you 
agree to join the study. If there is any part of this form which you do not understand be sure to 
ask questions about it. Do not sign until you have full answers to all your questions. When 
you are ready to be part of the study, please tick one of the two boxes and print and sign your 
name on the lines below. 
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Appendix E: Information and consent form for RSV Study extension. 
STUDY EXTENSION 
STUDY OFA MAJOR CAUSE OF PNEUMONIA IN KILIFI DISTRICT 
Why we are here 
Your family (yourself and your children) are involved in a study of a germ (known as RSV) that is known to be a major cause of chest infections throughout the world. We would first like to thank you for 
Your involvement up to now. 
From our study we now know that RSV is a serious problem in Kilifi. For example, we found that 1 
in 
100 children in the study were admitted to Kilifi District Hospital (KDH) through RSV infection in the first year of life. 
We originally asked you to participate for the first two years of your child's (the index) life. This was 
in 
order to learn more about infections in the children's first and second years of life how they get infected. However, in the first year (2002) fewer of the 300 children that we were following were infected than we 
expected. We therefore would like to continue to monitor children and therefore your family for another RSV season, that is expected next year (2005). 
What are we asking for We are therefore inviting you and your children to continue to participate in the study for another year, 
which is until October 2005 at the latest. 
What changes come with continued participation If you agree to continue to participate there is no change in the way you and your family participate or the 
compensation that we offer. 
In summary; 
" We will make house visits every week during the RSV germ season (first half of year) when it is 
known to cause more illness in community, and monthly otherwise. You are encouraged to take 
your children {or yourself) to the Out-Patient research clinic at KDH if there are signs of nose or 
chest infection. 
" If your children {or yourself) have signs of nose or chest infection that might be due to RSV we 
will collect a nasal specimen (fluid from the nose) in which we will check for the virus. 
" If our tests confirm that {you or} your child(ren) is infected with RSV we will request a small 
sample of blood (less than half a teaspoon) and saliva soon after and again after 3-4 weeks 
by 
which to see how the child's immune defences are reacting. 
" Additionally, every 3 months we will collect a sample of saliva. 
" If your child is participating in the pneumococcal pneumonia study (Kilifi Birth Cohort) and you 
have agreed to allow us to use a small amount of the blood collected every 3 months, we ask you 
to continue providing this sample for a third year. The blood and saliva samples are to look for 
evidence of infection that we have missed by our observation. 
If you would like us to go over the details of your involvement, how we collect samples, what we do with 
them and the risk and benefits of participation then please say so. 
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More information 
Please feel free to ask any questions about the study. You are free to join in the study or not, and may also withdraw your child from the study at any time, for any reason. If, after discussing this with us, you decide to allow your child to continue to participate in the study we would like you to sign this form. 
We have given you a copy of this consent form. When you sign below, it shows that you agree to join the study. If there is any part of this form which you do not understand be sure to ask questions about it. Do not sign until you have full answers to all your questions. When you are ready to be part of the study, please tick one of the two boxes and print and sign your name on the lines below. 
Consent form for household study. 
STUDY OF A MAJOR CAUSE OF PNEUMONIA IN KILIFI DISTRICT 
To Mother/Father 
" Have you read, or had read to you, the invitation letter? " Have you had an opportunity to ask questions and discuss this study? 
" Have you received satisfactory answers to those questions? 
' Have you received enough information about the study? 
" Do you understand that you are free to withdraw from the study 
- at any time 
- without having to give a reason why 
- without affecting your child's access to medical provision 
I 'Wish my family to continue to participate in the study 
Print Parents Name: 
Print Parents Name: 
Child name Child name 
Child name 
Child name 
Child name 
Child name 
Child name Child name 
Child name Child name 
Signature Date 
Witness 
I observed the process of consent. The parent/guardian of the prospective participant was read 
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this form, was given the chance to ask questions, appeared to accept the answers, and signed 
to enroll his/her child in the study. 
Name: 
Signature Date 
The study co-ordinators are Dr James Nokes and Emelda Okiro. If you have any questions 
about the ethics of this study you can contact Dr Charles Mbogo, at KEMRI/Wellcome Trust, Kilifi District Hospital or telephone Kilifi 22535. 
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RSV Active surveillance 
Notes to the FW for completion of the active surveillance form 
Before you dart 
(i) Obtain list of children to be visited today + details of how to locate 
(ii) Identify which of them have previously had a nasal washing in the last two weeks, and the 
lab result. 
(iii) fill out date of active visits at top of the active surveillance form and date of next 
appointment (1 week or I month). 
(iv) Check to take adequate materials/supplies for blood slides, nasal washings, and referrals. 
At the house of the child 
1. Remember to introduce yourself to the family/mother/head of household and identify 
yourself as from KEMRI for the RSV study. Remember to always be polite and to respect the 
wishes of the family. 
2. Enter child's KBC# and NAMEs/SEX - take care to be accurate 
MALARIA 
FLWK - Ask mother if her child has had fever - hot body - in the last 7 days. This includes 
today. 
TEMP - take axillary temperature using a Becton-Dickinson Thermometer (BD, New Jersey, USA) and record here. 
Actions to take on the basis of these details are given in the manual. 
NASAL WASHING 
RSV2w - record here if child has had positive (see scenarios) RSV specimen in last 2 weeks. If so then we will not collect a further nasal washing today 
BDWK / KEYWK - Now check mother for occurrence of 
difficulty in breathing and which of 
the key signs she has observed in her child over the last 7 days (including today). Note these 
are mother's observations, not the FW. 
BDOBS / KEYOB - Observe child and record if s/he 
has difficulty in breathing now (allow 
child to settle before making observation). Observe child and record which of the key signs 
you can observe now (ie nasal discharge/congestion = dc; cough = c; hot body ie fever, =J). 
Note that these are FW observations, not what the mother indicates. Note that today, the 
mother could indicate the child has fever, but on inspection the FW cannot identify this. Hence 
record f for question KEYWK, but do not include f against KEYOB. One instance where 
this is different: the mother may indicate the child has a cough this day of observation, but you do not hear a cough. In this instance we assume the mother is correct since you may not be 
present long enough to hear a child cough. 
NWREQ 
-A nasal washing is required if (at least) the following are 
indicated by either the 
mother OR the FW observation (i) the child has difficulty in breathing (db) OR 
(ii) the child 
has nasal discharge / congestion (dc), OR (iii) the child has cough (c). IMPORTANT - note 
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that these observations should be co-occurring to merit NW collection, i. e. it would not count 
if the mother observed a cough one day and hot body on another). 
If NW required then carefully follow instructions in manual for collection. 
REFERRAL 
Brate - record the breathing rate as accurately as possible. Ensure child has settled before 
recording. 
Assess if child has fast breathing (rate is 50 or more per minute, OR rate is 40 or more and child 
is older than one year ie 12 months or more in age). 
Should remind mother of key signs and difficulty in breathing to decide when to bring child in 
again. 
REFER - if child has fast breathing for age AND cough OR 
difficulty in breathing, then refer 
the child to the OP clinic for review (complete referral note in RSV exercise book), and 
provide mother with single journey bus fare to clinic. Emphasise that the mother should take 
the child today. 
OTHER 
AWAY - ask mother if the child has been out of the District since the last visit and, 
if yes, for 
how many FULL weeks. 
319 
Appendix G: Field Work Procedures 
The following is the series of field study processes. It includes all the assessments of symptoms 
carried out in during active and passive surveillance and actions required (flow diagrams) details 
of which formed part of the Field worker manual not included in this thesis. Following these are 
the procedures for sample collection (nasal, oral-fluid and blood) used during the study. 
Details of Flow Diagrams Included 
RSV Active surveillance - weekly home visits by Field workers 
Flow diagram 1- Assessment for fever and the requirement of blood slide (p 331) 
Flow diagram 2- Assessment for respiratory signs and nasal wash requirement (p 332) 
Flow diagram 3- Assessment for referral due to respiratory disease (p 333) 
Follow-up visits 
Flow diagram 4- Review for fever on last visit (p 334) 
Flow diagram 5- Review for nasal wash result (p 335) 
Out Patient Clinic Visits 
Flow diagram 6- Out patient clinic visit (p 336) 
Standard Operating Procedures for Sample collection 
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Weekly visits by field worker to households 
This is the main component of active surveillance of the study. On each visit the following 
assessments should be followed and prescribed actions taken (see appended flow diagrams). 
Appended also is an ACTIVE surveillance form that should be completed (notes accompany this 
form). 
1. FEVER ASSESSMENT - IS A BLOOD SLIDE REQUIRED? See flow diagram p 331 
If the child's measured temperature is raised >37.49°C: Take TWO malaria slides 
and spot blood onto one filter paper, Complete TWO active surveillance forms. Give 
one slide and one form to the mother and take one back to the Unit. In addition, refer 
mother to study clinic (using exercise book) and issue one-way bus fare. Arrange to 
review child with result of film whether film +/-. 
" If history of fever during last 7 days but measured temperature not raised: Take 
ONE malaria blood film and spot blood onto filter paper and take back to Unit for 
reading. Arrange to review child the following day only if film result is positive. 
2. RESPIRATORY INFECTION - IS A NASAL SPECIMEN REQUIRED? - See flow 
diagram G2 p 332 
if the child was POSITIVE for RSV within the last 2 weeks (14 days) - no action is 
required, review next week. 
" if NEGATIVE (or EQUIVOCAL) for RSV over last 2 weeks - the following questions 
must be asked: 
i) "Does your child have difficulty in breathing OR nasal-discharge/congestion 
OR cough today OR fever+ cough/nasal discharge? " Answer Y or N. 
ii) "Has he/she had difficulty in breathing OR any of the key symptoms since the 
last visit? " Answer Y or N 
If the answer to question i) is "i" a nasal specimen should be collected. 
If the answer to question ii) is "Y" find out if the child has already had a nasal washing since the 
last visit. If not then a nasal sample should be collected. 
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Difficulty in breathing - signs 
- nasal flaring 
- use of accessory muscles, eg neck muscles 
- indrawing (sucking in of lower bony chest wall on inspiration) 
The key symptoms you need to be able to identi are: 
Difficulty in breathing; cough (less than 30 days); fever (hot 
body or axillary >37.49C); nasal congestion/ discharge 
If a nasal sample is collected then: 
" Request that the mother monitors the child's health and if it does not improve or deteriorates 
(ie any of the symptoms worsen) then she should seek medical help from a local clinic or 
KDH. 
" The nasal specimen should be transported back to the lab AS SOON AS POSSIBLE. 
3. ACUTE RESPIRATORY DISEASE - IS REFERRAL REQUIRED? See Flow diagram 
G3 p 333 
" Does the child have COUGH (for less than 30 days) or BREATHING DIFFICLTY and 
does the child have FAST BREATHING? 
If the answer is "Y" 
" The child should be referred to KDH research clinic for assessment. Issue referral note and 
one way bus fare to the clinic. 
"A nasal washing should be taken, unless the child (i) has given a nasal wash nasal wash 
already this day OR (ii) was RSV positive within the last 2 weeks (14 days) 
Consider a child to have fast breathing if., 
breathing rate is 60 AND age <2 months 
breathing rate is z 50 AND age < 12 months 
OR 
breathing rate is z 40 AND age ý 12 months 
(modification of WHO guidelines) 
* You need to be able to accurately assess breathing rate. 
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Monthly visits of field worker to households 
This activity is primarily to support the passive surveillance component of the study. 
During each monthly visit, the field worker will revisit the signs indicative of RSV infection 
with the mother as a general reminder of the study. The mothers will continuously be 
encouraged to present to KDH with an infant who has breathing difficulty or any two or more of 
the key symptoms (described earlier) consistent with RSV infection. 
In addition, the three assessments made during weekly visits will also be carried out (as 
described above) ie, 1. Fever assessment - is a malaria slide required? 2. Respiratory infection - 
is a nasal specimen required? 3. Acute respiratory disease - is referral required. (note: read 'last 
week' for'last visit'). 
Oral-fluid will be collected every three months throughout the study period. In some instances 
venous blood will also be collected at the same time. 
Passive visits or Active referral to the OP Clinic 
Infants may be brought to the OP Clinic by parents either as part of the passive referral 
procedure or after referral from the field for one reason or another. Having ascertained the 
reason why the child is presenting, the relevant clinic form should be completed, and child 
reviewed by clinical officer (CO). See appended 'RSV study sick child clinic visit' form. 
Child follow u 
1. CHILD WITH FEVER - see flow diagram G4 p 334 
ARRANGEMENTS FOR FOLLOW UP AND TREATMENT 
" All malaria slides will be examined at the unit on the same day. 
All children with positive slides OR children with current fever (>37.49C) should 
be reviewed the next day. If a child seen at routine follow-up has a measured fever 
>37.49°C s/he will be expected at the clinic the following day. If they attend clinic they 
will receive definitive assessment and treatment. Active surveillance hospital form will 
be completed in clinic. If they fail to attend the clinic as arranged, they should be 
reviewed in the field the next working day. 
Review in the field 
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Slide positive 
" Measure temperature and completed follow-up section of form. 
" Administer malaria drugs. 
" Advise parents that they must take the child to a clinic (preferably KEMRI) or other 
outlet if s/he deteriorates or fails to improve within 1-2 days. 
" Make it clear that if the family chooses to bring the child to KEMRI clinic, the fare will 
be refunded. 
0 Visit routinely the following week/month according to time of year. 
Slide negative 
" If child no longer gives history of fever and is improving - no further action. 
" If child remains unwell or febrile (either measured or on history) -repeat slide and 
filter paper and refer to KEMRI OPD (issue one-way bus fare). 
2. CHILD GIVING NASAL SPECIMEN - see flow diagram G5 p 335 
" If a nasal washing was RSV negative then the result is reported to the mother at the next 
visit. 
" If the nasal washing result is RSV positive or equivocal, the field worker will be required to 
revisit the child AS SOON AS POSSIBLE to collect (i) acute blood (2ml) (ii) oral-fluid and 
(iii) make an appointment to return after one month to collect convalescent blood and oral 
fluid. 
3. CHILD REFERRED WITH ACUTE RESPIRATORY DISEASE - see flow diagram G6 p 
336 
At the OPD research clinic, a clinical officer will review the child. 
If symptoms of ARI are serious involving risk or danger signs indicative of severe or v. 
severe pneumonia, the child will be admitted to Ward 1. 
" If symptoms of ARI are moderate or mild, then home (symptomatic) treatment will be 
recommended. Request that the mother monitors the child's health and if it does not 
improve or deteriorates (any of the symptoms worsens) then she should seek medical help 
from a local clinic or KDH. A review will be made by the field worker at the following 
visit. 
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A note on making appointments 
Mothers will be bringing their infants/children in to KDH for routine 3 monthly blood sampling 
as part of the main cohort and for vaccination appointments at the MCH clinic. Wherever 
possible make RSV appointments at the research clinic rather than at the home to coincide with 
these visits. 
Accuracy in data collection and storage of samples 
Accuracy in data collection is a top priority. The following are some simple guidelines: 
" Label all bottles and tubes for saliva, nasal and blood collection BEFORE TAKING A 
SAMPLE - it is easy to forget to label materials in the noise and confusion of sample taking. 
All samples should be labelled with the individual's name, serial number and the date of 
collection of the sample. 
" Make every effort to return collected specimens to the research unit as quickly as possible, 
maintaining cold conditions as required. 
" Complete forms and questionnaires carefully. Complete all sections required. Do not be 
hurried. Do not make assumptions about answers elicited - if unsure, return to the question 
and ask again. 
" Be methodical in your actions. Make sure you are clear exactly what you intend to do before 
arriving at the household. 
On return to the unit (i) go through the forms to ensure that there are no blatant mistakes and 
hand in the forms to the field co-ordinator. (ii) Relate all the problems encountered in the 
field to the field co-ordinator and also note them down for discussion. (iii) Enter data onto 
computer, or provide to data entry clerk, as soon as you can, (iv) enter kbc# into day book in 
OP clinic of individuals from whom nasal washing s have been collected (update this as and 
when the NW result is known, and make appointments as necessary)/ 
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Sample Collection Procedures 
Temperature recording 
All temperatures will be taken from the armpit (axillary temperatures) using a Becton- 
Dickinson Digital Thermometer (New Jersey, USA). Do not round off the figures on the 
thermometer but record it as it is on the forms. 
Recording breathing rates 
Defined as the number of breaths per minute. Obtained by observing the frequency of 
inspiratory phase over 30 seconds then multiply by 2. 
Collecting nasal specimens 
(i) Nasal washing using blue bulb - observe short video presentation 
1. Requirements 
" RSV sample/screen form 
" Normal saline 
" Ioz (30m1) Davol bulb syringe (Abbort, Ashland, Ohio-USA) 
" Collection bijou/universal/medicine cup 
" Marker pen 
" Disposable gloves/paper towel. 
2. Procedure 
2.1 Wash hands (if possible) and replace gloves 
2.2 Explain procedure to the mother/carer 
2.3 Pour required quantity of saline into collection container - 
child <6m 5m1 
child 6-11 m 7m1 
child 12+m lOml 
child >5yr 15m1 
adult 20m1 
label with date, name and KBC or RSV number. 
2.4. Have the mother hold child from behind in upright position and stabilize head (neutral or 
slightly extended) 
2.5 Suction saline into bulb. Insert bulb into one nostril (holding bulb horizontally) until 
pares occluded (you should be firm and deform the nose slightly). Hold collection container 
under other nostril Tip bulb slightly towards patient, instill firmly all fluid into nose using 
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thumb action. Fluid should eject from other nostril. Suction residual mucus from both 
nostrils into the bulb syringe and mix with the saline. Transfer residual fluid from bulb into 
collecting container. 
2.6 If no or little fluid emits from other nostril, or if less than 1 ml of fluid recovered, 
replenish fluid to correct amount (see above) in container, suck into bulb, and repeat 
procedure in alternative nostril. 
IMPORTANT: It is crucial that you make every effort to have fluid pass out of the 
alternative nostril. In this way we know fluid has gone to the nasopharynx where the virus 
replicates. 
2.7 Dispose of gloves and wash hands. 
3. Storage of specimens 
3.1 Immediately after collection, and securing screw cap lid tightly, put the specimen 
in the 
icebox. Transport to lab as soon as possible 
3.2 Complete Microbiology request form. 
IMPORTANT: Contamination between containers, syringes used to withdraw saline, gloves, 
and bulbs, should be avoided. We will be using very sensitive techniques to detect the virus 
and any contamination will be detectable. So, DO dispose of gloves, and store separately 
used bulbs, after each procedure, make sure lids of vials are in firmly, DO NOT reuse 
bijous/universals. 
Oral fluid collection 
1. Requirements 
" RSV sample/screen form 
" Indelible marker pen 
" Disposable gloves and paper towel 
" ORACOL collection device (Malvern Medical Developments, Worcester, UK) 
2. Procedure 
2.1 Wash hands and replace gloves 
2.2 Explain procedure to the mother/carer 
2.3 Remove ORACOL device from covering and transport tube 
2.4 Holding by stick rub sponge gently but firmly around gums (front and back, upper and 
lower, including base) for 1 minute. 
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IMPORTANT - the sponge must be fully saturated with oral 
fluid and so one minute of use 
is required. 
2.5 Replace device into stoppered tube (sponge at bottom), label with KBC number, 
date, 
`RSV-NO'. 
2.6 Dispose of gloves and wash hands 
3. Storage of specimens 
3.1 Immediately after collection, put the specimen in the icebox. 
Transport to lab as soon as 
possible 
3.2 Complete Microbiology request form. 
Collecting venous blood 
1. Venepuncture 
1.1 Explain procedure to parent/guardian. 
1.2 Ask the mother/guardian to help you hold the child. 
1.3 Select an appropriate site and apply a tourniquet beyond. 
1.4 Clean the site with spirit and leave to dry. 
1.5 Identify vein visually or by palpation and introduce the needle or 
butterfly. 
1.6 Withdraw blood. 
1.7 Apply swab, press firmly and withdraw needle/butterfly. 
1.8 Check that there is no bleeding from the VP site. 
Problems 
Inability to draw blood? 
" Needle not in the vein (commonest). 
" Needle in vein but not properly positioned. 
"A clot may be blocking the needle. 
' Syringe may be leaking. 
Risks of taking blood 
To Fieldworker 
Accidental needle stick injuries may transmit diseases like HIV, Hepatitis. 
To 
- Pain at the VP site 
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- Bleeding and swelling of the VP site. 
- Infection at VP site which may spread elsewhere. 
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Appendix H: Sick child clinic visit questionnaire 
RSV STUDY - SICK CHILD CLINIC VISIT QUESTIONNAIRE 
FIELD WOKER 
complete page 1+ record Oxygen Sat/Pulse/Weight/Axillary temp on page 2 
KBC# [][][]j][] 
RSV# [][)j] 
Child Name [][)[] 
Date of Birth [ ][ ]/[ ][ ]/[ ][] dd/mm/yy 
Date today [ ]j ]/[ ][ ]/j ][] dd/mm/yy 
Visit type [] active (referral by FW) [] passive (self-referral) - Tick one box 
IFACTIVE REFERRAL (le referred by FWfrom home) - Refer to clinician to complete 
only pages 2-3 
IF PASSIVE REFERRAL (ie mother self referred) - FW complete the below 
1. Ask mother - has child had a fever in the last 7 days? 
[] y/n 
2. Has the child a temperature >37.49C (see page 2) [] y/n 
If either 1 or 2 is 'yes' then do blood slide. 
3. Blood slide taken [] y/n 
4. Blood slide result +/- 
5. Ask mother - has the child had difficulty in breathing in last 7 days? [] y/n 
6. Ask mother - which of the key symptoms in the last 7 
days? [ ] 
7. Observe the child to have difficulty breathing today? [] y/n 
8. Observe which key symptoms today ?[ l 
9. Is a nasal washing required? [I y/n 
10. NW time [ ][ ]: [ ][ J hh: mm, 
11. NW result [I +/- 
12. Breathing rate (cycles / min) [J [ 
13. Does child have fast breathing for age [] y/n 
14. Refund single (whole shillings) [ ][ ] ksh 
Key symptoms: cough c, fever f, nasal discharge/congestion dc 
Now refer child to clinician ........ next page 
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To be completed by CLINICIAN 
HISTORY 
How long has the child been sick? ........................................ ............... 
[ ][ ] DAYS 
What is/are the main problems? (Please answer Y/N) 
FEVER 
............................ .......................................... 
[ 
COUGH 
.............................. ............................................. 
[ 
RUNNING NOSE/NASAL DISCHARGE/NASAL CONGESTION......... [ 
DIFFICULTY IN BREATHING .................................................... 
[ 
OTHERS(specify below ................................... 
[ 
PHYSICAL EXAMINATION 
OXYGEN SATURATION [ if ]1 1% 
AXILLARY TEMPERATURE [][]"[][ )c 
WEIGHT [][ ]" [J[] kg 
HEART RATE [][][ ]/min 
COUGH HEARD I ]YIN 
HOARSENESS t) YIN 
SORETHROAT I Y/N 
RHINITIS '} YIN 
PHARYNGITIS II Y/N 
CYANOSIS I] Y/N 
EAR INFECTION [] Y/N 
CONJUCTIVITIS [] YIN 
PROSTRATED [) Y/N 
RESPIRATORY RATE [][ ]/min 
NASAL FLARING L] YIN 
INDRAWING [] YIN 
CRACKLES [] YIN 
WHEEZES [] YIN 
FW to 
complete 
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STRTDOR 
DIAGNOSIS 
Indicate if any of these: LRTI / URTI 
Bronchiolitis 
pneumonia - mild / severe I 
V. severe 
PLAN 
TREATMENT 
I Y/N 
*Nasal washing required y/n [ 
Admit child y/n [ 
* Note: Request nasal washing (NW) if (i) child has nasal discharge/congestion OR (ii) cough + fever OR (iii) difficulty in breathing OR (iv) has any of 
respiratory disease diagnoses given above"AND FW has not already taken NW. 
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Notes to the FW for completion of the RSV cohort child visit proforma 
The FW is to enter information on pages 1. 
Also the FW will record (i) Oxygen saturation (ii) Axillary temperature, (iii) Weight, 
(iv) Pulse, and enter these measurements on page 2 of the form. 
Page 1 
COHORT NUMBERS 
Record KBC and RSV numbers - take care to ensure accuracy. 
CHILD DETAILS 
Record other child details - names and date of birth - accurately. 
DATE TODAY 
Record date of interview/visit 
REFERRAL type 
Record 'ACTIVE' if this is a referral by FW from child's home. Record 'PASSIVE' if mother/child self-referred to clinic. 
If ACTIVE, then (having taken measurements for page 2) pass child onto clinician 
for medical review (page 1 will have been collected at the child's home). If PASSIVE, then complete remaining part of page 1. 
PASSIVE visit 
1. Ask mother if her child has had fever - hot body - in the last 7 days. This 
includes 
today. 
2. Answer'y' if the temperature is 37.5C or more. If answer to 1. or 2. is'y' then take a malaria blood slide. 
3-4. Answer these questions relating to collection of blood slide and recording result. 
5-6. Now check mother for occurrence of difficulty in breathing and which of the key signs she has observed in her child over the last 7 days (including today). Note 
these are mother's observations, not the FW. Note that today, the mother could indicate the child has fever, but on inspection the FW cannot identify this. Hence 
record 'f for question 6, but do not include in the answer to question 8. 
7-8. Observe child and record if s/he has difficulty in breathing now (allow child to 
settle before making observation). Observe child and record which of the key signs 
you can observe now (ie nasal discharge/congestion = dc; cough = c; hot body ie fever, = f. Note that 7-8 are FW observations, not what the mother indicates. 
9. A nasal washing is required if (at least) the following are indicated by either the 
mother or the FW observation (i) the child has difficulty in breathing (db) OR (ii) 
the child has nasal discharge/congestion, OR (iii) the child has fever + cough. 
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10-11. Complete if nasal washing is required. Make sure the sample is properly 
labelled and sent to Micro lab with request form. 
12. Record breathing rate as accurately as possible. Ensure child has settled before 
recording. 
13. Assess if child has fast breathing. 'y' if rate is 50 or more per minute. 'y' if rate is 
40 or more and child is one year or older ie 12 months or more in age. 
Should remind mother of key signs and difficulty in breathing to decide when to 
bring child in again. 
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Appendix I: Limitation on provision of services 
RSV COHORT STUDY 
LIMITATIONS ON PROVISION OF SERVICES 
CHILDREN PRESENTING TO OPD CLINIC - POSSIBLE SCENARIOS: 
I. Child presents with symptoms/signs consistent with an acute respiratory 
infection (upper or lower) as defined by study*. 
ACTION: (i) review by CO, (ii) free treatment#, (iii) refund travel cost®. 
2. Child presents with fever only (which is consistent with malaria) 
ACTION: (i) review by CO, (ii) blood film as appropriate, (iii) free treatment, 
(iv) refund travel cost. 
3. Child presents with other illness e. g. eye/ear infection, wounds, scabies, 
jaundice, oral thrush etc. 
ACTION: (i) review by CO, (ii) free treatment (iii) NO travel fare refund. 
4. RSV child is accompanied by a sick sibling, or mother is sick and not in HH 
study. 
ACTION: (i) review by CO (ii) prescription/treatment paid for by the mother, 
(iii) NO travel fare refund (not applicable if RSV child is sick also). 
S. RSV child, on being seen by the clinician, is referred to the ward. 
ACTION: the study will not cover any additional costs that may result. 
Definitions: 
*History ofARLsymptoms - Difficulty in breathing, nasal discharge/congestion 
OR 
cough + fever. However, in practice, any sign of respiratory infection is sufficient 
to merit free treatment and travel costs. 
#Free treatment - free provision of prescribed drugs routinely dispensed 
from OPD. 
If the required drug is not available at OPD, the mother is advised that she will have 
to pay for the drug, or she can take an alternative (less appropriate) drug from OPD 
free of charge. 
@Travel cost - reasonable return travel fare. 
Any dý ifficulties contact: Emeida Okiro (x126/107) or James Nokes (x131) 
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1. Laboratory Procedures Appendices 
The attached appendices give details of Laboratory procedures used during the 
study. The first set of appendices (Appendix J and K) details the procedures for 
handling nasal specimen. Following this is the SOP used to perform the RT-PCR 
(Appendix L). The next few appendices provide specific details on standard 
operating procedures for both the IgG capture ELISA and the RSV-specific ELISA 
used to process the oral-fluid samples. 
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Appendix J: Cytospin method for cell separation 
SOP: CYTOSPIN METHOD FOR CELL SEPARATION 
Date of implementation Date of review 
Signed by Signed by 
The cytospin method is another technique of depositing cells onto slides for IFA. 
This rapid method is used to detect viral antigens in cellular specimens such as 
nasopharyngeal aspirates and for the identification and typing of virus isolates in 
tissue culture cells. 
Nasopharyngeal aspirates should be processed first to deposit and concentrate the 
cells according to SOP: Manual Cell Separation. 
]Procedure 
Prepare the cytofunnel assembly. Ensure the slide is right way around and 
filter is positioned correctly (for re-usable funnels). 
" Load the cytofunnel assembly into the cytospin centrifuge bowl. 
" Inoculate 200µ1 of the cell suspension (Nasal wash bulb or Nasal wash 
syringe) into the cytofunnel and close the funnel with the lid provided, in the 
safety cabinet. 
NOTE: Do not allow funnel to tilt allowing fluid to contact filter or to touch 
sides of the funnel during inoculation. 
" For NPA first perform one cell suspension wash using PBS (refer to SOP: 
Manual Cell Separation) then proceed to inoculate 150µl of the cell 
suspension into the cytofunnel. 
" Balance the bowl and replace lid before removing from the cabinet. 
" Load centrifuge bowl into centrifuge. 
" Spin at 1000rpm for 10 minutes. 
" After spinning transfer to safety cabinet and remove the slide from the 
cytofunnel assembly and discard the funnel (if disposable) or place the 
funnel in Virkon solution (if re-usable funnel). 
" Air dry the slide and fix the cells in 100% acetone @ 4°C for 15 minutes. 
" The cells are then ready for IFAT staining. 
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Appendix K: The detection of Respiratory Syncytial Virus (RSV) using the 
direct immunofluorescence test. 
SOP: THE DETECTION OF RESPIRATORY SYNCYTIAL 
VIRUS (RSV) USING THE DIRECT IMMUNOFLUORESCENCE 
TEST. 
Date of implementation Date of review. 
Signed by Signed by 
PURPOSE 
Light Diagnostics Respiratory Syncytial Virus DFA Kit is intended for the detection 
and identification of RSV in inoculated cell cultures and direct respiratory specimen 
cell preparations. 
PRINCIPLE OF THE TEST 
Light Diagnostics RSVDFA kit utilizes a direct immunofluorescent antibody 
technique for identifying RSV in cell preparations made from nasopharyngeal 
aspirates (NPA). The monoclonal antibodies are labelled with FITC (fluorescein 
isothiocyanate), which fluoresce apple - green when illuminated with ultraviolet light. The labelled antibody will bind to viral antigen present in the specimen. 
Unbound reagent is removed by washing with buffer. Cells in positive specimens 
will fluoresce apple - green while uninfected cells will stain 
dull red due to the 
presence of Evans blue. 
MATERIALS 
" The recommended respiratory sample is nasopharyngeal aspirate which, when 
correctly collected, should provide large numbers of respiratory epithelial cells. 
Nasopharyngeal aspirate/nasal washing will be obtained as per protocol 
KEMRUWTRL/ 
" Acetone - to be stored at 4°C 
+ Phosphate buffered saline (PBS) pH 7.5 (prepared as per instructions in the kit). 
" Teflon coated microscope slides with single 6mm well (Shandon cytoslides) 
" Control slides 
" Precision pipette to deliver 251iI. 
" Wash baths 
" Wide bore disposable pipettes 
" Decontaminant - Virkon 
Cover slips. 
" Moist incubator at 37°C. 
Low speed centrifuge. 
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Epifluorescence microscope with filter system for FITC (maximum excitation 
wavelength 490nm, mean emission wavelength 520nm) and x200-x400 
magnification. 
The sample will be brought from the ward / OPD to the microbiology department. 
Upon receipt in microbiology laboratory the following steps will be performed: 
CELL SEPARATION 
¢ Place the sample at 4°C, until washing is initiated. The specimen should, 
however, be processed immediately. > All manipulations of specimen should be done in a safety cabinet and discarding 
of material should be done in a disinfectant (Virkon). > Add 6m1 PBS to the sample prior to centrifugation in disposable centrifuge tube 
(blue top) to reduce the viscosity and break the mucus. > Centrifuge at room temperature (15°- 30°C) for 10minutes at 1800rpm. > Discard supernatant. Suspend the cell deposit in 6m1 PBS and gently pipette the 
cells up and down with a wide bore pipette, until the mucus is broken up and 
cellular material released. Avoid vigorous pipetting / vortexing to prevent 
damage to the cells.. > Remove and discard any visible flecks of mucus remaining at this point. Excess 
mucus must be removed as it will prevent adequate penetration of the reagent 
and may result in non-specific fluorescence. 
Centrifuge at room temperature (15°- 30°C) for 10minutes at 1800rpm. 
Discard the supernatant and resuspend in a little PBS depending on the visual 
assessment of the suspension (not too dilute and not too cloudy). > Add 25µl of the suspension on the cytoslide. 
Air-dry the slide. > Fix the slide in cold acetone at 4°C for 10 minutes. 
Dry the slides completely at room temperature and store at -70°C until ready for 
immunofluorescent assay. > Pipette the remaining cell suspension into a vial and add an equal amount of 
freezing mixture. Label RSV NWB-2 and store at -70°C. 
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PROCEDURE 
" Place a drop of Light Diagnostics RSVDFA reagent to the fixed cell preparation 
and to a positive control slide. Ensure that the reagent covers the entire well area. 
+ Incubate the slides with reagent for 30 minutes at 37°C in a moist chamber. Do 
not allow the reagent to dry on the specimen, as this will cause the appearance of 
non-specific staining. 
" Wash off excess reagent in a fresh change of PBS. 
" Drain off PBS and allow the slide to air dry at room temperature. 
" Add one drop of mounting fluid to the centre of each well and place a coverslip 
over the mounting fluid and specimen ensuring that no air bubbles are trapped. 
" Examine the entire 6mm well area containing the stained specimen using an 
epifluorescence microscope. Fluorescence should be visible at X200-X500 
magnification. (For best results specimens should be read immediately after 
staining, but specimens may be stored at 2- 8°C in the dark for up to 72hours). 
INTERPRETATION OF RESULTS 
1. Control slides 
RSV-infected cells will show apple-green fluorescence in the cytoplasm and 
associated with syncytia. 
The negative control well should show cells staining a dull red. 
2. Clinical specimens 
" Apple-green fluorescent intracellular cytoplasmic granules are seen in 
respiratory epithelial cells infected with RSV. 
" In later stages of infection, RSV antigen may be restricted to isolated areas in the 
cytoplasm appearing as small ill-defined granules singly or in clusters. 
" Uninfected cells stain with the Evans blue counter stain and appear red. 
Interpretation 
" Positive diagnosis is made when one or more cells show typical fluorescence in 
the fixed, stained specimen. 
" Negative diagnosis is made when fixed, stained specimens do not exhibit 
fluorescence after staining with the reagent. 
" For directly stained nasopharyngeal aspirate specimens at least 20 uninfected 
respiratory epithelial cells must be visible within the slide well before a negative 
result is reported. 
"A sample containing fewer than 20 cells is considered inadequate, and the test 
invalid. 
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QUALITY CONTROL 
" Viewing slides by second person blind to first 
A second person should examine the slides without knowing the results of the 
first person then compare the two results. Results found to differ between the 
technicians should be reassessed and consensus obtained. 
" Checking procedure and quality of slides - cell count, staining, etc 
Always check that there are at least 20 cells in the entire preparation on the slide. 
The stain should not dry on the slide and so always make sure there is water in 
the incubator (i. e. there's enough moisture in the incubator). Proper washing of 
the slides after staining should be ensured - make sure there is fresh PBS every 
time slides are to be washed. 
" Equivocal result procedure 
If two people get equivocal results on the same slide, then it should be reported 
so. If one says equivocal and the other a different result, then the two should 
come to an agreement on what result to give to the clinician. 
" Set of slides with cell dilutions 
These should be used once every month to Q. C the entire staining procedure as 
an internal quality assessment scheme. 
" Sending slides to the UK for second opinion 
This should be at least once in every 3months. There should be at least 10 of 
each (i. e. 10 positives, 10 negatives and 10 equivocal). 
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REAGENT PREPARATION 
1. Freezing mixture for the NPA 
> 20% Foetal Calf Serum (FCS) 
> RPMI 
> Antibiotics 
2. Freezing mixture for saliva 
> PBS 
> 20%Foetal calf Serum (FCS) 
> 0.02% Sodium Azide 
3. Phosphate Buffered Saline (PBS) 
> Packet of PBS salts in 1 litre distilled / deionised water. 
> 10ml Tween 20 / Sodium Azide Solution 
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Appendix L: RSV protocols for RT-PCR 
RSV protocols for RT-PCR from random primer cDNA for multiplex and nasal 
washing samples (due to low levels of RNA) 
1) Extraction of RNA from samples 
" This protocol uses the Qiagen Viral RNA extraction kit and follows the 
protocol in the manufacturers handbook (supplied with the kit) with the 
exception that the addition of the carrier RNA to buffer AVL is not done. 
Also the optional spin in the handbook (step 9) is not necessary. 
2) To make cDNA for use in RSV multiplex and RT-PCR from nasal washings 
(make up reagent mix with exception of RNA in the clean room, do not take 
RNA into this room). 
" Using the Qiagen Omniscript Reverse Transcription kit, all of the reagents 
(I OX buffer, 5mM dNTPs, 250ng/ul random primers (diluted from lug/ul 
stock I in 4) and nuclease free water) are thawed and vortexed to mix prior 
to use. 
" Label 0.5m1 tubes with the sample names and also label the tubes with "rp 
cDNA" so that you know what the samples are if you need to go back to 
them at a later date. 
" The reagents are added to one 0.5ml tube according to the following table, 
resulting in a mix for the number of samples that will be used (e. g. if 
working with 5 samples and a negative control, then the volumes will be 
multiplied by 6): 
Rea ent Volume per sample Final concentration 
lOX RT Buffer 4. Ou1 1X 
5mM dNTPs* 4. Ou1 
250ng/ul random 
primers 
1. Oul 
Omniscript RT enzyme I. Oul 
Water (provided 10.0ul 
*Note: dNTPs provided with the kit will run out quickly using this method, 
therefore separate dNTPs will need to be purchased and made up at the same 
concentration for use to prevent wastage of the kit. 
The contents of the tube are mixed by vortexing and then 20ul aliquoted 
into each of the sample tubes. 
The caps on the tubes are then closed and taken to the main lab, where 
20ul of RNA for each sample is added to the corresponding tube of 
cDNA reagents. 
The tubes are then capped and incubated at 37°C for 1 hour and then 
either used for PCR directly, or frozen until needed at -20°C. 
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3) RSV/Flu multiplex RT-PCR from random primer cDNA 
A) Primary PCR 
" Start PCR block on program 19 (94°C for 2 minutes; 35 cycles of - 94°C 
for 1 minute, 50°C for 1 minute, 72°C for 1 minute; extension at 72°C for 
5 minutes and cooled) 
" In clean room, take out Qiagen Taq mastermix, primary multiplex primer 
mix (5uM)(see attached sheet for sequences), 25mM MgCI2 and water 
vials and defrost. 
" Once defrosted, add reagents as follows per sample (except for cDNA - 
done in main lab prior to running PCR): 
Reagent Volume per sample 
PCR Mastermix SOul 
25mM M C12 8u1 
SuM first round primers lul 
Water 21 ul 
CDNA to be added in main lab 20u1 
" Aliquot 80u1 of this PCR mix to separate labelled tubes for the samples 
" Take to main lab and add 20u1 cDNA to each tube from the 
corresponding sample. 
" Vortex to mix and put on PCR machine and start the programme (enter 
key on machine) and leave to allow PCR reaction to complete (about 4 
hours). 
" Once complete, proceed directly with secondary PCR and then freeze 
PCR samples for future use in the N gene PCR. 
Secondary PCR 
" Run program 20 of PCR block (94°C for 2 minutes; 35 cycles of - 94°C 
for 1 minute, 60°C for 1 minute, 72°C for 1 minute; extension at 72°C for 
5 minutes and cooled). Also defrost all reagents (mastermix, water, 
MgC12 and second round primer mix (2.5uM)) 
" Once defrosted, add reagents as follows per sample (except for first 
round product - done in main lab prior to running PCR): 
Reagent Volume er sample 
PCR Mastermix 25u1 
25mM MgC12 4u1 
5uM first round primers I Out 
Water Ilul 
Is` round PCR product to be added in main lab 2u1 
" Aliquot 48u1 of this PCR mix to separate labelled tubes for the samples 
" Take to main lab and add 2u1 first round PCR product to each tube from 
the corresponding sample. 
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" Vortex to mix and put on PCR machine and start the programme (enter 
key on machine) and leave to allow PCR reaction to complete (about 4 
hours). 
" Once complete, proceed directly with detection of products by gel 
electrophoresis or freeze PCR samples for analysis next day. 
4) N Gene RT-PCR 
(Note: this is carried out as a secondary PCR on the first round products from 
the RSV/Flu multiplex protocol) 
" Start PCR block on program 11 (95°C for 2 minutes; 30 cycles of - 95°C 
for 45 seconds, 54°C for 45 seconds, 72°C for 1 minute; extension at 
72°C for 5 minutes and cooled) 
" In clean room, take out Qiagen Taq mastermix, N1+N2 primer mix 
(l Opmol/ul - made with 40u1 water and 5u1 each of N1 and N2 
I OOpmol/ul stocks) and water vials and defrost. 
" Add 25u1 mastermix, 23u1 water and Iul N1+N2 primer mix per sample 
to a tube and mix. 
" Aliquot 49u1 of this PCR mix to separate labelled tubes for the samples 
" Take to main lab and add lul of the first round PCR products from the 
multiplex analysis above to each tube from the corresponding sample. 
" Vortex to mix and put on PCR machine and start the programme (enter 
key on machine) and leave to allow PCR reaction to complete (about 3-4 
hours). 
" Once complete, proceed directly with detection procedure and then freeze 
PCR samples for future use in N gene digestion analysis. 
5) Agarose gel electrophoresis 
" Make the following solutions if needed (5X TBE buffer - dissolve a 
sachet of Sigma 5X TBE in 1L of sterile distilled water and mix on the 
magnetic stirrer - dilute l OX prior to use; Loading dye - 3g Glycerol, 
7m1 sterile distilled water and a dash of bromophenol blue) 
" Depending on the number of samples either a 30m1 gel (14 samples and 2 
ladders) or 100m1 gel (26 samples and 2 ladders) should be made. For a 
30m1 gel, make up in a 250ml conical flask 0.3g agarose and 30m1 0.5X 
TBE. 
" Plug the top of the flask loosely with paper roll and microwave for 1 
minute at power level 9 to melt the agarose. 
" Cool the base of the flask under cold running water (care should be taken 
not to allow any water to get in the flask, or to burn yourself) until it can 
be held in your hand without overheating. 
" Add 3u1 10mg/ml ethidium bromide (NOTE: ethidium bromide is very 
toxic. Always wear gloves when handling it) and gently swirl to mix. 
" Pour the gel into a mini tank containing metal blocks and combs and 
allow to set. Remove any bubbles by piercing with a pipette tip. 
" Gently load 8ul of ladder (consists of lul ladder, 2ul loading dye and 7ul 
water) in the first well and then load 20u1 (multiplex second round 
product) or 8u1 (N gene PCR) of your samples in the remaining wells 
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(one sample per well) -NOTE: it's best to add 8ul of your samples to 
clean 0.5m1 tubes and add the 2u1 of loading dye to these, rather than 
adding the dye to your PCR product tubes 
Run the gel using a power pack (ask someone to show you how to use the 
particular pack you are going to use, as they all work differently) at 
30mA for 30 minutes 
For a 100ml gel, use lg agarose in the 100ml 0.5X TBE and microwave 
for 2 minutes and pour into a large gel tray sealed at each end with tape 
6) Digestion of N gene PCR products for typing of the N gene 
" The following digest mixes are made in separate labelled 0.5m1 tubes for 
each sample to be typed from the N gene PCR product to give us the NP 
patterns: 
Volume to add per sample 
Reagents HindIII PstI BgIII HaeIII RsaI 
I OX buffer (colour coded 
with enzyme ca 
2uI 2u1 2ul 2u1 2u1 
Enzyme 0.5u1 0.5u1 0.5u1 0.5u1 0.5u1 
Sterile Distilled Water 10.5u1 10.5u1 10.5u1 10.5u1 10.5u1 
Cleaned PCR product 7u1 7u1 7u1 7u1 7u1 
Once made up, these tubes are incubated in the 37°C waterbath for 1 hour 
and then run on a 2% agarose gel (for mini gels, use 30m1 0.5X TBE, 
0.6g agarose) and the patterns analysed (see below for example digestion 
patterns) 
When running these digests on the gel, group by sample, so that on the 
gel you have sample I (HindlIl, PstI, Bg1II, HaeIII, Rsal), then sample2 
(HinduIl, PstI, BgIII, HaeIII, Rsal), etc... 
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7) Patterns for known RSV types 
The following table shows which enzymes should cut the N gene PCR 
products for the commonly known NP types: 
Enzymes (cut = +; uncut = -) A type or B 
PstI Bg1II HaeIII Rsal type RSV 
NP I B 
C i 
+ + A 
+ + B 
+ + + A 
NP8 
8) G gene RT-PCR from random primer cDNA used in multiplex analysis 
" Set up the primary PCR reactions in the clean room by mixing the 
following reagents per sample: 
Reagent Volume er sample 
Ta Mastermix 25u1 
25mM M902 2u1 
AG20+F164 (A type RSV) orBGlO+F164 (B type 
RSV) primers 10 mol/ul each, premixed) 
2ul 
Sterile Distilled Water 18u1 
Aliquot 46u1 of the mix into individual labelled 0.5m1 tubes. 
Take the PCR mixes to the main lab and add 4ul of each sample's 
random primer cDNA to the corresponding PCR tubes and load the tubes 
into the PCR block and run on programme 11 (same as above for N 
gene) 
Once complete, set up the secondary PCR reactions in the clean room as 
follows and freeze the remainder of the primary PCR products for future 
use: 
Reagent Volume per sample 
Ta Mastermix 50uI 
25mM M C12 
10 mol/ul BG 10+F 1 primer mix 2u1 
Sterile Distilled Water 44u1 
Aliquot 98u1 of the mix into individual labelled 0.5m1 tubes. 
Take the PCR mixes to the main lab and add 2ul of each primary PCR 
sample to the corresponding PCR tubes and load the tubes into the PCR 
block and run programme 11 (same as above for N gene) 
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" Proceed to agarose gel electrophoresis to view bands. Successful 
samples are subjected to PCR clean-up using the Qiagen PCR 
purification kit and stored at -20C. 
8) Digestion of G gene RT-PCR products for typing 
" For any G gene RT-PCR products that showed clear bands in the gel, 
clean up the whole product, using the Qiagen PCR purification kit. 
" The following digest mixes were made in separate labelled 0.5ml tubes 
for each sample to be typed from the G gene PCR product to give us the 
G gene patterns: 
Volume to add per sample 
Reagents AIuI TaqI Mbol Msel 
I OX buffer (colour 
coded with enzyme cap 
2u1 2ul 2u1 2u1 
Enzyme 0.5u1 0.5u1 0.5u1 0.5u1 
Sterile Distilled Water 10.5u1 10.5u1 10.5u1 10.5u1 
Cleaned PCR product 7u1 7ul 7u1 7u1 
" Once made up, these tubes were incubated in the 37°C waterbath for I 
hour (Except for Taql which is incubated at 60°C for 1 hour) and then run 
on a 2% agarose gel (for mini gels, use 30m1 0.5X TBE, 0.6g agarose) 
and the patterns analysed (see below for example digestion patterns). 
" Run these products in groups according to the enzyme used. For example 
if you have 5 samples that are digested with these enzymes, run all 5 AIuI 
digests together, then all Taql digests together, then all MboI digests and 
finally all Msel digests (i. e. group by enzyme) 
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Appendix M: Standard Operating Procedure for Oral-Fluid ELISA 
IgG Capture Assay 
Reagents: 
" COAT (rabbit IgG in sodium carbonate buffer). 
" PBST (phosphate buffered saline/0.05% Tween). 
" STANDARDS (180µg/ml IgG calibrant standards (Binding Site, Edgbaston, 
England). 
" CONJUGATE (Horseradish peroxidase-conjugated rabbit antihuman IgG 
(Dako) 
" SUBSTRATE (O-phenylenediamine). 
" ACID (2.5M sulphuric acid, H2SO4). 
Reagent Preparation 
" Sodium Carbonate Coating Buffer 
1.59g N2C03 (4.29g if decahydrate) and 2.93g N2 HCO3 in IL distilled water 
" Blocking Solution 5g of Marvel in 100ml PBST 
" PBS-T (PBS with 0.05 % Tween 20) 
Procedure 
1. Frozen saliva samples thawed 
2. Dilute rabbit anti-human IgG (Dako Ltd., Cambridge) 1/3000 in Sodium 
Carbonate (NaCO3) coating buffer 
3. Coat 96 well plates overnight at 37 °C with 100µl/well diluted rabbit anti-human 
IgG 
4. Wash plates 4 time with PBS-T (PBS containing 0.05% Tween) 
5. Block plates with 200µU well of 5% Marvel in PBS-T. Seal plates and incubate at 
37 °C for 60 minutes 
6. Flick off block and bang plate on towel 
7. Meanwhile, prepare IgG calibrant standards; 0.0039-2.5 mg/l by doubling 
dilutions in PBS-T, assay in duplicate (Take 45µl of 180mg/l standard in 135µ1 of 
PEST to make a 45mg/l std. Take 10µl of the 45 mg/l in 170µl PBST to make the 
2.5mg/l standard and double dilute to 0.0039 mg/1 standard). 
8. Dilute saliva 1/100 (or doubling dilutions 1/10 to 1/20480) in PBS-T and assay in 
triplicate alongside standards in duplicate (10µl sample or std /well in 40µi/ well 
blocking solution). Seal plates and incubate at 37 °C for 90 minutes. 
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9. Wash 8x with PBS-T. Flick off and bang plate dry on paper towel 
10. Add I00µ1 conjugate (Horseradish Peroxidase-conjugated rabbit anti-human IgG 
(Dako) diluted 1/1000 and incubate at 37 °C for 2 hours 
11. Wash 8 times with PBS-T. Flick off and bang plate dry on paper towel 
12. Develop with substrate (O-phenylenediamine) for 10 minutes (30mg tablet in 
30mis PBS, add 3O41 H202 prepared just before use. Use 100µI per well. 
13. Stop reaction with 50µl 2.5 mol/L HZS04 and read at 492nm. 
RSV specific ELISA 
1. Block plates with 200µU well of 5% Marvel in PBS-T. Seal plates and incubate at 
at 37 °C for 60 minutes 
2. Flick off block and bang plate on towel 
3. Add saliva 50µU well (Diluted 1/2 to 1/64 in PBS-T or diluted to a Img/I 
concentration) and assay in triplicate. Seal plates and incubate at 37 °C for 90 
minutes. 
4. Wash 4x with PBS_T. Flick off and bang plate dry on paper towel 
5. Add 100µU well conjugate (Horseradish peroxidase-conjugated rabbit/goat anti. 
human IgG (Dako)) diluted 1/1000 and incubate at 37 °C for 2 hours 
6. Wash 8 times with PBS-T. Flick off and bang plate dry on paper towel 
7. Develop with substrate (O-phenylenediamine) for 10 minutes (30mg tablet in 
30mis PBS, add 301l H202 prepared just before use). 
8. Stop reaction with 50µl/ well of 2.5M H2SO4 per well and read at 492nm. 
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Appendix N: SOP for Cell Culture and Preparation of Lysate 
Cell culture work to produce virus antigen and coated plates were supplied by Dr P. 
Scott from Health Protection Agency in Birmingham 
CELL CULTURE 
HEp-2 
MATERIALS 
500ml Minimal Essential Medium + Earles salts + L-Glutamine (MEM) 
5m1 HEPES buffer (1M) 
5ml non-essential amino acids (NEAA, 100X) 
5m1 pen/strep (10 000U) 
25m1 Fetal calf serum (FCS, 5%) 
Place CMEM (MEM + HEPES + NEAA + pen/strep + FCS) in water bath at 37°C to 
warm up. 
Take 1 vial of HEp-2 cells from liquid N2 quickly thaw a water bath at 37°C (NB. 
wear face protection when handling vials from liquid N2). 
Place cells in 5 ml of pre-warmed CMEM in a T-25 flask and allow cells to settle for 
5-6 hours and then replace medium. 
1. Incubate and check cells daily. When cells confluent, go on to split. 
SPLITTING HEp-2 CELLS 
MATERIALS 
Trypsin-EDTA 
CMEM 
Sterile PBS 
I. Pre-warm CMEM and trypsin-EDTA to 37°C prior to use. 
2. Pipette off old media, add 5m1 PBS to wash off medium (repeat). 
3. Add 5m1 trypsin-EDTA, wash cells briefly with this and then pipette off 
leaving just a film on the cells, incubate at 37°C but check every few minutes 
4. When cells starting to lift off, tap flask firmly on your hand so all detach 
5. Add 10 ml medium. Pipette up and down to break up cell clumps but don't 
make bubbles. 
6. Distribute cells into new flasks and add appropriate amount of new medium. 
7. Incubate all flasks at 37°C, check on flasks daily to monitor growth. 
PREPARATION OF HEp-2 STOCK 
1. Trypsinize cells, from a 150cm2 T-flask and place cells in a centrifuge tube 
and spin at 1000rpm for 10mins. 
2. Gently pipette off medium without disturbing pellet, and then gently re- 
suspend pellet in 2.4 ml of CMEM. 
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3. Label 6 ampoules (Name, date, passage #) and for each vial, add: 
0.4m1 cells 
O. lml DMSO 
0.5m1 FCS 
4. Do a step wise freeze down of cells (i. e. -70°C overnight and then transfer as 
quickly as possible to liquid N2). 
5. Take note of rack and tray used. 
RESPIRATORY SYNCYTIAL VIRUS 
MATERIALS 
Slow Grow Medium 
500m1 Minimal Essential Medium + Earles salts + L-Glutamine (MEM) 
5ml HEPES buffer (1M) 
5ml non-essential amino acids (NEAA, 100X) 
5ml pen/strep (10 000U) 
10ml Fetal calf serum (FCS, 2%) 
1. Place slow grow CMEM (MEM + HEPES + NEAA + pen/strep + FCS) in a 
water bath at 37°C to warm up. 
2. Take I vial of A2 virus from -70 and thaw rapidly in 37°C waterbath. 3. Take 2 T-25 flasks of Hep-2 cells showing approximately 75% confluency 
and pipette off old media until about 1 ml left. 
4. Infect 1 flask by adding A2 virus to T-25 flask, the other T-25 flask is a 
CONTROL flask. 
5. Incubate flasks at 33°C for 2-3 hours, gently tipping both flasks every 15 
mins, to allow for virus adherence to Hep-2 cells. 
6. Top up the volume to bring up the final volume to 5ml. 
7. Re-incubate both flasks at 33 °C and check daily; look for cytopathic effect 
(CPE) and change in pH of medium in infected flask in comparison to 
control. 
8. Go on to make up RSV stocks. 
PREPARATION OF VIRUS LYSATE for ELISA 
MATERIALS 
Nonidet-P40 (NP40) 
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PBS 
Cell scraper 
I. When extensive CPE (50-75%) is noted in infected cell, scrape cells into 
medium, and place in a centrifuge tube, similarly for control flasks. 
2. Spin at 1500 rpm for 10 mins and then decant off supernatant (CAUTION: 
Infectious) 
3. Resuspend pellet in 1Oml PBS, spin at 1500 rpm for 10 mins. 
4. Decant off supernatant (CAUTION: Infectious). 
S. Resuspend in 10ml sterile water + 0.5% NP40 and vortex very hard. 
6. Spin at 1500 rpm for 10 mins. 
7. Aliquot supernatant in 2ml quantities and store at -70°C until further use. 
PREPARATION OF VIRUS STOCK 
MATERIALS 
Sterile glass beads 
I. When note extensive CPE (50-75%) harvest. 
2. Label 7 ampoules appropriately (Name, date, virus stock no. ) 
3. Take sterile glass beads and place enough to cover the bottom surface of a 
clean bijou. 
4. Pour these into the T-25 flask, vigourously shake to dislodge cells (check 
under light microscope). You may need to bkast cells off using pipette also. 
S. Carefully pipette cell suspension, avoiding sucking up glass beads, and 
divide the cell suspension evenly between the 7 ampoules and store cells at - 
70°C until further use. 
NB general: Bubbles kill cells but not virus! It is always best to thaw quickly not 
slowly. If you want to grow up a really good stock of virus in the early passes avoid 
freeze thawing, and instead inoculate a fresh flask directly with virus from the first 
flask. 
ELISA 
Plate preparation 
Dilution of lysate must first be determined. 
Dilute lysate 1: 2,4,8,16,32,64 in water + 0.5%NP40 (both infected and 
uninfected) 
(To prepare plates for screening of sera then coat only with predetermined dilution 
of lysate) 
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Add 50 µl to each well (always do wells in triplicate) of 96 well TC plates 
Allow to dry o/n in cat 1 hood 
Fix with 100 ilIwell 80% acetone in H2O for 10 mins. 
Flick off acetone and allow to dry. 
Store plates in bag at -20C 
To carry out ELISA 
Block plates with 200 pl/well 5% Marvel in PBS-T (PBS with 0.05% Tween 20). 
Seal plates and incubate for 1 hr at 37C. (Marvel is essential: some other brands 
don't work) 
Flick off block and bang plate on paper towel 
Meanwhile dilute sera in block (ie 5% Marvel in PBS-T) 
Add sera 100 pl/well (For Mabs use 1/100 & 1/500 dilution; for sera 1/100 and 
doubling dilns to 1: 3200) 
Seal plate and incubate for 1.5 hr at 37C 
If plate washer working, wash plates 4 times with 200 ul PBS-T. 
If plate washer not working: remove sera and discard tips and contents as 
infectious. Add 200µl PBS-T to each well. Flick off and bang plate dry on paper 
towel. Repeat 3 times 
Add 100 pl secondary antibody to each well (for Mabs use Biorad goat anti mouse, 
HRP conjugated, for sera goat anti human HRP conjugated, both diluted 1: 1000 in 
block) 
Incubate at 37 °C for 1 hour 
Wash as above 
Develop with 100 pl 0-phenylenediamine (10 mg tablet in 10 ml PBS, add 10 µl 
H202 (fresh) just before use); care: carcinogenic, per well for 10 mins 
Add 50 pl 2.5 M H2SO4 per well. Read at 492 nm 
For determination of optimum lysate dilution: 
360 
Dilute lysate in H2O with 0.5% NP40 as above. 
Coat plate: A 1-3,1: 2; A4-6,1: 4 (infected) , A7-9,1: 2, A 10-12 1: 4 (uninfected) 
B, 1: 8,1: 16 
C, 1: 32,1: 64 
D: leave empty (Ab Control) 
E-H repeat as above 
Fix and block etc 
Antibodies: 021/1G diluted 1: 500 for A-D, 0121/2G dil 1: 500 for E-H 
You want to choose the best lysate dilution that gives a good positive signal with the 
infected but not with the uninfected lysate. 
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Appendix P: Incidence estimated by age and child class 
Incidence estimates of ARI by age and child class including 95% CI 
Number of events, person years of observation 
(Incidence + 95% CI) 
Age Pre-school children Pre-school children School children 
(years) with siblings in school without siblings in 
school 
0 460,56.9 134,18.6 
8.06 (7.19,9.03) 7.23( 5.10,10.25) 
1 537,52.4 127,15.4 
10.22 (9.09,11.49) 8.09 (5.58,11.73) 
2 161,27 41,8.6 
5.97 (5.03,7.07) 4.71 (2.74,8.09) 
3 255,35.3 60,10.7 13,1.30 
6.73 (5.46,8.30) 5.43 (2.82,10.46) 8.24(2.60,26.06) 
4 121,23.6 33,7.7 32,8.6 
4.78 (3.56,6.42) 4.06 (1.63,10.10) 3.45 (1.39,8.56) 
5 36,9.30 22,5.6 48,15 
3.81 (2.46,5.90) 3.70 (1.18,11.58) 3.11 (1.14,8.47) 
6 12,2.59 12,2.88 79,25.7 
4.74 (1.87,12.01) 4.51 (0.51,39.81) 2.99 (0.44,20.17) 
7 0 1,0.57 78,29.5 
1.75 (0.21,14.23) 2.63 (0.04,177.06) 
8 59,22.1 
2.60 (1.58,4.29) 
9 26,14.9 
1.83 (0.98,3.43) 
10 31,18.7 
0 1.61 (1.02,2.52) 
11 2,0.66 19,21.5 
3.04 (0.53,17.62) 0.86 (0.01,119.82) 
12 1,0.42 27,16.1 
2.40 (0.25,23.20) 1.68 (0.03,87.53) 
13 35,15.2 
2.34 (1.56,3.44) 
14 17,9.1 
1.62 (0.76,3.47) 
15 5,4.8 
1.80 (0.49,6.60) 
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Incidence estimates (95 % CI) of RSV infection by age and child class 
Incidence + 95% CI 
Age class Pre-school children Pre-school children School children 
with siblings in school without siblings in 
school 
0-1 lm 351(227-544) 431 (123-1517 
12-17m 741 (478-1,148) 509 (112-2,309) 
18-24m 533 (321-883) 361 (63-2,069) 
25-36m 377 (203-701) 111 (8-1,608) 0 
37-59m 339(216-532) 291 (69-1,223) 99 (8-1,164) 
5-9yr 165 (41-661) 333 (14-7,967) 86 (5-1,611) 
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Appendix Q: Incidence rates of RSV infection and disease stratified by age class 
Table 1: Incidence rates of total infection and disease stratified by age class 
Incidence/1000 cyo (95% CI) 
Age class Infection RSV-LRTI severe LRTI 
0-11m 459 (316,665) 33(8,131) 33(8,131) 
12-17m 495 (197,1,242) 165 (9,3,114) 41 (1,1,174) 
18-24m 346 (132,911) 58 (2,1,385) 0 
25-36m 409 (140,1,194) 37 (1,1,645) 0 
37-59m 254 (102,633) 0 0 
60-108m 100 (36,281) 0 0 
109+m 9(1,95) 0 0 
Table 2: Incidence of primary infection and disease stratified by age class 
Incidence/1000 cyo (95% Cl) 
Age class Infection RSV-LRTI severe LRTI 
0-l lm 406 (270,612) 35(9,141) 35 (9,141) 
12-17m 873 (315, 349 (18,6,609) 87 (3,2,490) 
2,414) 
18-24m 267 (72,995) 45 (1,1,969) 
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Risk Factor Survey 
Included in this section are the risk factor survey questionnaire and the 
accompanying rubric for its completion. 
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Appendix S: Risk Factors Survey Questionnaire 
RSV RISK FACTORS STUDY QUESTIONNAIRE 
. General Date today ............................................ (DD/MM/YYYY)_ _// 
2004 
PID [ ][ ][ ][ ][ ][ ][ ] KBc #[ ][ ][ ][ ][ ] RSV #[ ][ ][ ] 
Child names 12 3 
Date of birth .......................................... (DD/IVIM/YYYY) 
Birth weight ................................................................ Kg 
I J. [ J[ J 
Sex:.... 
.... .................... M/F ............................................. .......... 
Number of babies born. Circle one 
Singleton Twins Triplets Other 
If other, spec ................................................ 
2. Primary care taker details 
Names 123 
Age of PCT: ..................................................................... years 
I][ 
Sex of PCT: ............................................................................ MIF 
2.1 How many years of schooling/education have you had?............ number [ ][ ] 
2.2 Can you read? (Give reading card} ........................................... 
Y/N [] 
2.3 Occupation of the major income provider. Circle only one. 
Police/armed Farmer Hotel Fishing Petty Registered 
forces industry Trader Business 
Transport Carpenter/ Health Teacher Civil Other 
industry Mason personnel Servant 
If other; specify 
2.4 Do you rely on assistance from relative/person(s) living away to make ends 
meet? ................................................................................ Y/N { 
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3. Demographic, Social-economic and Environmental factors 
3.1 How many months of its life has the child breastfed? (Duration of breastfeeding) 
Never 
All of life 
Part of life (Indicate number of months) 
3.2 At what age was the child weaned? .............................. age 
in months [] 
3.3 How many people are in the family unit? ......................... number 
[][] 
3.4 How many of these are children (< 15 years)? ................... number 
[ ][ ] 
(enter details of each in the table below) 
(On this space make a diagram of the house and the sleeping arrangements in 
relation to the most recent epidemic) Applies to those in the household study ONLY 
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3.6 How many siblings of the index have passed away? ................... number 
[ 
3.7 Where does the index child normally remain during the day? Circle one 
LI Inside the home Outside home 
3.8 Who usually takes care of the index child during the day? Circle one 
Mother Another family member House help Other 
If other, spec 
3.9 Which of the following do you have in the household at the present time? 
Circle any applicable 
Bicycle Telephone/Cell Radio TV/video deck 
Motorcycle Electricity 
3.10 How many animals do you have Cows [) Goats [] Sheep I 
3.11 What type of main house does the PCT live in? Circle one 
Mud wall house Block wall house 
3.12 Is this HH: Circle one 
fOwner occupied Rented No rent/with consent of owner Other 
If other, spec 
3.13 What type of toilet do you have? Circle one 
Flush toilet inside Latrine inside No toilet 
Flush toilet outside Latrine outside 
3.14 Do you burn your refuse within the homestead? ......................... Y/N 
[] 
3.15 What type of fuel do you use for cooking? Circle more than one if necessary 
Fire wood I Wood Charcoal I Gas I Paraffin 
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3.16 Where do you do your cooking? Circle more than one if necessary 
Same house as you sleep Different house from where F Outside in you sleep 
3.17 Where do you get water for domestic use? Circle one 
Piped Open or Closed Well Surface 
3.18 Site of piped or well water Circle one 
L Into dwelling In compound or plot Public 
3.19 How many members of the family unit smoke? ..................... number [ 
FIELD WORKER OBSERVATIONS - please write overleaf 
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Appendix T: Guide for completing RSV risk factor study questionnaire 
Guide for completing RSV risk factor study questionnaire 
Explain the purpose of the study to the head of the household/ mother before 
you begin 
DATE. 
Record date of interview. Other details concerning the child will be filled in 
automatically 
1 Ask the Primary Caretaker (PCT) how many babies were born. 
2.1 EDUCATION - Level of education attained. Record number of years of 
education. Put 0 if no school, 1 if attended only for one year etc, if completed 
secondary education and went to college, add years of college to years in school. 
[Some go to adult school - include this in years of schooling] 
2.2 LITERACY - Ask if the PCT can read by letting them read the card provided. It is up to the fieldworker to classify the PCT as can read or not after hearing the PCT 
read this card. If they feel that the PCT can't read write `N' 
2.3 OCCUPATION - record a single occupation that nearest describes that of the 
major income earner of family unit. Draw big circle around number and occupation. 
If none apply, then circle 'other' and specify. 
2.4 RELIANCE ON ASSISTANCE - Ask how often the family receives monetary 
assistance from another party (this may be a relative e. g. their children or from 
friends) and whether without this they would be unable to make ends meet. We are 
trying to establish the level of reliance on this help 
3.1. BREASTFEEDING - Ask how many months the mother breastfed the child. Insert 0 for never, 99 if child still breast-feeding to date else fill in the actual length 
(completed months) of time the child was breast-fed. 
3.2 EXCLUSIVITY OF BREAST FEEDING - Ask at what age the child was 
weaned 
3.3. FAMILY UNIT - Record the number of people in this family unit - defined as 
the number that normally eat at the same meal. Give maximum inclusive of those 
who are temporarily away i. e. in boarding school 
3.4 Record the number of children less than 15 years of age in the family unit. 
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Example diagram {adult-filled triangle, children<1Syear solid circle, index-blank 
cirle) 
00 00 
ýI 
TABLE - Record the number of siblings for the index child (brothers/sisters). 
Include half siblings or other children in the family unit who are not siblings. 
- ask how many of the siblings are aged <5yrs , 5-14 yrs, 15+yrs (note explain grps) 
- ask how many of the siblings are male 
ASK THESE NEXT QUESTIONS IN RELATION TO THE THREE DIFFERENT 
EPIDEMICS AS SHOWN ON THE TABLE 
- ask if the siblings live in the same house as the index child 
- ask if the siblings sleep in the same room as the index child 
- ask if the siblings normally attend school - primary and secondary 
{Explain that some will have missed epidemic 1 and 2) 
3.5 Ask how many adults sleep in the same room as index child 
3.6 DEATHS - Ask if there is any brother or sister of index child who has passed 
away, then record the numbers who have died. 
3.7. LOCATION DURING DAY - Ask PCT where the index child normally 
(PREDOMINANTLY i. e. more often than not) remains during the day. Circle 
appropriate location i. e. (1) Did the child normally remain in the home with mother 
or maid, or siblings in and around home (2) go out of the house for example with 
mother during her normal daily activities, to the work place, market, other 
compound/homestead 
3.8 Ask with whom the child remains during the day. Other family member excludes 
the house help 
3.9 OWNERSHIP LIST - Record what the index household/family unit owns which is a measure of social-economic standard. Circle as many boxes as are relevant. 
3.10 Record count of how much livestock the household has 
3.11 WALL TYPE - record if wall of house of index child is concrete/stone/coral 
walled or mud walled. 
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3.12 RENTAL - Ask the PCT whether they live in rented accommodation or not (i. e. 
if they pay a rent to someone or what sort of arrangement they have). 
3.13TOILET FACILITY - Record the type of toilet the family uses or no toilet, 
circle only one. And then record the location of the toilet. 
3.14 BURNING RUBBISH - Record whether or not they burn their refuse within 
the house/homestead i. e. `Y'or `N' 
3.15 FUEL - Ask for the kind of fuel they use 
for cooking in the house. Circle the 
MAIN fuel only. 
3.16 COOKING LOCATION - Ask where the cooking actually takes place 
3.17/8 WATER SUPPLY - Record water source for 
domestic use. 
3.19 SMOKING - Ask how many members of the 
family unit smoke as a regular 
daily activity. 
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Appendix U: The means, ranges and distributions of variables used to compute 
the asset index 
Variable Mean Std. Dev Min Max 
Phone 0.2250 0.4179 0 1 
Radio 0.6635 0.4730 0 1 
Motor bike 0.0095 0.0969 0 1 
Television set or video 0.1342 0.3412 0 1 
Bicycle 0.4839 0.5002 0 1 
Electricity 0.0737 0.2616 0 1 
Cows 0.7599 2.1692 0 20 
Goats 3.1550 9.8390 0 200 
Sheep 0.3856 6.5931 0 150 
Block walled house 0.3629 0.4813 0 1 
Mud walled house 0.6371 0.4813 0 1 
Owned house 0.7845 0.4116 0 1 
Rented house 0.1853 0.3889 0 1 
Not rented not owned 0.0302 0.1714 0 1 
Flush toilet 0.0624 0.2421 0 1 
Latrine 0.5936 0.4916 0 1 
No toilet 0.3440 0.4755 0 1 
Main fuel firewood 0.7448 0.4364 0 1 
Main fuel charcoal 0.2420 0.4287 0 1 
Main fuel non biomass 0.0302 0.1714 0 1 
Drinking water from well 0.0586 0.2351 0 1 
Drinking water from piped 0.8960 0.3055 0 1 
source 
Water site owned 0.0832 0.2764 0 1 
Water site public 0.7750 0.4179 0 1 
Water site shared 0.1474 0.3549 0 1 
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Appendix V: WHO Child Growth Standards 
Description 
1. The macro (igrowup. ado) calculates z-scores for the five anthropometric 
indicators, weight-for-age, length/height-for-age, weight-for-length, weight-for- 
height and body mass index (BMI)-for-age, based on the WHO Child Growth 
Standards. 
2. It flags any extreme (i. e. biologically implausible) z-scores for each indicator 
according to the following system: 
Weight-for-age z-score (zwei) zwei < -6 or zwei >5 
Length/height-for-age z-score (zlen) zlen < -6 or zlen >6 
Weight-for-length/height z-score (zwfl) zwfl < -5 or zwfl >5 
BMI-for-age z-score (zbmi) zbmi < -5 or zbmi >5 
3. The macro produces sex- and age-specific estimates for the prevalence of 
under/over nutrition and summary statistics (mean and SD) of the z-scores for each 
indicator. 
Pre-requisites 
STATA Version 7.0 or higher is required to run "igrowup. ado". The macro requires 
a STATA data set containing age, sex and the anthropometric measurements. input 
variables are specified in the Parameters section. 
Precautions: 
1. Avoid any variable names starting with underscore "_" in the input 
STATA data set; otherwise they may be replaced by the derived ones created by the 
macro. 
2. Avoid any temporary format names starting with underscore 
otherwise they may be replaced by the temporary ones created by the macro. 
3. Avoid any STATA global macro variable names staring with underscore 
", except those defined by the system. 
Macro Parameters 
The macro requires 12 parameters that must be specified without any quotation 
marks. 
reflib: to specify the package directory where the five STATA data sets 
containing the WHO Child Growth Standards are stored. 
" datallb: to specify the working directory where the input STATA data set 
containing anthropometric measurements is stored. 
datalab: to specify the name that will prefix the output files (datalab_z, 
datalab jrev_st or datalab prev_rc). 
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" sex: to specify the name of a variable containing sex information. If it is a 
numeric variable, its values must be, 1 for males and 2 for females. And if it is a 
character variable, it must be, "m" or "M" for males and "f' or "F" for females. 
Users must code any missing values as ". " (for a numeric variable) or "" (for a 
character variable), in which case no z-scores will be calculated. 
" age: to specify the name of a numeric variable containing age information. Age 
can be in either days or months. An exact age is expected here and should not be 
rounded if age is in months. Users must code any missing values as ". ", in which 
case the age-related z-scores are not calculated. 
" ageunit: to specify the age unit for the age variable. It must be specified as either 
"days" or "months" (they are case sensitive). To convert age in months to days, 
the macro multiplies by 30.4375 and rounds the result to integer for use with the 
reference tables. 
" weight: to specify the name of a numeric variable containing body weight 
information. Body weight must be in kilograms. Users must code any missing 
values as ". ", in which case weight-related z-scores are not calculated. 
" lenhei: to specify the name of a numeric variable containing length (recumbent) 
or height (standing) information. Length or height must be in centimeters. Users 
must code any missing values as ". ", in which case length- or height-related z- 
scores are not calculated. For children aged below 24 months (< 731 days) and 
measured standing, the macro converts the height to recumbent length by adding 
0.7 cm; and for children aged 24 months or above who are measured in 
recumbent position, the macro converts the length to standing height by 
subtracting 0.7 cm. In other words, all the z-scores for children below 24 months 
are length-based, and height-based otherwise. The exported variable_clenhel is 
the converted length/ height according to age. 
measure: to specify the name of a character variable indicating whether 
recumbent length or standing height was measured. The values of this variable 
must be "1" or "L" for recumbent length, and "h" or "H" for standing height. 
Users must code any missing values as " ", and the macro imputes any missing 
values according to the following algorithm: 
a. If age is given, then it is recumbent length if the child's age is below 
24 months (< 731 days), and standing height if the child's age is 24 
months or above. 
b. If age is missing, then it is recumbent length if lenhel < 87 cm and 
standing height if lenhei > 87 cm. 
oedema: to specify the name of the character variable containing oedema 
information. The values of this variable must be "n" or "N" for non-oedema, and 
"y" or "Y" for oedema. Users must code any missing values as " ", and the 
macro assumes that they are non-oedema. For oedema cases, weight-related z- 
scores (_zwei, 
_zwfl and _zbmi) are not calculated, 
but they are treated as being 
< -3 SD in their prevalence estimations. 
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" sw: to specify the name of a numeric variable containing sampling weight. If 
"sw=1" for all records, the un-weighted analysis is performed. If otherwise 
specified, negative values in sampling weight are not allowed and in this case no 
prevalence tables will be produced. 
flagsys: to specify how to handle flagged z-scores in the summary report. Only 
values 0 or 1 can be attributed to this parameter; if "flagsys=l", records with at 
least one flagged z-score (flagged, true missing or with oedema) are excluded for 
the computation of all prevalences (restricted analysis). This option would 
generate the output datlabprev_rc. xls. If "flagsys=0", all available (non- 
missing and non-flagged) z-score values are used for each indicator-specific 
prevalence estimation and oedema cases contribute as mentioned above 
(standard and recommended analysis). This option would generate the output 
datalab prev_st. xls. 
Exported files 
1. The macro creates, in the working directory, a STATA data set. The name of the 
data set is datalabz. dta (see the Parameters section). This data set retains all the 
records and variables from the input STATA data set and adds on the following 11 
variables derived by the macro: 
Variable name Variable label 
_agedays calculated 
age in days for deriving z score 
_clenhei converted 
length/height (cm) for deriving z score 
_cbmi calculated 
bmi=weight / squared(_clenhei) 
_zwei 
Weight-for-age z-score 
_zlen 
Length/ height-for-age z-score 
_zwfl 
Weight-for-length/height z-score 
_zbmi 
BMI-for-age z-score 
_fwei 
Flag for 
_zwei 
< -6 or _zwe 
i> 5 
lien Flag for 
_zlen 
< -6 or _zlen 
>6 
_fwfl 
Flag for 
_zwfl 
< -5 or _zwf 
1> 5 
_fbmi 
Flag for 
_zbmi 
< -5 or _zbmi 
>5 
2. The macro creates, in the working directory, a data set in XLS format that has the 
same data structure as the one in STATA format. The name of the data set is 
datalab z. xls. 
3. The macro creates, in the working directory, a MS Excel file that contains the 
point estimates and 95% confidence intervals for the indicator prevalences and z- 
scores summary statistics. Only children aged below 61 completed months are 
included in the analysis. The age groups are: Total (0-60), 0-6,7-11,12-23,24-47 
and 48-60 completed months. Where age is missing, only weight-for-length/ height 
z-scores can be derived and these cases are included in the Total (0-60) age group. 
The name of this file is datalabprev st or datalab_prev_rc. The extension 
" prev_st" or "jrev_rc" depends on the type of analysis requested via the macro 
parameterfagsys (see the Parameters section). 
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Recommended setup and run 
Step 1. Create a sub-directory, for example "D: \WHO igrowup STATA", 
where you wish to save the package (igrowup stata. zip). This directory 
should be reserved only for the references tables (*anthro. dta) and the 
macro (igrowup. ado) that are contained in the zip file. 
Step 2. Create a sub-directory, for example "D: \WHO igrowup workdata", 
where the example data (survey. dta) and your STATA input data can be 
stored and where all the macro output files will be written to. 
Step 3. It is recommended that you start by loading and running the example 
code below (also found in survey. do) in the STATA do-file editor to see 
how the data should be prepared and to fill in the macro parameters 
according to their requirements. 
/* Example: survey. do using survey. dta 
clear 
set more I 
/* Higher memory might be necessary for larger datasets 
set memory 10m 
/* Indicate to the Stata compiler where the igrowup. ado file is 
stored*/ 
adopath + "D: \WHO igrowup STATA/" 
/* Load the data file */ 
use "D: \WHO igrowup workdata\survey. dta", clear 
/* generate the first three parameters reflib, datalib & datalab 
gen str6O reflib="D: \WHO igrowup STATA" 
lab var reflib "Directory of reference tables" 
gen str60 datalib="D: \WHO igrowup workdata" 
lab var datalib "Directory for datafiles" 
gen str30 datalab="mysurvey" 
lab var datalab "Working file" 
/* check the variable for "sex" 1= male, 2=female 
desc gender 
tab gender 
/* check the variable for "age" 
desc agemons 
summ agemons 
/* define your ageunit */ 
gen str6 ageunit="months" /* or [gen ageunit="days") */ 
lab var ageunit "=days or =months" 
/* check the variable for body "weight" which must be in kgs*/ 
desc weight 
summ weight 
/* check the variable for "lenhei" which must be in cms 
desc height 
summ height 
/* check the variable for "measure"*/ 
/* NOTE: if not available, please create as [gen strl measure-" 
desc measure 
tab measure 
/* check the variable for "oedema"*/ 
/* NOTE: if not available, please create as [gen strl oedema="n"]*/ 
desc oedema 
tab oedema 
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/* check the variable for "sw" for the sampling weight */ 
*/ /* NOTE: if not available, please create as [gen sw=11 
desc sw 
summ sw 
/* define the variable "flagsys"=0 if standard tables; 
"flagsys"= 1 if restricted tables 
gen flagsys=0 /* if standard table */ 
lab var flagsys "=0 Standard table; =1 Restricted table" 
*replace flagsys=l /* if restricted table */ 
/* Fill in the macro parameters to run the command */ 
igrowup reflib datalib datalab gender agemons ageunit weight height 
measure oedema sw flagsys 
References 
WHO Multicentre Growth Reference Study Group. WHO Child Growth Standards: 
Length/height-for-age, weight-for-age, weight-for-length, weight-for-height and 
body mass index-for-age: Methods and development. Geneva: World Health 
Organization, 2006. 
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eo^survey. do using survey. dta 
clear 
set more 1 
/* Higher memory might be necessary for larger datasets 
set memory 10m 
/* Indicate to the Stata compiler where the igrowup. ado file is 
stored*/ 
adopath + "C: \My Documents\EOkiro\WHOigrowupSTATA/" 
/* Load the data file */ 
use "C: \My Documents\EOkiro\WHOigrowup workdata\survey. dta", clear 
/* generate the first three parameters reflib, datalib & datalab */ 
gen str60 reflib="C: \My Documents\EOkiro\WHOigrowupSTATA" 
lab var reflib "Directory of reference tables" 
gen str6O datalib="C: \My Documents\EOkiro\WHOigrowup workdata" 
lab var datalib "Directory for datafiles" 
gen str30 datalab="mysurvey" 
lab var datalab "Working file" 
check the variable for "sex" 1= male, 2=female */ 
desc gender 
tab gender 
check the variable for "age" 
desc agemons 
summ agemons 
define your ageunit 
gen str6 ageunit="months" 
lab var ageunit "=months" 
check the variable for body "weight" which must be in kgs*/ 
desc weight 
summ weight 
check the variable for "height" which must be in cms 
desc height 
summ height 
check the variable for "measure"*/ 
NOTE: if not available, please create as [gen strl measure; " 
"I */ 
desc measure 
tab measure 
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check the variable for "oedema"*/ 
NOTE: if not available, please create as [gen stri 
oedema="n") 
desc oedema 
tab oedema 
check the variable for "sw" for the sampling weight*/ 
NOTE: if not available, please create as (gen sw=l)*/ 
desc sw 
sunup sw 
define the variable "flagsys"=0 if standard tables; 
"flagsys"= 1 if restricted tables 
gen flagsys=O /* if standard table */ 
lab var flagsys "=0 Standard table; =l Restricted table" 
*replace flagsys=l /* if restricted table */ 
Fill in the macro parameters to run the command */ 
igrowup reflib dätalib datalab gender agemons ageunit weight height 
measure oedema sw flagsys 
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Appendix W: Results from univariate analysis 
In this appendix we present results of the univariate risk factor analysis of the three 
outcomes studies RSVI, RSV-LRTI and all cause LRTI 
Täbie 1 Univäriäte analyses of factors associated with LRTI using Cox Regression 
Appendix W: Results from univariate analysis 
In this appendix we present results of the univariate risk factor analysis of the three outcomes 
studies RSVI, RSV-LRTI and all cause LRTI 
Table 1: Univariate analyses of factors associated with LRTI using Cox Regression 
Potential riskfactors Categories 
(number of events) 
Hazard 
Ratio 
P>IzJ' 95% Conf 
Interval 
SES poor (312) - - - " 
SES Middle (317) 1.02 0.896 0.81 1.28 
SES rich (228) 0.70 0.003 0.55 0.89 
Gender Female (429) - - - 
Gender Male (428) 1.11 0.275 0.92 1.35 
current age_0 0-5 months (245) - - - - 
current age 1 6-11 months (120) 0.58 0.000 0.43 0.77 
current age _3 
12- 17 months (290) 1.85 0.000 1.40 2.43 
current age_4 18+ months (202) 0.85 0.360 0.59 1.21 
birth weight 0 1.2- <2.0 kg (40) - - - - 
birth weight 
_1 
2- <2.5 kg (76) 0.74 0.286 0.43 1.28. 
birth weight 
_2 2.5- <3.0 kg (276) 
0.83 0.480 0.49 1.40 
birth weight 
_3 
3.0+ kg (447) 0.87 0.611 0.52 1.47 
multiple babies-0 1 child (790) - - - - 
multiple babies-! Twins (50) 1.02 0.973 0.75 1.34 
multiple babies-2 Triplets (17) 3.85 0.000 3.35 4.42 
PCT* agegroup 0 13-20 years (125) - - - - 
PCT agegroup_1 21-30 years (428) 0.99 0.980 0.74 1.31 
PCT agegroup 2 31-40 years (226) 0.93 0.654 0.68 1.28 
PCT agegroup_3 41-50 years (51) 0.88 0.537 0.58 1.32 
PCT_agegrp_4 51-63 years (27) 1.36 0.083 0.96 1.92 
education -0 no schooling 
(249) - - - - 
education _1 
1-7 years (353) 0.94 0.493 0.80 1.11 
education _2 
8-12 years (241) 0.80 0.080 0.63 1.03 
education _3 
>12 years (14) 0.34 0.000 0.21 0.55 
literacy No (349) - - - - 
literacy Yes (508) 0.82 0.038 0.67 0.98 
family_assisted No (665) - - - - 
family_assisted Yes (192) 1.20 0.091 0.97 1.49 
breast feeding 0 0-12 months (123) - - - - 
breast feeding 
_1 
13- 18 months (193) 1.01 0.899 0.81 1.27 
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breast feeding 2 19- 23 months (81) 1.04 0.783 0.79 1.38 
breast feeding 3 24+ (460) 1.00 0.966 0.82 1.23 
age at weaning 
_0 
0-2 months (310) - - - - 
age at weaning 
_1 
3- 6 months (532) 0.84 0.085 0.69 1.02 
age at weaning 2 7+ months (15) 0.59. 0.166 0.28 1.24 
Weight-age-z score_0 >-1 (507) - - - - 
Weight-age-z score_I -1.99 to -1 (205) 1.06 0.471 0.90 1.25 
Weight-age-z score 2 < -2 (145) 1.30 0.006 1.08 1.56 
Height-age-z score_0 >-1 (363) - - - - 
Height-age-z score _1 -1.99 
to -1(239) 1.32 0.001 1.12 1.56 
Height-age-z score_2 <_ -2 (255) 1.60 0.000 1.36 1.89 
Weight-height-z score-0 >-1 (652) - - - - 
Weight-height-z score 
_1 -1.99 
to -1 (136) 0.91 0.327 0.76 1.10 
Weight-height-z score _2 
<_ -2 (69) 1.41 0.007 1.10 1.81 
family_unit_0 2-5 members (261) - - - - 
family_unit 1 6-7 members (203) 1.05 0.716 0.80 1.38 
family_unit 2 8-10 members (207) 1.21 0.159 0.93 1.57 
family_unit 3 11+ (186) 1.19 0.164 0.93 1.53 
family_children 0 1-4 children (598) - - - - 
family_children_1 6-10 children (214) 1.08 0.497 0.86 1.37 
family_children_2 11+children (45) 1.80 0.000 1.31 2.47 
siblings under 6 years 
-0 
no siblings <6 yrs - - - - 
(185) 
siblings under 6 years _1 
1-2 siblings<6 yrs 1.37 0.000 1.16 1.62 
(517) 
siblings under 6 years -2 
3-4 siblings<6 yrs 1.50 0.000 1.21 1.88 
(129) 
siblings under 6 years 3 5+ siblings<6 yrs (26) 1.70 0.000 1.28 2.26 
siblings 6 years or more_0 1-3 siblings 6+ yrs - - - - 
(290) 
siblings 6 years or more-1 4-6 siblings 6+ yrs 0.98 0.864 0.76 1.15 
(292) 
siblings 6 years or more_2 7-10 siblings 6+ yrs 1.14 0.282 0.90 1.37 
(202) 
siblings 6 years or more -3 
11+ siblings 6+ yrs 1.00 0.994 0.72 1.29 
(73) 
male-siblings-0 0-2 male siblings - - - - 
(601) 
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male_siblings 1 3-6 male siblings 
(241) 
1.22 0.087 0.97 1.54 
male_siblings_2 7+ male siblings (15) 1.15 0.621 0.65 2.04 
female_siblings_0 1-4 female sibs (426) - - - - 
femalesiblings 1 5-9 female sibs (343) 1.12 0.283 0.91 1.39 
female siblings 2 10+ female sibs (88) 1.01 0.935 0.75 1.36 
# of dead siblings None (640) - - - - 
# of dead siblings 1 (157) 1.03 0.835 0.79 1.36 
# of dead siblings 2 (60) 1.11 0.582 0.76 1.63 
child stays mostly inside house - - - - 
(817) 
child stays mostly outside house 0.79 0.261 0.53 1.19 
(40) 
child's care-0 mother (670) - - - - 
child's care _1 another 
family 1.24 0.060 0.99 1.56 
member (129) 
child's care 2 House help (20) 0.56 0.008 0.36 0.86 
child's care 3 School (0) - - - - 
child's care _4 mother 
/ family 1.89 0.004 1.22 2.93 
member (38) 
house type block walled (267) - - - - 
house type mud walled (590) 1.37 0.002 1.12 1.67 
house ownership owner occupied (690) - - - - 
house ownership rented (149) 0.87 0.316 0.67 1.14 
house ownership not owned/ rented (18) 0.62 0.104 0.35 1.10 
toilet type 0 no toilet (318) - - - - 
toilettype 1 Flush (25) 0.40 0.001 0.24 0.67 
toilet type 2 Latrine (514) 0.93 0.510 0.76 1.14 
burn refuse No (189) - - - - 
burn refuse yes (668) 1.16 0.172 0.94 1.45 
main-fuel-0 gas/paraffin (16) - - - - 
main-fuel-1 Charcoal (158) 1.61 0.070 0.96 2.68 
main-fuel-2 Firewood (660) 2.16 0.001 1.35 3.46 
main fuel 3 firewood/charcoal 2.27 0.027 1.10 4.69 
(23) 
cooking location 
-0 
Outside (67) - - - - 
cooking location-1 different house from 1.01 0.945 0.66 1.55 
sleep area (496) 
cooking location _2 
same house as you 0.92 0.690 0.59 1.42 
sleep (294) 
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water source 0 both well & piped (43) - -- - 
water source 
-I 
open/closed well (50) 0.95 0.837 0.57 1.57 
water source 
_2 
Piped (764) 0.86 0.431 0.60 1.24 
watersite 0 own source (38) - -- - 
watersite 1 Public (686) 2.12 0.000 1.50 3.00 
watersite_2 Shared (133) 2.07 0.001 1.37 3.11 
job description of major non-skilled (359) - -- - income provider 0 
job description of major Trade (146) 0.94 0.667 0.71 1.24 
income provider 1 
job description of major Skilled (384) 0.86 0.190 0.68 1.07 
income provider 2 
job description of major Professional (68) 0.69 0.009 0.53 0.91 
income provider 3 
smokers in HH_0 None (597) - -- 
smokers in HH_1 1(216) 1.08 0.490 0.87 1.35 
smokers in HH_2 2 or more (44) 1.15 0.442 0.81 1.64 
adults in index's room-0 None (32) - -- - 
adults in index's room _1 
1 adult (263) 0.96 0.889 0.54 1.71 
adults in index's room_2 2 adults (528) 0.79 0.411 0.45 1.38 
adults in index's room_3 3+ adults (34) 0.85 0.666 0.41 1.78 
# siblings <6yr living in no siblings <6 yrs - -- - 
same house as index0 
_ 
(314) 
# siblings <6yr living in 1 sibling (366) 1.10 0.384 0.89 1.35 
same house as index-1 
# siblings <6yr living in 2-4 siblings (150) 1.41 0.017 1.06 1.86 
same house as index 2 - # siblings 6+ years living in no siblings 6+ years - -- - 
same house as index_O (296) 
# siblings 6+ years living in 1-2 siblings (379) 1.14 0.238 0.92 1.42 
same house as index 1 
- # siblings 6+ years living in 3-4 siblings (117) 0.86 0.251 0.66 1.12 
same house as index-2 
# siblings 6+ years living in 5-7 siblings (38) 1.45 0.128 0.90 2.36 
same house as index 
-3 # siblings <6yr sleeping in no siblings <6 yrs - -- - 
same room as index 
-O 
(411) 
# siblings <6yr sleeping in 1 -2 sibling <6 yrs 1.30 0.007 1.07 1.57 
same room as index 1 (408) 
- # siblings <6yr sleeping in 3 siblings <6 yrs (11) 1.41 0.541 0.47 4.28 
same room as index 2 
390 
# siblings 6+ years sleeping 
in same room as index 0 
no siblings 6+ years 
(535) 
---- 
# siblings 6+ years sleeping 1 siblings (194) 1.27 0.047 1.00 1.62 
in same room as index 1 
- # siblings 6+ years sleeping 2-3 siblings (88) 0.95 0.741 0.72 1.26 
in same room as index_2 
# siblings 6+ years sleeping 4 siblings (13) 0.83 0.631 0.38 1.79 
in same room as index 2 
# siblings <6yr sleeping in no siblings <6 yrs ---- 
same bed as index 0 (526) _ # siblings <6yr sleeping in 1 sibling (280) 1.22 0.061 0.99 1.51 
same bed as index 1 
# siblings <6yr sleeping in 2-3 siblings (24) 1.48 0.222 0.79 2.75 
same bed as index 2 
# siblings 6+ years sleeping no siblings <6 yrs ---- in same room as index_0 (727) 
# siblings 6+ years sleeping 1-2 siblings (103) 0.99 0.919 0.75 1.29 
in same room as index _1 # siblings <6yr going to no siblings <6 yrs ---- 
school-0 going to school (709) 
# siblings <6yr going to 1 sibling (86) 0.77 0.033 0.60 0.98 
school-1 
# siblings <6yr going to 2-3 siblings (35) 1.69 0.042 1.02 2.80 
school-2 
# siblings 6+ years going to no siblings <6 yrs ---- 
school 0 going to school (235) - # siblings 6+ years going to 1- 2 sibling (347) 1.13 0.309 0.87 1.44 
school-1 
# siblings 6+ years going to 3-5 siblings (216) 1.12 0.404 0.84 1.48 
school-2 
# siblings 6+ years going to 6-9 siblings (32) 1.46 0.092 0.98 2.26 
school 3 
*PCT (Primary care taker) 
§p-values (bold<0.05) for the tests of the null hypothesis that each hazard ratio is one. 
Table 2: Results from univariate analysis using Cox regression with RSV-LRTI as the 
outcome variable. Significant variables are in bold. 
Potential risk factors Categories Hazard P> I zl 95% Conf. 
(number o events) Ratio Interval 
SES Poor (28) 
SES Middle class (41) 1.49 0.089 0.94 2.37 
SES Rich (23) 0.80 0.401 0.48 1.34 
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Gender Female (48) - - - - 
Gender Male (44) 1.03 0.883 0.70 1.52 
current age -O 
0-5 months (28) - - - - 
current age -I 
6-11 months (21) 1.20 0.753 0.38 3.77 
current age _2 
12- 17 months (16) 1.44 0.591 0.38 5.39 
current age_3 18+ months (27) 1.06 0.927 0.28 4.05 
birth weight j 1.2- <2.0 kg (5) - - - - 
birth weight _1 
2- <2.5 kg (8) 0.66 0.424 0.24 1.82 
birth weight _2 
2.5- <3.0 kg (25) 0.68 0.370 0.29 1.59 
birth weight 
_3 
3.0+ kg (47) 0.78 0.552 0.34 1.78 
multiple babies-0 1 child (83) - - - - 
multiple babies-1 Twins (8) 1.54 0.203 0.79 3.01 
multiple babies_2 Triplets (1) 1.99 0.351 0.47 8.50 
PCT*_agegroup 0 13-22 years (6) - - - - 
PCT_agegroup_1 23-30 years (44) 2.15 0.109 0.84 5.47 
PCT_agegroup 2 31-40 years (28) 2.43 0.067 0.94 6.27 
PCT agegroup 3 41-63 years (14) 3.65 0.012 1.34 9.98 
education-0 no schooling (25) - - - - 
education 
_1 
1-7 years (31) 0.84 0.530 0.49 1.44 
education 2 8-12 years (34) 1.14 0.624 0.68 1.92 
education_3 >12 years (2) 0.51 0.340 0.13 2.04 
literate PCT No (34) - - - - 
literate PCT Yes (58) 0.96 0.849 0.63 1.46 
Family assisted No (69) - - - - 
Family assisted Yes (23) 1.40 0.131 0.91 2.15 
breast feeding 
_0 
0- 12 months (13) - - - - 
breast feeding 
_I 
13- 18 months (21) 1.05 0.899 0.53 2.07 
breast feeding 2 19- 23 months (11) 1.29 0.510 0.60 2.78 
breast feeding 
_3 
24+ (47) 1.02 0.929 0.57 1.84 
age at weaning 
_0 
0-2 months (30) - - - - 
age at weaning 
_I 
3- 6 months (60) 0.98 0.919 0.64 1.49 
age at weaning 
_2 
7+ months (2) 0.84 0.804 0.22 3.23 
Weight-age-z score-0 >-1 (49) - - - - 
Weight-age-z score-1 -1.99 to -1 (27) 1.37 0.179 0.86 2.17 
Weight-age-z score_2 S -2 (16) 1.37 0.228 0.82 2.28 
Height-age-z score 
-0 
>-1 (38) - - - 
Height-age-z score-1 -1.99 to -1 (26) 1.43 0.162 0.87 2.36 
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Height-age-z score-2 <-2 (28) 1.85 0.011 1.15 2.97 
Weight-height-z score_0 >-1 (71) - - - - 
Weight-height-z score_1 -1.99 to -1 (13) 0.70 0.241 0.40 1.26 
Weight-height-z score_2 < -2 (8) 1.17 0.656 0.58 2.37 
family_unit 0 2-5 members (28) - - - - 
family_unit I 6-7 members (14) 0.66 0.208 0.35 1.26 
family_unit 2 8-10 members (25) 1.35 0.248 0.81 2.27 
family_unit 3 11+members (25) 1.50 0.116 0.90 2.48 
family_children_0 1-5 children (60) - - - - 
family_children_I 6-10 children (26) 1.32 0.214 0.85 2.04 
family_children_2 11+ children (6) 2.51 0.005 1.32 4.76 
siblings under 6 years_0 no siblings< 6 yrs (16) - - - - 
siblings under 6 years-1 1-2 siblings<6 yrs 1.78 0.028 1.06 2.98 
(58) 
siblings under 6 years -2 
3-4 siblings<6 yrs 2.00 0.048 1.00 3.97 
(15) 
siblings under 6 years-3 5+ siblings<6 yrs (3) 2.39 0.116 0.81 7.09 
siblings 6 years or more-0 1-3 siblings 6+ yrs(30) - - - - 
siblings 6 years or more-1 4-6 siblings 6+ yrs 0.84 0.523 0.50 1.42 
(26) 
siblings 6 years or more_2 7-10 siblings 6+ yrs 1.43 0.157 0.87 2.34 
(26) 
siblings 6 years or more 3 11+ siblings 6+ yrs 1.36 0.350 0.71 2.60 
- (10) 
male_siblings_0 0-2 male siblings (61) - - - - 
male_siblings_1 3-6 male siblings (27) 1.36 0.170 0.87 2.10 
male siblings 2 7+ male siblings (4) 3.28 0.000 1.76 6.17 
female_siblings_0 1-4 female sibs (39) - - - - 
female_siblings_I 5-9 female sibs (42) 1.49 0.065 0.98 2.27 
female_siblings_2 10+ female sibs (11) 1.40 0.272 0.77 2.56 
# of dead siblings None (67) - - - - 
# of dead siblings 1 (18) 1.13 0.654 0.67 1.90 
# of dead siblings 2 (7) 1.21 0.596 0.60 2.41 
child stays mostly inside house - - - - 
(91) 
child stays mostly outside house 0.18 0.081 0.03 1.23 
(1) 
child's care 
-O 
mother (73) - - - - 
child's care 1 another family 1.12 0.692 0.63 1.98 _ member (13) 
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child's care _2 
house help (3) 0.78 0.658 0.27 2.31 
child's care 3 school (0) - - - - 
child's care 4 mother / family 1.28 0.622 0.48 3.38 
member (3) 
house type block walled (32) - - - - 
house type mud walled (60) 1.15 0.507 0.76 1.76 
house ownership owner occupied (80) - - - - 
house ownership rented (10) 0.52 0.035 0.28 0.96 
house ownership not owned/ rented (2) 0.55 0.370 0.15 2.00 
toilet type 0 no toilet (33) - - - - 
toilet type 1 flush (1) 0.16 0.066 0.02 1.13 
toilet type_2 latrine (58) 1.03 0.889 0.68 1.57 
burn refuse No (18) - - - - 
burn refuse yes (74) 1.33 0.237 0.83 2.14 
main fuel 0 Charcoal (12) - - - - 
main_fuel_I gas/paraffin (0) - - - - 
main-fuel-2 firewood (79) 2.08 0.011 1.18 3.66 
main fuel_3 firewood/charcoal (1) 0.82 0.831 0.13 5.29 
cooking location 
-0 
Outside (8) - - - - 
cooking location_i different house from 1.00 0.994 0.52 1.92 
sleep area (59) 
cooking location 
-2 same 
house as you 0.65 0.228 0.32 1.31 
sleep (25) 
water source 
-O 
both well & piped (6) - - - - 
water source 
-I open/closed well 
(4) 0.52 0.279 0.16 1.70 
water source_2 Piped (82) 0.66 0.270 0.31 1.38 
watersite 0 Public (79) - - 
watersite 1 own source (2) 0.22 0.030 0.06 0.86 
watersite 2 Shared (11) 0.71 0.269 0.38 1.31 
job description of MIP_0 non-skilled (35) - - - - 
job description ofMIP_1 Trade (21) 1.42 0.187 0.84 2.40 
job description of MIP 2 Skilled (27) 0.84 0.470 0.53 1.34 
job description of MIP 3 Professional (9) 0.97 0.936 0.46 2.03 
smokers in HH 
-0 
None (66) - - - - 
smokers in HH 
-1 
1(21) 0.93 0.770 0.56 1.53 
smokers in HH 
_2 
2 or more (5) 1.21 0.687 0.47 3.11 
adults in index's room 0 0 -1 adult (36) - - - - 
adults in index's room _2 
2 or more adults (52) 0.66 0.047 0.44 1.00 
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adults in index's room -3 
3 or more adults (4) 0.82 0.653 0.34 1.95 
# siblings <6yr living in no siblings <6 yrs ---- 
same house as index 0 (34) - # siblings <6yr living in 1 sibling (37) 1.00 0.995 0.65 1.55 
same house as index 1 - # siblings <6yr living in 2-4 siblings (21) 1.73 0.041 1.02 2.93 
same house as index-2 
# siblings 6+ years living in no siblings 6+ years ---- 
same house as index_0 
# siblings 6+ years living in 
(34) 
1-2 siblings (36) 0.92 0.726 0.59 
1.44 
same house as index-1 
# siblings 6+ years living in 3-4 siblings (15) 0.91 
0.771 0.49 1.69 
same house as index -2 # siblings 6+ years living 5-7 siblings (7) 2.10 
0.029 1.08 4.10 
in same house as index 3 
# siblings <6yr sleeping in no siblings <6 yrs ---- 
same room as index_0 
# siblings <6yr sleeping in 
(50) 
1 -3 sibling <6 yrs 
1.05 0.797 0.71 1.55 
same room as index 1 (42) 
_ # siblings 6+ years sleeping no siblings 6+ years ---- 
in same room as index O (63) 
- # siblings 6+ years sleeping 1 siblings (19) 1.05 0.855 
0.64 1.71 
in same room as index 1 _ # siblings 6+ years sleeping 2-4 siblings (10) 0.77 0.462 
0.39 1.53 
in same room as index 2 
_ # siblings <6yr sleeping in no siblings <6 yrs ---- 
same bed as index 0 (59) 
_ # siblings <6yr sleeping in 1-3 siblings (33) 1.16 0.456 0.78 
1.72 
same bed as index 1 
_ # siblings 6+ years sleeping no siblings <6 yrs ---- in same bed as index 
-O 
(84) 
# siblings 6+ years sleeping 1-2 siblings (8) 0.64 0.186 0.33 1.24 
in same bed as index I _ # siblings <6yr going to no siblings <6 yrs --- 
school -0 going 
to school (77) 
# siblings <6yr going to 1 sibling (10) 0.75 0.366 0.40 1.41 
school -I # siblings <6yr going to 2-3 siblings (5) 1.77 0.182 0.76 4.12 
school 2 - # siblings 6+ years going to no siblings <6 yrs ---- 
school 0 going to school (25) 
# siblings 6+ years going to 1- 2 sibling(33) 1.02 0.944 0.61 
1.70 
school 1 
# siblings 6+ years going to 3-5 siblings (27) 
1.31 0.310 0.78 2.20 
school 2 
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# siblings 6+ years going 6-9 siblings (7) 3.04 0.002 1.48 6.22 
to school 3 
*PCT (Primary care taker) 
§p-values (bold<0.05) for the tests of the null hypothesis that each hazard ratio is one. 
Table 3: Results form univariate analysis using Cox Regression with RSV 
infection as 
outcome 
Potential risk factors Categories 
(number of events) 
Hazard 
Ratio 
P> Iz( 95% Conf. 
Interval 
SES Poor (128) - - - - 
SES Middle class (134) 1.02 0.818 0.83 1.26 
SES Rich (100) 0.75 0.015 0.60 0.95 
current age 0 0-5 months (69) - - - - 
current age_l 6-11 months (88) 1.44 0.281 0.74 
2.80 
current age_2 12- 17 months (55) 1.16 0.700 0.54 
2.45 
current age 3 18+ months (150) 0.98 0.956 0.48 
2.00 
gender Female (198) - - - - 
gender Male (164) 0.92 0.334 0.77 1.09 
birth weight j 1.2- <2.0 kg (16) - - - - 
birth weight 
_1 2- <2.5 kg (36) 
0.82 0.466 0.49 1.39 
birth weight 2 2.5- <3.0 kg (109) 0.77 0.307 0.47 1.27 birth Weight 3 3.0+ kg (197) 0.92 0.750 0.57 1.51 
multiple babies 0 1 child (337) - - 
multiple babies 
_1 Twins (22) 1.05 0.803 0.73 
1.51 
multiple babies 
-2 Triplets (3) 1.77 0.028 1.06 
2.93 
PCT*_agegroup`0 13-20 years (49) - - - - PCT agegroup_1 21-30 years (186) 1.14 0.379 0.85 1.51 
PCT agegroup 2 31-40 years (92) 0.98 0.896 0.71 1.35 
PCT agegroup_3 41-50 years (23) 0.96 0.851 0.62 1.48 
PCT agegrp 4 51-63 years (12) 1.73 0.007 1.16 2.59 
education -0 
no schooling (92) - - - - 
education _1 
1-7 years (156) 1.11 0.391 0.88 1.39 
education 2 8-12 years (105) 0.96 0.715 0.76 1.21 
education _3 
>12 years (9) 0.61 0.067 0.36 1.04 
literate PCT No (130) - - - - 
literate PCT Yes (231) 1.00 0.991 0.83 1.21 
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Family assisted No (273) - - - " 
Family assisted Yes (89) 1.34 0.003 
1.11 1.63 
breast feeding 0 0- 12 months (45) - - - - 
_ breast feeding 2 13- 18 months (78) 1.13 0.436 0.83 1.54 
_ breast feeding 3 19- 23 months (27) 1.01 0.946 0.68 1.51 
_ breast feeding 4 24+ (212) 1.15 0.329 0.87 1.51 
age at weaning 0 0-2 months (130) - - - - _ 
age at weaning 1 3- 6 months (219) 
0.85 0.107 0.71 1.03 
_ 
age at weaning 2 7+ months (13) 1.33 0.164 
0.89 2.00 
Weight-age-z score 0 >-1 (214) - - - _ Weight-age-z score 1 -1.99 to -1(92) 
0.99 0.961 0.80 1.24 
Weight-age-z score-2 <_ -2 (56) 
1.01 0.962 0.79 1.29 
Height-age-z score 0 >-1 (162) - - - - 
_ Height-age-z score-1 -1.99 to -1 (97) 
1.07 0.547 0.85 1.36 
Height-age-z score-2 <-2 (103) 1.18 0.131 
0.95 1.47 
Weight-height-z score 0 >-1 (280) - - " 
_ Weight-height-z score-1 -1.99 to -1(56) 
0.82 0.141 0.63 1.07 
Weight-height-z score-2 < -2 (26) 
0.97 0.854 0.69 1.36 
family unit 0 2-5 members (122) - - - - 
family_unit 1 6-7 members (77) 0.85 0.197 0.67 
1.09 
family unit 2 8-10 members (80) 0.99 0.927 0.76 
1.29 
family unit 3 11+ (83) 1.15 0.210 0.92 1.43 
family-Children0 1-3 children (152) - - - - family_children_1 4-5 children (105) 1.04 0.744 0.84 
1.27 
family-children 2 6+children (105) 1.09 0.437 0.87 1.36 
siblings under 6 years 0 no siblings <6yrs (88) - - - - - siblings under 6 years_1 1-2 siblings<6yrs 1.17 0.181 0.93 1.47 
(212) 
siblings under 6 years 
_2 
3-4 siblings<6yrs (53) 1.32 0.048 1.00 1.73 
siblings under 6 years_3 5+ siblings<6yrs (9) 1.34 0.178 0.87 2.06 
siblings 6 years or more_0 1-3 siblings 6+ yrs - - - - 
(129) 
siblings 6 years or more-1 4-6 siblings 6+ yrs 0.84 0.144 0.68 1.06 
(113) 
siblings 6 years or more_2 7-10 siblings 6+ yrs 1.11 0.380 0.88 
1.40 
(89) 
siblings 6 years or more_3 11+ siblings 
6+ yrs 0.99 0.971 0.74 1.33 
(31) 
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male_siblings_0 0-2 male siblings - - - - 
(260) 
male_siblings_1 3-6 male siblings (95) 1.09 
0.423 0.88 1.34 
male_siblings_2 7+ male siblings (7) 1.36 
0.064 0.98 1.88 
female_siblings_0 1-4 female sibs (183) - - - - 
1 siblings female 5-9 female sibs (141) 1.07 
0.452 0.89 1.30 
_ _ female_siblings 2 10+ female sibs (38) 1.04 0.748 0.80 1.36 
# of dead siblings None (270) - - - 
# of dead siblings 1 (72) 1.09 
0.439 0.88 1.34 
# of dead siblings 2 (20) 0.86 0.478 
0.56 1.31 
child stays mostly inside house - - - 
(340) 
child stays mostly outside hse 1.06 0.766 0.72 
1.55 
(22) 
child's care 0 Mother (300) - - - 
- 
child's care 
_1 another 
family 0.91 0.505 0.68 1.21 
member (41) 
child's care 2 House help (7) 0.45 0.008 0.24 
0.81 
_ 
child's care 3 School (1) 1.13 0.039 1.01 1.26 
child's care 4 mother / family 1.52 0.078 0.95 
2.43 
member(13) house type block walled (116) - - - 
house type mud walled (246) 1.29 0.008 1.07 
1.56 
house ownership_0 owner occupied (293) - - - house ownership1 Rented (58) 0.83 0.145 0.64 1.07 
house ownership_.; ' not owned/ rented (11) 0.94 0.766 0.62 1.42 
toilet type 0 no toilet (139) - - - 
toilet_type 1 Flush (14) 0.52 0.002 0.34 0.78 
toilet type_2 Latrine (209) 0.85 0.093 0.71 1.03 
burn refuse No (91) 
burn refuse yes (271) 0.99 0.945 0.82 1.21 
main fuel_0 gas/paraffin (11) - 
main fuel_1 Charcoal (66) 1.07 0.824 0.61 1.88 
main fuel 2 Firewood (276) 1.37 0.239 0.81 2.33 
main fuel_3 firewood/charcoal (9) 1.26 0.590 0.53 2.97 
cooking location_0 Outside (28) - - - - 
1 cooking location different 
house from 0.96 0.812 0.69 1.33 
_ sleep area (196) 
2 cooking location same 
house as you 1.01 0.961 0.72 1.42 
_ sleep (138) 
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water source 0 both well & piped (14) ---- 
water source_1 open/closed well (22) 1.37 0.246 0.80 2.34 
water source 
-2 Piped (326) 1.23 0.384 0.77 1.96 
watersite 0 own source (27) --- 
_ 
watersite 1 Public (284) 1.19 0.309 0.85 1.66 
_ 
watersite 2 Shared (51) 1.17 0.434 0.79 1.72 
job description ofMIP_0 non-skilled (145) --- 
job description of MIP 1 Trade (74) 1.17 0.168 0.93 1.48 
job description of MIP_2 Skilled (115) 0.85 0.147 0.68 
1.06 
job description of MIP_3 Professional (28) 0.71 0.029 0.52 
0.96 
smokers in HH 0 None (255) --- 
smokers in HH-1 1 (83) 0.99 0.897 0.78 1.24 
smokers in HH 2 2 or more (24) 1.47 0.005 1.13 1.93 
adults in index's room 0 None (11) --- - adults in index's room_i 1 adult (97) 0.92 0.706 0.58 
1.44 
adults in index's room 2 2 adults (242) 0.94 0.793 0.62 
1.45 
_ 
adults in index's room_3 3+ adults (12) 0.81 0.481 0.44 
1.47 
# siblings <6yr living in no siblings <6 yrs --- 
same house as index 0 (139) 
_ # siblings <6yr living- iving in 1 sibling (164) 1.07 0.512 0.87 
1.30 
same house as index 1 - # siblings <6yr living in 2-4 siblings (59) 1.01 0.941 0.78 
1.31 
same house as index 2 
- # siblings 6+ years living in no siblings 6+ yrs -- same house as index 0 (134) 
_ # siblings 6+ years living in 1-2 siblings (158) 1.02 0.882 0.84 1.25 same house as index I 
_ # siblings 6+ years living in 3-4 siblings (57) 0.87 0.285 0.67 1.12 
same house as index 2 
_ # siblings 6+ years living in 5-7 siblings (13) 0.98 0.867 0.65 1.43 
same house as index 3 
# siblings <6yr sleeping in no siblings <6 yrs ---- 
same room as index_0 (190) 
# siblings <6yr sleeping in 1 -3 sibling <6 yrs 1.08 0.373 0.91 1.30 
same room as index _1 
(172) 
# siblings 6+ years sleeping no siblings 6+ years ---- 
in same room as index_0 (250) 
# siblings 6+ years sleeping I siblings (70) 0.96 0.776 0.74 1.25 
in same room as index_I 
# siblings 6+ years sleeping 2-4 siblings (42) 0.81 0.117 0.62 1.05 
in same room as index 2 
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# siblings <6yr sleeping in no siblings <6 yrs ---- 
same bed as index 0 (224) _ # siblings <6yr sleeping in 1-3 siblings (138) 1.21 0.038 1.01 1.45 
same bed as index 1 _ # siblings 6+ years sleeping no siblings <6 yrs ---- 
in same bed as index 0 (309) 
# siblings 6+ years sleeping 1-2 siblings (53) 1.18 0.240 0.89 1.56 
in same bed as index _1 # siblings <6yr going to no siblings <6 yrs ---- 
school 0 going to school (289) - # siblings <6yr going to I sibling (53) 0.88 0.303 0.68 1.12 
school 1 
- # siblings <6yr going to 2-3 siblings (20) 1.40 0.059 0.99 2.00 
school 2 
# siblings 6+ years going to no siblings <6 yrs ---- 
school 0 going to school (109) - # siblings 6+ years going to 1- 2 sibling (143) 0.97 0.749 0.78 1.19 
school 1 
- # siblings 6+ years going to 3-5 siblings (98) 0.97 0.828 0.76 1.25 
school 2 
# siblings 6+ years going to 6-9 siblings (12) 1.17 0.482 0.76 1.80 
school 3 
*PCT (Primary care taker) 
§p-values (bold<0.05) for the tests of the null hypothesis that each hazard ratio is one. 
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Appendix X: Testing the Proportional Hazard Assumption 
Test and graphs based on Schoenfeld residuals 
1. RSV infection 
Time: Log(t) 
Variables rho chit df Prob>chi2 
PCT age group _1 -0.01754 
0.08 1 0.7748 
PCT age group 
_2 -0.00454 
0.01 1 0.9387 
PCT age group _3 -0.00574 
0.01 1 0.9242 
PCT age group _4 -0.00092 
0.00 1 0.9889 
care giver _1 -0.03683 
0.40 1 0.5246 
care giver 2 0.08581 1.57 1 0.2107 
care giver _3 
0.04153 0.34 1 0.5583 
care giver_ 4 -0.06639 1.01 1 0.3153 
family assisted 0.04269 0.39 1 0.5310 
house toilet 1 -0.0437 0.33 1 0.5659 
house-toilet-2 -0.02495 0.17 1 0.6793 
house toilet 3 -0.05702 0.94 1 0.3315 
house_toilet_4 -0.01654 0.03 1 0.8692 
house-toilet-5 -0.00969 0.02 1 0.8951 
smokers in HH 
-1 
0.10178 3.08 1 0.0791 
smokers in HH 
_2 -0.05376 
0.43 1 0.5099 
global test 7.60 16 0.96 
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2. RSV-LRTI model 
Time: Log(t) 
Variables rho chi2 df Prob>chi2 
house toilet 1 0.04997 0.36 1 0.551 
_ _ house toilet 2 -0.02583 0.08 
1 0.7718 
_ _ house toilet3 -0.05431 0.41 1 
0.5203 
house- 4 toilet 0 1 
_ _ house toilet 5 0.02908 0.14 1 0.7078 
_ care giver _1 -0.0303 
0.1 1 0.7551 
care giver 2 0.07026 0.45 1 0.5007 
care giver 3 
care giver 4 
0 
-0.08484 0.46 
1 
1 0.4994 
_ family assisted -0.02106 0.04 1 
0.8326 
smokers in HH 1 0.12797 2.33 1 0.1269 
_ smokers in HH 2 -0.10636 1.23 1 
0.2679 
_ PCT age group 1 0.20378 6.21 1 0.0127 
_ PCT age group 2 0.01011 0.01 1 
0.9088 
PCT age group 3 0.1041 1.35 1 0.2445 
height for age z-score _1 
0.00893 0.01 1 0.9178 
height for age z-score _2 
0.18827 3.58 1 0.0585 
siblings under 6 years_1 -0.13606 1.92 1 
0.1659 
siblings under 6 years , 2 -0.02614 
0.11 1 0.7346 
_ 
siblings under 6 years_3 -0.07343 0.45 1 
0.5037 
family children_1 0.14783 2.98 1 0.0844 
family_children_2 0.00562 0 1 0.9505 
job description of MIP_1 0.0641 0.37 1 0.541 
job description of MIP_2 0.10201 1.24 1 0.2657 
job description of MIP_3 0.05525 0.42 1 0.5148 
global test 21.71 25 0.6524 
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3. LRTI model 
Time: Time 
Variable rho chi2 df Prob>chi2 
current age_1 -0.01115 0.10 1 0.7473 
current age_2 -0.00955 0.09 1 0.7620 
current age_3 -0.00894 0.09 1 0.7656 
education 1 0.00011 0.00 1 0.9966 
_ education 2 0.00284 0.01 1 0.9120 
education 3 -0.03226 1.18 1 0.2768 
height-age-z score _1 
0.00054 0.00 1 0.9865 
height-age-z score_2 0.01837 0.37 1 0.5436 
family_children 1 0.01198 0.21 1 0.6476 
family_children_2 -0.06846 7.94 1 0.0048 
main fuel 1 -0.01687 0.33 1 0.5638 _ _ main fuel 2 0.01571 0.29 1 0.5900 
_ main fuel 3 0.00106 0.00 1 0.9694 
# siblings <6yr sleeping in same -0.03445 1.57 
1 0.2099 
room as index I 
# siblings <6yr sleeping in same - 0.00379 0.02 1 0.8942 
room as index 2 
# siblings 6+ years sleeping in 0.03362 1.60 1 0.2063 
same room as index I _ # siblings 6+ years sleeping in 0.07068 6.54 1 0.0106 
same room as index 2 
_ # siblings 6+ years sleeping in -0.00222 0.01 
1 0.9357 
same room as index 3 
_ # siblings <6yr going to 0.03548 1.42 1 0.2338 
school 1 
- # siblings <6yr going to -0.00073 0.00 
1 0.9786 
school 
-2 
global test 29.24 20 0.0831 
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Appendix Y: Assessment of Goodness of fit of the Cox regression models. 
M 
0 .511.5 CS 
ý..; Nelson-Aalen cumulative hazard cs 
Figure 1: Plot of Nelson-Aalen cumulative hazard function and the cs residuals for 
RSVI 
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Figure 2: Plot of Nelson-Aalen cumulative hazard function and the cs residuals for 
RSV-LRTI 
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Figure 3: Plot of Nelson-Aalen cumulative hazard function and the cs residuals for 
LRTI 
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